ANNUAL MEETING

PROGRAM BOOK
2014

DECEMBER 5 - 9
Washington State Convention Center | Seattle, WA
5thBiennial North American Regional Epilepsy Congress
 Visit BOOTH #405 to learn more

R e ad y to F i g h t Bobby, age 47,

diagnosed with LGS.

ONFI (clobazam) is FIERCELY DEDICATED

to helping Bobby & Julian ght their seizures.
ONFI is indicated for the adjunctive treatment of
seizures associated with Lennox-Gastaut syndrome (LGS)
in patients 2 years of age or older.

Julian, age 6,
diagnosed with LGS.

Important Safety Information

ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was
dose-related. In general, somnolence and sedation begin within the rst month of treatment and may diminish with continued
treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central
nervous system (CNS) depressants. Prescribers should caution patients against engaging in hazardous activities that require mental
alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known.
ONFI has a CNS depressant effect. Patients should be cautioned against the simultaneous use with other CNS depressant drugs
or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated.
As with all antiepileptic drugs (AEDs), ONFI should be gradually withdrawn to minimize the risk of precipitating seizures, seizure
exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuation of ONFI; the risk
of withdrawal symptoms is greater with higher doses.
Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been
reported with ONFI in both children and adults during the post-marketing period. ONFI should be discontinued at the rst sign
of rash, unless the rash is clearly not drug-related.
Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents
because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported
following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment.
AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be
informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or
any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to
the AED or illness, because epilepsy itself can increase these risks.
The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group
clinical trial who received clobazam as adjunctive therapy (10% in any treatment group and at least 5% greater than placebo,
respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%),
drooling (14% vs. 3%), aggression (14% vs. 5%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%).
Please see Brief Summary of Prescribing Information on the following pages. For full Prescribing Information, Medication Guide,
and Instructions for Use, go to www.ONFI.com.

2014 Lundbeck. All rights reserved.

ONFI is a registered trademark of Lundbeck CLB-B-00123 09/2014

1
ONFI (clobazam) tablets, for oral use, and may not reect the rates observed in practice. During its development
ONFI (clobazam) oral suspension, for the adjunctive treatment of seizures associated with LGS, ONFI was
Brief Summary of Prescribing Information administered to 333 healthy volunteers and 300 patients with a current
(See package insert for full Prescribing Information or visit www.ONFI.com) or prior diagnosis of LGS, including 197 patients treated for 12 months
or more. The conditions and duration of exposure varied greatly and
Rx Only
included single- and multiple-dose clinical pharmacology studies in healthy
INDICATIONS AND USAGE ONFI (clobazam) is indicated for the adjunctive volunteers and two double-blind studies in patients with LGS (Study 1 and 2)
treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients [see Clinical Studies]. Only Study 1 included a placebo group, allowing comparison
2 years of age or older. of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions
CONTRAINDICATIONS None [see Contraindications]. Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1):
WARNINGS AND PRECAUTIONS Somnolence or Sedation: ONFI causes The adverse reactions associated with ONFI treatment discontinuation in 1%
somnolence and sedation. In clinical trials, somnolence or sedation was reported of patients in decreasing order of frequency included lethargy, somnolence,
at all effective doses and was dose-related. In general, somnolence and sedation ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in
begin within the rst month of treatment and may diminish with continued an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 in the full Prescribing
treatment. Prescribers should monitor patients for somnolence and sedation, Information lists the adverse reactions that occurred in 5% of ONFI treated
particularly with concomitant use of other central nervous system depressants. patients (at any dose), and at a rate greater than placebo treated patients, in the
Prescribers should caution patients against engaging in hazardous activities randomized, double-blind, placebo-controlled, parallel group clinical study of
requiring mental alertness, such as operating dangerous machinery or motor adjunctive AED therapy for 15 weeks (Study 1).
vehicles, until the effect of ONFI is known [see Warnings and Precautions]. Table 3. Adverse Reactions Reported for 5% of Patients and More Frequently
Potentiation of Sedation from Concomitant Use with Central Nervous System than Placebo in Any Treatment Group
Depressants: Since ONFI has a central nervous system (CNS) depressant effect, ONFI Dose Level
patients or their caregivers should be cautioned against simultaneous use with Placebo Lowa Mediumb Highc All ONFI
other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS N=59 N=58 N=62 N=59 N=179
depressant drugs or alcohol may be potentiated [see Warnings and Precautions]. % % % % %
Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided. Gastrointestinal Disorders
ONFI should be tapered by decreasing the dose every week by 5-10 mg/day
Vomiting 5 9 5 7 7
until discontinuation [see Dosage and Administration]. As with all antiepileptic
drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating Constipation 0 2 2 10 5
seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms Dysphagia 0 0 0 5 2
have been reported following abrupt discontinuance of benzodiazepines. The General Disorders and Administration Site Conditions
more severe withdrawal symptoms have usually been limited to patients who Pyrexia 3 17 10 12 13
received excessive doses over an extended period of time, followed by an Irritability 5 3 11 5 7
abrupt discontinuation. Generally milder withdrawal symptoms have been Fatigue 2 5 5 3 5
reported following abrupt discontinuance of benzodiazepines taken continuously Infections and Infestations
at therapeutic doses for several months [see Warnings and Precautions]. Upper respiratory 10 10 13 14 12
Serious Dermatological Reactions: Serious skin reactions, including Stevens- tract infection
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported Pneumonia 2 3 3 7 4
with ONFI in both children and adults during the post-marketing period. Patients
Urinary tract infection 0 2 5 5 4
should be closely monitored for signs or symptoms of SJS/TEN, especially during
the rst 8 weeks of treatment initiation or when re-introducing therapy. ONFI should Bronchitis 0 2 0 5 2
be discontinued at the rst sign of rash, unless the rash is clearly not drug-related. Metabolism and Nutrition Disorders
If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed Decreased appetite 3 3 0 7 3
and alternative therapy should be considered [see Warnings and Precautions]. Increased appetite 0 2 3 5 3
Physical and Psychological Dependence: Patients with a history of substance Nervous System Disorders
abuse should be under careful surveillance when receiving ONFI or other Somnolence or Sedation 15 17 27 32 26
psychotropic agents because of the predisposition of such patients to habituation Somnolence 12 16 24 25 22
and dependence [see Drug Abuse and Dependence]. Suicidal Behavior and Sedation 3 2 3 9 5
Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal
Lethargy 5 10 5 15 10
thoughts or behavior in patients taking these drugs for any indication. Patients
treated with any AED for any indication should be monitored for the emergence Drooling 3 0 13 14 9
or worsening of depression, suicidal thoughts or behavior, and/or any unusual Ataxia 3 3 2 10 5
changes in mood or behavior. The increased risk of suicidal thoughts or behavior Psychomotor hyperactivity 3 3 3 5 4
with AEDs was observed as early as one week after starting drug treatment with Dysarthria 0 2 2 5 3
AEDs and persisted for the duration of treatment assessed. Because most trials Psychiatric Disorders
included in the analysis did not extend beyond 24 weeks, the risk of suicidal Aggression 5 3 8 14 8
thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal Insomnia 2 2 5 7 5
thoughts or behavior was generally consistent among drugs in the data analyzed. Respiratory Disorders
The nding of increased risk with AEDs of varying mechanisms of action and
Cough 0 3 5 7 5
across a range of indications suggests that the risk applies to all AEDs used for any
indication. The relative risk for suicidal thoughts or behavior was higher in clinical
a
Maximum daily dose of 5 mg for 30 kg body weight; 10 mg for >30 kg body weight
trials for epilepsy than in clinical trials for psychiatric or other conditions, but the
b
Maximum daily dose of 10 mg for 30 kg body weight; 20 mg for >30 kg body weight
absolute risk differences were similar for the epilepsy and psychiatric indications.
c
Maximum daily dose of 20 mg for 30 kg body weight; 40 mg for >30 kg body weight
Anyone considering prescribing ONFI or any other AED must balance the risk of Post Marketing Experience: These reactions are reported voluntarily from
suicidal thoughts or behavior with the risk of untreated illness. Should suicidal a population of uncertain size; therefore, it is not possible to estimate their
thoughts and behavior emerge during treatment, the prescriber needs to consider frequency or establish a causal relationship to drug exposure. Adverse reactions
whether the emergence of these symptoms in any given patient may be related to are categorized by system organ class. Blood Disorders: Anemia, eosinophilia,
the illness being treated. Patients, their caregivers, and families should be informed leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred;
that AEDs increase the risk of suicidal thoughts and behavior and should be advised Gastrointestinal Disorders: Abdominal distention; Investigations: Hepatic
of the need to be alert for the emergence or worsening of the signs and symptoms of enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders:
depression, any unusual changes in mood or behavior, or the emergence of suicidal Agitation, anxiety, apathy, confusional state, depression, delirium, delusion,
thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be hallucination; Respiratory Disorders: Aspiration, respiratory depression;
reported immediately to healthcare providers [see Warnings and Precautions]. Skin and Subcutaneous Tissue Disorders: Rash, Stevens-Johnson syndrome
ADVERSE REACTIONS Because clinical trials are conducted under widely (SJS) and toxic epidermal necrolysis (TEN), urticaria.
varying conditions, adverse reaction rates observed in the clinical trials of a DRUG INTERACTIONS Effect of ONFI on Other Drugs: ONFI is a weak CYP3A4
drug cannot be directly compared to rates in the clinical trials of another drug inducer. As some hormonal contraceptives are metabolized by CYP3A4,

2
their effectiveness may be diminished when given with ONFI. Additional
non-hormonal forms of contraception are recommended when using ONFI
[see Clinical Pharmacology, Patient Counseling Information]. ONFI inhibits
CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary
[see Clinical Pharmacology]. Effect of Other Drugs on ONFI: Strong and moderate
inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam,
the active metabolite of clobazam. This may increase the risk of dose-related
adverse reactions. Dosage adjustment of ONFI may be necessary when
coadministered with strong CYP2C19 inhibitors (e.g., uconazole,
uvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole)
[see Clinical Pharmacology]. CNS Depressants and Alcohol: Concomitant use of
ONFI with other CNS depressants may increase the risk of sedation and somnolence
[see Warnings and Precautions].
USE IN SPECIFIC POPULATIONS Pregnancy - Pregnancy Registry: To provide
information regarding the effects of in utero exposure to ONFI, physicians are advised to
recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic
Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number
1-888-233-2334, and must be done by patients themselves or their caregiver. Information
on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
Pregnancy Category C: There are no adequate and well-controlled studies of ONFI
in pregnant women and no adequate developmental toxicity studies of clobazam in
animals. Although limited, the available animal data suggest developmental toxicity,
including an increased incidence of fetal abnormalities following oral administration
of clobazam to pregnant animals at doses similar to those used clinically. Data
for other benzodiazepines suggest the possibility of adverse effects in animals
and humans. Long-term effects on neurobehavioral and immunological function
have been reported in rodents following prenatal exposure to benzodiazepines.
Neonatal accidity, respiratory and feeding difculties, hypothermia, and
withdrawal symptoms have been reported in infants born to mothers who
received benzodiazepines, including clobazam, late in pregnancy. Therefore, ONFI
should be used during pregnancy only if the potential benet justies the potential
risk to the fetus [see Use in Specic Populations]. Nursing Mothers: ONFI is
excreted in human milk. The effects of this exposure on infants are unknown
[see Use in Specic Populations]. Pediatric Use: The safety and effectiveness
in patients less than 2 years of age have not been established. In a study in
which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats
during the juvenile period of development (postnatal days 14 to 48), adverse
effects on growth (decreased bone density and bone length) and behavior
(altered motor activity and auditory startle response; learning decit) were
observed at the high dose. The effect on bone density, but not on behavior,
was reversible when drug was discontinued. The no-effect level for juvenile
toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to
clobazam and its major active metabolite, N-desmethylclobazam, less than
those expected at therapeutic doses in pediatric patients. Geriatric Use:
Clinical studies of ONFI did not include sufcient numbers of subjects aged
65 and over to determine whether they respond differently from younger subjects.
However, elderly subjects appear to eliminate clobazam more slowly than younger
subjects based on population pharmacokinetic analysis. For these reasons, the
initial dose in elderly patients should be 5 mg/day. Patients should be titrated
initially to 10-20 mg/day. Patients may be titrated further to a maximum daily dose
of 40 mg if tolerated [see Dosage and Administration, Clinical Pharmacology].
CYP2C19 Poor Metabolizers: Concentrations of clobazams active metabolite,
N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in
extensive metabolizers. For this reason, the initial dose in patients known
to be CYP2C19 poor metabolizers should be 5 mg/day. Dose titration
should proceed slowly according to weight to 10-20 mg/day, and may be
titrated further to a maximum daily dose of 40 mg on day 21 based upon
clinical response [see Dosage and Administration, Clinical Pharmacology].
Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with
mild and moderate renal impairment. There were no signicant differences
in systemic exposure (AUC and Cmax) between patients with mild or moderate
renal impairment and healthy subjects. No dose adjustment is required for
patients with mild and moderate renal impairment. There is essentially no
experience with ONFI in patients with severe renal impairment or ESRD.
It is not known if clobazam or its active metabolite, N-desmethylclobazam,
is dialyzable [see Dosage and Administration, Clinical Pharmacology].
Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited
data to characterize the effect of hepatic impairment on the pharmacokinetics of
ONFI. For this reason, the initial dose in patients with mild to moderate hepatic
impairment (Child-Pugh score 5-9) should be 5 mg/day. These patients should be
titrated according to weight to 10 to 20 mg/day, and may be titrated further to a
maximum daily dose of 40 mg on day 21 based upon clinical response. There is
inadequate information about metabolism of ONFI in patients with severe hepatic
impairment. Therefore no dosing recommendation in those patients can be given
[see Dosage and Administration, Clinical Pharmacology].
DRUG ABUSE AND DEPENDENCE Controlled Substance: ONFI contains
clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be
abused in a similar manner as other benzodiazepines, such as diazepam. The
pharmacological prole of ONFI is similar to that of other benzodiazepines
listed in Schedule IV of the Controlled Substance Act, particularly in its
potentiation of GABAergic transmission through its action on GABAA
receptors, which leads to sedation and somnolence. The World Health
Organization epidemiology database contains reports of drug abuse, misuse,
and overdoses associated with clobazam [see Drug Abuse and Dependence].
Dependence: In clinical trials, cases of dependency were reported following
abrupt discontinuation of ONFI. The risk of dependence is present even with use
of ONFI at the recommended dose range over periods of only a few weeks. The
risk of dependence increases with increasing dose and duration of treatment.
The risk of dependence is increased in patients with a history of alcohol or
drug abuse. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal
symptoms. As with other benzodiazepines, ONFI should be withdrawn
gradually [see Dosage and Administration, Warnings and Precautions].
In ONFI clinical pharmacology trials in healthy volunteers, the most common
withdrawal symptoms after abrupt discontinuation were headache, tremor,
insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea
[see Warnings and Precautions]. Other withdrawal reactions to clobazam reported
in the literature include restlessness, panic attacks, profuse sweating, difculty in
concentrating, nausea and dry retching, weight loss, blurred vision, photophobia,
and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause
seizures, psychosis, and hallucinations [see Warnings and Precautions].
OVERDOSAGE Signs and Symptoms of Overdosage: Overdose and
intoxication with benzodiazepines, including ONFI, may lead to CNS
depression, associated with drowsiness, confusion and lethargy, possibly
progressing to ataxia, respiratory depression, hypotension, and, rarely,
coma or death. The risk of a fatal outcome is increased in cases of combined
poisoning with other CNS depressants, including alcohol [see Overdosage].
Management of Overdosage: The management of ONFI overdose may include
gastric lavage and/or administration of activated charcoal, intravenous uid
replenishment, early control of airway and general supportive measures, in addition
to monitoring level of consciousness and vital signs. Hypotension can be treated
by replenishment with plasma substitutes and, if necessary, with sympathomimetic
agents. The efcacy of supplementary administration of physostigmine
(a cholinergic agent) or of umazenil (a benzodiazepine antagonist) in ONFI overdose
has not been assessed. The administration of umazenil in cases of benzodiazepine
overdose can lead to withdrawal and adverse reactions. Its use in patients with
epilepsy is typically not recommended [see Management of Overdosage].
Lundbeck
Deereld, IL 60015, U.S.A.
ONFI is a registered trademark of Lundbeck
November 2013
CLB-L-00001a
3
 Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369 | 1-800-654-2299
2014 Upsher-Smith Laboratories, Inc. 109864.01
4
Booth 823

5
 FRIDAY November 30, 2007

UCB welcomes
you to AES
Visit us at booth 205 for exciting new
information on VIMPAT for your patients.

VIMPAT is a registered trademark under license from Harris FRC Corporation.

2014, UCB, Inc., Smyrna, GA 30080.

All rights reserved. LCM-PRM-035038-0914

6
 Visit the 1 in 3
readers take action as a result
AES Booth of reading AES Connections
in their inbox every other Friday
to
n Socialize
n Watch Video Interviews

n Review Publications

n See Live Demos

n Learn More About AES

See You at Booth #125 AES Connections

in the Exhibit Hall
Become an Engaged Member

AES Career Center ...Great Conversation

...Connected Community
Your hub for hundreds of jobs, maximum
exposure to top opportunities, and highly ...Different Perspectives
qualified applicants
Clinical and research positions for epilepsy and Share Yours Today
neurology professionals
Easy-to-use and highly targeted resources for
AES Connect
online employment connections connect.aesnet.org
Access to the National Healthcare Career
Network (NHCN), connecting you to the career
centers of over 290 top healthcare associations
and professional organizations.

careers.aesnet.org

7
 WELCOME MESSAGE

Welcome to Seattle and our 68th AES Annual Meeting!

To previous attendees, we are thrilled to have you back. To first time attendees, it is a pleasure to
welcome you into the AES Community. As you settle in and start off your week, I encourage you to take
notice of the energy within the convention center. I like to refer to the Annual Meeting as the Annual
Reunion, a time when colleagues, friends and even family, reunite under the common goal to cure the
epilepsies. I assure you that your time in Seattle will be filled with learning, networking and fun. Dont
forget to connect with the larger AES Community on Twitter #aesmtg14.
Within this program book you will find a broad schedule of programs, exhibits, social events and
networking opportunities that invite your participation. Quality educational sessions have been organized
by your AES Annual Meeting and Scientific Program Committees targeted to the professional needs and
wide interests of meeting attendees. This years lineup of programs was carefully selected based on your
feedback:
n Poster Walking Tours Take a stroll through the Exhibit Hall and experience an enhanced learning
opportunity as authors present their posters throughout the week. Enjoy this feature of the AES
meeting by joining one of the popular Poster Walking Tours led by thought leaders. See page 15 for the
schedule.
n Fellows Program We are proud to continue the AES Epilepsy Fellows Program, which supports 95
trainees in epilepsy fellowships, and 10 Ph.D.s doing epilepsy research. Fellows are paired with mentors
for career guidance and support, giving them the opportunity to learn and connect with others
throughout the meeting.
n Social Networking Groups SIG, Investigators Workshops and symposium participants have a greater
opportunity to meet and continue group discussions during social networking hours on Sunday from
8:00 p.m. to 10:00 p.m.
n Annual Meeting Mobile App Access meeting information. Network with fellow attendees. Even
organize your schedule at your fingertips! If you have not done so already, download the AES Annual
Meeting App to your smartphone.
I invite you to join me at that this years Presidential Symposium, The AES International Biomarker Competition:
The Crowd, the Cloud, Detection and Prediction, taking place on Saturday, December 6 from 8:30 a.m. to
11:45 a.m. Together we will find out who the winners are and their novel solutions in seizure detection
and prediction. This session is a must see, I guarantee it!
Have a great meeting!

Elson So, M.D.

President, American Epilepsy Society

2014 AES BOARD OF DIRECTORS

PRESIDENT
Elson L. So, M.D.
FIRST VICE PRESIDENT
Amy Brooks-Kayal, M.D.
SECOND VICE PRESIDENT
Michael D. Privitera, M.D.
TREASURER
William D. Gaillard, M.D.
PAST PRESIDENT
Jacqueline A. French, M.D.
BOARD MEMBERS
Bruce E. Hermann, Ph.D.
David M. Labiner, M.D.
Jack M. Parent, M.D., Ph.D.
Helen E. Scharfman, Ph.D.
Shlomo Shinnar, M.D., Ph.D.
Karen S. Wilcox, Ph.D.
EX-OFFICIO
Eileen M. Murray, MM, CAE, AES Executive Director
Brandy Fureman, Ph.D. (NIH/NINDS)
Philip Gattone (Epilepsy Foundation)
Sheryl Haut, M.D. (North American Commission / ILAE)
Robert E. Hogan , M.D. (Education)
Jaideep Kapur, M.D., Ph.D. (Development)
Kimford J. Meador, M.D. (Research)
Joseph I. Sirven, M.D. (Epilepsy Foundation PAB)
Carl E. Stafstrom, M.D., Ph.D. (Epilepsy Currents)
William H. Theodore, M.D. (Communications & MOC Liaison)
James W. Wheless, M.D. (Clinical Council & AAN Liaison)

8
 TABLE OF CONTENTS

Schedule-at-a-Glance ..............................................................................12
Poster Walking Tours ...............................................................................15
Poster Schedule .........................................................................................17

TABLE OF CONTENTS
Meeting
AES Special Recognition ......................................................................18
Berry, Grass and Nurse Awardees ............................................20 Watch for
Information Young Investigator Awardees ..........................................................21
Special Interest Group Schedule .................................................22 these
Scientific Exhibit Schedule .................................................................23
Exhibitor Locations ...................................................................................82
2015 dates!
Abstract Author Index ...........................................................................93
General Information ...............................................................................120
Faculty Ready Room and Photos ..............................................122
Annual Meeting
Epilepsy Specialist Symposium ......................................................28 Call for Abstracts
Annual Fundamentals of Epilepsy Symposium .................28
Available
28th Annual Advances in the Management of
Epilepsy and the Epilepsy Clinic .................................................29 March 1, 2015
FRIDAY Professional Development in AES ...............................................29
Special Interest Group Meetings ................................................29
Hoyer Lecture ................................................................................................30
Spanish Symposium ..................................................................................30
Special Interest Group Meetings ................................................30 AES Research
Recognition
Mentoring Session for Junior Investigators .....................32 and Distinguished
Special Interest Group Meetings ................................................32
Achievement Awards
Presidential Symposium........................................................................33
SATURDAY Antiepileptic Therapy Symposium ................................................33 Nominations
Investigators Workshop ......................................................................34 August 1, 2015
Professionals in Epilepsy Care Symposium ........................34
North American Commission Symposium ............................35
Poster Session 1 ........................................................................................36

AES 2015
Investigators Workshops ...................................................................47
Annual Course ................................................................................................49 Annual Meeting
SUNDAY
Special Interest Group Meetings ................................................50 December 4 - 8
Social Networking Groups ..................................................................50 Philadelphia, PA
Poster Session 2 ........................................................................................51
Pennsylvania Convention Center

Special Interest Group Meetings ................................................61

Merritt-Putnam Symposium .............................................................61
Special Interest Group Meetings ................................................62
Lennox and Lombroso Lecture .......................................................62
MONDAY Investigators Workshop ......................................................................63
FDA Town Hall Update ............................................................................63
Pediatric Epilepsy Highlights Session......................................63
Pediatric State of the Art Symposium ..................................64
Platform Sessions ......................................................................................65
Poster Session 3 ........................................................................................66

Special Interest Group Meetings ................................................77

TUESDAY Hot Topics Symposium ...........................................................................78
Scientific Symposium ..............................................................................78

AES is an ACCME accredited provider.

9
 Lighten your load and receive session handouts
and important meeting information electronically!
Accounts have been pre-created for all
pre-registered attendees.
On-site registrants may sign up online.
For instructions:
Please refer to the flyer provided in your
meeting bag or for further details go to
www.aesnet.org/meetings_events/
annual_meeting/general_info

Questions
virtualTotebag Support Desk: 410.402.1062 Go here:
email: support@virtualtotebag.com www.aesnet.org/meetings_events/
annual_meeting/meeting_app

The AES Annual Meeting

is at your fingertips!

Stay up to the minute about sessions, schedules,

conversations and activities at the 68th Annual Meeting.

#AESMTG14 official meeting hashtag

Wi-Fi available throughout Convention Center
(except in the Exhibit Hall and Poster Sessions)

American Epilepsy Society

10
 is proud to recognize the following supporters
of the 2014 Annual Meeting.

Benefactor Level
$500,000 +
Sunovion Pharmaceuticals, Inc.

Leader Level
$250,000 $499,999
Eisai, Inc.
UCB, Inc.

Partner Level
$100,000 $249,999
Lundbeck Pharmaceuticals, Inc.
Upsher-Smith Laboratories, Inc.

Supporter Level
$50,000 $99,999
Cyberonics, Inc.
Natus Neurology Incorporated
Supernus Pharmaceuticals, Inc.
Mallinckrodt Pharmaceuticals
Acorda Therapeutics

Contributor Level
$25,000 $49,999
Nihon Kohden America, Inc.
Cadwell Laboratories, Inc
Compumedics Limited
Pfizer Inc.

Advocate Level
$10,000 $24,999
Neuropace, Inc.
ELEKTA
Electrical Geodesics, Inc.
GW Pharmaceuticals
Medtronic, Inc.
Blackrock Microsystems, LLC

Patron Level
$5,000 $9,999
Rhythm Link
Ad-Tech Medical Instrument Corp.
Monteris Medical, Inc.
Medical Neurogenetics, LLC
Nexstim, Inc.
Neurolynx, Inc.
PMT Corporation
Ripple LLC
Lifelines Neurodiagnostics Systems, Inc.
The Jack Pribaz Foundation
Listing is in order of support level as of October XX, 2014
Listing is in order of support level as of October 21, 2014 11
 SCHEDULE-AT-A-GLANCE

THURSDAY December 4
5:00 p.m. - 7:00 p.m. Registration
Convention Center South Lobby, Level 4

FRIDAY December 5
7:00 a.m. - 6:00 p.m. Registration 3:30 p.m. - 5:30 p.m. Hoyer Lecture
Convention Center South Lobby, Level 4 Convention Center Ballroom 6E, Level 6
8:30 a.m. - 11:30 a.m. Epilepsy Specialist Symposium: 3:30 p.m. - 6:00 p.m. Spanish Symposium: Complementary and
The Generalized Epilepsies Alternative Approaches to Epilepsy Treatments
Convention Center Ballroom 6E, Level 6 Convention Center Room 612, Level 6
12:30 p.m. - 3:00 p.m. Annual Fundamentals of Epilepsy Symposium: 5:30 p.m. - 6:15 p.m. Symposia Break
The Side Effects of Epilepsy Treatment Convention Center Level 6
Convention Center Ballroom 6E, Level 6 6:00 p.m. - 7:30 p.m. Special Interest Group Meetings
1:30 p.m. - 3:00 p.m. Professional Development in AES: A Program See page 30
for Junior Members and Those in Transition
Convention Center Room 603, Level 6
Special Interest Group Meetings
See page 29

SATURDAY December 6

6:30 a.m. - 6:00 p.m. Registration
Convention Center South Lobby, Level 4
6:30 a.m. - 7:00 a.m. Continental Breakfast
Convention Center Level 6
7:00 a.m. - 8:30 a.m. Mentoring Session for Junior Investigators
Convention Center Room 307 / 308, Level 3
7:00 a.m. - 8:30 a.m. Special Interest Group Meetings
See page 32
8:30 a.m. - 11:45 a.m. Presidential Symposium: The AES International
Biomarker Competition: The Crowd, the Cloud,
Detection and Prediction
Convention Center Ballroom 6C, Level 6
Noon - 6:00 p.m. Exhibit Hall Grand Opening
Convention Center Hall 4B, Level 4
Poster Session 1
Convention Center Hall 4B, Level 4
Lunch: Noon - 1:00 p.m.
2:15 p.m. - 5:00 p.m. Antiepileptic Therapy Symposium:
The New AEDs: Where Do They Belong in
Your Armamentarium?
Convention Center Ballroom 6C, Level 6
2:30 p.m. - 4:00 p.m. Investigators Workshop
Convention Center Ballroom 6E, Level 6
5:00 p.m. - 6:00 p.m. Symposium Break
Convention Center Hall 4B, Level 4
5:15 p.m. - 7:45 p.m. Professionals in Epilepsy Care Symposium:
Practical Applications for the Comprehensive
Treatment of Epilepsy
Convention Center Ballroom 6C, Level 6
5:30 p.m. - 7:30 p.m. North American Commission Symposium:
Pediatric Epilepsy Surgery: Update on Current
Practice
Convention Center Ballroom 6E, Level 6
7:00 p.m. - 10:00 p.m. Third Annual Wine Tasting and Silent Auction
See page 27

SUNDAY December 7
7:30 a.m. - 6:00 p.m. Registration 8:45 a.m. - 5:15 p.m. Annual Course: Seizures and EEG in the
Convention Center South Lobby, Level 4 Critically Ill Patient
8:00 a.m. - 5:00 p.m. Scientific Exhibits Convention Center Ballroom 6C, Level 6
See page 23 10:00 a.m. - 6:00 p.m. Exhibit Hall
8:00 a.m. - 6:00 p.m. Poster Session 2 Reception: Suds for Science 5:00 p.m. - 6:00 p.m.
(includes late-breaking abstracts) Convention Center Hall 4B, Level 4
Continental Breakfast 6:00 p.m. - 7:30 p.m. Special Interest Group Meetings
Convention Center Hall 4B, Level 4 See page 50
8:45 a.m. - 4:45 p.m. Investigators Workshops 8:00 p.m. - 10:00 p.m. Social Networking Groups
IW Posters / Boxed Lunch: Noon - 1:30 p.m. Sheraton Madrona, Second Floor
See page 47

12
 SCHEDULE-AT-A-GLANCE

MONDAY December 8

SCHEDULE-AT-A-GLANCE
6:30 a.m. - 6:00 p.m. Registration 2:15 p.m. - 3:00 p.m. Lennox and Lombroso Lecture
Convention Center South Lobby, Level 4 Convention Center Ballroom 6C, Level 6
6:30 a.m. - 7:00 a.m. Continental Breakfast 3:00 p.m. - 4:30 p.m. Investigators Workshop
Convention Center Level 6 Convention Center Room 607, Level 6
7:00 a.m. - 8:30 a.m. Special Interest Group Meetings 3:00 p.m. - 5:00 p.m. FDA Town Hall Update: SUDEP and
See page 61 Clinical Trials
8:00 a.m. - 3:00 p.m. Poster Session 3 Convention Center Room 612, Level 6
Continental Breakfast 3:00 p.m. - 5:15 p.m. Pediatric Epilepsy Highlights Session
Convention Center Hall 4B, Level 4 Convention Center Ballroom 6E, Level 6
8:00 a.m. - 5:00 p.m. Scientific Exhibits Platform Sessions (3 Concurrent)
See page 23 See page 65
8:45 a.m. - Noon Merritt-Putnam Symposium: Stress, 5:00 p.m. - 5:30 p.m. Symposia Break
Cannabinoids and Epilepsy: The Science Convention Center Level 6
Behind the Buzz 5:30 p.m. - 8:00 p.m. Pediatric State of the Art Symposium:
Convention Center Ballroom 6C, Level 6 Long-term Outcomes of Neonatal Seizures
9:00 a.m. - 10:30 a.m. Special Interest Group Meetings Convention Center Ballroom 6C, Level 6
See page 62
10:00 a.m. - 3:00 p.m. Exhibit Hall
Convention Center Hall 4B, Level 4

TUESDAY December 9

6:30 a.m. - 11:00 a.m. Registration 8:45 a.m. - 10:45 a.m. Hot Topics Symposium: Epilepsy Updates
Convention Center South Lobby, Level 4 Convention Center Ballroom 6C, Level 6
6:30 a.m. - 7:00 a.m. Continental Breakfast Scientific Symposium: The Epidemiology,
Convention Center Level 6 Pathophysiology & Prevention of SUDEP
7:00 a.m. - 8:30 a.m. Special Interest Group Meetings Convention Center Ballroom 6E, Level 6
See page 77

Suds for Science and

Exhibit Hall Reception EQUIPMENT AUCTION TO BENEFIT:
Sunday, December 7
The Lennox and Lombroso Trust
5:00 p.m. 6:00 p.m. for Research & Training
Convention Center Hall 4B, Level 4 and The Susan S. Spencer Fund for
Network with attendees from
Clinical Education and Research
around the world at the general
reception in the Exhibit Hall. Join
us for appetizers and visit AES thanks Natus
Sunovion Pharmaceuticals at
Booth #105 to receive your complimentary
for participating in the
drink tickets. A portion of the funds received equipment auction.
from support and beverage sales will benefit
the Lennox and Lombroso Trust.

Supported by Sunovion Pharmaceuticals, Inc.

13
 EQUIPMENT AUCTION TO BENEFIT:
The Lennox and Lombroso Trust for Research & Training
and
The Susan S. Spencer Fund for Clinical Education and Research

EEG Machine Becomes Research Dollars for AES

For six years, Nihon Kohden has pioneered a unique giving program by auctioning off its EEG-1200 machine and
donating 100 percent of the proceeds to the Lennox and Lombroso Trust for Research & Training and the Susan S.
Spencer Fund for Education and Research.
This year, Dignity Health Neurological Institute of Northern California (Sacramento) is the EEG-1200 Auction winner
at $23,263.75.
Nihon Kohden executives will present a check to the American Epilepsy Society on Saturday, December 6 at
1:00 p.m. on the floor of the Exhibit Hall.
AES thanks Nihon Kohden Booth #617 for their continued support and for again participating in the annual
equipment auction. We also thank those that participated in the bidding.

The American Epilepsy Society

is pleased to announce

INNOVATION PAVILIONS
located inside the Exhibit Hall Convention Center Hall 4B, Level 4

These pavilions offer companies an opportunity to provide education and training

to Annual Meeting attendees in a convenient and more personal environment.

The Innovation Pavilions will be open on the following days:

Saturday, December 6: Noon 6:00 p.m.

Sunovion Pharmaceuticals, Inc. (A) Lundbeck Pharmaceuticals, Inc. (B)
NeuroPace, Inc. (C) Cyberonics, Inc. (D)

Sunday, December 7: 10:00 a.m. 6:00 p.m.

Sunovion Pharmaceuticals, Inc. (A) Lundbeck Pharmaceuticals, Inc. (B)
NeuroPace, Inc. (C) Cyberonics, Inc. (D)

Monday, December 8: 10:00 a.m. 3:00 p.m.

Eisai, Inc. (C)

14
 Poster Walking Tours
Convention Center Exhibit Hall 4B, Level 4

The Poster Walking Tours will take place on the days noted below,
beginning at 12:15 p.m. each day, and tours will depart every 10 minutes.

Join AES leaders and visit interesting, compelling or novel posters and discuss perspectives on how the presented data is meaningful.

Leaders and participants will meet and gather at the Poster Information table near the front of the Poster Hall. Announcements will be made
in the Poster Hall prior to each tour departure. A schedule of topics and tour leaders will be available at the Poster Information Table.

POSTER SESSION 1: Saturday, December 6

Poster tour leaders: David Prince, Andres Kanner, Jean Gotman,
Bruce Hermann, Karen Wilcox
POSTER SESSION 2: Sunday, December 7
Poster tour leaders: Jackie French, Ilo Leppik, Steve Roper,
Joseph Sirven, Andrew Cole
POSTER SESSION 3: Monday, December 8
Poster tour leaders: Anne Anderson, Greg Bergey, Dennis Spencer,
Kimford Meador, Eric Kossoff

Poster tour leaders are subject to change

Join us in the Epilepsy Resource Center (located in the

Participate in the AES Exhibit Hall) for daily prize drawings and a grand prize
drawing on Monday, December 8.

PASSPORT Prize Drawing Schedule:

TO PRIZES SATURDAY, DECEMBER 6

Prize Drawing 5:30 p.m.

PROGRAM SUNDAY, DECEMBER 7

Prize Drawing 5:30 p.m.
MONDAY, DECEMBER 8
Prize Drawing & Grand Prize Drawing 2:30 p.m.

In your AES Annual Meeting bag, as well as the virtualTotebag,

you will find a Passport brochure. To be included in the drawing
to win a variety of great prizes, visit the booths of participating
exhibitors to get your Passport validated. The more exhibitors
you visit, the better your chances.

Please complete your contact information and drop the passport

in the raffle drum located in the Epilepsy Resource Center.
Participants must be present to win. See your Passport for a
list of participating exhibitors.

15
 colleague COMMUNITYfriend
fellow inspire innovation GRATITUDE
THANKYOU
applause
insight
COLLABORATION catalyst
mentor
appreciation

mentee admiration
CARING
Show your appreciation to
Someone Who.....
Has influenced your career or your work in epilepsy

Is someone you admire

Has been a great colleague or collaborator

Is celebrating a personal or professional milestone

The Community of Caring pin symbolizes the collaborative energy, the community
spirit and the supportive professional exchange among AES members.

Pins are available for sale at the AES Booth #125 in the Exhibit Hall.

All proceeds will benefit the AES New Initiatives Fund, supporting research and education
to advance the prevention, treatment and cure of epilepsy.

Those who purchase and receive pins will be recognized in a special way during the
Annual Meeting.

Community of Caring Pin

16
 POSTER SCHEDULE
Detailed map of the Poster Hall is available in the virtualTotebag and at the Poster Information Table

Saturday, December 6
Poster Session 1: Noon 6:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 36-46)
Authors Present: Noon 2:00 p.m.

POSTER SCHEDULE
Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15)

Translational Research 1.001 1.078

Behavior / Neuropsychology / Language 1.079 1.101
Genetics 1.102 1.121
Neuropathology of Epilepsy 1.122
Neurophysiology 1.123 1.180
Clinical Epilepsy 1.181 1.232
Neuroimaging 1.233 - 1.269
Comorbidity (Somatic and Psychiatric) 1.270 1.293
Antiepileptic Drugs 1.294 1.345
Surgery 1.346 1.377

Sunday, December 7
Poster Session 2: 8:00 a.m. 6:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 51-60)
Authors Present: Noon 2:00 p.m.
Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15)

Behavior / Neuropsychology / Language 2.001 2.030

Health Services 2.031 2.060, 2.366
Practice Resources 2.061 2.066
Epidemiology 2.067 2.083
Public Health 2.084 2.097
History of Epilepsy 2.098 2.100
Case Studies 2.101 2.130
Professionals in Epilepsy Care 2.131 2.143
Neurophysiology 2.144 2.163
Clinical Epilepsy 2.164 2.234
Neuroimaging 2.235 2.256
Comorbidity (Somatic and Psychiatric) 2.257 2.275
Antiepileptic Drugs 2.276 2.333
Surgery 2.334 2.365

Investigators Workshop Lunch Poster Session

Noon 1:30 p.m.
Convention Center Room 6F, Level 6 (see pages 47-48)

Monday, December 8
Poster Session 3: 8:00 a.m. 3:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 66-75)
Authors Present: Noon 2:00 p.m.
Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15)

Translational Research 3.001 3.074

Behavior / Neuropsychology / Language 3.075 3.085
Genetics 3.086 3.107
Neuropathology of Epilepsy 3.108 3.125
Epidemiology 3.126 3.145
Neurophysiology 3.146 3.195
Clinical Epilepsy 3.196 3.253
Neuroimaging 3.254 3.287
Antiepileptic Drugs 3.288 3.317
Non-AED / Non-Surgical Treatments 3.318 3.342
Surgery 3.343 3.375

Abstract Author Index see pages 93-108

17
 AES SPECIAL RECOGNITION
AES Service Award Co-Recipients
Friday, December 5 3:30 p.m.
Convention Center Ballroom 6E, Level 6
(Immediately preceding the
Hoyer Lecture)
Robert L. Ruff, M.D., Ph.D.
Dr. Robert Ruff is a Professor of Neurology and Neurosciences at Case Western Reserve
University. He has been the VAs National Director for Neurology for eight years. Dr. Ruff
received his M.D. and Ph.D. in Physiology and Biophysics from the University of Washington.
He did his Neurology Residency at New York Hospital Cornell Medical Center.
Served as Chief of Neurology at the Cleveland VAMC, Chairman of the Neurology Field
Advisory Committee, and oversaw the operations of the six Parkinsons Disease Research,
Educational, and Clinical Centers (PADRECC), four Epilepsy Centers of Excellence (ECoE), and
the two Multiple Sclerosis Centers of Excellence (MSCoE). Under his direction, the ECoEs,
PADRECC and MSCoE developed into national neurology care networks with more than 50
sites in each of the networks. Dr. Ruff developed the ECoE program in response to a request
from Congress. Under his leadership, the ECoE program passed through a trail period which
demonstrated its value to veterans and the ECoE program will be continuously funded.
In addition, Dr. Ruff served as the VAs Acting Director, Rehabilitation Research and
Development Service. Dr. Ruff is Medical Director of the Functional Stimulation Center at Case
Western Reserve University School of Medicine. He also serves as the Deputy Editor, Journal
of Rehabilitation Research and Development.
The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research.
The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for the improved understanding and
treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program.
Award for Basic Science
Saturday, December 6 8:30 a.m.
Convention Center Ballroom 6C, Level 6
(Immediately preceding the
Presidential Symposium)
Carolyn R. Houser, Ph.D.
Dr. Carolyn Houser is Professor of Neurobiology in the David Geffen School of Medicine at
the University of California, Los Angeles. She received her Doctoral degree in Anatomy from
UCLA, and completed postdoctoral training in the Division of Neuroscience at the City of Hope
Research Institute, Duarte, CA. Dr. Houser then joined the Comprehensive Epilepsy Program at
the VA Greater Los Angeles Healthcare System and the faculty of the Department of
Neurobiology at UCLA.
Dr. Housers research has focused on neuroanatomical alterations and plasticity in epilepsy.
Her studies provided the first descriptions of granule cell dispersion in patients with temporal
lobe epilepsy and contributed to the early descriptions of mossy fiber sprouting in humans
with epilepsy. Dr. Housers studies have been published in leading journals of neuroscience,
neurology and epilepsy, and have provided a neuroanatomical foundation for numerous
electrophysiological and neurochemical studies in the field.
Dr. Houser is strongly committed to education in neuroscience and has received numerous
teaching awards. Her service to the profession has includes AES Committees boards and
Committees of the Epilepsy Foundation, NIH and other epilepsy-related organizations, and
Chair of a recent Gordon Research Conference.
18
AES Service Award Co-Recipients
Friday, December 5 3:30 p.m.
Convention Center Ballroom 6E, Level 6
(Immediately preceding the
Hoyer Lecture)
Karen L. Parko, M.D.
Dr. Karen Parko is a Professor of Neurology at the University of California, San Francisco
(UCSF), and the National Director of the Veterans Affairs Epilepsy Centers of Excellence. She
is a retired Commissioned Officer from the United States Public Health Service (USPHS).
Dr. Parko received a B.A. degree in Psychobiology from New York University and an M.D.
degree from the F. Edward Hebert School of Medicine at the Uniformed Services University
in Bethesda, M.D. Following an internship in Internal Medicine at the Washington Hospital
Center in Washington, D.C., she completed a residency in Neurology at UCSF. After residency
she worked in the Indian Health Service as a solo neurologist for ten years on the Navajo
reservation, where she established the reservations first neurology clinic, providing adult and
pediatric neurology services and neurodiagnostic testing to this population of nearly 300,000.
Dr. Parko has been involved in disaster and humanitarian relief medicine and served as a
medical officer aboard NOAA vessel McArthur during its Stenella Mission in the Eastern
Pacific. Dr. Parko serves on the National Professional Advisory Board of the Epilepsy
Foundation and previously chaired the Professional Advisory Board of the Northern
California Chapter.
She has received many awards for her work including being named the Public Health
Service Clinical Physician of the Year in 2001, was a finalist for The Frank Brown Berry
Prize in Federal Healthcare in 2003, and she received the Epilepsy Foundation of
Northern Californias Commitment to Progress Award in 2011.
Award for Clinical Science
Saturday, December 6 8:30 a.m.
Convention Center Ballroom 6C, Level 6
(Immediately preceding the
Presidential Symposium)
Ruth Ottman, Ph.D.
Dr. Ruth Ottman is Professor of Epidemiology (in Neurology and the Sergievsky Center),
Deputy Director for Research, Gertrude H. Sergievsky Center, Columbia University, and
Research Scientist, Division of Epidemiology, New York State Psychiatric Institute. She is also
Deputy Director of the Columbia Center for Research on Ethical, Legal, and Social Implications
of Psychiatric, Neurologic, and Behavioral Genetics. She received her B.A. in zoology and
Ph.D. in genetics from the University of California at Berkeley, and has been at Columbia
University throughout her career.
Dr. Ottman is a genetic epidemiologist whose research addresses the role of inherited factors
in susceptibility to neurologic disorders, primarily focusing on epilepsy. Her research group
was the first to recognize the epilepsy syndrome autosomal dominant epilepsy with auditory
features and to identify LGI1 as a major susceptibility gene for the disorder. She developed
and validated several research instruments for standardized data collection on epilepsy in
large-scale studies. She has recently begun to focus on the clinical and psychosocial impact
of genetic information on individuals with epilepsy and their family. She is a major
collaborator in the Epilepsy Phenome / Genome Project and in the Epi4K Center without
Walls for Collaborative Research in the Epilepsies.
 AES SPECIAL RECOGNITION
J. Kiffin Penry Excellence in
Epilepsy Care Award
Saturday, December 6 2:15 p.m.
Convention Center Ballroom 6C, Level 6
(Immediately preceding the AET Symposium)
Joyce A. Cramer, B.S.
Joyce A. Cramer is now a consultant after a career in basic and clinical research at Yale
University School of Medicine. She also served as President and Chief Scientific Officer of
Epilepsy Therapy Project, a non-profit organization providing grants and investments for
new epilepsy therapies.
Joyce worked in pre-clinical research before initiating several decades of work in clinical
trials. She developed methods for the evaluation of drug efficacy and adverse effects,
study design and management, and enhancement of medication compliance and persistence,
as well as instruments to assess quality of life, treatment satisfaction and other patient-
reported outcomes for various medical disorders. The QOLIE quality of life instruments,
Seizure Severity Questionnaire (SSQ), and Systemic and Neurotoxicity Scales are widely
used in research around the world. A current focus is on development of the Personal
Impact of Epilepsy Scale (PIES).
Her publications include five books, more than 200 peer-reviewed papers, and numerous
book chapters covering a variety of topics. She is a frequent lecturer and consultant on
these topics.
Joyce served as AES Treasurer and on the AES Board of Directors. She was Chair of the
Board of Trustees of the Lennox Trust Fund. She has served on the Boards of Directors of
the International Society for Pharmacoeconomics and Outcomes Research and the Society
for Clinical Trials, as well as the Editorial Boards of Epilepsia and Epilepsy & Behavior and
currently of Acta Neurologica Scandinavica. She has received the ILAE International
Ambassador Award and the AES Service Award.
William G. Lennox Award
Monday, December 8 8:45 a.m.
Convention Center Ballroom 6C, Level 6
(Immediately preceding the Merritt-Putnam
Symposium)
A $10,000 award is provided by the
Lennox and Lombroso Trust Fund
Hans O. Lders, M.D., Ph.D.
Dr. Hans O. Lders is Professor of Neurology and staff at the Epilepsy Center, Case Medical
School, Cleveland, OH. He received his degree in medicine from the Catholic University,
Santiago, Chile and trained in neurology at the Neurological Institute, Kyushu University,
Fukuoka, Japan. He joined the Mayo Clinic as a clinical fellow in Electroencephalography
and received a Ph.D. in Neurophysiology from the University of Minnesota. He trained under
Prof. Eli Goldensohn at the Neurological Institute in New York. He became head of the
Epilepsy Center at the Department of Neurology, Cleveland Clinic Foundation where he
served as Chairman of Neurology until he moved to University Hospital, Case Medical Center,
to lead and develop the epilepsy program.
Dr. Lders established the intensive course in Epilepsy and Clinical Neurophysiology and
developed the highly specialized Epilepsy Surgery Program which are now offered at the
Cleveland Clinic and at University Hospitals. He has edited of more than 19 books including
the most advanced Textbook of Epilepsy Surgery. Dr. Lders established the Cleveland
Clinic International Epilepsy Symposia and the International Epilepsy Colloquia sponsored
by France, Germany, England and Cleveland, OH.
He developed an original, strictly semiological classification of epileptic seizures and the
original description of several semiological seizure types as well as identified several cortical
centers by electrical stimulation of the human brain. Dr. Lders pioneered the use of
subdural electrodes in the presurgical evaluation of epilepsy surgery in the 1980s and is
supporting the introduction from Europe of depth electrodes in the U.S.
Extraordinary Contributions Award
Monday, December 8 2:15 p.m.
Convention Center Ballroom 6C, Level 6
(Immediately preceding the
Lennox and Lombroso Lecture)
AWARDEES
Karen Gale, Ph.D.
Awarded posthumously
The AES community was saddened by the recent passing of, Karen Gale, Ph.D., Professor in
the Department of Pharmacology & Physiology at Georgetown University. During her more
than 35 years at Georgetown, Dr. Gale left an indelible mark as a researcher, educator and
stalwart advocate for faculty, students and staff.
Dr. Gale was a widely recognized expert in seizure circuitry, and the mechanisms of
seizure-induced brain damage and neuroprotection. She was an NIH-funded researcher for
more than 20 years, and the founding director of Georgetowns Interdisciplinary Program in
Neuroscience (IPN) that has 50 faculty members from 11 departments campus-wide.
AES selected Dr. Gale for her pioneering research on the critical roles of subcortical structures,
including the substantia nigra, and on seizure control and propagation that has been seminal
in shaping the understanding about the distributed nature of seizures and how they might be
controlled, and her recent work on comorbidities of epilepsy including deleterious effects of
antiepileptic compounds on neural development.
Dr Gale was also recognized for her tireless commitment to the development of early career
investigators, women and minority scientists in the epilepsy community through mentorship
and advocacy.
Lennox and Lombroso Lecturer
Monday, December 8 2:15 p.m.
Convention Center Ballroom 6C, Level 6
Anne Berg, Ph.D.
Dr. Anne Berg received her Ph.D. from Yale University in 1986. The focus of her research for
over 25 years has been in the area of pediatric seizures and epilepsy with
a specific emphasis on seizure outcomes, developmental and cognitive consequences, the
impact on quality of life and the implications of all of these considerations for care and
care-models. She is the lead investigator of the NINDS-funded Connecticut Study of Epilepsy
which spanned two decades and is providing an unprecedented understanding of the impact
of childhood epilepsy later in early adulthood. In 2007, she played a key role in focusing
NINDS research priorities on the cognitive, developmental, and behavioral comorbidities
of epilepsy and has organized sessions at American Epilepsy Society meetings to investigate
these areas and identify research opportunities for improving patients outcomes. Dr. Berg
was Co-Chair of the 2013 NINDS-sponsored Curing Epilepsies conference and also organized
and led the workshop, Priorities in Pediatric Epilepsy Research: Improving Childrens Futures
Today held in Chicago, November 2013. She helped spearhead the formation of the
Pediatric Epilepsy Research Consortium (PERC) which has grown to 37 centers nationwide and
is laying the foundation and creating the infrastructure for practice-changing clinical research
to improve the diagnosis, treatment, and outcomes of children with pediatric epilepsies.
Dr. Berg received a Jacob K. Javits Neuroscience Investigator Award from NINDS in 2007
and the American Epilepsy Society Research Recognition Award for Clinical Research, 2008.
19
 SUZANNE AND PETER BERRY
INTERNATIONAL TRAVEL AWARDEES

This award is given to recognize and honor two young investigators doing research in clinical neuroscience related to epilepsy in Asia, Africa, Oceania,
Middle East or Latin America by supporting travel to present research at the AES Annual Meeting.
Contact Author Abstract Title Poster
Leyla Baysal Kirac, M.D. Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies: 1.128
Possible Prediction of Patients at Risk For SUDEP

Rie Sakuraba, M.H.Sc. High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity 3.159

GRASS YOUNG INVESTIGATOR AWARDEES

This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy.
Awardees are selected from young investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined
resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the
American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer
Lecture on Friday, December 5. Congratulations to the following awardees:

Contact Author Abstract Title Poster / Platform

Chad R. Frasier, Ph.D. Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes C.02
Have Increased Sodium Current Density And Increased Beating Rate

Ethan M. Goldberg, M.D., Ph.D. A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy C.06
And Cortical Circuit Dysfunction

SeokJun Hong, M.Sc. Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy: B.04
Class II Diagnostic Evidence

Lawrence Hsieh, Ph.D. New Model Of Focal Cortical Dysplasia Associated Epilepsy 3.030

Esther Krook-Magnuson, Ph.D. Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy C.03

Lena H. Nguyen, B.S. Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And Associated Neuropathology 3.050
In The NS-Pten KO Mouse Model Of Cortical Dysplasia

Vineet Punia, M.D., M.S. Factors Influencing Driving Impairment In Persons With Refractory Epilepsy A.02

Jacy Wagnon, Ph.D. Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy C.09

NURSE AWARDEES

Contact Author Abstract Title Poster

Rachael Mealey, M.S.N., CRNP Improving Quality Of Care Following EMU Discharge 2.135

Kimberly Orton, RN To Coordinate Or Not To Coordinate? 2.134

Guinevere T. Que, NP Pregnancy And Seizures: Review Of Practice At George Washington University 2.066
In The Past 5 Years

Patsy Ramey, MSN, RN Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear 1.338
Elimination Kinetics In Some Individuals

Acknowledgment: Nurse awards are supported by Eisai Inc.

20
 YOUNG INVESTIGATOR AWARDEES

Poster /
Contact Author Abstract Title Platform
Karlene T. Barrett, Ph.D. TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During 1.025
Development In Mice

AWARDEES
Monica Dhakar, M.D. Broadband Intracranial Ictal EEG Analysis In Lesional And Non-lesional Pharmacoresistant Epilepsy 3.174

Dario J. Englot, M.D., Ph.D. Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery 1.369

Alejandra M. Fernandez, B.S. A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures In Pilocarpine-Induced 3.342
Epileptic Mice

Federica Frigerio, Ph.D. Pro-Resolving Receptors ChemR23 and ALXR Expression During Epileptogenesis In Mice 1.020

Stephen Gliske, Ph.D. Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone 3.067

Abhijeet Gummadavelli, B.A. Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures 1.044

Se Hee Kim, M.D. Adaptive Function In Dravet Syndrome 3.244

Seongtaek Lee, M.S, B.S. Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures 1.236

Tiffani L. McDonough, M.D. Prediction Of Future Epilepsy In Neonates Who Received Selective Head Cooling For HIE 2.221

Rawad Obeid, M.D. The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic 2.159
Ischemic Encephalopathy Undergoing Hypothermia

Reesha R. Patel, B.S. Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current 1.294
Generation That Could Be Preferentially Targeted With Cannabidiol

Sandra Petty, M.B.B.S, FRACP Ph.D. Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts 1.291

Craig A. Press, M.D., Ph.D. Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For 1.326
Medically Refractory Epilepsy

Rajsekar R. Rajaraman, M.D. Predictive Model For Early Posttraumatic Seizures In The PICU A.09

Udaya K. Seneviratne, FRACP Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies 1.227

Kyle Thomson, Ph.D. Use Of An Automated-Feeding System For The Testing Of Potential Anticonvulsant Compounds 1.050
In Chronic Epileptic Rats

Ebru Nur Vanli-Yavuz, M.D. How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones? 2.224

Matthew Weston, Ph.D. Hyperactivation Of mTOR Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of 1.013
Synaptic Transmission

Jennifer Wong, Ph.D. Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models 3.106
Of Refractory Epilepsy

Ackowledgment: Young Investigator Awards are supported by Eisai Inc. and Medtronic, Inc.

21
 SPECIAL INTEREST GROUP SCHEDULE
Friday, December 5: 1:30 p.m. 3:00 p.m.
n Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal
and Dendritic Homeostasis (Convention Center Room 620, Level 6)
n Neuroimaging: MRI Normalcy A Moving Target!
(Convention Center Room 607, Level 6)
n Quality, Value and Safety: Improving the Epilepsy Monitoring Unit
(Convention Center Room 617, Level 6)
Friday, December 5: 6:00 p.m. 7:30 p.m.
n Cognitive and Behavioral Interventions for Epilepsy: PNES Case
Reports and Underlying Mechanisms
(Convention Center Room 607, Level 6)
n EEG: Dense Array EEG and EEG Source Localization in Clinical Practice
(Convention Center Room 609, Level 6)
n Head Trauma and Military Epilepsy Care: Practical Guide to Caring for
Epilepsy Patients in the VA System
(Convention Center Room 620, Level 2)
n Junior Investigators: Mentorship
(Convention Center Room 615, Level 6)
n Neuropharmacology: Medication Discontinuation Post Surgery: To Do
or Not to Do? (Convention Center Room 617, Level 6)
n SUDEP: Hot Topics in SUDEP
(Convention Center Room 603, Level 6)
Saturday, December 6: 7:00 a.m. 8:30 a.m.
n Basic Neuroscience: Brain Mosaicism in Epilepsy (Convention Center
Room 607, Level 6)
n Childrens Hour: Dravet Syndrome in 2014
(Convention Center Room 609, Level 6)
n Ictal Semiology Cases: How Semiology Helps to Localize the Seizure
Onset Zone and Elucidate the Propagation Pattern
(Convention Center Room 612, Level 6)
n Neurostimulation and Neuroengineering: New Developments
(Convention Center Room 603, Level 6)
n Private Practice: How to Survive with Private Epilepsy Centers in the
Changing Health Care Environment
(Convention Center Room 617, Level 6)
n Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis
and Treatment Issues (Convention Center Room 615, Level 6)
Sunday, December 7: 6:00 p.m. 7:30 p.m.
n Drug Resistant Epilepsy Definition, Epidemiology, Predictors,
Using Big Data for Epidemiological Research (Convention Center
Room 617, Level 6)
n Frontal Lobe Epilepsy: Semiology and Cognitive Aspects
(Convention Center Room 608, Level 6)
n MEG / MSI Source Imaging (MSI) Source Localization Results: Blind
Faith, Black Art, or Scientific Method?
(Convention Center Room 620, Level 6)
n Neonatal Seizures: Should We Pursue Comparative Effectiveness
Studies for the Treatment of Neonatal Seizures?
(Convention Center Room 609, Level 6)
22
n Neuroendocrinology: Sex Differences in Epileptogenesis
(Convention Center Room 613, Level 6)
n Pediatric Case Discussions
(Convention Center Room 612, Level 6)
n Psychogenic Nonepileptic Seizures: What Can We Learn From PNES
Semiology? (Convention Center Room 615, Level 6)
Monday, December 8: 7:00 a.m. 8:30 a.m.
n Ketogenic Diet: Does the Ketogenic Diet Offer a Cure for Epilepsy?
(Convention Center Room 613, Level 6)
n Neuropsychology: Can We Spare Memory With Newer Surgical
Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data
from Laser Ablation, Multiple Hippocampal Transection, and Fornix
DBS (Convention Center Room 609, Level 6)
n NINDS and Non-Profit Research Resources
(Convention Center Room 620, Level 6)
n Nursing (Convention Center Room 608, Level 6)
n Status Epilepticus Are We Over-Treating Status Epilepticus, and
Especially, Nonconvulsive Status Epilepticus?
(Convention Center Room 612, Level 6)
Monday, December 8: 9:00 a.m. 10:30 a.m.
n NEW Epilepsy and Aging
(Convention Center Room 620, Level 6)
n Surgery: Surgical Failure in Pediatric and Adult Epilepsy: The Slam
Dunk Case that Wasnt! (Convention Center Room 609, Level 6)
n Tuberous Sclerosis: Thinking Outside the Tuber in TSC
(Convention Center Room 612, Level 6)
Tuesday, December 9: 7:00 a.m. 8:30 a.m.
n Critical Care (ICU EEG Monitoring): Controversies in ICU EEG
Interpretation and Management
(Convention Center Room 612, Level 6)
n Genetics: Personalized Epilepsy Diagnosis and Treatment
(Convention Center Room 613, Level 6)
n NEW Global Health in Epilepsy: How Can You Get Involved?
(Convention Center Room 603, Level 6)
n Practice Management (Convention Center Room 618, Level 6)
n Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We
Missing A Diagnostic / Therapeutic Opportunity?
(Convention Center Room 606, Level 6)
n Temporal Lobe Club: The Thalamus in Epilepsy Player or Bystander?
(Convention Center Room 620, Level 6)
n Tumor Induced Epilepsy Meningiomas
(Convention Center Room 604, Level 6)
n Womens Issues: Controversies in Caring for Women with Epilepsy
(Convention Center Room 615, Level 6)
 SCIENTIFIC EXHIBIT SCHEDULE

Scientific exhibits will be on display at this years annual meeting and will be located in
Rooms 603, 604, 607, 612 and 615 on Level 6 of the Washington State Convention Center.
These exhibits will provide meeting attendees an opportunity to update themselves on the
latest research. Authors will be present throughout the exhibit.

Sunday, December 7 8:00 a.m. 11:00 a.m.

Room
Cyberonics, Inc. 603
VNS Therapy: Foundational Treatment for Drug-Resistant Epilepsy

Lundbeck Pharmaceuticals, Inc. 607

Research Updates for Antiepileptic Therapies Clobazam, Vigabatrin, and IV Carbamazepine

UCB, Inc. 612

Continuing UCBs Long-Term Commitment to Epilepsy Management

Sunday, December 7 8:00 a.m. 5:00 p.m.

EQUIGEN 604
Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation

Monday, December 8 8:00 a.m. 11:00 a.m.

Upsher-Smith Laboratories, Inc. 603

Upsher-Smith CNS Update

Sunovion Pharmaceuticals, Inc. 607

Aptiom (eslicarbazepine acetate) Scientific Exhibit Room

Sage Therapeutics 615

Clinical Progress of SAGE-547 in Status Epilepticus and Advances in Next-Generation Neurosteroids

Monday, December 8 8:00 p.m. 5:00 p.m.

EQUIGEN 604
Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation

23
 CHARACTERS!
OUR CAST OF
JOIN
WALK FOR AES
RESEARCH & TRAINING

RAISE FUNDS FOR EPILEPSY RESEARCH & TRAINING

The National Walk for Epilepsy
Washington, D.C. April 11, 2015
Walk with your colleagues! Join Lorna Myers, Nathan Fountain, Patrice Jackson-Ayotunde,
Dennis Spencer, Martin Penry, Elson So, Jaideep Kapur, Mike Privitera, Jacqueline French, Patty Shafer,
and many others for the 2015 National Walk for Epilepsy.
All funds raised by AES Teams Support AES Research and Training efforts even virtual teams
can participate! Teams can support any AES fund: Spencer, Lennox and Lombroso, Dreifuss,
Penry, Goldberg-Kaufman and New Initiatives Fund.

Raise the most money and win the AES trophy!

Sign up or get more information today!
Contact Kathy Hucks at 860-586-7505 x512 or khucks@aesnet.org.

24
Your place for ongoing professional education in epilepsy.

ELI is the new AES online tool offering quick

access to:
n Relevant CME-based programs for epilepsy
n Tailored Self-Assessments in Epilepsy (SAEs)
n Rich archived educational content
n Easy portal to AES partner projects for epilepsy
n Organized records for self-directed learning

Its all here at:

aesnet.org/professional_education
AES is an ACCME accredited provider.

25
 in !
Jo day
To
WHY JOIN THE AMERICAN EPILEPSY SOCIETY?
The American Epilepsy Society serves as a resource for its membership and the epilepsy community by providing
access to data on the latest breakthroughs, technologies and methodologies in epilepsy research.
The American Epilepsy Society promotes interdisciplinary communication, scientific investigation and exchange of
clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and
knowledge-sharing among its members and Annual Meeting attendees.
Become a member today by going to www.AESnet.org or visit the AES Booth #125 at the AES Annual Meeting located in
the Exhibit Hall.

AES MEMBERS ARE:

n Adult Neurologists n Internists n Psychiatrists
n Advanced Practice Nurses n Licensed Practical Nurses n Psychologists
n Basic Science Researchers n Neurosurgeons n Physicians Assistants
n Clinical Researchers n Non-Profit Staff n Registered Nurses
n Consultants n Nutritionists n Residents
n Doctors of Osteopathic Medicine n Office Managers n Social Workers
n Doctors of Veterinary n Pediatric Neurologists n Students
Medicine n Pharmacists n Technologists
n Emergency Room Physicians n Pharmacologists n and Others
n Epileptologists n Presidents/CEOs in
n Fellows Industry
n Government/Regulatory n Industry/Marketing
Professionals

AES MEMBERS RECEIVE:

n Epilepsy Currents, the official journal of AES
n Epilepsia, the official journal of ILAE
n Reduced annual meeting registration fees
n Discounted subscriptions to scientific journals
n Listing in Find-A-Doctor online directory
n Network with members through AES Connect
n Members-only discussion blogs
n Research funding opportunities
n Distinguished Achievement and Research Recognition Awards
n Weekly e-newsletters with relevant, timely news
n Full service career center

26
 Raise Your Glass for the...
Third Annual Wine Tasting
& Silent Auction
Join your friends, colleagues and hosts Mike Privitera, Greg Bergey and Dennis Spencer
in an evening to benefit the Susan S. Spencer Fund and Lennox and Lombroso Trust

Featuring locally sourced cuisine and hand-selected regional wines for your enjoyment.

Saturday, December 6th

7:00 PM to 10:00 PM
Where: 1927 EVENTS n 1927 3rd Avenue, Seattle, WA
a short stroll from the Convention Center!

Purchase your tickets today at the solutions counter at the

registration desk, Convention Center, South Lobby, Level 4.

More than 12,000 people visit the AES website each month
-- are you one of them?
The NEW AES website features:
Fresh news and daily updates

Dynamic content
Online community forum for AES members
www.AESNET.org
Mobile friendly content
Learning and research opportunities

JOIN US ON THE AES SITE TODAY!

27
 AES Fellows Program Friday, December 5, 2014
The goal of the AES Fellows program is to encourage and support epilepsy fellows in training to attend the AES Annual Meeting where they will receive the
latest updates in clinical and basic science research. A breakfast and lunch will be provided to allow fellows the opportunity to meet and pair with mentors
who will provide guidance regarding career planning, potential research paths, and clinical endeavors. Following the breakfast the fellows will attend the
Epilepsy Specialist Symposium and the Annual Fundamentals of Epilepsy Symposium, as well as the Hoyer Lecture. A panel of experts will present and discuss
their experiences in the fields of research, and clinical and private practice. This program is supported by UCB, Inc., Eisai, Inc., Supernus Pharmaceuticals, Inc.,
Upsher-Smith Laboratories, Inc. and Acorda Therapeutics.
8:30 a.m. 11:30 a.m. 12:30 p.m. 3:00 p.m.
Epilepsy Specialist Symposium: Annual Fundamentals of Epilepsy Symposium:
The Generalized Epilepsies The Side Effects of Epilepsy Treatment
(3.0 CME Credits) Convention Center Ballroom 6E, Level 6 (2.5 CME Credits) Convention Center Ballroom 6E, Level 6

Overview Overview
This symposium will address current knowledge regarding generalized This activity will provide comprehensive information about the potential side
epilepsies including idiopathic, symptomatic and progressive generalized effects of different epilepsy therapies, not limited to the usual side effects of
epilepsies. Faculty will address current understanding of their pathophysiology, antiepileptic drugs. Included will be a synopsis of the adverse effects that can
review data regarding prognosis and criteria for diagnosis, and discuss be encountered from treatment of seizures and epilepsy providing a
management options for patients with generalized epilepsies.
comprehensive overview that will assist in tailoring treatment to individual
Learning Objectives patients. The speakers will discuss antiepileptic drug side effects; side effects
of acute treatments for epilepsy (especially status epilepticus); side effects of
u Develop treatment plans and provide counseling based on current
devices that provide neuromodulation (VNS, RNS, DBS); side effects of epilepsy
understanding of the pathophysiology of generalized epilepsies and their
surgery evaluation and epilepsy surgery; and side effects of other treatments
prognosis
(diet, hormones, cannabinoids, herbal medications).
u Apply current criteria in diagnosing generalized epilepsies
u Recognize behavioral and cognitive comorbidities of generalized epilepsies Learning Objectives
and provides appropriate interventions. u Implement appropriate medical treatment based on improved understanding
of potential adverse effects of treatment options
Target Audience u Refer patients earlier in course of treatment for consideration of surgery or
Basic and Intermediate (see page 120 for details) for use of a device for seizure control
u Counsel patients more knowledgeably about the potential adverse effects of
Program their treatment and helps identify potential hazards arising from treatment
Chair: Michael R. Sperling, M.D. u Help patients communicate effectively about their care, including identifying
8:30 a.m. Introduction previously unrecognized adverse effects of their treatment
Michael R. Sperling, M.D. u Identify treatment-related cognitive and emotional adverse effects of newly
8:45 a.m. Pathophysiology of the Generalized Epilepsies emergent and alternative treatments.
Solomon L. Mosh, M.D. Target Audience
Basic and Intermediate (see page 120 for details)
9:15 a.m. Seizure Types and Syndromes in the Generalized Epilepsies
Prakash Kotagal, M.D. Program
9:45 a.m. Prognosis of the Generalized Epilepsies Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and Tracy A. Glauser, M.D.
Katherine Nickels, M.D. 12:30 p.m. Introduction
10:15 a.m. Treatment of the Idiopathic Generalized Epilepsies Tracy A. Glauser, M.D.
Michael S. Duchowny, M.D.
12:40 p.m. Antiepileptic Drug Side Effects
10:45 a.m. Treatment of Symptomatic and Progressive Generalized Eugen Trinka, M.D., M.Sc.
Epilepsies
Sandra L. Helmers, M.D., M.P.H. 1:05 p.m. Side Effects of Acute Treatments for Epilepsy
David M. Treiman, M.D.
11:15 a.m. Case Studies and Conclusions
Michael R. Sperling, M.D. 1:30 p.m. Side Effects of Devices (VNS, RNS, DBS)
Credit Designation Robert S. Fisher, M.D., Ph.D.
The American Epilepsy Society designates this live activity for a maximum of
1:55 p.m. Side Effects of Epilepsy Surgery Evaluation and Epilepsy
3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity. Resective Surgery
Mary L. Zupanc, M.D.
Nurses may claim up to 3.0 contact hours for this session.
2:20 p.m. Side Effects of Other Treatments (Diet, Hormones,
Pharmacy Credit Cannabinoids, Herbal Medications)
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-028-L01-P. Initial Kristen Park, M.D.
Release Date: 12/5/2014. 2:45 p.m. Conclusions
ABPN Core Competencies Elinor Ben-Menachem, M.D., Ph.D.
The American Board of Psychiatry and Neurology has reviewed the Epilepsy
Specialist Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS Continued on page 29
as a necessary component of maintenance of certification.
Core Competencies: Practice-based Learning and Improvement, and Medical
Knowledge
Acknowledgment
This program is supported by an educational grant from Eisai, Inc.
28
 FRIDAY December 5, 2014
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Nurse Practitioners may claim 1.5 hours of pharmacology for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-029-L01-P.
Initial Release Date: 12/5/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Annual
Fundamentals of Epilepsy Symposium and has approved this program as part
of a comprehensive lifelong learning program, which is mandated by the
ABMS as a necessary component of maintenance of certification.
Core Competencies: Patient Care, Medical Knowledge and System-based
Practice
Acknowledgment
This program is supported by an educational grant from UCB, Inc., Eisai, Inc.
and Lundbeck Pharmaceuticals, Inc. with additional support from Supernus
Pharmaceuticals, Inc. and Cyberonics, Inc.
separate registration required see below for instructions
9:00 a.m. 3:15 p.m.
28th Annual Advances in the Management of
Epilepsy and the Epilepsy Clinic
Sheraton Metropolitan Ballroom A, Level 3
This intensive, one-day conference is designed for those professionals who
participate in the care of persons with epilepsy. The overall purpose is to improve
services to individuals and families affected by epilepsy. The conference is
presented by the Department of Neurology of Wake Forest University School of
Medicine, Winston-Salem, North Carolina, through an unrestricted grant
committed to the education of health professionals, in an effort to promote the
comprehensive care of those with epilepsy and their families.
Registration for this program is done separately from the AES Annual Meeting
and begins on September 1, 2014. You may register by calling Wake Forest
School of Medicine at 800.642.0500.
Up to 5.0 AMA Category 1 CME credit will be given.
1:30 p.m. 3:00 p.m.
Professional Development in AES: A Program
for Junior Members and Those in Transition
Convention Center Room 603, Level 6
The American Epilepsy Society invites all interested meeting attendees to come
to a special session on volunteer and leadership opportunities within the Society.
AES has a variety of programs year round to improve the care and treatment of
patients with epilepsy. These efforts include education for basic scientists and
clinicians, research grant programs, leadership and organizational activities,
community outreach and advocacy. Greater participation in the Society offers
members extensive career development opportunities by providing a chance to
hone leadership skills, to network with other AES members and outside funding
organizations, and most importantly, to make significant contributions to improve
the lives of patients with epilepsy.
This session will be useful to trainees, basic scientists, clinicians and other allied
health professionals (nurses, psychologists, Pharm.D.s) who want to know more
about AES organizational structure or who want to become more involved. The
session will provide an overview of the professional development and volunteering
opportunities within the Society, followed by short presentations by members
active in AES leadership. The session will end with a chance to meet with AES
staff and committee leaders to learn more about available opportunities.
FRIDAY
1:30 p.m. 3:00 p.m.
Special Interest Group Meetings
Location listed under each session
Basic Mechanisms: Inflammation, Microglia and Their Role
in Neuronal and Dendritic Homeostasis
Convention Center Room 620, Level 6
Coordinators: Amy L. Brewster, Ph.D., Dane M. Chetkovich, M.D., Ph.D.
Speakers: Sookyong Koh, M.D., Ph.D., Robert S. Fujinami, Ph.D.,
Viji Santhakumar, Ph.D.
Activation of inflammatory mechanisms that include recruitment of reactive
microglia and associated signaling molecules such as cytokines and
complement cascade activation, among others, are often seen in surgical
resections from individuals with epilepsy and have been widely described
before, during, and after seizures in experimental models. The goal of this
session is to discuss potential mechanisms by which inflammatory mediators
may contribute to pathological epileptogenic changes in the brain.
Neuroimaging: MRI Normalcy A Moving Target!
Convention Center Room 607, Level 6
Coordinators: Matthias J. Koepp, M.D., Ph.D., Neda Bernasconi, M.D., Ph.D.
Speakers: Boris Bernhardt, M.D., R. Edward Hogan, M.D., William D. Gaillard, M.D.
About 30% of patients with electrographic evidence of temporal lobe epilepsy
(TLE) have normal MRI scans. The location of the seizure focus is unclear in this
patient population. Possibilities include (i) a subtle form of hippocampal sclerosis
that is not apparent on MRI; (ii) alterations in synaptic or receptor physiology not
visible on MRI; or (iii) pathology not detected by MRI, such as certain forms of
cortical dysplasia. Patients with MRI-negative TLE may be candidates for
additional neuroimaging techniques including advanced MR imaging with novel
acquisition or post-processing techniques, MRS, PET, and SPECT. Peri-ictal
imaging may increase the yield to detect abnormalities. This SIG will focus on the
management of MRI-normal TLE, emphasizing the neuroimaging perspective.
Quality, Value and Safety: Improving the Epilepsy
Monitoring Unit
Convention Center Room 617, Level 6
Coordinator: Katherine Noe, M.D., Ph.D.
Speakers: Gabriel U. Martz, M.D., Nathalie Jett, M.D., Khara M. Sauro, Ph.D.,
Janice Walbert, R.EEG/EPT
This years SIG will focus on current efforts to improve the quality, safety, and value
of care provided in epilepsy monitoring units. Reduction in 30-day readmission
rates is an ongoing focus of quality improvement efforts for all hospitalized patients,
and influences payments to hospitals from the Centers for Medicare and Medicaid
Services. Dr. Gabriel Martz, from the Medical University of South Carolina will
present his research into EMU readmissions. Continuing prior discussions on ways
to improve the patient experience in the EMU, Dr. Nathalie Jett and colleague
Dr. Khara Sauro will discuss their unique experience with a multidisciplinary EMU
Quality Improvement Team at the University of Calgary. Finally, Janice Walbert,
Executive Director of ABRET, will describe their challenges / successes to date in
developing and implementing certification of EEG laboratories. Time will be
available for audience questions and discussion.
29
 FRIDAY December 5, 2014
3:30 p.m. 5:30 p.m.
12th Judith Hoyer Lecture in Epilepsy:
Reshaping Epilepsy As a Spectrum Disorder:
Implications for Clinical Care, Research and
Education
Convention Center Ballroom 6E, Level 6
Presentation: Robert L. Ruff, M.D., Ph.D. and
Karen L. Parko, M.D., AES Service Awards, NINDS Update
Lecturer: Frances Jensen, M.D.
The 12th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer
Dr. Frances Jensen, is sponsored by the National Institute of Neurological
Disorders and Stroke. Dr. Jensens presentation is the twelfth in a series of
lectures highlighting the promise of epilepsy research. This series is held in
memory of Mrs. Judith Hoyer, an active member of the Board of Directors of
the Epilepsy Foundation and the late wife of Representative Steny Hoyer
(D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy
and promoting research into a cure and a better quality of life for those with
the disorder. The purpose of the lecture is to raise awareness of epilepsy
among researchers and the public and provide intellectual stimulation that will
encourage continuing progress toward finding a cure for epilepsy.
Supported in part by Upsher-Smith Laboratories, Inc. and NINDS.
3:30 p.m. 6:00 p.m.
Spanish Symposium: Complementary and
Alternative Approaches to Epilepsy Treatments
(2.5 CME Credits)
Convention Center Room 612, Level 6
Overview
This symposium will present an overview on the role of neurostimulation, diet,
vitamins and other supplements, herbal therapies, non-conventional medical
treatments (acupuncture, cannabis, others), and psychological and Mind-body
therapies (biofeedback, meditation, yoga, relaxation techniques) in the
treatment of epilepsy. Treatment paradigms and evidence-based approach will
be addressed. As a result of attending this symposium, the attendee will
recognize alternative treatments when managing patients with medically
refractory epilepsy and become familiar with current evidence and rationale
for their use, allowing for consideration of neurostimulation and other available
alternative treatment options.
Learning Objectives
u Utilize newer as well as established treatments such as neurostimulation,
dietary therapy and other alternative methods as therapeutic options in
refractory epilepsy
u Counsel families regarding neurostimulation and alternative therapies
based on currently defined indications
u Treat patients with refractory epilepsy through use of alternative
treatments not previously considered
u Recognize the value of treating refractory epilepsy through use of new
techniques such as mind-body techniques and psychological therapy.
Target Audience
Basic and Intermediate (see page 120 for details)
Program
Co-Chairs: Patricio E. Abad, M.D. and Mario A. Alonso-Vanegas, M.D.
3:30 p.m. Introduction
Patricio E. Abad, M.D.
3:40 p.m. Neurostimulation for Epilepsy
David King-Stephens, M.D.
30
4:10 p.m. Dietary Measures, Vitamins and Other Supplements,
Herbal Therapies
Carlos Medina-Malo, M.D.
4:40 p.m. Non-conventional Medical Treatments, Mind-body
Therapies
Blanca Vazquez, M.D.
5:10 p.m. Round Table
Mario A. Alonso-Vanegas, M.D., Patricio Abad, M.D.
5:50 p.m. Conclusions
Mario A. Alonso-Vanegas, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-030-L01-P.
Initial Release Date: 12/5/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Spanish
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competencies: Patient Care, Medical Knowledge, Practice-based
Learning and System-based Practice
6:00 p.m. 7:30 p.m.
Special Interest Group Meetings
Location listed under each session
Cognitive and Behavioral Interventions for Epilepsy:
PNES Case Reports and Underlying Mechanisms
Convention Center Room 607, Level 6
Coordinators: Lauren Frey, M.D., Marcio Sotero de Menezes, M.D.,
Rosa Michaelis, M.D., Steven C. Schachter, M.D., Siegward M. Elsas, M.D.
Speakers: Ivan Osorio, M.D., W. Curt LaFrance, Jr., M.D., M.P.H.,
Janelle Wagner, Ph.D.
Cognitivebehavioral therapy, mindbody approaches, and multimodal
educational interventions have consistently demonstrated positive effects
on patient well-being. Nevertheless, the evidence for their effects on seizure
control remains inconsistent, which is partly attributable to the
methodological difficulties inherent in rigorously testing these interventions.
In the first part of this SIG, Dr. Osorio will present observations from invasive
EEG monitoring that inform the hypothesis for a possible physiological
antiseizure mechanism of cognitive tasks. In the second part, we will review
case-based tools that may help SIG participants identify suitable candidates
for behavioral interventions, select appropriate interventions and monitor
intervention outcomes. A number of experienced therapists will demonstrate
how their therapeutic approaches would work in practice.
Dense Array EEG and EEG Source Localization in Clinical
Practice
Convention Center Room 609, Level 6
Coordinators: Kitti Kaiboriboon, M.D., Susan T. Herman, M.D.
Speakers: Susan T. Herman, M.D., Kitti Kaiboriboon, M.D.,
Serge Vulliemoz, M.D.
This SIG will review the use of dense array (64 or more channels) EEG and EEG
source localization for routine EEG and epilepsy monitoring. Routine EEG using
21 scalp electrodes has excellent temporal but relatively poor spatial resolution,
 FRIDAY December 5, 2014
limiting its utility in localization of epileptiform activity and seizures. Recent
advances in amplifier technology and electrode technology now allow recording
of 128-256 channels of EEG. EEG source imaging (ESI) is a model-based imaging
technique that determines the inverse EEG solution, or the generating source
of electrical potentials recorded on the scalp. Improved ESI software can now
build realistic head models based on individual patients MRIs, perform source
localization, and co-register results to imaging studies in less time and without
need for programming skills. These advances now put dense array EEG and ESI
tools in the hands of clinical electroencephalographers, but the clinical utility of
these techniques has not yet been fully explored. Speakers will debate the pros
and cons of dense array EEG in comparison to other techniques used for
epilepsy diagnosis and localization.
Head Trauma and Military Epilepsy Care: Practical Guide to
Caring for Epilepsy Patients in the VA System
Convention Center Room 620, Level 6
Coordinators: Tung Tran, M.D., Jonathan Halford, M.D.,
Enrique A. Feoli, M.D., Joseph Drazkowski, M.D.
Speakers: Tung Tran, M.D. and Kenneth R. Perrine, Ph.D.
We will discuss how epilepsy care in the VA system is different from epilepsy
care outside of a Veterans Affairs Medical Center (VAMC). Specifically, we
will discuss (1) how the VA medication formulary system works on a local
VAMC and national level and changes to the formulary for 2014 (2) technical
challenges to setting up a neurophysiology lab in a VAMC (3) the structure of
VA administration and how to request expansion of services for epilepsy care
at your VAMC and (4) an update on progress to develop the VA Epilepsy
Centers of Excellence (ECoEs) and what services they can provide non-ECoE
VAMCs. This SIG is designed to dovetail with a book, VA Epilepsy Manual
that is being prepared now (editor Aatif Husain, M.D.) and will be published a
few months before this SIG and will be handed out at this SIG meeting.
Junior Investigators: Mentorship
Convention Center Room 615, Level 6
Coordinators: William Stacey, M.D., Ph.D. and Mackenzie Cervenka, M.D.
Speakers: Kevin J. Staley, M.D., Gregory K Bergey, M.D.,
Frances E. Jensen, M.D.
Whether you are a clinician, a researcher, or both, effective mentorship is
critical to your academic success. Our interactive panel will discuss and
answer questions about finding and utilizing mentors at this early stage in
your career. Topics will include the importance of mentorship in grant
proposals, finding faculty positions, and collaborations. This panel discussion
is independent of the AES mentoring program, which attendees are also
encouraged to attend.
Neuropharmacology: Medication Discontinuation Post
Surgery: To Do or Not to Do?
Convention Center Room 617, Level 6
Coordinators: Jeannine Conway, Pharm.D., M.D. and Laura Strom, M.D.
Speakers: Laura Strom, M.D. and Pei Shieen Wang, Pharm.D.
This SIG brings together individuals in a debate format with an interest in
anticonvulsants and optimizing their use. This years session will address the
FRIDAY
decision to discontinue anticonvulsants post surgery; encouraging audience
participation. We will also discuss the practical challenges that can occur as
medication is being withdrawn, including adverse reactions and medication
interactions. Upon completion of the session, the participant should be able to
present reasonable options to their patients about making a decision about
medication discontinuation.
SUDEP: Hot Topics in SUDEP
Convention Center Room 603, Level 6
Coordinators: Elizabeth J. Donner, M.D. and Lawrence J. Hirsch, M.D.
Speakers: TBA
Our understanding of SUDEP is moving forward thanks to a broad range of
research including animal models, the search for clinical biomarkers, and
collaborative work with coroners, medical examiners and device developers.
This year, we will delve into hot topics with experts in the field. Speakers and
topics will be selected based on cutting-edge SUDEP-related research
presented at this AES meeting and at the recent Partners Against Mortality in
Epilepsy (PAME) conference. Ample time will be allowed for discussion with
audience members.
Supported by Sunovion Pharmaceuticals, Inc.
Get Your Annual Meeting
CME /CE Credit Online
Go to www.AESnet.org
See page 120 for details
31
 AES 68TH ANNUAL MEETING
SATURDAY December 6, 2014
www.AESnet.org
7:00 a.m. 8:30 a.m.
Mentoring Session for Junior Investigators
Convention Center Room 307 / 308, Level 3
Pre-application required
This program is targeted to fellows, postdoctoral researchers, instructors and
assistant professor level junior faculty. Epilepsy professionals at the Associate
Professor level will volunteer to serve as mentors. Accepted applicants will
meet with their assigned mentors during this time.
7:00 a.m. 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Basic Neuroscience: Brain Mosaicism in Epilepsy
Convention Center Room 607, Level 6
Coordinators: Martin Gallagher, M.D., Ph.D., Laura A. Jansen, M.D., Ph.D.
Speakers: Annapurna Poduri, M.D., Laura A. Jansen, M.D., Ph.D.,
Kathleen Millen, Ph.D., Franck K. Kalume, Ph.D.
The speakers will present an overview of genetic mosaicism in the brain,
studies of mosaic PI3K/AKT pathway mutations in human brain
malformations, and animal models of PI3K/AKT pathway activation.
Implications for the diagnosis and treatment of epilepsy in patients with
malformations of cortical development will be highlighted, and plenty of time
will be available for audience questions and discussion.
Childrens Hour: Dravet Syndrome in 2014
Convention Center Room 609, Level 6
Coordinators: Elaine C. Wirrell M.D., Lieven Lagae, M.D., Ph.D.
Speakers: Joseph Sullivan, M.D., Sarah Weckhuysen, M.D.,
Rima Nabbout, M.D., Ph.D.
In recent years, considerable progress has been made in the diagnosis and
treatment of Dravet syndrome. The speakers will focus on these clinically
relevant new achievements and present the key clinical features, guide us
through the complex genetic background and discuss the newer treatment
options in this drug-resistant childhood epilepsy syndrome. The goal of this
SIG is to be able to recognize a young child with Dravet Syndrome, to order
the right genetic testing and to apply standard and newer treatment options.
Supported by Acorda Therapeutics and GW Pharmaceuticals.
Ictal Semiology Cases How Semilogy Helps to Localize the
Seizure Onset Zone and Elucidate the Propagation Pattern
Convention Center Room 612, Level 6
Coordinators: Phillipe Kahane, M.D., Ph.D., Charles A. Szabo, M.D.
Speakers: Charles A. Szabo, M.D., Philippe Kahane, M.D., Ph.D.,
Hans O. Lders, M.D., Ph.D., Andrew Bleasel, M.D.
We will be presenting 4-8 cases of patients undergoing epilepsy surgery. The
cases will be primarily discussed in strong interaction with the audience
based on seizure semiology, to show how the careful analysis of subjective
and observable clinical elements help to localize the seizure onset zone and to
reconstruct the propagation pattern. The final explanation will be briefly given
at the end of each case presentation, based on intracranial EEG and / or
surgical result.
32
Seattle, WA
Neurostimulation and Neuroengineering: New Directions
Convention Center Room 603, Level 6
Coordinators: Christopher DeGiorgio, M.D., Catherine Schevon, M.D., Ph.D.,
Steven J. Schiff, M.D., Ph.D.
Speakers: Marom Bikson, Ph.D., Robert Fisher, M.D., Ph.D.,
Selim Benbadis, M.D.
The SIG will focus on the following topics: Transcranial Magnetic Stimulation
for the Treatment of Epilepsy Seizure Detection Devices: Detection Strategies,
Sensitivity, and Clinical Impact; Controversies in Neurostimulation 2014-2015:
An Interactive Debate with Audience Participation. The topics will be followed
by a period of interactive discussion.
Private Practice: How to Survive with Private Epilepsy
Centers in the Changing Health Care Environment
Convention Center Room 617, Level 6
Coordinators: Marcelo E. Lancman, M.D., Pavel Klein, M.D.
Speakers: John S. Ebersole, M.D., David J. Anschel, M.D.,
Thomas H. Swanson, M.D.
We will discuss several topics related to the ability of private practice centers
to survive and thrive in the fast-changing healthcare environment. First, we
will discuss the dramatic changes underway in many communities of large
academic institutions and hospital chains buying out private practice
physicians and how this may impact private epilepsy centers in terms of
competition, referral patterns, hospital access, and hospital and insurance
contract negotiations. Second, we will discuss the impact of ACA on the
practice of epilepsy at private centers the competing forces of decreased
utilizations (increased co-pays and physician access restriction vs. potential
increased coverage of previously uninsured patients with epilepsy); and the
flux/chaos (changes in insurance policies and insurance among insured
patients). Third, we will address the increased burden on time and resources
of both insurance and governmental requirements of medication and
procedure authorizations and denials, which have accelerated remarkably in
the last 12-24 months. Fourth, to end on a positive note, we will highlight
possibilities for how to compete in this changing environment, e.g. by offering
highly specialized services such as MEG by virtue of greater control over
resources, and of routine services at better access by virtue of flexibility and
responsiveness; and how in in both areas, super-specialized epilepsy care and
the routine epilepsy care private centers can have a competitive advantage
over large academic centers and hospital chains.
Supported by Acorda Therapeutics.
Psychiatry in Epilepsy: Aggression in People with Epilepsy,
Diagnosis and Treatment Issues
Convention Center Room 615, Level 6
Coordinators: John J. Barry, M.D., Rochelle Caplan, M.D.
Speakers: Mary Wojnaroski, Ph.D., Michael Kerr, M.B.ChB., FRCPSYCH
Aggressive behaviors in individuals with epilepsy have been a controversial
topic. The association of aggression or violence with epilepsy has been
debated despite being reproduced in some animal models and may have
significant psychological and environmental consequences. The Psychiatric
SIG will focus on 1) Evidence-based diagnostic and treatment options for
aggressive behaviors in children and adolescents and 2) Aggression in adults
appearing in the post-ictal state, especially affiliated with comorbid psychosis
and finally 3) Aggression seen in individuals with developmental delay. The
format of the SIG will utilize cases for both children and adults as a nidus for
group discussion.
Supported by Sunovion Pharmaceuticals, Inc.
 SATURDAY December 6, 2014
8:30 a.m. 11:45 a.m.
Presidential Symposium: The AES
International Biomarker Competition: The
Crowd, the Cloud, Detection and Prediction
(2.25 CME Credits)
Convention Center Ballroom 6C, Level 6
Presentation: Carolyn R. Houser, Ph.D. and
Ruth Ottman, Ph.D., Research Awards, ILAE Update
Overview
This symposium will address the role of electrophysiological biomarkers in
diagnosis, localization, and prediction of focal seizures and epilepsy. We
review the current state of the art of electrophysiological biomarkers in
epilepsy. Utilizing a large electrophysiology database (NIH-sponsored
International EEG Database) the concepts of data-sharing, large-scale
computation, and reproducible research will be introduced. Specific
applications using electrophysiological biomarkers to predict epilepsy
(epileptogenesis), predict seizures (ictogenesis), and map the epileptogenic
zone will be presented. Algorithms for detection and spatiotemporal mapping
of electrophysiological biomarkers from multiple research groups will be
presented. The performance of these algorithms will be rigorously evaluated
in an open competition applied to large-scale clinical and basic research
datasets: 1) Prediction of epilepsy in animal models, 2) Seizure forecasting in
dogs and humans, and 3) Localization of epileptogenic zone in humans. The
results of the competition between multiple international research groups will
be reviewed and awards presented for the best performance for predicting
epilepsy, predicting seizures, and mapping the epileptogenic zone.
Learning Objectives
u Recognize the role of the International EEG Database in developing spatial
and temporal prediction of epilepsy and seizures
u Understand the physiologic basis of epileptogenesis, understand impact of
localization on surgery outcomes and appreciate issues related to
research into seizure prediction
u Researchers will utilize described approaches with quantitative analysis
using large NIH database for developing new research questions and
methodology.
Target Audience
Advanced (see page 120 for details)
Program
Co-Chairs: Brian Litt, M.D. and Gregory A. Worrell, M.D., Ph.D.
9:30 a.m. Introduction
Elson So, M.D.
9:35 a.m. Review Current State of the Art of Electrophysiological
Biomarkers
Gregory A. Worrell, M.D., Ph.D.
10:05 a.m. Review Current State of the Art of Seizure: Detection
and Devices
Kathryn Davis, M.D.
10:30 a.m. Review Current State of the Art: Prediction and Devices
Mark J. Cook, M.D.
10:55 a.m. NIH International Electrophysiology Database and the
Competition
Brian Litt, M.D.
11:20 a.m. The Seizure Detection & Prediction Contest
Benjamin Brinkmann, Ph.D.
11:40 a.m. Conclusions
Brian Litt, M.D., Gregory A. Worrell, M.D., Elson So, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.25 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.25 contact hours (0.25 CEUs). UAN 0077-9999-14-031-L01-P.
Initial Release Date: 12/6/2014.
Acknowledgment
SATURDAY
The International Competition is co-sponsored by the American Epilepsy
Society, National Institute of Neurological Disorders and Stroke and the
Epilepsy Foundation.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Presidential Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Medical Knowledge
2:15 p.m. 5:00 p.m.
Antiepileptic Therapy Symposium:
The New AEDs: Where Do They Belong in
Your Armamentarium?
(2.5 CME Credits)
Convention Center Ballroom 6C, Level 6
Presentation: Joyce A. Cramer, J. Kiffin Penry Award
Overview
This symposium will present an overview of the 8 newest antiepileptic drugs
(AEDs) that include clobazam, eslicarbazepine, ezogabine, lacosamide,
perampanel, rufinamide, stiripentol, and vigabatrin. Discussion will cover the
developmental history of the drug, mechanisms of action, indications for use,
efficacy, safety issues, tolerability and ease of use to include drug
interactions, formulations and dosing. Treatment paradigms that demonstrate
the differential role of the medications will be presented. As a result of
attending this symposium, the attendee will have an understanding of how to
incorporate the newest AEDs into an integrative treatment algorithm for their
clinical practice and will be able to counsel patients and their families
regarding risks, benefits and alternatives.
Learning Objectives
u Recognize opportunities in their clinical practice to use one or more of
the eight newest AEDs and appropriately counsel patients regarding
risks, benefits and alternatives
u Participate in counseling patients and their families regarding use of one
or more of the eight newest AEDs
u Assist clinicians in their prescribing of one or more of the eight newest
AEDs through an understanding of pharmacology and drug-to-drug
interactions
u Assist in identifying tolerability of adverse effects in the use of one or
more of the eight newest AEDs, particularly in reference to cognitive
and behavioral outcomes.
33
 SATURDAY December 6, 2014

Target Audience 5:15 p.m. 7:45 p.m.

Basic and Intermediate (see page 120 for details) Professionals in Epilepsy Care Symposium:
Programs Practical Applications for the Comprehensive
Co-Chairs: Angus A. Wilfong, M.D. and Jerry J. Shih, M.D. Treatment of Epilepsy
2:30 p.m. Introduction (2.5 CME Credits)
Angus A. Wilfong, M.D. Convention Center Ballroom 6C, Level 6
2:45 p.m. Ezogabine / Eslicarbazepine
Martin J. Brodie, M.D. Overview
Recent research and practice recommendations include the comprehensive
3:10 p.m. Stiripentol / Vigabatrin care of persons with epilepsy and their families. Despite this recommendation
Elinor Ben-Menachem, M.D., Ph.D. no guideline exists for comprehensive epilepsy care. This symposium will
present recent research and practice evidence to assist interdisciplinary
3:35 p.m. Lacosamide / Perampanel providers about practical ways to provide comprehensive care for persons with

John Pollard, M.D.
4:00 p.m. Clobazam / Rufinamide
Joan A. Conry, M.D.
4:25 p.m. Integration of New AEDs Into Clinical Practice
William E. Rosenfeld, M.D.
4:50 p.m. Conclusions
Jerry J. Shih, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Nurse Practitioners may claim 2.5 hours of pharmacology for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-032-L01-P.
Initial Release Date: 12/6/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Antiepileptic Therapy Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Patient Care and Medical Knowledge
Acknowledgment
This program is supported by an educational grant from Eisai, Inc., UCB, Inc.,
Lundbeck Pharmaceuticals Inc. and Sunovion Pharmaceuticals, Inc.
SATURDAY
epilepsy and their families through the lifespan. Cases will be used to apply
interventions to improve health outcomes through early comorbidity screening
and health outcomes including: behavioral health screening, behavioral
interventions and resources, antiepileptic medication through the lifespan, as
well as care of special populations such as veterans and adolescents.
Learning Objectives
u Recognize when to screen for comorbid epilepsy conditions, initiate
appropriate treatment, and refer to the appropriate health care professional
u Participate in providing education, resources, and counseling to persons
with epilepsy and their families regarding the comprehensive treatment
needs of persons with epilepsy
u Assist the epilepsy care team / provider in identifying and treating the
comorbid conditions and identifying antiepileptic medication issues for
children, men, women, and the elderly
u Assist the epilepsy care team / provider in identifying and using best
screening instruments regarding epilepsy psychiatric / psychological /
neurodevelopmental comorbid conditions for persons with epilepsy and
their families. Learner will also assist in the practical provision of or
access to behavioral treatment of such comorbid conditions.
Target Audience
Basic and Intermediate (see page 120 for details)
Program
Co-Chairs: Georgette Smith, Ph.D., APRN, CPNP and Janelle Wagner, Ph.D.
5:15 p.m. Introduction and Case Presentation
Georgette Smith, Ph.D., APRN, CPNP
5:30 p.m. Behavioral Health and Cognitive Screening as Part of the
Epilepsy Clinic Visit
Bruce P. Hermann, Ph.D.
5:50 p.m. Finding Resources and Practical Solutions for Behavioral
Interventions
Loretta Carbone, M.S.W.

2:30 p.m. 4:00 p.m. 6:10 p.m. Antiepileptic Therapy: Pediatric, Elderly, Womens and
Mens Issues
Investigators Workshop Jeannine Conway, Pharm.D.
Convention Center Ballroom 6E, Level 6
6:30 p.m. Special Populations
Cannabinoids in Epilepsy: Do They Work? If So, How? Mary Jo Pugh, Ph.D., RN (Veterans)
Moderator: Kamil Detyniecki, M.D. Jonathan Edwards, M.D. (Adolescents)
Speakers: Charlotte Hill, Ph.D., Benjamin J. Whalley, BPharm, Ph.D., 7:10 p.m. Review of Cases: Panel Discussion
Orrin Devinsky, M.D. Sandra Cushner Weinstein, M.S.W.
This Investigator Workshop is supported in part by GW Pharmaceuticals. 7:30 p.m. Conclusions
Janelle Wagner, Ph.D.

34
 SATURDAY December 6, 2014

Credit Designation Programs

The American Epilepsy Society designates this live activity for a maximum of Chair: Gary W. Mathern, M.D.
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity. 5:30 p.m. Introduction
Gary W. Mathern, M.D.
Nurses may claim up to 2.5 contact hours for this session.
5:40 p.m. What Is Pediatric Epilepsy Surgery?
Pharmacy Credit Gary W. Mathern, M.D.
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-033-L01-P. 6:05 p.m. What Is So Special About Children?
Initial Release Date: 12/6/2014. J. Helen Cross, M.D.
ABPN Core Competencies 6:30 p.m. Pediatric Epilepsy Surgery: Is it Only Rare Syndromes?
The American Board of Psychiatry and Neurology has reviewed the William D. Gaillard, M.D.
Professionals in Epilepsy Care Symposium and has approved this program as
part of a comprehensive lifelong learning program, which is mandated by the 6:55 p.m. What is the Role of Social Media and Nonprofits?

SATURDAY
ABMS as a necessary component of maintenance of certification. Adam Hartman, M.D.
Core Competencies: Professionalism, Practice-based Learning, Interpersonal 7:20 p.m. Conclusions
and Communication Skills and System-based Practice Gary W. Mathern, M.D.
Acknowledgment
This program is supported by an educational grant from Eisai, Inc., and Credit Designation
UCB, Inc. The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.0 contact hours for this session.
5:30 p.m. 7:30 p.m.
North American Commission Symposium: ABPN Core Competencies
Pediatric Epilepsy Surgery: Update on Current The American Board of Psychiatry and Neurology has reviewed the North
American Commission Symposium and has approved this program as part of
Practice a comprehensive lifelong learning program, which is mandated by the ABMS
(2.0 CME Credits) as a necessary component of maintenance of certification.
Convention Center Ballroom 6E, Level 6 Core Competencies: Professionalism, Patient Care, Practice-based Learning,
Systems-based Practice
Overview
This symposium will present an overview of pediatric epilepsy surgery
presenting, in part, data from the ILAE Pediatric Epilelpsy Surgery Task Force.
This symposium will address criteria for when to refer, what constitutes
pediatric epilepsy surgery, what are effective outcome measures, the social
impact and co-morbities of pediatric epilepsy surgery syndromes, and the
emergence of non-profit parent groups to influence care and practice in the
field. Learners will be provided with established criteria for diagnosis of
intractable pediatric epilepsy.
Learning Objectives AES ANNUAL
u Determine which pediatric patients are candidates for epilepsy surgery
based on international standards suggested by the ILAE Pediatric Epilepsy
BUSINESS MEETING
Surgery Task Force
All AES members are encouraged
u Refer pediatric patients for epilepsy surgery based on international to attend this yearly meeting.
experience
u Counsel family regarding diagnosis of intractable epilepsy as currently
defined
u Explain the process of evaluating a child for epilepsy surgery in view of
international experience
u Assess children with intractable epilepsy in anticipation of referral for
surgical evaluation using current criteria, defining current psychological Youre invited to attend
and neuropsychological status.
Sunday, December 7
Target Audience 8:00 a.m. 8:30 a.m.
Basic, Intermediate, and Advanced (see page 120 for details)
Sheraton Seattle Hotel
Metropolitan Ballroom B, Third Floor
Coffee will be available

35

Saturday December 6, 2014
Authors Present: Noon 2:00 p.m.
Poster Walking Tours begin at 12:15 (see page 15 for details)
Translational Research
Mechanisms
1.001 Enhanced Histamine Release
During The Pilocarpine-Induced Status
Epilepticus Is Associated To
Hippocampal Neuronal Damage In Rats:
Effects Of Sodium Cromoglycate/
L. Rocha, M. Valle-Dorado,
C. Santana-Gomez, S. Orozco-Suarez
1.002 PET Imaging Of Translocator
Protein In Temporal Lobe Epilepsy/
L. Dickstein, P. Zanotti-Fregonara,
I. Dustin, J. Liow, J. Hirvonen,
W. Kreisl, K. Jenko, S. Inati, M. Fujita,
C. Morse, J. Hong, V. Pike, S. Zoghbi,
R. Innis, W. Theodore
1.003 Time- And Region-Specific
Alterations In Cyclin D1 Expression
Following STAT3 Inhibition In A Rat
Model Of Temporal Lobe Epilepsy/
Y. Cruz Del Angel, D. Strode,
A. Brooks-Kayal, H. L. Grabenstatter
1.004 Basic Mechanisms Of Acute
And Chronic Neocortical Epilepsy
Revealed By Multi-Electrodes
Extracellular Field Recordings In Brain
Slices/R. Serafini, J. Loeb
1.005 Adenosine Kinase Expression In
Cortical Dysplasia With Balloon Cells:
A Developmental Lineage Of Cell Types
Analysis Epilepsy Center, Beijing
Sanbo Brain Hospital, Capital Medical
University, Beijing 100093, China/
T. Li, G. Luan
1.006 Proteomic Analysis Of TrkB-
Mediated Synaptic Changes Following
Status Epilepticus/E. B. Ludmir,
Y. Huang, B. Gu, E. J. Soderblom,
M. Moseley, J. O. McNamara
1.007 Differential Toll-Like Receptor 4
Modulation Of Dentate Excitability In
The Normal And Injured Brain/
A. A. Korgaonkar, Y. Li, V. Santhakumar
1.008 T Cells Rapidly Relocate From
Spleen And Accumulate During
Epileptogenesis In A Rat Brain Of
Cortical Dysplasia Following A Second
Hit/K. Ayasoufi, A. Nemes,
A. Valujskikh, Z. Ying, I. Najm
1.009 Developmental Plasticity Of
Dentate Gyrus Granule Cells Following
Epileptiform Activity In Vitro/
K. P. Patterson, Y. Chen, G. P. Brennan,
C. Ly, T. Baram
1.010 New Animal Model Of SUDEP:
Brainstem Ictal EEG Is Associated
With Respiratory Arrest/T. Salam,
G. Montandon, R. Genov, J. Perez
Velazquez, P. Carlen
1.011 Mechanisms Underlying
Transitions Between Bursting And
Seizing In A Computational Network
Model/W. Swiercz, K. Lillis, K. Staley
1.012 Increased Expression Of
Growth Associated Protein 43 After
Seizures In Rodent Model Of
Irradiation-Induced Cortical
Dysplasia/A. Nemes, Z. Ying, I. Najm
36
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.013 Hyperactivation Of mTOR
Signaling In A Two-Neuron Microcircuit
Alters The Dynamics Of Synaptic
Transmission/M. Weston, H. Chen,
J. Swann
1.014 Unit Activity Of Subicular, CA1,
CA3, And Dentate Gyrus Principal
Cells And Interneurons Before
Spontaneous Seizures In A Rat Model
Of Temporal Lobe Epilepsy/
P. Buckmaster, I. Toyoda, S. Fujita,
A. Thamattoor
1.015 GABAB Receptors Regulate
Trafficking Of Extrasynaptic GABAA
Receptors In Dentate Gyrus Granule
Cells Via PKA- And PKC-Dependent
Signaling Pathways/W. Tao, W. Spain,
C. Ransom
1.016 Potassium Concentration
Bidirectionally Modulates Seizure-Like
Events In The 4-AP Epilepsy Model In
Vitro And In Vivo/P. Bazzigaluppi,
L. Wang, S. Dufour, T. Valiante,
P. Carlen
1.017 Onset Of Spontaneous Limbic
Seizures Is Associated With Changes
In Firing Dynamics Of Neuronal
Ensembles In Hippocampus And
Parietal Association Cortex/
A. Neumann, A. Luczak, M. Sprengers,
H. Steenland, K. Bzymek, J. Xie,
V. Lapointe, Z. Navratilova,
F. Kloosterman, K. Vonck, P. Boon,
B. L. McNaughton, R. Raedt
1.018 Human Single Neuron
Correlates Of High Frequency
Oscillations During Seizures/
O. J. Ahmed, E. N. Eskandar,
L. R. Hochberg, S. S. Cash
1.019 Invited Speaker Abstract
Submission
1.020 Pro-Resolving Receptors
ChemR23 And ALXR Expression
During Epileptogenesis In Mice/
F. Frigerio, A. Torello, M. Neveux,
K. Leclercq, A. del Prete, S. Sozzani,
R. Kaminski, A. Vezzani
1.021 Impermeant Anions Are
Involved In Setting The Neuronal
Chloride Concentration, Implications
For Seizure Treatment/J. Glykys,
V. Dzhala, K. Egawa, T. Balena,
Y. Saponjian, K. Kuchibhotla,
B. Bacskai, K. T. Kahle, T. Zeuthen,
K. Staley
1.022 Adenosinergic Pathway
Involvement In Protective Effect Of
Atorvastatin In Pentylenetetrazol-
Induced Seizures In Rats/A. Goyal,
R. Kumar, Y. K. Gupta
1.023 Does Enhancement Of
Ventilation Reduce Respiratory Arrest
In DBA/1 Mice?/C. Zeng, X. Long,
J. Cotten, S. Forman, K. Solt,
C. Faingold, H. Feng
1.024 The mTOR Inhibitor, Rapamycin,
Attenuates Acute Seizure-Induced
Dendritic Injury In Mice/D. Guo,
N. Rensing, M. Wong
1.025 TRPV1 Receptors Modulate
The Expression Of Experimental
Febrile Seizures During Development
In Mice/K. Barrett, L. Scott,
S. Mandadi, P. Whelan, M. Scantlebury
1.026 Hypothermia Prevents The
Development Of The Calcium Plateau
Following Status Epilepticus/
K. Phillips, L. Deshpande, R. DeLorenzo
Models
1.027 Tonic GABAergic Inhibitory
Signaling To Dentate Granule Cells In
Mice Following Controlled Cortical
Impact/J. Boychuk, C. Butler, B. Smith
1.028 The Action Potential Firing
Frequency Of Fast-Spiking Basket
Cells Is Reduced After Status
Epilepticus/H. Sun, H. Goodkin
1.029 Benzodiazepine Resistant
Status Epilepticus And Brain Injury In
DFP Model Of OP Intoxication/
R. Kuruba, X. Wu, D. Reddy
1.030 Postnatal Disruption Of The
Cytoskeletal Protein Ndel1 Induces
Hippocampal Structural Pathology And
Spontaneous Recurrent Seizures/
C. Gavrilovici, Y. Jiang, M. Chansard,
R. Liu, K. Parsons, S. Park,
M. Scantlebury, G. Teskey, J. M. Rho,
M. Nguyen
1.031 Midazolam Refractory Seizures
And Brain Injury Following Acute
Organophosphate Intoxication/X. Wu,
R. Kuruba, D. Reddy
1.032 Diminished Antiepileptogenic
Effects Of Neurosteroids In Mice
Lacking Delta-Subunit Extrasynaptic
GABA-A Receptors/B. Clossen,
D. Reddy
1.033 Perimenstrual Upregulation Of
Delta-Subunit Extrasynaptic GABA-A
Receptors Mediating Tonic Inhibition
And Neurosteroid Sensitivity/
C. Carver, X. Wu, O. Gangisetty,
D. Reddy
1.034 Alcohol And SUDEP In
Genetically Epilepsy Prone Rats
(GEPR-9s)/C. Faingold, M. Randall,
S. P. Kommajosyula
1.035 Hyperthermic Seizures And
Seizure Susceptibility: A Novel
Approach Using Zebrafish/J. Ullmann,
G. Leanage, D. Reutens
1.036 Alterations Of
Neurometabolites And Fear
Responses After NMDA-Induced
Spasms In Infant Rats/M. Lee,
M. Yum, D. Woo, T. Ko
1.037 Progesterone Increases AMPA
Receptor Cell Surface Expression Via
Mechanisms Involving Progesterone
Receptors/J. Kapur, S. Joshi,
C. Passmore, J. Williamson
1.038 Antiseizure Effects Of TrkB
Kinase Inhibition/R. Kotloski, G. Liu,
J. McNamara

Saturday December 6, 2014
1.039 GABA Agonists Restore
Inhibitory GABA Neurotransmission In
Mesiotemporal Lobe Epilepsy: In Vivo
And In Silico Modeling Evidence/
S. Stamboulian-Platel, A. Legendre,
T. Chabrol, P. Polack, J. Platel,
F. Pernot, V. Duveau, C. Roucard,
S. Charpier, M. Baudry, A. Depaulis
1.040 Higher Seizure Susceptibility In
Rats With Cortical Dysplasia: A
Feedback Systems Perspective/
B. Krishnan, A. Nemes, Z. Ying,
Z. I. Wang, I. Najm, A. Alexopoulos
1.041 Early Structural Changes In
The Methionine Sulfoximine Model of
Mesial Temporal Lobe Epilepsy/
H. Wang, Y. Huang, R. Dhaher,
D. Coman, H. Zaveri, F. Hyder, T. Eid
1.042 Changes In Neurotransmitter
Gene Expression Correlated With EEG
Stages During Lithium/Pilocarpine-
Induced Experimental Status
Epilepticus/D. M. Treiman,
D. E. Schooley, S. T. Marsh,
L. J. Treiman
1.043 Modeling PIK3CA-Related
Malformations Of Cortical
Development And Epilepsy In Mice/
A. Roy, J. Ni, J. Skibo, S. Rankin,
W. Dobyns, S. Baker, J. Zhao,
F. Kalume, K. J. Millen
1.044 Thalamic Deep Brain
Stimulation To Improve Consciousness
After Seizures/A. Gummadavelli,
J. Motelow, N. Smith, Q. Zhan,
N. Schiff, H. Blumenfeld
1.045 Electrical Stimulation Of The
Cerebral Cortex With A Disk
Electrode: A Modeling Study/P. Kudela,
W. Anderson
1.046 Examining The Roles Of SCN3A
And SCN9A In Epilepsy/T. Lamar,
J. Wong, L. Papale, A. Escayg
1.047 Neuroanatomical And
Neurodevelopmental White Matter
Differences Between Rat Strains
With Differing Vulnerability To
Epileptogenesis And Behavioural
Comorbidities/P. Sharma, M. E. Wlodek,
L. A. Johnston, K. L. Powell, K. Gilby,
T. J. OBrien
1.048 PTEN Deletion From Adult-
Generated Dentate Granule Cells
Disrupts Granule Cell Mossy Fiber
Axon Structure/C. L. LaSarge,
V. R. Santos, S. C. Danzer
1.049 Effects Of Seizures On
Breathing And Survival Are Dependent
On Vigilance State/K. I. Claycomb,
M. A. Hajek, D. A. Rappoport,
G. Buchanan
1.050 Use Of An Automated-Feeding
System For The Testing of Potential
Anticonvulsant Compounds in Chronic
Epileptic Rats/K. Thomson,
C. H. Rueda, M. Barker-Haliski,
H. White
1.051 Analysis Of Postictal Period In
Developing Rats/Z. Ben Salem,
H. Hankov, J. Othal, P. Mares
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.052 Early-Life Clonazepam
Exposure Leads To Persistent
Alteration Of Seizure Susceptibility/
H. Kubova, G. Tsenov, J. Virta,
P. Mares
1.053 Blood-Brain Barrier Integrity In
Epileptic WAG/Rij rats with rotational
movements/C. Gurses, D. Sahin,
C. Ugur Yilmaz, N. Orhan, B. Ahishali,
M. Kucuk, N. Arican, N. Ates,
M. Kaya
1.054 Treatment Of Convulsive
Status Epilepticus In An Animal Model
Of Glucose Transporter Type 1
Deficiency (G1D) Syndrome/C. Trent,
L. Good, D. Kelly, S. Kayani,
J. Pascual, K. Rajasekaran
1.055 Minocycline Reverses Pro-
Epileptogenic Effect Of Viral-Like Brain
Inflammation In The Mature And
Immature Rat Brain/N. Dupuis,
A. Mazarati, B. Desnous, S. Auvin
1.056 Systemic TLR3 Agonist
Injection Enhances Epileptogenesis In
Rat Pups But Does Not Affect The
Adult Rats/B. Desnous, A. Mazarati,
N. Dupuis, S. Auvin
Human Studies
1.057 Improving Seizure Outcomes In
Patients With Neocortical Epilepsy By
Resecting Brain Regions Generating
Ictal Phase Locked High-Frequency
Oscillations (HFOs)/S. A. Weiss,
R. Connors, G. Banks, E. Smith,
A. Lemesiou, B. Zhao, C. Filippi,
R. Emerson, L. Bateman, M. Nowell,
R. Rudoinov, B. Diehl, M. Walker,
C. Schevon
1.058 The Gamma Band Effect For
Episodic Memory Encoding Is Absent
In Epileptogenic Hippocampi/B. Lega,
A. Dionisio, W. Bingaman, I. Najm,
J. Gonzalez-Martinez
1.059 Structure And Risk Factors of
Epileptic Seizures At Patients With
Severe Head Injury/I. Trifonov, V.
Krylov, A. Talypov
1.060 Alternation Of Cross
Frequency Coupling In The Pre-Ictal
iEEG Of Epileptic Patients/K. Edakawa,
H. Kishima, T. Yanagisawa, S. Oshino,
Y. Inoue, H. Khoo, T. Maruo,
M. Kobayashi, M. Hirata, T. Yoshimine
1.061 Brain State Dynamics And The
Role Of The Epileptogenic Zone/
S. Burns, S. Santaniello,
W. Anderson, S. V. Sarma
1.062 Prospective Evaluation Of The
Effects Of Clinical And Subclinical
Epileptoform Discharges On Driving
Safety/Y. Si, E. Gudbranson, W. Chen,
M. Midura, R. Wu, B. Geng,
P. Vitkovskiy, A. Sivaraju, R. Sainju,
A. Fernandez, A. Alareddy, I. Quraishi,
R. Duckrow, L. Hirsch, H. Blumenfeld
1.063 The Frontal And Insular
Network: A Corticocortical Evoked
Potentials Study/R. Enatsu,
J. Gonzalez-Martinez, J. Bulacio,
Y. Kubota, J. Mosher, R. Burgess,
I. Najm, D. Nair
1.064 Seizure Propagation Across
Micro Domains In Epileptic Patients
Undergoing Intracranial Monitoring/
I. Basu, W. S. Anderson
1.065 Why Do Placebos Decrease
Seizures In Clinical Trials?/
D. Goldenholz, R. Moss, W. Theodore
Devices, Technologies, Stem Cells
1.066 Commercial Development Of
Advanced Wireless Technologies In
Implantable Neurostimulators For The
Treatment Of Epilepsy/E. Chow,
C. Warren, A. Shen, K. Venkatraman,
A. Jones, A. Adkins, O. Abdel-Latief,
SATURDAY
D. Thompson, B. Byerman
1.067 Cardiac-Based Seizure
Detection: Long-Term Patient Follow-
Up From The AspireSR E-36 Trial/
P. Boon, K. van Rijckevorsel,
R. El Tahry, C. Elger, N. Mullatti,
A. Schulze-Bonhage, K. Vonck,
G. Wagner, W. Van Grunderbeek,
R. McGuire
1.068 VNS Therapy Automatic
Magnet Mode Outcomes Study In
Epilepsy Patients Exhibiting Ictal
Tachycardia/R. Fisher, J. Harvey,
P. Afra, B. Najimipour
1.069 Immunomodulation For Long-
Lasting Anticonvulsant Effects After
Neural Xenografting In Rats
Neonatal Induction Of Tolerance
Versus Pharmacological
Immunosuppression/A. Handreck,
B. Backofen-Wehrhahn, E. M. Mall,
B. Petersen, H. Niemann, M. Gernert
1.070 Chronic Delivery Of Vigabatrin
Into The Subthalamic Nucleus Is
Anticonvulsant In A Rat Seizure
Model/L. Gey, M. Gernert, W. Loscher
1.071 Development Of A Technique
For Assessing The Effects Of
Selective Sleep Restriction In Mice/
S. Sunderam, F. Yaghouby, C. Schildt,
K. D. Donohue, B. F. OHara
1.072 Multichannel Portable fNIRS-
EEG System For Long-Term
Monitoring Of Seizures/A. Kassab,
P. Vannasing, J. Tremblay, D. Safi,
F. Lesage, M. Sawan, D. Nguyen
1.073 Sensing-Enabled Hippocampal
Deep Brain Stimulation In Idiopathic
Nonhuman Primate Epilepsy/
W. J. Lipski, V. DeStefino,
S. Stanslaski, A. Antony, J. Cameron,
M. Richardson
1.074 Development Of A Depth
Electrode Placement Planning System
For Direct Cortical Stimulation
Therapy/L. Cendejas, R. Dawe,
M. A. Rossi
1.075 Performance Of Limb-Based
Accelerometers In The Detection Of
Hypermotor Seizures/G. Carlson,
S. Sabesan, K. Rose, I. Chekhovtsov
37

Saturday December 6, 2014
1.076 Prospective Driving
Performance Evaluation Using A
Portable Handheld Device In The
Epilepsy Monitoring Unit/N. Li,
J. Thomson, W. Chen, D. Kluger,
C. Cunningham, R. Gebre, Y. Si,
J. Blumenfeld, E. Chen, M. Johnson,
P. Vitkovskiy, Y. Baykara, E. Gudbranson,
A. Morawo, H. Blumenfeld
1.077 Scoring Sleep In Interictal
Electrocorticographic Recordings/
F. Yaghouby, P. Modur, S. Sunderam
1.078 Medial Septal Theta
Stimulation Increases Seizure
Threshold And Improves Cognition In A
Rat Model Of Epilepsy/A. Izadi,
S. Seidl, D. Lee, A. Ekstrom,
K. Shahlaie, G. Gurkoff
Behavior/Neuropsychology/
Language
Adult
1.079 Direct Physiologic Evidence For
A Heteromodal Convergence Region
For Proper Naming In The Left
Anterior Temporal Lobe/T. J. Abel,
A. E. Rhone, K. V. Nourski,
H. Kawasaki, H. Oya, T. Ando,
M. Howard, D. Tranel
1.080 Executive Functioning Changes
In A Clinical Sample Of Older Adult
Patients With Temporal Lobe
Epilepsy/C. Sylvester, G. Risse,
R. Doss
1.081 Factors Analysis Of Korean
Version Of Liverpool Adverse Event
Profile (K-LAEP): Factors Explaining
The Scores Of K-LAEP And Their
Association With Drug Load And Drug
Number Of Antiepileptic Drugs/
O. Kwon, S. Kim, S. Park
1.082 The Influence Of Gender On
Personality Assessment Inventory
Scores Used To Support The
Diagnosis Of Psychogenic Nonepileptic
Seizures/M. Hoerth, K. Corallo,
D. Locke, R. Lanyon
1.083 Stress Coping Strategies In
Patients With Epilepsy And How They
Relate To Mood/K. Isaacs Lebeau,
L. Myers, M. Lancman, M. E. Lancman
1.084 Barriers And Facilitators To
Self-Management Among Persons
With Epilepsy And Mental Illness/
M. Sajatovic, R. K. Ramsey, E. Welter,
K. Coln-Zimmermann, A. T. Perzynski
1.085 Effects Of Adjunctive
Lacosamide On Mood And Quality Of
Life In Adult Patients With
Localization Related Epilepsy/
L. Nakhutina, S. D. Kunnakkat,
M. Coleman, C. Lushbough, V. Arnedo,
N. Soni, A. C. Grant
1.086 A Randomized Controlled Trial
Of HOBSCOTCH: A Self-Management
Intervention For Cognitive Impairment
In Epilepsy/T. A. Caller, K. L. Secore,
R. J. Ferguson, R. M. Roth,
F. P. Alexandre, J. Kleen,
J. Harrington, P. L. Henegan,
B. C. Jobst
38
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.087 Effect Of Seizures On Sleep
Quality In Patients With Chronic
Epilepsy/K. Hwang, S. Cho, J. Kim,
E. Joo, S. Hong
1.088 Depression, Anxiety And
Quality Of Life In Hispanic Spanish-
Speaking Patients With Psychogenic
Non-Epileptic Seizures (PNES)
Compared To Those With Epilepsy/
L. Myers, R. Zeng
1.089 Correlation Of Pre-Diagnosis
Illness Perception And Clinical
Outcome In Patients With
Psychogenic Non-Epileptic Seizures/
S. Majmudar, D. K. Chen
Pediatrics
1.090 Development Of The PedsQL-
Epilepsy Module/A. Modi, K. Junger,
A. Arnett, K. Mann, S. Guilfoyle,
D. Morita, J. Varni
1.091 Behavioral Medicine Services
Integrated Into Pediatric Epilepsy
Care/S. Guilfoyle, K. Junger,
A. Arnett, A. Modi
1.092 Children With Early Onset
Epilepsy Display Thalamic
Abnormalities At Diagnosis/M. Yoong,
M. Hunter, J. Shetty, M. McPhillips,
A. McLellan, R. F. Chin
1.093 Impact Of Epilepsy Surgery On
Behavior In Children/L. Ferguson,
R. M. Busch, K. Kim, J. Haut,
P. Klaas, W. Bingaman, D. Lachhwani,
T. Lineweaver
1.094 Treatment Of Psychogenic
Non-Epileptic Seizures In The
Pediatric Population/J. Doss,
E. Adams, M. Palmquist
1.095 Memory Functioning In Long-
Term Outcome After Epilepsy Surgery
In Childhood/M. Smith, K. Puka
1.096 Epilepsy Education: Parents
And Adolescents Learn Differently/
L. Carbone, R. Derry, M. Plegue,
S. Rau, R. Shellhaas
1.097 Behavioral Co-Morbidities In
Pediatric Epilepsy: What Is The Role
Of Cognition?/S. Eom, R. Caplan,
A. Berg
1.098 Continuous spikes And Waves
During Sleep (CSWS). Changes In
Seizure Frequency, Epileptiform
Activity And Cognition After High-
Dose Clobazam Treatment/J. Klehm,
I. Snchez Fernndez, C. Vega, A. Fasano, F. Borlot, A. E. Lang,
J. Peters, S. Thome-Souza, C. Harini,
M. Takeoka, G. Wilkening, K. Chapman,
T. Loddenkemper
1.099 Intellectual And Memory
Outcome Following Pediatric Epilepsy
Surgery Using Reliable Change
Methods/J. Haut, L. Ferguson,
T. Lineweaver, P. Klaas, D. Lachhwani,
W. Bingaman, R. M. Busch
1.100 Predictors Of Quality Of Life In
Childhood Epilepsy: The Childs
Perspective/N. Fayed, A. M. Davis,
D. L. Streiner, P. L. Rosenbaum,
L. Lach, C. E. Cunningham, M. Boyle,
G. Ronen
1.101 Support For Use Of The
Meyers Neuropsychological System
With Pediatric Patients With Epilepsy/
Y. C. Leon, S. Benbadis, D. Lisicki,
C. Ramirez, J. Ferreira
Genetics
Human Studies
1.102 WITHDRAWN
1.103 The Expanding Role For
Chromatin Remodeling In Epilepsy:
Gene Discovery To Pathogenic
Mechanisms/G. L. Carvill, J. McMahon,
H. Wang, J. Stamatoyannopoulos,
I. Scheffer, H. Mefford
1.104 Mutations In WWOX Gene In
Early Infantile Epileptic Encephalopathy:
Expansion Of The Phenotype And
Genotype Disease Spectrum/
B. Melaiki, F. ALMutairi, A. ALHashem
1.105 Distinct Phenotypes And
Genotypes Of SPTAN1 Encephalopathy/
J. Tohyama, M. Nakashima, Z. Rener
Primec, C. Gaik-Siew, S. Nabatame,
M. Kato, N. Matsumoto, H. Saitsu
1.106 Cornelia de Lange
Syndrome:Clinical Features & Course
of The Largest SMC1A Deletion/
L. R. Kaplan, N. Zadeh, A. Spitz,
G. Fernandez
1.107 De Novo Mutation In Sodium
Channel Gene SCN8A Causes Delay In
Neuromuscular Junction Development
In Early Onset Epileptic
Encephalopathy /N. Barisic
1.108 Familial Focal Epilepsy With
Paroxysmal Arousals Due To A Novel
CHRNA2 Loss Of Function Mutation/
V. Conti, P. Aracri, L. Chiti, S. Brusco,
F. Mari, C. Marini, A. Romigi,
A. Becchetti, R. Guerrini
1.109 WITHDRAWN
1.110 Presenilin 1 Mutation In A
Sporadic, Early-Onset Dementia With
Myoclonus And Epilepsy/M. Kinoshita,
H. Nakano, K. Park, H. Yamashita,
T. Kondo, R. Takahashi, A. Ikeda
1.111 A Novel LGI1 Variant In
Autosomal Dominant Lateral Temporal
Lobe Epilepsy/W. O. Pickrell, C. Hope,
J. G. Mullins, P. E. Smith, M. I. Rees,
S. Chung
1.112 Antecollis And Levodopa-
Responsive Parkinsonism Are Late
Features Of Dravet Syndrome/
D. Andrade
1.113 DEPDC5 Mutations In Familial
Temporal Lobe Epilepsies/C. Nobile,
E. Serioli, E. Dazzo, P. Striano,
S. Striano, R. Michelucci
1.114 De Novo Mutations In Synaptic
Transmission Genes Including DNM1
Cause Epileptic Encephalopathies/
S. Weckhuysen
1.115 Copy Number Variations In
Early Onset Absence Epilepsies/
H. Muhle, M. Pendziwiat, P. Striano,
R. S. Mller, C. Marini, A. Suls,
P. De Jonghe, B. Neubauer,
M. von Deimling, J. Jhn,
S. von Spiczak, Y. Weber,
G. Kurlemann, T. Polster, I. Vater,
I. Scheffer, T. Sander, R. Siebert,
U. Stephani, I. Helbig

Saturday December 6, 2014
1.116 Epilepsy In STXBP1
Encephalopathy: Clinical Delineation Of
32 Japanese Patients Including 14
Novel Patients/M. Kato, H. Saitsu,
H. Osaka, K. Nakamura, T. Watanabe,
H. Terashima, T. Ikeda, T. Kumada,
H. Matsumoto, T. Yamaguchi,
J. Azuma, Y. Tominaga, M. Shinpoo,
H. Arai, S. Hirai, S. Takeshita,
E. Nakagawa, H. Uchio, Y. Nonoda,
T. Iwasaki, T. Chiyonobu, A. Sudo,
1.117 Familial Focal Seizures And
Anterior Pachyghria In A Large Family
With A Novel DCX Mutation Combined
With A TUBB1 Mutation That Might
Be A Modifier For The Phenotype Of
Cognitive Deficit/Y. Kim, M. Kim,
S. Choi, Y. Woo
1.118 Distinctive Electro-Clinical
Features Of Epilepsy In Severe Early
Onset SCN8A Encephalopathy/
E. Gardella, J. Larsen, M. Wolff,
G. Schmiedel, M. Kirkpatrick,
N. Barisic, C. Depienne, M. Troncoso,
B. Jepsen, M. Nikanorova,
L. Troncoso, A. Bevot, H. Hjalgrim,
S. Beniczky, R. S. Mller
1.119 Targeted Massively Parallel
Sequencing Of Infantile Onset
Epileptic Encephalopathy/B. Lim,
H. Kim, H. Hwang, J. Chae, K. Kim,
Y. Hwang
1.120 Familial Epilepsy Due To A Point
Mutation In LIS1/D. E. Crompton,
M. S. Hildebrand, R. J. Leventer,
Y. Perchyonok, J. A. Damiano,
C. A. Wise, I. E. Scheffer,
G. D. Jackson, S. Berkovic
1.121 The Subcortical Band
Heterotopia/Lissencephaly Spectrum
And Epilepsy: Phenotypic, Molecular,
Functional, And Structural Analysis Of
Novel Causative DCX And LIS1
Mutations/D. Amrom, G. Brouhard,
S. Bechstedt, K. Toropova,
F. Andermann, F. Dubeau,
D. Melanson, D. Tampieri,
S. Reck-Peterson, E. Andermann
Neuropathology of Epilepsy
Human Studies
1.122 Temporal Lobe Epilepsy With
Hippocampal Sclerosis: The Role Of
5HT1A and 5HT2A Receptos In
Human Epileptogenesis/N. Fonseca,
H. P. Joaquim, V. D. de Paula,
S. Vincentiis, L. L. Talib, W. F. Gattaz,
K. Valente
Neurophysiology
Video EEG Epilepsy-Monitoring
1.123 Electroencephalographic
Patterns During Sleep In Children
With Chromosome 15q11.2-13.1
Duplications (Dup15q)/D. Arkilo,
O. Devinsky, R. Thibert
1.124 A Reduction Of Sleep Spindles
Precedes Seizures In Focal Epilepsy
By Minutes/J. Remi, F. Tezer-Filik,
S. Noachtar
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.125 How Long Is A Single, Scalp
Video EEG Monitoring Evaluation Valid
In The Pre-Surgical Evaluation For
Focal Epilepsy?/D. M. Bonno,
A. Fessler
1.126 Representation Of Memory
Strength And Subjective Confidence
By Individual Neurons In The Human
Medial Temporal Lobe/U. Rutishauser,
S. Ye, M. Koroma, J. Chung,
A. Mamelak
1.127 Synergy Between Epileptogenic
Cortex And Thalamus Projecting
Generalized Paroxysmal Fast Activity
(GPFA) In Children With Intractable
Localization-Related Epilepsy/S. Baba,
M. Mohammadi, T. Okanishi,
K. Okanari, S. Sakuma, A. Ochi,
E. Widjaja, C. Go, O. C. Snead III,
H. Otsubo
1.128 Importance Of Routine Ictal
Heart Rate Analysis In Drug
Resistant Epilepsies: Possible
Prediction Of Patients At Risk For
SUDEP/L. Baysal Kirac, B. Baykan,
C. Gurses, N. Bebek, A. Gokyigit
1.129 Scalp High Frequency
Oscillations Help To Identify Patients
With Poor Postsurgical Seizure
Outcome/C. Klus, M. Duempelmann,
M. Mader, A. Schulze-Bonhage,
J. Jacobs
1.130 A Study On Clinical Usefulness
Of 3D EEG Source Localization
Analysis/C. Park, D. Kim, B. Abibullaev,
H. Kwon, J. Seo, E. Joo, D. Seo,
Y. Lee, S. Hong
1.131 The Diagnostic Yield Of Video-
EEG in the inpatient versus
Ambulatory Settings In Adults With
Episodes Of Unclear Nature/E. Fertig,
E. Feoli, J. Sabri, C. Lambrakis,
O. Laban-Grant, S. Mesad,
J. Politsky, M. Lancman
1.132 Electroencephalogram
Characteristics In Pediatric Patients
With Anti-NMDA Receptor
Encephalitis/E. Cruz, S. Manganaro,
L. Bello, M. Andriola, L. Manganas
1.133 Interictal And Ictal Video EEG
Findings In Patients With Epilepsy And
Autism Spectrum Disorder/
J. Avallone, J. Misajon, S. Iyer,
O. Devinsky
1.134 Pathognomonic
Electroencephalogram Findings In A
Case Of Isodicentric Chromosome
15/V. S. Vajjala, J. B. Wollack,
S. A. Hosain
ICU EEG
1.135 Clinical Correlates And
Outcome Of Lateralized Periodic
Discharges In Patients Without Acute
Brain Injury: A Case-Control Study/
R. Sainju, L. Manganas, E. Gilmore,
O. Petroff, N. Rampal, L. Hirsch,
N. Gaspard
1.136 Interrater Agreement In The
Interpretation Of Neonatal
Electroencephalography/C. J. Wusthoff,
J. Sullivan, H. C. Glass, R. Shellhaas,
N. Abend, T. Chang, T. Tsuchida
1.137 Development Of Epilepsy In
Neonates With Hypoxic Ischemic
Encephalopathy (HIE) Receiving Whole
Body Therapeutic Hypothermia(TH)
Compared To A Non-TH Group/
K. Khusiwilai, M. Cordeiro, T. Czech,
K. Harris, A. Massaro, T. Chang,
T. Tsuchida
1.138 Seizure Detection In Adults
Using Feature Baseline Correction On
A Neonatal EEG Trained Classifier/
G. Bogaarts, E. Gommer, D. Hilkman,
V. van Kranen-Mastenbroek
1.139 Comparison Of Seizures
Captured With Extended Versus
SATURDAY
Reduced EEG Electrode Arrays In
Neonates Undergoing Therapeutic
Hypothermia/G. Diaz-Medina, Y. Lai,
A. L. Thompson, W. Laura, A. Anderson
1.140 Early Identification Of Patients
With PRES Using Continuous EEG
Reduces The Comorbidity Of SAH And
Impacts its Treatment Approach/ J.
Politsky, I. Ugorec, D. Baker,
P. Rodgers, E. Fertig
1.141 Prognostic Value Of
Continuous EEG During And After
Therapeutic Hypothermia In Patients
With Cardiac Arrest/B. Legros,
M. Lamartine Sabido Monteiro,
C. Depondt, I. Lamanna, N. Ligot,
N. Mavroudakis, G. Naeije, J. Vincent,
F. Taccone
1.142 Analysis Of Pediatric
Electroencephalogram Characteristics
During Therapeutic Hypothermia In
Post Cardiac Arrest Patients/L. Bello,
E. Cruz, S. Manganaro, M. Andriola
MEG
1.143 Pre-Ictal And Ictal Pathological
High Frequency Oscillations (HFOs) In
Focal Epilepsy: Analysis Of MEG
Recording/J. Velmurugan, S. Sinha,
N. Mariyappa, P. Satishchandra
1.144 Magnetoencephalographic
Characteristics Of Cortical Dysplasia
In Children/N. Agarwal, U. Thome
Costa, B. Krishnan, R. Burgess,
R. Prayson, A. Alexopoulos, A. Gupta
1.145 Volume And Location Of Focal
Cortical Dysplasia Type Ii Correlating
With Magnetoencephalography;
Convexity Vs. Bottom Of Sulcus/
M. Nakajima, Y. Sato, S. Wong,
K. Okanari, S. Sakuma, C. Boelman,
S. Baba, A. Ochi, S. Doesburg,
H. Otsubo
1.146 Automatic Detection Of Focal
Slow Waves In Patients After Epilepsy
Surgery Is Related To Recurring
Seizures/S. Rampp, M. Schnherr,
K. Roessler, M. Buchfelder, H. Hamer,
H. Stefan
1.147 Comparative Analysis Of Spike
Source Between High-Density EEG
And MEG/R. Honda, Y. Kaneko,
Y. Saito, E. Nakagawa, K. Sugai,
M. Sasaki, T. Kaido, A. Takahashi,
T. Otsuki
39

Saturday December 6, 2014
1.148 Coherence And Source
Localisation In Reflex-Eating Epilepsy:
A MEG Based Analysis/S. Sinha,
V. Jayabal, M. Narayanan,
S. Parthasarathy
1.149 Application Of Multiple
Equivalent Current Dipole Modeling
And Minimum Norm Modeling For
Analyzing Magnetoencephalography
Activities Of An Unusual Form Of
Benign Childhood Epilepsy With
Occipito-Frontal Sharp Waves/
H. Murakami, J. Mosher, A. Naduvil
Valappil, E. Wyllie, A. Alexopoulos,
R. Burgess
1.150 MEG Source Imaging Of
Interictal Spikes Using Samepi:
Comparison With Area Of Surgical
Resection And Seizure Outcomes/
J. Scott, S. Robinson, K. Zaghloul,
J. Heiss, S. Sato, W. Theodore,
S. Inati
1.151 Epileptic Networks In Genetic
Generalized Epilepsy: A MEG Study/
A. Zillgitt, B. Assaad, J. Moran,
K. Mason, D. Burdette,
J. Constantinou, G. L. Barkley,
S. Bowyer
1.152 Comparison Of Ictal And
Interictal Source Localization Using
MEG And dEEG In Pediatric Drug
Resistant Epilepsy/H. Fujiwara,
H. Greiner, J. Tenney, D. Rose
Brain Stimulation
1.153 Cortical-Cortical Evoked
Potentials (CCEPs) Distinguish Early
Versus Late Seizure Spread In
Stereoelectroencephalography/
A. Dionisio, B. Lega,
J. Gonzalez-Martinez, P. Flanagan,
D. Nair
1.154 Physiological Consequences Of
Abnormal Connectivity In A
Developmental Epilepsy/M. Shafi,
M. Vernet, D. Klooster, M. E. Barnard,
K. Romatoski, M. Westover,
J. Christodoulou, J. D. Gabrieli,
S. Whitfield-Gabrieli, A. Pascual-Leone,
B. S. Chang
1.155 Chronic Cortical Optogenetic
Stimulation For The Prevention Of
Posttraumatic Epileptogenesis In
Mice/X. Ping, W. Xiong, G. Chavez,
J. Gao, X. Jin
1.156 (DYS) Functional Connectivity
Of The Seizure Onset Zone: Low
Frequency Stimulation And Cortico-
Cortical Evoked Responses Study/
R. Alkawadri, H. Zaveri, R. Duckrow,
D. Spencer, J. Gerrard, L. Hirsch
1.157 Exploring Seizure Networks
Using Cortico-Cortical Evoked
Potentials: Internally Hyperconnected,
Externally Hypoconnected?/L. Entz,
P. Megevand, D. Groppe, E. Toth,
D. Fabo, Z. Fallil, C. Harden,
S. Hwang, S. Bickel, C. Keller,
A. Mehta
1.158 Paired-Pulse Transcranial
Magnetic Stimulation (ppTMS) In
Measures Of Cortical Inhibition During
Propofol Infusion/C. F. Paredes Saenz,
R. Gersner, J. Goldie, A. Rotenberg
40
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.159 State-Dependent Modulation
Of Cortical Activity By Intracranial
Stimulation/S. Alagapan, S. Schmidt,
D. Bernardo, F. Frohlich, H. Shin
1.160 Sleep, Seizures And Cortico-
Cortical Evoked Potentials: A
Dynamical System Perspective/
J. Slater, G. Kalamangalam
Animal Studies
1.161 Short-Term Synaptic
Reorganization In The Rat Neocortex
After Perinatal Hypoxia-Ischemia/
J. Bastar, J. Spampanato, F. Dudek
1.162 Supramammillary Hypothalamic
Neurons That Co-Release GABA And
Glutamate Promote Wakefulness And
Hippocampal Theta Rhythm/
N. P. Pedersen, L. Ferrrari,
J. L. Wang, E. Arrigoni, P. M. Fuller,
C. B. Saper
1.163 Electroconvulsive Seizure
Induces The Changes Of NMDAR,
AMPAR, And STEP61 Protein In Rat
Hippocampus/S. Jang
1.164 Peri-Ictal Impairment Of
Brainstem 5-HT Neurons: Insight Into
Depressed Arousal, Reduced
Ventilation And Sudden Unexpected
Death In Epilepsy (SUDEP)/Q. Zhan,
G. Buchanan, J. Motelow, F. Serout,
W. Chen, A. Gummadavelli,
J. Andrews, P. Vitkovskiy, M. Furman,
W. Li, G. Richerson, H. Blumenfeld
1.165 Seizure-Induced Kcnq
Upregulation Alters The Functional
Properties Of Hippocampal M
Currents In The Pilocarpine Model Of
Temporal Lobe Epilepsy/C. T. Taylor,
D. B. Jaffe, M. S. Shapiro
1.166 Selective, Unilateral Ablation
Of Hippocampal Interneurons Causes
Acute Seizures/J. Spampanato,
F. E. Dudek
Computational Analysis & Modeling
Of EEG
1.167 Power-Weighted Narrowband
Changes During Epileptic Bursts In
Invasive EEG Identify The Epileptogenic
Zone/M. Heers, X. Wang,
M. Duempelmann, J. Jacobs,
A. Schulze-Bonhage, T. Ball
1.168 An Interictal EEG Spectral
Metric For Temporal Lobe Epilepsy
Lateralization/L. Cara, G. Kalamangalam
1.169 Correlation Of EEG Spectra
With Quantitative Measures Of
Intelligence And Attention In Children
With Idiopathic Epilepsy/D. Hsu,
K. Rayer, M. Hsu, P. Ferrazzano,
K. Dabbs, D. Jackson, C. Stafstrom,
G. Worrell, J. Jones, B. Hermann
1.170 Lateralizing Shift Of Current
Source Of Generalized Spikes In
Childhood Absence Epilepsy:
Relationship Between The Shift And
Response To Valproic Acid/O. Kwon,
T. Yang, S. Jung, J. Yeom
1.171 High Frequency Oscillations
And Spikes: Separating Oscillations
From Broad Band Activities/M. Amiri,
J. Gotman
1.172 Spatial Relationship Between
The Fast And Slow Components Of
Ictal Activities And Interictal
Epileptiform Discharges In Children
With Epileptic Spasms/T. Akiyama,
M. Akiyama, K. Kobayashi, T. Okanishi,
C. Boelman, D. A. Nita, A. Ochi,
C. Go, C. Snead, J. Rutka, J. Drake,
S. Chuang, H. Otsubo
1.173 Dynamic Measures Applied To
A Cohort Of Children With Childhood
Absence Seizures/M. J. Schwabe,
K. C. Hecox
1.174 Epileptogenic Networks
Revealed By Varying Patterns Of
Propagation Of High Frequency Ictal
Activity (70-175 Hz)/A. Korzeniewska,
P. Franaszczuk, M. Cervenka,
C. Jouny, G. Bergey, N. Crone
1.175 Pathologic Generation Of High
Frequency Oscillations In The Seizure
Onset Zone During A Motor Task/
P. A. Peters, J. Cimbalnik,
B. Brinkmann, V. Svehlik, V. Vasoli,
M. T. Kucewicz, R. Marsh, F. Meyer,
M. Stead, G. Worrell, J. Matsumoto
1.176 WITHDRAWN
1.177 Modulation Of Neuronal
Activity And Functional Connectivity In
Transition To Ictus/T. Matsuo,
R. Staba, A. Bragin, I. Fried
1.178 Scale-Free Properties Of
Intracerebral EEG Improve Seizure
Prediction In Mesial Temporal Lobe
Epilepsy/K. Gadhoumi, J. Gotman, J. Lina
1.179 Coherence Analysis Of Diffuse
Bisynchronous Ictal iEEG Discharges
For Seizure Localization/P. Chen,
M. Korostenskaja, E. Castillo, J. Seo,
J. Baumgartner, K. Lee
1.180 Noninvasive Dense Array
Electroencephalography For Localizing
The Seizure Onset Zone/C. Kuo,
D. Tucker, P. Luu, K. Jenson, M. D. Holmes
Clinical Epilepsy
Clinical Diagnosis
1.181 A Case Of Takotsubo
Cardiomyopathy Due To Status
Epilepticus An Underreported And
Lethal Sequela/N. Mirchandani,
I. Khan, G. Pushchinska
1.182 Development And Validation Of
A Seizure Prediction Model In
Critically Ill Children/A. Yang, D. Arndt,
R. Berg, J. Carpenter, K. Chapman,
D. Dlugos, W. Gallentine, C. Giza,
J. Goldstein, C. Hahn, J. Lerner,
T. Loddenkemper, J. Matsumoto,
K. Nash, E. Payne,
I. Snchez Fernndez, J. Shults,
A. Topjian, K. Williams, C. Wusthoff,
N. Abend
1.183 Obesity In Adult Patients With
Psychogenic Non-Epileptic Seizures/
A. Abubakr, I. Wambacq
1.184 Ambulatory EEG In Epilepsy
Diagnosis For Adults Aged 65 And
Older/K. Upchurch, D. McCarthy,
E. Baker, J. Pathmanathan

Saturday December 6, 2014
1.185 Coprolalia As A Manifestation
Of Epileptic Seizures/A. Massot-Tarrs,
C. Dove, R. McLachlan, J. G. Burneo,
S. Mirsattari
1.186 Comparison Of Patients With
Coexisting Epileptic Seizures And
Psychogenic Nonepileptic Spells To
Patients With Psychogenic
Nonepileptic Spells Only: A Search For
Unique Clinical Characteristics/
S. C. Block, B. Abou-Khalil,
H. Sonmezturk
1.187 Which Clinical Features Help In
Differentiating Epileptic From
Nonepileptic Convulsive Seizures? A
Systematic Review Of Initial Clinic
Encounters/K. Kleinfeld, A. Peltier,
N. Azar
1.188 Delays In Diagnosis And
Treatment Of Acute Seizures/
S. VanHaerents, E. Bachman,
K. Romatoski, L. Knopf, M. Ebril,
T. Pang
1.189 Clinical, EEG, MRI And Surgical
Outcomes Of Pediatric Epilepsy With
Astrocytic Inclusions Versus Focal
Cortical Dysplasia/L. Alshafai, A. Ochi,
C. Go, B. McCoy, C. Hawkins,
H. Otsubo, O. Snead, J. Rutka,
E. Widjaja
1.190 Sleep Homeostasis In Children
With Focal Epilepsy Following Sleep
Deprivation: Relationship To Seizure
Propensity/S. Chan, C. Chevalier-Riffard,
T. Baldeweg, J. Cross
1.191 Networks Of Laughing Seizures
A Stereoelectroencephalographic
Study/I. Mindruta, L. Minotti, A. Job,
D. Hoffmann, S. Chabardes,
A. Barborica, J. Ciurea, P. Kahane
1.192 Super Refractory Status
Epilepticus: A Case Report/
I. Noviawaty, A. Naduvil Valappil,
A. Zeft, D. Lachhwani
1.193 Predictors Of Length Of Stay
In Children Admitted For A Pre-
Surgical Evaluation/P. Y. Sun,
K. Wyatt, K. Nickels, L. Wong-Kisiel,
E. Wirrell
1.194 Navigating The Benefits And
Limitations Of Current Molecular
Testing Options For The Clinical
Identification Of Disease-Causing
PCDH19 Mutations/S. Gandomi,
M. Parra, K. D. Farwell Gonzalez,
K. Waller, R. Baxter, B. Tippin Davis
1.195 Electroencephalographic
Findings By Stage In Rasmussens
Encephalitis/H. Kim, H. Ryu, B. Lim,
H. Hwang, J. Chae, J. Choi, K. Kim,
Y. Hwang
1.196 Type I Interferon Levels In
Cerebrospinal Fluid Samples From
Newborn Infants With Seizures,
Rotavirus Infections, And Diffuse
Cerebral White Matter Lesions/
K. Lee, C. Moon
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.197 A Retrospective Study Of
Continuous EEG Monitoring In A
Single Tertiary Care Pediatric Site/
L. St. Louis, A. Sansevere,
I. Snchez Fernndez, E. Nagarajan,
J. Klehm, P. Pearl, R. Tasker,
T. Loddenkemper
1.198 Comparison Of Number Of
Patient-Reported Allergies In Adult
Patients With Epileptic And Non-
Epileptic Seizures/A. Fu, D. Denny,
S. Cerven, N. Moorley, S. S. Chung
1.199 Prevalence Of Headache In
Patients With Epileptic Versus Non-
Epileptic Seizures/S. Cerven, A. Fu,
N. Moorley, D. denny, S. S. Chung
1.200 Comparing Duration To
Diagnosis Made Via Video-
Electroencephalography For Non-
Epileptic Seizures And Epileptic
Seizures/D. denny, A. Fu, S. Cerven,
N. Moorley, S. S. Chung
1.201 Comparison Of Number Of
Events Captured In Epilepsy
Monitoring Unit Between Patients
With Epileptic Versus Non-Epileptic
Seizures/N. Moorley, A. Fu, D. Denny,
S. Cerven, S. S. Chung
1.202 Cefepime Induced
Encephalopathy In A Tertiary Medical
Center In Korea/J. Jeon, H. Moon,
G. Motamedi, Y. Cho
Clinical Treatments
1.203 What Do Epileptologists
Recommend About Discontinuing
AEDs For A Second Time In Seizure-
Free Children When The First
Attempt Failed?/A. McCarthy,
C. Camfield, P. Camfield, I. Valencia
1.204 Clinical Predictors For Delirium
Tremens In Patients With Alcohol-
Withdrawal Seizures/D. Kim
1.205 Repetitive Transcranial
Magnetic Stimulation For Refractory
Focal Status Epilepticus/
S. VanHaerents, S. Herman, T. Pang,
A. Pascual-Leone, M. Shafi
1.206 Why Do Patients Get Admitted
For ACTH For Infantile Spasms?A
Survey Of ACTH Delivery Across
United States/C. Joshi, A. Berg,
E. Wirrell
1.207 Ictal Religious Speech In
Temporal Lobe Epilepsy/I. Yildirim
Capraz, M. Mercan, E. Bilir
1.208 Maximizing The Efficacy Of The
Ketogenic Diet Treatment For Super-
Refractory Status Epilepticus/
Y. C. Liu, H. Lowe, S. C. Shen,
M. Zak, V. Chan, J. Kobayashi,
E. J. Donner
1.209 Interrater Reliability In
Interpretation Of
Electrocorticographic Seizure
Detections Of The Responsive
Neurostimulator/M. Quigg, B. Jobst,
N. Fountain, V. S. Wong, F. Sun,
E. Mirro, S. Brown, D. Spencer
1.210 Hereditary Hyperekplexia
And Generalized Epilepsy In A Child
Responsive To Levetiracetam/
A. Lowden, J. Munoz, R. Said
1.211 Comparison Of Efficacy
Between A Modified Atkins Diet And A
Classic Ketogenic Diet In Childhood
Intractable Epilepsy/J. Kim, J. Yoon,
E. Lee, J. Lee, H. Kim, H. Kang
1.212 WITHDRAWN
1.213 Clinical Characteristics And
Treatment Pattern In Cluster
Seizures: A Preliminary Chart Review
Analysis/B. Vazquez, E. Wu,
D. Macaulay, M. Sidovar, H. Roberts,
D. Squillacote, A. L. Rabinowicz, A. Guo
1.214 IV Lacosamide As Adjunctive
Therapy In Treatment Of Refractory
Status Epilepticus/S. Kohli, P. Li,
B. Teter, K. Kavak, A. Weinstock
SATURDAY
1.215 Effectiveness Of Routine
Management Of Status Epilepticus In
Dravet Syndrome/S. N. Misra,
S. Agadi
1.216 Responsive Neurostimulation
in Patients with Mesial Temporal Lobe
Epilepsy and Prior Temporal
Lobectomy/T. Crowder Skarpaas,
R. Duckrow, A. Herekar, C. Heck,
C. Skidmore, D. Spencer, G. Bergey,
D. Shields, D. Nair, D. King-Stephens,
M. Morrell
1.217 The Effects Of Experimental
Febrile Seizures On The Expression Of
Forelimb Motor Maps In A Rodent
Model Of Mesial Temporal Lobe
Epilepsy/K. B. Rivard, K. Scullion,
G. Teskey, M. Scantlebury
Prognosis
1.218 Family Factors Contributing To
Depression In People With Epilepsy/
S. Han, B. Kim, E. Koh, M. Kim,
D. Shin, J. Lee, K. Ji, S. Park,
H. Nam, Y. Cho, E. Joo, S. Kim,
D. Kim, K. Park, S. Han, Y. Sohn,
K. Heo, E. Lee, H. Han, K. Kim,
W. Shin, G. Kim, J. Lee, S. Koh,
W. Kim, Y. Cho, J. Kim, S. Lee
1.219 Early Intensive Care Is Critical
For The Outcome Of The Refractory
Status Epilepticus/Y. Choi, K. Kang,
S. Lee, M. Kim
1.220 Demographics And Outcomes
Of Pediatric Febrile Convulsive Status
Epilepticus/M. Nishiyama, T. Tanaka,
K. Fujita, A. Maruyama, H. Nagase,
D. Toyoshima, T. Nakagawa,
N. Morisada, S. Takada, K. Iijima
1.221 Predictors Of Recurrent
Febrile Seizure/M. Oh, S. Kim
1.222 Early Anatomical Injury
Patterns Predict Post-neonatal
Epilepsy In Infants Treated With
Selective Head Cooling For Neonatal
Hypoxic Ischemic Injury/D. Jung,
C. Venkatesan, D. Nordli,
D. G. Ritacco, S. Koh
1.223 Gender Alters The Prognosis
Of Cryptogenic Epilepsy/F. Babtain,
M. Abu Abthan, S. Al Ghamdi,
H. Bhatia, M. Velmurugan
41

Saturday December 6, 2014
1.224 Epilepsy In Childhood After
Acute Encephalopathy With Reduced
Subcortical Diffusion/Y. Ito,
J. Natsume, H. Kidokoro, N. Ishihara,
Y. Azuma, T. Tsuji, A. Okumura,
T. Kubota, N. Ando, K. Miura,
T. Negoro, K. Watanabe
1.225 Succinic Semialdehyde
Dehydrogenase Deficiency And
Worsening Epilepsy In Adulthood/
S. LaPalme-Remis, E. Lewis,
W. Theodore, M. Gibson, P. Pearl
1.226 The Relevance Of
Somatosensory Auras In Refractory
Temporal Lobe Epilepsies/G. Perven,
L. Jehi, R. Yardi
1.227 Electroencephalographic
Correlates Of Seizure Freedom In
Genetic Generalized Epilepsies/
U. Seneviratne, M. Cook, W. DSouza
1.228 How Many Patients With
Temporal Lobe Epilepsy Are Well
Controlled With Medications?/
J. Tellez-Zenteno, L. Hernandez
Ronquillo, S. Buckley, L. D. Ladino
1.229 The Evaluation Of Left
Ventricular Diastolic Function Of
Newly Diagnosed Idiopatic Generalized
Epilepsy Patients With Tissue Doppler
Imaging/O. Dokgoz, C. Yilmaz,
A. nalp, T. Mese, U. Karaarslan
1.230 Clinical Outcome Following
Medical Treatment In Drug-Nave
Epilepsy Patients With Cavernous
Malformation/K. Cho, Y. Lee, Y. Cho,
K. Heo, B. Lee
1.231 Mortality In Patients Assessed
For Suspected New-Onset Seizures/
T. OBrien, T. Hakami, M. Todaro,
L. Danny, P. Kwan, S. Yerra, M. Tan,
C. French, S. Li, Z. Matkovic,
A. McIntosh
1.232 Long Term Surgical Outcome
Of Non-Lesional Temporal Lobe
Epilepsy (NLTLE)/J. Chu, W. DSouza,
M. Murphy, S. Schachter, M. Cook
Neuroimaging
Animal Studies
1.233 Intrinsic Optical Signal Imaging
Of Afterdischarges Induced By Acute
Kindling Of The Rat Hippocampus/
K. Tsuchiya, A. Kobayashi, N. Inoue,
S. Kogure, M. Nemoto
1.234 The Effect Of De Novo KCNQ2
Epileptic Encephalopathy Mutations
On KCNQ2/3 Channel Trafficking And
Hippocampal Neuronal Excitability/
J. Cavaretta, K. Lee, H. Chung
Structural Imaging
1.235 Diffusion Tensor Imaging Study
In Dravet Syndrome/J. Natsume,
O. Chikako, H. Yamamoto, Y. Ito,
T. Takeuchi, S. Yokoi, Y. Sakaguchi,
Y. Azuma, N. Ishihara, H. Kidokoro,
K. Miura, T. Negoro, K. Watanabe
1.236 Investigation Of White Matter
Integrity In Patients With Psychogenic
Non-Epileptic Seizures/S. Lee,
J. Allendorfer, T. Gaston, K. Hernando,
R. C. Knowlton, J. Szaflarski,
L. W. Ver Hoef
42
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.237 The Severity Of Brain Atrophy
In Temporal Lobe Epilepsy Is Unrelated
To The Side Of The Focus: An Engel
Class I Study/M. Liu, N. Bernasconi,
A. Bernasconi, B. Bernhardt
1.238 Epileptogenic Tubers:
Conventional MRI Findings/Y. Hirata,
A. Yogi, R. Harris, B. Ellingson,
N. Salamon
1.239 Unilateral Brain Oedema
Related To Focal Status Epilepticus/
N. Ali, S. Palat Chirakkara, J. Reddy,
S. Sinha
1.240 Voxel-Based Morphometric MRI
Post-Processing May Provide Relevant
Targets For Reoperation In
Nonlesional Epilepsies/Z. Wang,
P. Suwanpakdee, S. E. Jones,
Z. Jaisani, B. Krishnan, R. Prayson,
R. Burgess, I. Najm,
J. Gonzalez-Martinez, W. Bingaman,
A. Alexopoulos
1.241 Callosal And Diffusion Features
In High-Functioning Subjects With
Pyridoxine-Dependent Epilepsy/
S. D. Friedman, G. E. Ishak,
A. V. Poliakov, S. L. Poliachik,
C. B. Budech, D. W. Shaw,
S. M. Gospe
1.242 A Case Of Periodic Lateralized
Epileptiform Discharges (PLEDs)
Causing Concordant Reversible MRI
Changes/S. Chen, S. Schmitt,
K. Davis
1.243 Longitudinal Diffusion Tensor
Imaging Study In Cryptogenic West
Syndrome/C. Ogawa, J. Natsume,
T. Fukasawa, H. Kidokoro,
H. Yamamoto, Y. Sakaguchi, Y. Ito,
T. Takeuchi, S. Yokoi, Y. Azuma,
N. Ishihara, K. Miura, T. Kubota,
N. Ando, T. Negoro, K. Watanabe
1.244 MRI Spectrum Of Unilateral
Temporal Lobe Epilepsy: A Surface-
Based Pattern Analysis Of
Mesiotemporal Sub-structures/
B. Bernhardt, H. Kim, A. Bernasconi,
N. Bernasconi
1.245 Usefulness Of DTI Analysis Of
Brain Tissue Surrounding The Cortical
Tuber For Predicting Epileptogenicity
In Tuberous Sclerosis Patients/A. Yogi,
Y. Hirata, E. Karavaeva, J. Wu,
S. Yudovin, B. Ellingson, G. Mathern,
N. Salamon
1.246 Impaired Perception Of Anxiety
In Others Is Related To Right Superior
Temporal Gyrus Volume In Temporal
Lobe Epilepsy/G. P. Thomas,
K. Bujarski
1.247 Hippocampal Internal
Architecture Asymmetry In Well-
Controlled And Drug-Resistant
Temporal Lobe Epilepsy/T. E. Gaston,
L. Perry, L. Ver Hoef
1.248 Evidence Of Regional Thinning
Of The Cerebral Cortex In
Asymptomatic Siblings Of Patients
With Mesial Temporal Lobe Epilepsy/
S. Alhusaini, C. Doherty,
M. Fitzsimons, G. Cavalleri,
N. Delanty
1.249 Toward A Quantitative
Measure Of Hippocampal Internal
Architecture Clarity: A Proposed
Method And Its Utility In Predicting
Seizure Laterality In Temporal Lobe
Epilepsy/L. Perry, T. E. Gaston,
L. Ver Hoef
1.250 Volume Renderings Of
Intraoperative Electrocorticography In
Epilepsy/S. Poliachik, R. Hevner,
E. Novotny, A. V. Poliakov, G. Ishak,
H. Eslamy, J. Kuratani, R. Saneto,
J. Ojemann
1.251 Cortical Thickness And
Surgical Outcome In Patients With
Non-Lesional Neocortical Epilepsy/
V. Pilli, D. Kamson, C. Juhasz,
J. Jeong, E. Asano, S. Sood, H. Chugani
1.252 Psychopathology, Cortical
Thickness And Sulcal Depth In
Pediatric Epilepsy/R. Caplan,
P. Siddarth, D. Tosun, S. Gurbani,
J. Levitt
1.253 Loss Of Hippocampal Internal
Architecture In Temporal Lobe
Epilepsy Demonstrated With High
Resolution 4.7-T Fast Spin Echo
Imaging/T. A. Steve, Y. Huang,
N. V. Malykhin, A. H. Wilman,
D. W. Gross
1.254 Pediatric Epilepsy:
Developmental Vulnerability Of
Cortical Thickness And Sulcal Depth/
P. Siddarth, D. Tosun, S. Gurbani,
J. Levitt, R. Caplan
Functional Imaging
1.255 Can Resting-State Functional
Connectivity Predict Seizure Outcome
After Anterior Temporal
Lobectomy?/G. Doucet, D. Pustina,
P. Barnett, A. Ghani, C. Skidmore,
A. Sharan, J. Evans, M. Sperling,
J. Tracy
1.256 Spatiotemporal Mapping Of
Multiple Spikes Using Distributed
Source Analysis/N. Tanaka, N. Suzuki,
S. Stufflebeam
1.257 Stress Perception And Seizure
Control Modulate The Neural
Response To Psychosocial Stress In
Patients With Left Temporal Lobe
Epilepsy/J. B. Allendorfer, H. Heyse,
B. A. Szaflarski, L. Mendoza,
N. Cohen, E. B. Nelson,
J. C. Eliassen, J. M. Storrs,
J. Szaflarski
1.258 Language Mapping In Epileptic
Patients Represented By
Magnetoencephalography: Utility Of
Movement Compensation Algorithm/
N. Suzuki, N. Tanaka, S. Stufflebeam
1.259 Temporal Lobe Spikes: EEG-
fMRI Contributions to the Mesial Vs.
Lateral Debate/S. Watanabe,
F. Dubeau, J. Gotman
1.260 Modeling Channel-Specific
Hemodynamic Response Function In
Epilepsy With EEG-fNIRS Data/
K. Peng, D. K. Nguyen, T. Tayah,
P. Vannasing, J. Tremblay, M. Sawan,
F. Lesage, P. Pouliot

Saturday December 6, 2014
1.261 Can FDG-PET Find
Epileptogenic Tuber In Tuberous
Sclerosis Complex?/Y. Hirata, A. Yogi,
E. Karavaeva, R. Harris, B. Ellingson,
N. Salamon
1.262 Studies In Epilepsy Patients
Using Simultaneous PET/MR:
Preliminary Results/Y. S. Ding,
B. Chen, C. Glielmi, K. Friedman,
O. Devinsky
1.263 Electric Source Imaging (ESI)
In Presurgical Epilepsy Investigations:
The Importance Of High Electrode
Density And Temporal Lobe Coverage
In Patients With Mesiotemporal And
Neocortical Temporal Foci/G. Lantz,
M. Terrill, T. Gilbert, P. Luu,
A. Bunnenberg, D. Tucker
1.264 Widespread BOLD Activation In
MR Negative Patients With Bi-Temporal
Epileptiform Discharges Studied With
Simultaneous Intracranial EEG fMRI/
C. Beers, I. Gaxiola Valdez,
D. J. Pittman, Y. Aghakhani,
P. Federico
1.265 Evaluation Of The Changes In
Interictal Magnetoencephalography
(MEG) Spikes By Gradient Magnetic
Field Topography (GMFT) Analysis
Before And After Anterior Corpus
Callosotomy For Symptomatic
Generalized Epilepsy With Drop-
Attacks/K. Kagawa, K. Iida,
A. Hashizume, M. Kartagiri, Y. Kiura,
R. Hanaya, K. Arita, K. Kurisu
1.266 Quantitative FDG-PET
Neuroimaging In Medically Refractory
Epilepsy: UPenn Experience/
A. A. Thaker, J. G. Dubroff, M. Brown,
K. A. Davis
1.267 MRI, PET, SPECT, And
Pathology Results Do Not Predict
Seizure Outcome Following Epilepsy
Surgery In Children With Focal
Cortical Dysplasia/R. W. Dudley,
B. Badesch, V. Allen, A. White,
D. Mirsky, S. Nick, B. ONeill, S. Koh,
M. Handler, P. Laoprasert
1.268 Effect Of EEG Electrode
Number On Epileptic Source
Localization In Pediatric Patients/
A. Sohrabpour, Y. Lu, P.
Kankirawatana, B. He
1.269 Dynamic FRET-FLIM Imaging Of
TrkB Activation In Living Cells/
S. C. Harward, N. G. Hedrick,
R. Yasuda, J. McNamara
Comorbidity (Somatic and
Psychiatric)
Medical Conditions
1.270 Analgesic Opioid Use In A
Health-Insured Epilepsy Population
During 2012/A. Wilner, B. Sharma,
A. Soucy, A. Krueger
1.271 Prevalence Of Restless Leg
Syndrome In Patients With Epilepsy/
N. K. Sethi, T. Tropea, L. Katus
1.272 Prevalence Of Epilepsy As A
Comorbidity With Stroke In The U.S./
A. K. Birnbaum, I. E. Leppik,
K. H. Svendsen, L. E. Eberly
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.273 Association Between
Depressive Symptoms And Seizure
Response Among Subjects With
Refractory Partial-Onset Seizures In
Clinical Trials Of Eslicarbazepine
Acetate/F. F. Velez, T. C. Bond,
X. Wang, K. P. Anastassopoulos,
R. Sousa, D. Blum, F. Rocha,
J. A. Cramer
1.274 Non-Epileptic Seizures In A
Population Of Diagnosed Pediatric
Epilepsy Patients/R. Villalobos,
E. Gonzales
1.275 Reproductive Health In Indian
Women With Epilepsy A Cross
Sectional Quantitative Survey/
M. Singh, A. EB, M. Agarwal,
R. Pandey
Psychiatric Conditions
1.276 Paroxysmal Non-Epileptic
Events In A Pediatric Population/
T. Sawchuk, J. D. Smith, S. DAlfonso,
J. Buchhalter
1.277 Medications Implicated In
Psychogenic Seizures: Insights From
The OpenFDA Initiative/V. S. Wong,
P. Motika
1.278 Differentiating Epileptic From
Non-Epileptic Seizures Through
Patterns Of Comorbidities And
Pharmacologic Management/
W. T. Kerr, E. A. Janio, C. T. Braesch,
J. M. Hori, J. M. Le, K. R. Raman,
A. B. Patel, S. E. Barritt,
E. S. Hwang, E. C. Davis,
D. Torres-Barba, N. Salamon,
J. Engel, J. Stern, M. S. Cohen
1.279 Psychiatric Comorbidity In
Idiopathic Generalised Epilepsies/
A. Loughman, N. Bendrups,
S. C. Bowden, W. DSouza
1.280 Stress-Triggered Seizures: A
Focus On Anxiety, Depression, And
Childhood Trauma/H. R. McKee,
A. Linane, R. Azzam, B. Abou-Khalil
1.281 Personalities Of Patients With
Psychogenic Non-Epileptic Seizures/
P. Rawal, M. Szaflarski, J. Saenz,
Z. Richardson, B. Dworetzky,
J. Szaflarski
1.282 The Impacts Of Attention-
Deficit Hyperactivity Disorder On
Epilepsy Children/S. Park
1.283 Behavioural Features Of
Patients With Psychogenic Non-
Epileptic Seizures (PNES)/
C. Helmstaedter
1.284 Why Are We Excluding
Patients With Epilepsy From Clinical
Trials Of Transcranial Magnetic
Stimulation To Treat Depression?/
S. D. Forman, J. Roberts,
B. A. Congedo, B. H. Hanusa,
A. C. Van Cott
1.285 Patterns And Frequency Of
The Treatment Of Depression In
Persons With Epilepsy/K. M. Fiest,
S. B. Patten, C. Altura, A. G. Bulloch,
C. Maxwell, S. Wiebe, S. Macrodimitris,
N. Jett
1.286 Reducing Severity Of Comorbid
Psychiatric Symptoms In An Epilepsy
Clinic Using A Co-Location Model/
J. J. Chen, T. Caller, J. N. Mecchella,
D. S. Thakur, K. A. Homa, C. Finn,
E. Kobylarz, K. Bujarski, V. Thadani,
B. Jobst
1.287 Seizure Severity Among
Subjects With Refractory Partial-
Onset Seizures: Analysis Of The
Seizure Severity Questionnaire In A
Phase III Trial Of Eslicarbazepine
Acetate/J. A. Cramer, T. C. Bond,
F. F. Velez, X. Wang,
K. P. Anastassopoulos, R. Sousa,
SATURDAY
F. Rocha, D. Blum
1.288 New Risk Factor
Considerations In The Nonepileptic
Patient Population: A Medication Use
Review/S. Mason, P. Penovich,
R. Lyons
Animal Studies
1.289 Interaction Between Recurrent
Seizures And Autism-Like Behavior In
A Mouse Model Of Maternal Immune
Activation/A. Mazarati,
J. Washington III, R. Sankar, D. Shin,
U. Kumar
1.290 Seizures Amplify Autistic
Behavioral Deficits In Mouse Models
Of 15q Duplication: A Potential Role
For Heightened PI3K/AKT Signaling/
V. Krishnan, M. Anderson
1.291 Carbamazepine Inhibits Native
Sodium Currents In Murine
Osteoblasts/S. J. Petty,
C. J. Milligan, M. Todaro, T. J. OBrien,
J. D. Wark, E. J. Mackie, S. Petrou
1.292 A Single Acute Pre-Training
Seizure Impairs Long Term Fear
Memory In Mice/A. Holley, J. Lugo
1.293 Seizure Propagation To Sleep
Triggers In The Lateral Hypothalamus
Of Kcna1-Null Knockout Mice/
K. Simeone, T. Simeone
Antiepileptic Drugs
Mechanisms Of Action
1.294 Epilepsy-Associated Mutant
Voltage-Gated Sodium Channels Alter
Resurgent Current Generation That
Could Be Preferentially Targeted With
Cannabidiol/R. Patel, C. Barbosa-Nunez,
T. R. Cummins
1.295 Levetiracetam Modify Synaptic
Vesicle Protein Expression And
Reduce Abnormally Augmented
Presynaptic Vesicular Release After
Pilocarpine-Induced Status
Epilepticus/E. Garrido, L. Pacheco,
V. Funck, N. Ruvalcaba, J. Rodriguez,
D. Taylor, R. Garcia, J. Martinez,
C. Castro, C. Upreti, P. Stanton
1.296 Novel GABAA Positive
Alllosteric Modulator Neuroactive
Steroids As Potential Therapies For
Epilepsy/A. J. Robichaud, J. Doherty,
R. Hammond, G. Belfort, F. Salituro,
G. Martinez, M. Ackley
43

Saturday December 6, 2014
Animal Studies
1.297 Inhibitory Effect Of Cys LT
Receptor Antagonist Pranlukast On
MES And PTZ Induced Seizures/
Y. Ueda, L. Willmore
1.298 Consistent Seizure
Suppression By Brivaracetam In
Animal Models Of Partial Epilepsy
Includes Protection Against
Pilocarpine- And Kainic Acid-Induced
Partial Seizures In Rats/A. Matagne,
H. Klitgaard
1.299 TrkB Receptor Activation
Improves Interneuronal Function And
Suppresses Epileptiform Activity
Following Traumatic Brain Injury/F. Gu,
Y. Ma, I. Parada, L. Faria, F. M. Longo,
D. A. Prince
1.300 High Dose Levetiracetam
Could Be Used Prophylactically To
Reduce The Severity Of Brain
Damages Associated With Status
Epileptics In Pilo Model/K. Itoh,
Y. Ishihara, Y. Chiba, M. Ueno
1.301 Lacosamide And Levetiracetam
Modulate The Development Of
Interictal Spikes And High-Frequency
Oscillations During Epileptogenesis/
M. Lvesque, C. Behr, M. Avoli
1.302 Huperzine A Increases Cortical
Inhibition And Prevents
Pentylenetetrazole-Induced Seizures
In Rat/R. Gersner, D. Ekstein,
S. Schachter, A. Rotenberg
1.303 Neuroactive Steroids Halt
Electrographic Seizures In The
Lithium-Pilocarpine Model Of
Pharmaco-Resistant Status
Epilepticus/G. Belfort, R. Hammond,
E. Christian, M. Ackley, C. Maciag,
A. Robichaud, J. Doherty
1.304 Acute Spasm Reduction With
Celastrol In The Multiple-Hit Rat
Model Of Infantile Spasms/
O. Shandra, W. Mowrey,
A. S. Galanopoulou
1.305 Efficacy And Tolerability Of An
Interleukin 1 Receptor Antagonist
(IL-1Ra) In The Multiple- Hit Rat Model
Of Refractory Infantile Spasms/T.
Brima, W. Mowrey, S. Mosh,
A. S. Galanopoulou
Clinical Trials
1.306 An Evaluation Of The Impact Of
Memory On Antiepileptic Drug
Adherence/J. McAuley, N. Passen,
C. Prusa, J. Jih, S. Hart, B. Shneker
1.307 Efficacy Of USL255 (Qudexy
XR; Extended-Release Topiramate) In
Patients With Refractory Partial-
Onset Seizures: PREVAIL and
PREVAIL OLE/A. M. Clark,
S. S. Chung, I. Blatt, B. Anders,
M. B. Halvorsen, R. E. Hogan
1.308 Long-Term Efficacy Of USL255
(Qudexy XR; Extended-Release
Topiramate) In Patients With
Refractory Partial-Onset Seizures:
PREVAIL OLE/R. Hogan, I. Blatt,
A. M. Clark, B. Anders,
M. B. Halvorsen, S. S. Chung
44
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.309 Effects Of Topiramate On
Growth And Development In Children
With New Or Recent- Onset Epilepsy:
A Phase-4 Randomized, Active-
Controlled Study/L. Ford, Y. Shi,
P. Manitpisitkul
1.310 Prospective Randomized
Single-Blinded Trial Of Lacosamide
Versus Fosphenytoin For Seizure
Prophylaxis In Traumatic Brain
Injury/J. Szaflarski, L. A. Shutter,
L. Mendoza, M. Szaflarski
1.311 Treatment Of Refractory
Status Epilepticus With Enteral
Topiramate/A. Asadi-Pooya
1.312 Relationship Between
Eslicarbazepine Exposure And Safety
Endpoints For Eslicarbazepine
Acetate Monotherapy/T. Fakhoury,
J. Harvey, R. T. Wechsler, J.
Passarell, J. Fiedler-Kelly, E. Ludwig,
D. Blum, S. Sunkaraneni
1.313 The Impact Of Anticonvulsants
On Neurological Outcomes In
Neonatal Seizures/J. Han, I. Lee,
E. Kim, S. Park
1.314 Relationship Between
Exposure And Efficacy Of
Eslicarbazepine Acetate
Monotherapy/J. Rogin, A. J. Cole,
L. Strom, J. Passarell, J. Fiedler-Kelly,
E. Ludwig, D. Blum, S. Sunkaraneni
1.315 Incidence Of Falls, Fractures,
And Injuries With Adjunctive
Eslicarbazepine Acetate In Patients
With Refractory Partial-Onset
Seizures: A Pooled Analysis Of Three
Placebo-Controlled Trials/
W. Rosenfeld, S. Benbadis, P. Klein,
L. Specchio, P. Kowacs, H. Gama,
F. Rocha, R. Claus, D. Blum
1.316 Hepatic Safety Of
Eslicarbazepine Acetate: Summary Of
Five Phase II And Three Phase III
Adjunctive Trials/D. Blum, P. Van Ness,
G. Krauss, S. Chung, C. Elger,
C. Galimberti, H. Gama, F. Rocha,
R. Claus
1.317 Eslicarbazepine Acetate As
Adjunctive Therapy For Refractory
Partial-Onset Seizures: Analysis Of
Cognitive Adverse Events/
E. Andermann, S. Benbadis, A. Shah,
E. Trinka, A. Biraben, R. Sousa,
H. Gama, D. Blum, R. Claus
1.318 Eslicarbazepine Acetate
Monotherapy In Adults With Partial-
Onset Seizures: A Pooled Analysis Of
Two Randomized Double-Blind Studies
With Use Of A Historical Control/
L. Pazdera, J. French, M. Sperling,
M. Jacobson, H. Cheng, D. Blum
1.319 Relationship Between
Eslicarbazepine Exposure And Efficacy
Of Eslicarbazepine Acetate Adjunctive
Therapy/J. Harvey, E. Andermann,
S. Chung, E. Trinka, F. Cendes,
J. Passarell, J. Fiedler-Kelly,
E. Ludwig, S. Sunkaraneni, R. Sousa,
F. Rocha, D. Blum
1.320 Relationship Between
Eslicarbazepine Exposure And Safety
Endpoints For Eslicarbazepine
Acetate Adjunctive Therapy/
P. Penovich, G. Krauss,
M. R. Sperling, S. Striano, C. Elger,
J. Passarell, J. Fiedler-Kelly,
E. Ludwig, S. Sunkaraneni, R. Sousa,
F. Rocha, D. Blum
1.321 Eslicarbazepine Acetate
Monotherapy: A Population
Pharmacokinetic Analysis/
B. Abou-Khalil, I. Ali, A. Shah,
J. Fiedler-Kelly, E. Ludwig,
S. Sunkaraneni, D. Blum
1.322 Lack Of Exacerbation Of
Partial-onset Seizures During
Adjunctive Treatment With
Eslicarbazepine Acetate: A Pooled
Analysis Of Three Phase III Controlled
Trials/S. Benbadis, M. Carreo,
S. Striano, R. Sousa, F. Rocha,
D. Blum, H. Cheng
1.323 Evaluation Of Physical
Dependence Potential Following
Abrupt Discontinuation Of Adjunctive
Eslicarbazepine Acetate: A Pooled
Analysis Of Adverse Events From Ten
Studies/K. A. Schoedel,
M. R. Sperling, M. Bensalem-Owen,
D. Blum, R. Sousa, H. Gama, R. Claus
1.324 Bioequivalence Testing Of
Disparate Generic Lamotrigine
Products Using Chronic Dosing In
People With Epilepsy: The Equigen
Study/M. Privitera, F. Diaz,
B. Dworetzky, P. Bolger, R. Krebill,
B. Gidal, E. Elder, A. Paige,
J. Szaflarski, T. Welty, J. Pollard,
W. Jiang, N. McBee, M. Berg
1.325 Assessment Of Renal Toxicity
In Perampanel-Treated Subjects:
Pooled Results From Phase III Clinical
Studies/I. Leppik, H. Yang, B. Williams,
D. Xing, A. Laurenza
Cohort Studies
1.326 Parental Reporting Of
Response To Oral Cannabis Extracts
As Adjunctive Treatment For Medically
Refractory Epilepsy/C. Press,
K. Knupp, K. Chapman
1.327 Lacosamide Efficacy And
Tolerability In Clinical Practice Post
Marketing Analysis/M. Baker,
H. Sonmezturk, A. Arain, K. Haas,
N. Azar, B. Abou-Khalil
1.328 Efficacy And Tolerability Of
Intravenous Levetiracetam Versus
Phenobarbital In Children With Status
Epilepticus Or Acute Repetitive
Seizures/Y. Lee, M. Yum, E. Kim,
T. Ko
1.329 Clobazam Higher-Evening
Differential Dosing As An Add-On
Therapy In Refractory Epilepsy/
M. Jackson, S. Thome-Souza,
J. Klehm, N. E. Kadish, I. Snchez
Fernndez, T. Loddenkemper

Saturday December 6, 2014
1.330 The Effects Of Antiepileptic
Drugs On Cortical Irritability In
Patients With Tumoral Epilepsies/
P. Warren, L. B. Nabors, J. Szaflarski
1.331 Adjunctive Perampanel For
Focal-Onset Seizures An Interim
Analysis/K. Kelly, L. Stephen,
P. Parker, M. Brodie
1.332 Fydata Study: Retrospective
Analysis Of Perampanel In A Real-Life
Setting/V. Villanueva, M. Garces,
F. Lpez Gonzalez,
X. Rodriguez-Osorio, J. Rodriguez
Uranga, E. Lpez-Gomriz, J.
Montoya, J. Poza Aldea, A. Molins,
R. Saiz-Diaz, J. Gonzlez de la Aleja,
J. Mauri, A. Castillo, F. Lopez-Trigo
Picho, M. Toledo, J. Salas Puig,
D. Campos Blance, J. Flores
1.333 Intravenous Intiation Of
Lacosamide For Status Epilepticus
And Following Video EEG Monitoring/
G. Morris, J. Burgos, A. Van Kampen,
M. Hanson, J. Dagam
1.334 Clobazam Vs. Clonazepam For
Adults With Epilepsy: Long-Term
Results From A UK Primary Care
Database/M. Brodie, S. S. Chung,
A. G. Wade, C. Quelen,
A. Guiraud-Diawara, C. Franois,
P. Verpillat, V. Shen, D. Jones,
J. Isojarvi
1.335 Long-Term Utilization
Differences Between Children Treated
With Clobazam Vs. Clonazepam For
Epilepsy In The UK/S. S. Chung,
M. Brodie, A. G. Wade, C. Quelen,
A. Guiraud-Diawara, C. Franois,
P. Verpillat, V. Shen, D. Jones,
J. Isojarvi
1.336 Evolution Of Clobazam,
Clonazepam, And Diazepam Usage In
The UK For Epilepsy And Other
Diseases/D. Jones, S. S. Chung,
M. Brodie, A. G. Wade, C. Quelen,
A. Guiraud-Diawara, P. Verpillat,
V. Shen, J. Isojarvi, C. Franois
Other
1.337 Population Pharmacokinetic
Modeling Of Immediate And Extended-
Release Topiramate (SPN-538,
Trokendi XR) In Adults With Epilepsy:
Characterization f Different
Absorption Rates/E. Roers,
S. T. Brittain, J. D. Stocks,
J. K. Johnson
1.338 Unexplained Spikes In
Lamotrigine Serum Concentration
Suggest Nonlinear Elimination
Kinetics In Some Individuals/P. Ramey,
M. Osborn, K. Lowen, B. Abou-Khalil
1.339 A New Method To Determine
Linear Non-Steady State
Pharmacokinetic Parameters In The
Acute Care Setting/L. Olson
1.340 A Comparison Among The
Various Carbamazepine-Related
Antiepileptic Drugs/E. Vernier,
S. R. Benbadis, M. Giarratano
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.341 Acute Seizure Management
With Intravenous Levetiracetam In
Neonates And Children/B. Kirmani,
W. Hastings, O. Khan, P. Patel,
A. Sarode, R. Castillo,
M. Kempapura, S. Agadi, J. Aceves
1.342 A Systematic Review And
Network Meta-Analysis Of
Eslicarbazepine Acetate And Other
Recently-Approved Anti-Epileptic
Drugs For Adjunctive Treatment Of
Partial-Onset Seizures In Adults/
K. Betts, V. Bollu, G. De, D. Blum,
F. Velez
1.343 Once-Daily Trokendi XR
(SPN-538) Dosing In Children With
Epilepsy/J. D. Stocks, S. T. Brittain,
J. K. Johnson
1.344 Cost-Effectiveness Of
Eslicarbazepine Acetate In Refractory
Partial-Onset Epilepsy/K. ODay,
F. Velez, K. Meyer
1.345 Ezogabine Usage In Pediatric
Patients: A Retrospective Review Of
Safety And Efficacy From Two
Academic Institutions/J. Toler,
K. Chapman, T. Loddenkemper,
J. Klehm
Surgery
Adult
1.346 Magnetoencephalography-
Guided Surgery In MRI Negative Or
Ill-Defined Frontal Lobe Epilepsy Using
Neuronavigation And Intraoperative
MR Imaging/B. Sommer, K. Roessler,
I. Blumcke, S. Rampp, H. Hamer,
M. Buchfelder, H. Stefan
1.347 Effects Of Invasive EEG
Monitoring On Memory And Language
After Left Anterior Temporal
Lobectomy: A Propensity Model
Analysis/R. M. Busch, T. E. Love,
L. E. Jehi, L. Ferguson, R. Yardi,
W. Bingaman, J. Gonzalez-Martinez
1.348 Temporal Plus Seizures Are
The Main Prognostic Factor For
Unfavourable Surgical Outcome In
Patients With Temporal Lobe
Epilepsy/C. Barba, S. Rheims,
L. Minotti, J. Isnard, D. Hoffmann,
S. Chabardes, M. Guenot, P. Ryvlin,
P. Kahane
1.349 Stereotactic Laser Ablation Is
A Potentially Curative Procedure After
Unsuccessful VNS Or RNS For Mesial
Temporal Lobe Epilepsy/J. J. Shih,
R. Wharen, W. Tatum, R. Gross,
J. Willie, D. Labiner, M. Weinand,
A. Sharan, M. Sperling
1.350 Intraoperative Supplementary
Motor Area (SMA) Monitoring For
Medial Frontal Lesions/S. Shibata,
T. Kunieda, R. Matsumoto, Y. Yamao,
R. Inano, S. Nishida, T. Nakae,
T. Kikuchi, Y. Arakawa, Y. Takagi,
A. Ikeda, R. Takahashi, S. Miyamoto
1.351 Postoperative Interictal
Epileptiform Discharges Within One
Month After Selective
Amygdalohippocampectomy For Mesial
Temporal Sclerosis/H. Yu, S. Hsu,
C. Lin, Y. Shih
1.352 Individualized Epilepsy Surgical
Outcome Prediction Based On Neural
Network Architecture/L. Bonilha,
J. Lin, D. Drane, J. Jensen,
R. Kuzniecky
Pediatrics
1.353 Language Mapping By
Spontaneous Conversation Related
High- Synchronization And
Comparison With Conventional
Electrical Cortical Stimulation/
R. Arya, J. A. Wilson, J. Vannest,
A. W. Byars, H. Greiner, J. Buroker,
H. Fujiwara, F. Mangano, K. Holland,
SATURDAY
N. Crone, D. Rose
1.354 The Influence Of Lesion Volume,
Perilesional Resection Volume And
Completeness Of Resection On
Seizure Outcome Following Resective
Epilepsy Surgery For Cortical
Dysplasia In Children/C. Oluigbo,
D. Depositario-Cabacar, S. Magge,
J. Myseros, M. Whitehead,
R. Keating, W. Gaillard
1.355 Yield And Predictors Of
Epilepsy Surgery Candidacy In Children
Admitted For Surgical Workup/
O. Haque, K. Nickels, N. Wetjen,
L. Wong-Kisiel, E. Wirrell
1.356 Epilepsy Surgery Outcomes
For Lesionectomy In Non-Dysplastic
Lesions In Children With Intractable
Epilepsy/R. Villalobos, E. Gonzales,
J. Torrez-Corzo
1.357 A Circuitous Journey: Parent
Perspectives Of Getting To Pediatric
Resective Epilepsy Surgery/C. Bower
Baca, H. Pieters, T. Iwaki,
G. Mathern, B. Vickrey
1.358 Posterior Quadrant
Disconnection Surgery For
Sturge-Weber Syndrome/H. Sugano
1.359 Central Cortex-Preserving
Multilobar Surgery: An Alternative
Option For Patients With Hemispheric
Pathology And Minimal Motor
Deficit/T. Ono, H. Baba, K. Toda,
R. Honda
1.360 The Impact Of Epilepsy Surgery
On Paediatric Quality Of Life/W. Hader,
L. Ruttle-Soon, H. Carlson, D. Slick,
L. Bello-Espinosa, E. Sherman
1.361 Is Diffusion Tensor Imaging
Useful To Localize The Epileptic Focus
In Children With MRI-Negative
Epilepsy?/K. Toda, H. Baba, T. Ono,
R. Honda
1.362 Seizure Outcomes After
Resective Epilepsy Surgery In Children
With Lennox-Gastaut Syndrome/
P. Suwanpakdee, A. Naduvil Valappil,
L. Jehi, A. Gupta, W. Bingaman,
J. Gonzalez-Martinez, I. Najm,
E. Wyllie
1.363 Analysis Of Epileptic
Discharges Using Implanted Subdural
Electrodes In Patients With Sturge-
Weber syndrome/Y. Iimura, H. Sugano,
M. Nakajima, T. Higo, H. Arai
45

Saturday December 6, 2014
1.364 Risk Of Seizure Recurrence In
Children With Pathology Confirmed
Focal Cortical Dysplasia Undergoing
Surgical Resection/A. Mrelashvili,
E. Wirrell, K. Nickels, L. Wong-Kisiel
1.365 Surgical Versus Medical
Treatment For Children With Epileptic
Encephalopathy In Infancy And Early
Childhood. An Observational Cohort
Study By Far-East Asia Catastrophic
Epilepsy (FACE) Study Group/T. Otsuki,
H. Kim, G. Luan, Y. Inoue, H. Baba,
H. Oguni, S. Hong, S. Kameyama,
K. Kobayashi, S. Hirose, H. Yamamoto,
S. Hamano, K. Baba, A. Takahashi,
T. Kaido, K. Sugai
1.366 Visualization Of Epileptogenic
Networks From Interictal iEEG Using
Granger Causality/J. R. Madsen,
E. Park
1.367 Clinical Factors For Long-Term
Seizure Remission And Developmental
Outcome After One-Stage Total
Corpus Callosotomy/M. Iwasaki,
M. Uematsu, T. Nakayama,
N. Hino-Fukuyo, K. Haginoya,
S. Osawa, Y. Shimoda, K. Jin,
N. Nakasato, T. Tominaga
All Ages
1.368 Long-Term EEG And Clinical
Outcome Of Laser Thermal Ablation In
Large Series Of Lesional And Non-
Lesional Epileptic Foci In Adults And
Children/M. Chez, A. Ghassemi,
S. Ciricillo
46
Poster Session 1
Noon - 6:00 p.m.
Convention Center Hall 4B, Level 4
1.369 Factors Associated With Failed 1.375 Long-Term Product Reliability
Extra-Temporal Lobe Epilepsy For Implantable VNS Therapy
Surgery/D. J. Englot, K. Raygor, Generators And Leads/C. M. Gordon,
P. Garcia, R. C. Knowlton, M. T. Bunker
K. I. Auguste, E. Chang 1.376 Conformal Laser Ablation: A
1.370 Inflammatory Mediators Role In Safe & Effective Treatment For Focal,
Epileptogenesis Caused By Cavernous Non-Mesial Temporal Lobe Epilepsy/
Angioma/M. Nakajima, H. Sugano, S. Bandt, A. H. Hawasli, R. E. Hogan,
Y. Iimura, T. Higo, Y. Harada, H. Arai E. Leuthardt
1.371 The Role Of Corpus 1.377 Development And Validation Of
Callosotomy And Vagus Nerve A Prognostic Nomogram Of Seizure-
Stimulation For Medically Refractory Freedom After Resective Epilepsy
Epilepsy And Their Future As Palliation Surgery/L. Jehi, R. Yardi, K. Chagin,
In Epilepsy Surgery/T. Yamamoto, L. Tassi, G. Worrell, F. Cendes,
A. Fujimoto, T. Yamazoe, T. Okanishi, M. Morita, F. Bartolomei, P. Chauvel,
T. Yokota, H. Enoki I. Najm, J. Gonzalez-Martinez,
1.372 Temperatures Achieved In W. Bingaman, M. Kattan
Human And Canine Neocortex During
Intraoperative Passive Or Active Focal
Cooling/R. Han, C. Yarbrough,
S. Rothman, E. Patterson, X. Yang,
J. Miller, R. DAmbrosio, M. Smyth
1.373 Medical Cost Reduction By
Vagus Nerve Stimulation/A. Onomura,
T. Yamamoto, H. Iseki, K. Iwasaki,
M. Umezu
1.374 Surgical Outcome Of
Lesionectomy Vs Lesionectomy +
Temporal Lobectomy For Lesional
Temporal Lobe Epilepsy/V. Rajasekaran,
D. B. Burkholder, G. Worrell,
R. Marsh, F. Meyer, J. Mandrekar,
J. Britton
 AES 68TH ANNUAL MEETING
SUNDAY December 7, 2014
www.AESnet.org
8:45 a.m. 4:45 p.m.
Investigators Workshops
Location listed under each session
Overview
These workshops, conducted informally and designed to encourage
interaction, will address several important areas of rapidly-emerging
knowledge in clinical and basic research in epilepsy. The workshops are
intended to identify challenges in current research, propose methods to
overcome those challenges, and encourage areas for future investigation.
The Basic Science Investigator Workshops will highlight a number of research
areas that have been developing rapidly over the last year. Participants include
established and junior epilepsy investigators as well as researchers outside
the epilepsy community who have specialized expertise that may be applied
to epilepsy basic science. In addition, one of the workshops features
presentations by junior investigators in cutting-edge areas of research.
The Clinical Investigators Workshops provide a series of working seminars in
matters of active clinical investigation and controversy. Speakers present
results from their ongoing research and place their findings in the context of
current understanding.
Most of the workshops will run as concurrent sessions on Sunday, with a
single workshop on Saturday afternoon on cannabis and epilepsy and another
Monday afternoon on stem cells.
Target Audience
Basic scientists, neurologists, neuroscientists, pharmacologists,
neuropsychologists and neurosurgeons who are performing research in
epilepsy
Program
Investigators Workshop Chair: Michael Wong, M.D., Ph.D.
Clinical Investigators Workshop Chair: Hal Blumenfeld, M.D., Ph.D.
Morning Session I 8:45 a.m. - 10:15 a.m.
1. Yes, Focal Epilepsy Is a Network, But Does it Matter?
Convention Center Room 608, Level 6
Moderator: Jean Gotman, Ph.D.
Speakers: Christophe Grova, Ph.D., Philippe Kahane, M.D., Ph.D.,
Michael R. Sperling, M.D.
This Investigator Workshop is supported in part by Acorda
Therapeutics.
2. How Does Status Epilepticus Provoke the Generation of
'Epileptic Neurons'?
Convention Center Room 613, Level 6
Moderator: Tallie Z. Baram, M.D., Ph.D.
Speakers: Katja Kobow, Ph.D., Jong M. Rho, M.D., Ph.D.,
Gary P. Brennan, Ph.D.
3. Unraveling the Basis of Heterogeneity in Genetic Epilepsy
Convention Center Room 609, Level 6
Moderator: Samuel F. Berkovic, M.D.
Speakers: Christopher Reid, Ph.D., Dennis Dlugos, M.D.,
Peter B. Crino, M.D., Ph.D.
Break: 10:15 a.m. - 10:30 a.m.
Seattle, WA
Morning Session II 10:30 a.m. - Noon
4. Teratogenesis of Antiepileptic Drugs
Convention Center Room 608, Level 6
Moderator: Kimford J. Meador, M.D.
Speakers: Patrick Forcelli, Ph.D., Page B. Pennell, M.D.,
Kimford J. Meador, M.D.
5. Hot Topics and Late-breaking Research from Young Investigators in
the Epilepsy Community
Convention Center Room 613, Level 6
Moderators: Chris Dulla, Ph.D., Michael Wong, M.D., Ph.D.
Speakers:
Gemma Carvill, Ph.D.: The Expanding Role for Chromatin Remodeling
in Epilepsy: Gene Discovery to Pathogenic Mechanisms
Bethany Hosford, Ph.D.: Impact of Targeted Ablation Of Developing
Dentate Granule Cells On Temporal Lobe Epileptogenesis
Matt Weston, Ph.D.: Hyperactivation of mTOR Signaling in a Two-
Neuron Microcircuit Alters the Dynamics of Synaptic Transmission
SUNDAY
Dan Xu, Ph.D.: A Novel Therapy for Status Epilepticus Using
Biodegradable Immune-Modifying Nanoparticles
6. Low-frequency Stimulation in Epilepsy
Convention Center Room 609, Level 6
Moderator: Mohamad Koubeissi, M.D.
Speakers: Mohamad Koubeissi, M.D., Dominique Durand, Ph.D.,
G. Campbell Teskey, Ph.D.
Noon - 1:30 p.m. Poster Session (Lunch)
Convention Center Room 6F, Level 6
Note: Number below refers to poster assignment
1.001 Enhanced Histamine Release During The Pilocarpine-Induced Status
Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats:
Effects Of Sodium Cromoglycate/Luisa Rocha
1.003 Time- And Region-Specific Alterations In Cyclin D1 Expression
Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/
Y Cruz Del Angel
1.007 Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability
In The Normal And Injured Brain/Viji Santhakumar
1.014 Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal
Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of
Temporal Lobe Epilepsy/Paul Buckmaster
1.018 Human Single Neuron Correlates Of High Frequency Oscillations
During Seizures/Omar Ahmed
1.024 The mTOR Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced
Dendritic Injury In Mice/Dongjun Guo
1.025 TRPV1 Receptors Modulate The Expression Of Experimental Febrile
Seizures During Development In Mice/Karlene Barrett
1.026 Hypothermia Prevents The Development Of The Calcium Plateau
Following Status Epilepticus/Kristin Phillips
1.027 Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In
Mice Following Controlled Cortical Impact/Jeffery Boychuk
1.030 Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces
Hippocampal Structural Pathology And Spontaneous Recurrent
Seizures/Cezar Gavrilovici
1.039 GABA Agonists Restore Inhibitory GABA Neurotransmission in
Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/
Antoine Depaulis
1.043 Modeling PIK3CA-Related Malformations Of Cortical Development
And Epilepsy In Mice/Franck Kalume
1.044 Thalamic Deep Brain Stimulation To Improve Consciousness After
Seizures/Abhijeet Gummadavelli
47
 SUNDAY December 7, 2014

1.054 Treatment Of Convulsive Status Epilepticus In An Animal Model Of Afternoon Session I 1:30 p.m. - 3:00 p.m.
Glucose Transporter Type 1 Deficiency (G1D) Syndrome/Cary Trent
1.055 Minocycline Reverses Pro-Epileptogenic Effect Of Viral-Like Brain 7. Brain Connectivity in Health and Epilepsy
Inflammation In The Mature And Immature Rat Brain/Nina Dupuis Convention Center Room 608, Level 6
1.056 Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat Moderator: Jeffrey G. Ojemann, M.D.
Pups But Does Not Affect The Adult Rats/Stephane Auvin Speakers: Catherine Chu-Shore, M.D., Luigi Maccotta, M.D., Ph.D.,
1.105 Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/ Kurt Weaver, M.D.
Jun Tohyama 8. SUDEP Mechanisms: A Basic Science Perspective
1.294 Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Convention Center Room 613, Level 6
Resurgent Current Generation That Could Be Preferentially Targeted With Moderators: Gordon F. Buchanan, M.D., Ph.D.
Cannabidiol/Reesha Patel Speakers: Gordon F. Buchanan, M.D., Ph.D., Isamu Alba, Ph.D.,
1.303 Neuroactive Steroids Halt Electrographic Seizures In The Carl L. Faingold, Ph.D.
Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/
James Doherty 9. Finding Risk Alleles in Generalized Epilepsies: Next Generation
1.377 Development And Validation Of A Prognostic Nomogram Of Sequencing and the Virtues of Large Collaborations
Seizure-Freedom After Resective Epilepsy Surgery/Lara Jehi Convention Center Room 609, Level 6
3.001 Increase In Dendritic Spines Correlates With Increased Synapses In Moderator: Slav Petrovski, Ph.D.
Hippocampal CA1 Following Hypoxia-Induced Neonatal Seizures/ Speakers: Slav Petrovski, Ph.D., Roland Krause, Dr. Sci.,
Jocelyn Lippman-Bell Patrick Cossette, M.D.
3.005 Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. Adult-
Born Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/ Break: 3:00 p.m. - 3:15 p.m.
Xi Du Afternoon Session II 3:15 p.m. - 4:45 p.m.
3.006 Disabled 1-Deficient Mice Exhibit Hippocampal Structural
Abnormalities And A Reduced Seizure Threshold/Matthew Korn 10. Stress and Seizures
3.014 Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient Convention Center Room 608, Level 6
With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep Moderators: Michael D. Privitera, M.D.
Syndrome/Hongjie Yuan Speakers: Jane B. Allendorfer, Ph.D., James Herman, Ph.D.,
3.016 Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To Michael D. Privitera, M.D.
KCNT1 Mutations/Imran Quraishi
11. Understanding Infantile Spasms: A Pathogenic Perspective
3.017 A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel
Convention Center Room 613, Level 6
Targeting To The Axon Initial Segment/Baouyen Tran
Moderators: Chris Dulla, Ph.D., Aristea S. Galanopoulou, M.D., Ph.D.
3.022 Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of
Speakers: Chris Dulla, Ph.D., Jeffrey L. Noebels, M.D., Ph.D.,
Drug-Resistant Seizures/Volodymyr Dzhala
John W. Swann, Ph.D.
3.027 Unravelling The EEG Footprints That Develop Into Spontaneous
Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse 12. Which Parts of the Brain Participate in Seizures, and Why
Model Of Temporal Lobe Epilepsy (TLE)/Thimmasettappa Thippeswamy Does It Matter?
3.030 New Model Of Focal Cortical Dysplasia Associated Epilepsy/ Convention Center Room 609, Level 6
Lawrence Hsieh Moderator: Catherine Schevon, M.D., Ph.D.
3.032 Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal Speakers: Andrew Trevelyan, M.D., Ph.D., Hal Blumenfeld, M.D., Ph.D.,
Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe Catherine Schevon, M.D., Ph.D.
Epilepsy/Jennifer Pearson
3.035 Enhancing KCC2 By Acute TrkB Inhibition Rescues Phenobarbital-
Resistant Seizures In A Model Of Neonatal Ischemia/Shilpa Kadam
3.036 Cardiac Consequences Of Repeated Brief Seizures In Chronic
Experimental Temporal Lobe Epilepsy/John Jefferys
3.039 Flupirtine Is More Efficacious Than Phenobarbital In The Treatment
Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/
Dayalan Sampath
3.043 Lithium-Pilocarpine And DFP-Induced Status Epilepticus In
Immature Rats: Behavioral, Electrographic, And Neuropathological
Characteristics/Erika Scholl
3.047 Comparison Of Spike-Wave Discharges And Other Oscillatory
Activity In Normal Animals With Spontaneous Recurrent Seizures Across
Several Animal Models Of Acquired Epilepsy/F. Edward Dudek
3.050 Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And
Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical
Dysplasia/Lena Nguyen
3.063 Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By
Nanoparticles/Sara Eyal
3.070 Early Seizure Detection Using Relative Gamma And Ripple Band
Phase Decoherence/Zoltan Nadasdy
3.089 Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive
Myoclonus Epilepsy/Mikko Muona
3.145 Etiologies And Yield Of Investigations For Infantile Spasms: Results
Of A US Multicenter, Prospective Study/Elaine Wirrell

48
 SUNDAY December 7, 2014

8:45 a.m. 5:15 p.m. Who Should be Reading cEEGs? The Role of the
Annual Course: Seizures and EEG in the Neurointensivist
Edward M. Manno, M.D.
Critically Ill Patient (6.0 CME Credits)
11:50 a.m. Morning Wrap-Up
Convention Center Ballroom 6C, Level 6 Eric Kossoff, M.D.
Noon-2:00 p.m. Lunch Break in Exhibit Hall
Overview
The Annual Course will focus on diagnosis and management of seizures in Treatment Challenges
patients admitted to intensive care units (ICU), both those with known epilepsy
2:00 p.m. Introduction to Afternoon Session
and those with seizures due to systemic illnesses or infection. Topics include:
Eric Kossoff, M.D.
diagnostic challenges, initially regarding etiologies of seizures in ICU patients;
how routine and / or continuous EEG can help (or hinder) management. Financial 2:05 p.m. Case (Johnny, Part 3)
issues and management options for patients having seizures as well as Status Jack Lin, M.D.
Epilepticus in ICU settings. Lectures will cover standard anticonvulsants, 2:10 p.m. Lecture: Pharmacologic Treatment of Status
sedative and coma-inducing agents, as well as non-standard treatments such Epilepticus in the ICU
as surgery, diet, immunomodulatory agents, and TMS. The Annual Course will Daniel H. Lowenstein, M.D.
conclude with a discussion of prognosis and outcomes from seizures as well as 2:30 p.m. Lecture: Pharmacologic Treatment of
status epilepticus. The course will include case presentation, debate and use of Super-refractory Status Epilepticus
audience response system. Joseph I. Sirven, M.D.
Learning Objectives 2:55 p.m. Debate: Should We Treat Anoxic / Myoclonic
u Recognize interictal and ictal EEG patterns in critically ill patients Seizures?
u Define intervention strategies for critically ill patients with both subclinical David M. Ficker, M.D. (Pro) / Jennifer L. Hopp, M.D. (Con)
and refractory clinical Status Epilepticus 3:25 p.m. Lecture: AES Treatment Guidelines for Status

SUNDAY
Epilepticus
u Implements rational medical therapy for seizures in critically ill patients
Tracy A. Glauser, M.D.
u Counsel families regarding implications and prognosis of sub-clinical and 3:40 p.m. Break
clinical Status Epilepticus
3:55 p.m. Flash Panel: Other Treatments to Try When
u Assist physicians in treating subclinical and clinical seizures through use Nothing Else Works
of appropriate medications
Surgery
u Recognize the implications of seizures in a critically ill patient who Yu-tze Ng, M.D.
survived and is now facing neuropsychological difficulties. Ketogenic Diet
Target Audience Mackenzie Cervenka, M.D.
Intermediate and Advanced (see page 120 for details) Steroids / IVIG How Do They Work?
Annamaria Vezzani, Ph.D.
Program
Chair: Eric Kossoff, M.D. Transcranial Magnetic Stimulation
Alexander Rotenberg, M.D., Ph.D.
Diagnostic Challenges 4:35 p.m. Lecture: Long-term Prognosis and Outcomes
8:45 a.m. Introduction to Morning Session Elizabeth J. Waterhouse, M.D.
Eric Kossoff, M.D. 4:55 p.m. Case (Johnny, Part 4 and Conclusion)
8:55 a.m. Case Presentation (Johnny, Part 1) Jerzy P. Szaflarski, M.D., Ph.D.
Andreas Alexopoulos, M.D., M.P.H. 5:00 p.m. Conclusions
9:00 a.m. Lecture: Etiologic Considerations in Seizure Eric Kossoff, M.D.
Screening
Nicholas S. Abend, M.D. Credit Designation
The American Epilepsy Society designates this live activity for a maximum
9:25 a.m. Lecture: EEG in the ICU: Nomenclature and of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
Current Trends commensurate with the extent of their participation in the activity.
Susan T. Herman, M.D.
9:50 a.m. Debate: Utility of Continuous EEG Monitor All Nurses may claim up to 6.0 contact hours for this session.
vs. Be Selective? Pharmacy Credit
Lawrence J. Hirsch, M.D. (Pro) / Paul Vespa, M.D. (Con) AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
10:20 a.m. Break activity for 6.0 contact hours (0.6 CEUs). UAN 0077-9999-14-034-L01-P.
Initial Release Date: 12/7/2014.
10:35 a.m. Case (Johnny, Part 2)
Lily Wong-Kisiel, M.D. ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Annual
10:40 a.m. Lecture: Neonates and Children: Are They
Course Symposium and has approved this program as part of a
Different?
comprehensive lifelong learning program, which is mandated by the ABMS as
Cecil Hahn, M.D.
a necessary component of maintenance of certification.
11:05 a.m. Lecture: NORSE, FIRES, and Encephalitis
Nicolas Gaspard, M.D., Ph.D. Core Competencies: Patient Care, Medical Knowledge and Practice-based
Learning
11:30 a.m. Flash Panel: Financial and Logistical Issues
Is Continuous EEG Worth the Cost and Use of Acknowledgment
Resources? This program is supported in part by an educational grant from Electrical
Thomas P. Bleck, M.D. Geodesics, Inc.
49
 SUNDAY December 7, 2014
6:00 p.m. 7:30 p.m.
Special Interest Group Meetings
Location listed under each session
Drug Resistant Epilepsy Definition, Epidemiology,
Predictors, Using Big Data for Epidemiological Research
Convention Center Room 617, Level 6
Coordinator: Nathalie Jett, M.D., FRCPC
Speakers: Samuel Wiebe, M.D., Martin J. Brodie, M.D.,
Elaine C. Wirrell, M.D., Jakob Christensen, M.D., Ph.D.
This SIG will provide participants with an up to date review about drug-resistant
epilepsy. We will begin by reviewing the latest definition of drug resistant
epilepsy and consider the evidence behind it. We will review the epidemiology of
drug-resistant epilepsy and whether patterns are changing over time, discuss
risk factors for pharmaco-resistance in children with epilepsy and will examine
whether big data can be exploited to study drug-resistance in epilepsy.
Frontal Lobe Epilepsy: Semiology and Cognitive Aspects
Convention Center Room 608, Level 6
Coordinators: Andrea Bernasconi, M.D., Fernando Cendes, M.D., Ph.D.
Speakers: Prof. Patrick Chauvel, Bruce Hermann, Ph.D.
Frontal lobe epilepsy is the second most common type of localization-related
epilepsy that undergoes surgical treatment, and probably the most challenging in
terms of medical and surgical management. The causes are diverse and often
undetected by current standards of neuroimaging investigation, and a large
proportion of patients need invasive EEG investigation. Despite advances in
technology, many patients with frontal lobe epilepsy cannot undergo surgery either
due to the seizure onset zone being close to or involving eloquent areas (motor and
language) or because there is a lack of clear localization of epileptogenic lesion /
seizure focus. We will discuss the pathophysiological aspects of the complex
seizure semiology and cognitive changes in frontal lobe epilepsy.
Magnetoencephalography (MEG) / Magnetic Source Imaging
(MSI) Source Localization Results: Blind Faith, Black Art, or
Scientific Method?
Convention Center Room 620, Level 6
Coordinators: Anto I. Bagic, M.D., Ph.D.
Speakers: Steven Stufflebeam, M.D., Ph.D., Richard C. Burgess, M.D., Ph.D.,
Michael Funke, M.D., Ph.D., John S. Ebersole, M.D.
Although MEG is an established tool for localizing normal and pathological fields,
and clinical MEG is a recognized diagnostic subspecialty, there is a need to
improve the understanding and thus usefulness of MEG source modeling results for
the practitioner to facilitate further growth of the field. To this end, it is essential to
review the concepts of source localization accuracy based not only on the
equivalent current dipole (ECD) but also on various extended models. Thus,
Dr. Stufflebeam will introduce distributed source localization methods; Dr. Burgess
will scrutinize the criteria for acceptance of a dipole fit; Dr. Funke will discuss the
methods for improving source localization yield and accuracy (spike averaging,
tSSS, region of interest sub-selection, etc.) and Dr. Ebersole will elucidate on the
concept of dipole-worthiness.
Neonatal Seizures: Should We Pursue Comparative
Effectiveness Studies for the Treatment of Neonatal
Seizures?
Convention Center Room 609, Level 6
Coordinators: Renee A. Shellhaas, M.D., M.S., Courtney Wusthoff, M.D.
Speakers: Ronnie Guillet, Tracy A. Glauser, M.D.
There remains a paucity of evidence regarding optimal treatment for neonatal
seizures. While there are a few ongoing RCTs for specific agents in the
treatment of neonatal seizures, all have faced significant challenges. Some
have proposed the solution to this knowledge gap lies in comparative
effectiveness research, using the existing wide variation in clinical practice to
study impact on outcomes. Others argue that a well-designed and executed
RCT remains feasible and is preferable as the gold standard to provide an
evidence basis in this area. Following presentation of three relevant posters,
our speakers will debate the sides of this issue.
50
Neuroendocrinology: Sex Differences in Epileptogenesis
Convention Center Room 613, Level 6
Coordinator: D. Samba Reddy, Ph.D., RPh
Speakers: Aristea S. Galanopoulou, M.D., Ph.D., Cynthia L. Harden, M.D.,
D. Samba Reddy, Ph.D., RPh, Asla Pitkanen, M.D., Ph.D.
Sex difference in seizure susceptibility is one of the long-standing issues of
epilepsy. Clinical evidence shows gender- and age-related expression of many
seizure syndromes. The incidence of epilepsy is generally higher in males than
in females. More women than men are diagnosed with idiopathic generalized
epilepsy, but localization-related symptomatic epilepsies are more frequent in
men, and cryptogenic localization-related epilepsies are more frequent in
women. Changes in seizure sensitivity are also evident at puberty, which is
associated with rigorous changes in reproductive hormones and behavioral
patterns. Overall, there is considerable evidence indicating that men exhibit
greater seizure susceptibility than females, while many females exhibit greater
fluctuations in susceptibility to seizures, including menstrual cycle-related
changes in seizure activity. Although sex differences in epileptogenesis are
widely recognized, there is little discussion on their mechanisms and
therapeutic implications. In this SIG, sex-based differences in seizure sensitivity
and epileptogenesis will be discussed, with emphasis on variations between
men and women in factors such as steroid hormones, gender-specific
developmental consequences, biologic differences in neuronal networks in the
brain and gender-based differential therapeutic interventions.
Pediatric Case Discussions
Convention Center Room 612, Level 6
Coordinator: Elaine Wyllie, M.D.
Speakers: TBA
Six expert faculty will present impactful cases illustrating important clinical
points in diverse topics including pediatric epilepsy diagnosis, seizure
semiology, EEG, antiepileptic medications, surgery, genetics, comorbidities, and
other topics.
Psychogenic Nonepileptic Seizures: What Can We Learn from
PNES Semiology?
Convention Center Room 615, Level 6
Coordinators: Markus Reuber, M.D., Ph.D., FRCP, Sigita Plioplys, M.D.
Speakers: Roderick Duncan, M.D., Ph.D., FRCP, Gaston C. Baslet, M.D.,
Julia Doss, Psy.D., LPN
This SIG will focus on the visible and subjective symptomatology of PNES in
adults and children and explore whether different semiological features can tell
us anything about the etiology, course or optimal management of patients with
PNES. A wide range of subjective semiological features have been reported
during PNES, including sensory experiences from different modalities,
symptoms indicative of hyperarousal, distressing experiences and varying
degrees of preserved awareness. Similarly, the objectively observable
semiology of PNES has been studied extensively, and characteristic features
have been described. Some PNES experiences have been linked to antecedent
trauma and better or worse outcome. Other than this, little is known about how
PNES semiology might relate to etiology or mechanism, and whether some
elements of it might have implications for choice of therapy. Drs. Duncan and
Baslet will summarize published observations of PNES subjective and objective
semiology in adults, will discuss the implication of these observations and will
explore possibilities for future research. While PNES in children shares similar
semiological features to those in adults, there are few studies assessing
subjective experience and how this may inform treatment choice or treatment
outcome. Dr. Doss will discuss PNES semiology in the pediatric population.
8:00 p.m. 10:00 p.m.
Social Networking Groups
Sheraton Madrona, Second Floor
(registration is not required)
Informal gathering and networking for SIG participants. Space is limited so
participants are welcome on a first-come, first-served basis. Roundtable topics
include: Adolescent Epilepsy and Transitional Clinics.

Sunday December 7, 2014
Authors Present: Noon 2:00 p.m.
Poster Walking Tours begin at 12:15 p.m. (see page 15 for details)
Behavior/Neuropsychology/
Language
Adult
2.001 Utility Of RBANS In Intractable
Epilepsy Patients In A Arab Cohort/
N. A. Moussa, S. A. Al Jarrah,
K. A. Siddiqui
2.002 Quality Of Life And Mood
Status Of New Patients In Outpatient
Clinic For Epilepsy/R. Hanaya,
Y. Kashida, H. Hosoyama, K. Iida,
T. Otsubo, K. Arita
2.003 Long-Term Follow-Up Of
Memory Functions In Patients With
Chronic Vagal Nerve Stimulation/I.
Tyrlikova, Z. Hummelova, R. Kubikova,
S. Telecka, M. Tyrlik, R. Kuba,
M. Brazdil, J. Chrastina, J. Hemza,
Z. Novak, I. Rektor
2.004 Mapping The Cognitive
Network In Adults With Temporal Lobe
Epilepsy/T. Kellermann, J. Lin,
L. Bonilha, B. Hermann
2.005 Better Executive Function
Associated With Higher
Frontoparietal Functional Connectivity
In The Spared Hemisphere In Left
Mesial TLE/N. Kucukboyaci, K. Leyden,
N. Kemmotsu, E. Tecoma, R. Q. Loi,
D. Lee, C. McDonald
2.006 The Social Experience Of
Stigma In A Midwestern Epilepsy
Population/J. L. Moore,
C. Bosler Walton
2.007 Mediators Of Quality Of Life In
An Underserved Population Of
Epilepsy Patients/D. Becker,
A. Shallcross, D. Friedman, A. Singh,
J. French, R. Jurd, T. Spruill,
O. Devinsky
2.008 Unprovoked Seizures In
Patients Diagnosed With Dementia:
Clinical And Neurophysiologic
Characteristics/R. Sarkis,
B. Dickerson, Z. Chemali
2.009 A Randomized Efficacy Trial Of
A Clinic-Based Decision Support
System For Epilepsy Self-Management/
R. Shegog, C. Begley
2.010 Reinstatement Of Distributed
Spatiotemporal Patterns Of
Oscillatory Power During Associative
Memory/K. A. Zaghloul, R. B. Yaffe,
M. S. Kerr, S. Damera, S. V. Sarma,
S. K. Inati
2.011 Relations Between Social
Cognition And Quality Of Life In
Epilepsy/K. Janke, Y. Cukier, S. Hwang,
A. Mehta, C. Harden, S. Schaffer
Pediatrics
2.012 Neuropsychological Outcome In
Children With Focal Cortical Dysplasia
Following Surgical Resection For
Intractable Epilepsy/R. Boada,
G. Berrios-Siervo, D. L. Cohen,
G. Wilkening, P. Laoprasert
2.013 Memory And Executive
Functioning In Monolingual And
Bilingual Children With Epilepsy/
A. Veenstra, J. Riley, J. Romain,
M. Muhonen, J. Lin, M. Zupanc,
G. Mucci
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.014 Language Localization In
Pediatric Epilepsy: Comparison
Between Functional Magnetic
Resonance Imaging (fMRI) And
Electrical Stimulation Mapping
(ESM)/C. M. Salinas, P. Chen,
M. Korostenskaja, E. Castillo,
J. Baumgartner, J. Seo, K. Lee,
M. Westerveld
2.015 Neurodevelopment In
Preschool Children Of Fife And Lothian
Epilepsy Study: Neuroprofiles A
Population-Based Study/M. B. Hunter,
K. Verity, R. Sumpter, A. McLellan,
J. Shetty, M. Yoong, R. Chin
2.016 Unexpected Subclinical Spikes:
Clinical And Neurophysiological
Correlations/M. Mintz, L. Szklarski,
M. Chadehumbe, G. Alberts,
S. Woldoff, M. Mohamadpour,
J. Keating
2.017 Neuropsychological Profiles Of
Children With Benign Rolandic Epilepsy
Highlight Vulnerability In Cognitive
Efficiency, Learning And Memory/
K. Boyer, J. Girard, C. Vega,
D. P. Waber, M. Takeoka
2.018 Psychiatric Disturbance In
Children With Epilepsy/F. Besag,
A. Aldenkamp, R. Caplan, D. Dunn,
G. Gobbi, M. Sillanpaa
2.019 Computerized Training Of
Working Memory In Children With
Epilepsy Update/V. Terwilliger, M. Berl,
E. Fisher, L. Sepeta
2.020 Gender Differences And ADHD
Among Children With Epilepsy/R.
Trobliger, M. E. Lancman, M. Lancman
2.021 Minnesota Epilepsy Groups
Multidisciplinary Clinic for New Onset
Pediatric Epilepsy (NOPE)/E. Adams,
J. Doss, K. Berg, C. Opperman,
F. Ritter
2.022 Postoperative
Neuropsychological Outcomes in
Pediatric Patients Undergoing
Temporal Lobe Epilepsy Surgery/
L. Bailey, T. Parsons, H. Blumenthal,
A. Boals, M. Perry
2.023 Psychiatric Comorbidity In
Children With Recent-Onset Epilepsy:
A 2-Year Prospective Controlled
Investigation/J. Jones, D. Almane,
D. Jackson, D. Hsu, L. Zawadzki,
C. Stafstrom, M. Seidenberg,
B. Hermann
2.024 Left Centrotemporal Spikes
Affect Language Function In BECTS/
J. Vannest, T. Maloney, J. Tenney,
J. Szaflarski, K. Hibbard, D. Morita,
T. Glauser
All Ages
2.025 Cognitive Consequences Of
Interictal Spikes/L. Groomes,
R. Madhavan, H. Tang, N. E. Crone,
J. Madsen, A. Golby, F. Lenz,
G. Kreiman, W. Anderson
2.026 Use Of Magnetic Source
Imaging Language Mapping To Predict
Language Decline Following Left
Temporal Lobe Epilepsy Surgery/
R. Doss, G. Risse, W. Zhang, R. Lyons
2.027 Spatial Dissociation Between
Phonological And Semantic Speech
Processing In The Lateral Temporal
Lobe/M. J. Hamberger,
G. M. McKhann, II, M. Miozzo
2.028 Pre- And Post-Neurosurgical
Longitudinal Psychiatric Outcome In
Intractable Mesial Temporal Lobe
Epilepsy Patients Receiving
Psychiatric Care/R. Pella, A. Velez,
O. Lie, L. Morgan, K. Karkar, C. Szabo
2.029 The Impact Of Mood On
Memory Complaints And Memory
Performance In Patients With
Epilepsy/Y. Cukier, K. Janke,
B. Rabinovitz, D. Hwang, D. Mehta,
C. Harden, D. Schaffer
2.030 Complication Rates During The
WADA Test: One Centers
Experience/N. J. Beimer, H. Buchtel,
SUNDAY
S. Glynn
Health Services
Delivery of Care
2.031 Survey Of Online Patient
Communities To Analyze Perceptions
Of Healthcare Value/G. Cohen,
B. Leymon-Porter, J. Fishman
2.032 Epilepsy Surgery Trends In A
Universal Health System: Ontario,
Canada (1999-2010)/J. G. Burneo,
K. Liu, S. Shariff, S. Leonard,
A. Garg, G. Saposnik
2.033 Antiepileptic Drug Therapy And
Model Predictions Of Treatment
Success/C. Dilley, M. Rozen-Zvi,
J. Harrington, Y. Goldschmidt,
C. Clark, P. Fritz, O. Devinsky
2.034 Outpatient Education Reduces
Emergency Room Use By Epilepsy
Patients/F. T. Pascual, K. Hoang,
C. Hollen, R. Swearingen, A. Hakimi,
J. King, D. M. Thompson
2.035 Time Elapsed From Onset Of
Infantile Spasms To Diagnosis And
Treatment/S. An, E. Nagarajan,
I. Snchez Fernndez, C. Joshi,
K. Knupp, I. Valencia, E. Wirrell,
A. Berg, T. Loddenkemper
2.036 Review Of Outpatient Home
Clinical Video Telehealth (CVT) In
Epilepsy And Pilot Experience Within
The Veterans Health Administration
(VHA)/T. T. Tran, P. Kelly, A. Husain
2.037 Standardized Seizure
Assessment In The EMU/O. Hope,
M. Tapia, A. Balabanov
2.038 Impact Of Psychogenic Non-
Epileptic Seizure (PNES) Diagnosis On
Acute Care Resource Utilization, Role
For Psychiatric Consultation, And
Follow-Up Within A Dallas County
Hospital System/C. B. Culver,
J. J. Konikkara, L. Howe-Martin,
P. Van Ness, M. Agostini, R. Hays,
P. Modur, K. Ding, P. Gupta
51

Sunday December 7, 2014
2.039 PACES In Epilepsy: Results Of
A Self-Management Randomized
Controlled Trial/R. T. Fraser,
E. K. Johnson, S. Lashley, J. Barber,
N. Chaytor, J. Miller, P. Ciechanowski,
N. Temkin, L. Caylor
2.040 A Survey Of Family
Satisfaction Of Pediatric Epilepsy
Care Via Telemedicine In British
Columbia (BC)/A. Faber, S. Peinhof,
S. Richards, Y. Pan, M. Connolly
2.041 Yield Of Monitoring In An Adult
Epilepsy Monitoring Unit/S. Agrawal,
L. Turco, S. Goswami, M. Faulkner,
S. P. Singh
2.042 Reducing Urgent Hospital
Re-Encounters Following Epilepsy
Monitoring Unit Discharge/K. Secore,
J. J. Chen, A. F. Van Straten,
S. P. Wei, K. A. Birney,
J. J. Harrington, B. Jobst,
K. Bujarski, E. J. Kobylarz, V. Thadani,
T. A. Caller
2.043 Hospital Crossover Increases
Utilization For People With Epilepsy:
A Retrospective Cohort Study/
Z. Grinspan, J. S. Shapiro,
E. L. Abramson, H. Jung, R. Kaushal,
L. M. Kern
2.044 Health Care Resource
Utilization And Costs Of Immediate
vs. Delayed Second-Line Treatment
Initiation Among Patients With
Epilepsy/V. Divino, V. Bollu, C. Makin,
F. Velez
2.045 Does Adherence To Epilepsy
Quality Measures Predict Seizure
Control?/L. V. Moura, D. Mendez,
B. Vickrey, D. Hoch
2.046 Quality Of Life Outcomes After
Referral To A Tertiary Epilepsy
Center/M. Tom, P. Penovich, R. Doss,
A. Olson
2.047 Improving The Standard Of
Care For Patients With Epilepsy:
Factors Influencing Hospitalization
Rates/C. Begley, S. Helmers,
D. Thurman, C. Dilley, C. Clark,
P. Fritz, E. Faught
Access to Care
2.048 Leveraging Technology To
Improve Access - Epilepsy Centers Of
Excellence (ECoE) Capitalizes On The
Telemedicine Opportunity/P. Kelly,
R. Rehman, A. Husain
2.049 Reduction Of ED Visits By
Implementation Of An Urgent Clinic
For Children With Established
Epilepsy/D. Terry, J. Pacheco-Phillips
2.050 The Michigan Pediatric Epilepsy
Telemedicine Project- Innovative
Subspecialty Care Within A Medical
Home/S. Joshi, S. Clark, L. Fletcher,
S. Jordan
2.051 Patterns Of Neurological And
Neurosurgical Care For Persons With
Epilepsy/K. Sauro, S. Mah, B. Li,
L. Svenson, C. DeCoster, S. Wiebe,
N. Jett
2.052 Gaps In Medicaid Coverage
Among Persons With Epilepsy/
P. Bakaki, S. Koroukian, J. Albert,
K. Kaiboriboon
52
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.053 Process Improvement To
Reduce Time To Epilepsy Surgery/
C. Drees, R. DeBello, L. Frey, P. Korb,
A. Shrestha, L. Strom, M. Spitz,
C. OBrien
2.054 Assessment Of Knowledge And
Attitudes As Well As Patterns Of
Referral About Epilepsy Surgery
Among Family Doctors In Ontario,
Canada/N. Cothros, J. G. Burneo,
S. Brown, D. Steven
Health Care Models
2.055 Comorbidities Associated With
Frequent Emergency Department
Visits Among Children With
Epilepsy/A. Patel, B. Haridas,
Z. Grinspan
2.056 Using The Measure Of
Processes Of Care (MPOC-20) To
Assess Family-Centred Care In
Children With Epilepsy: Evaluating This
Application/K. C. Joachim, P. Wilk,
B. Ryan, K. Speechley
2.057 Changing Practice Pattern
Before And After The Modification Of
EMU At UNC/R. Davis, N. Odom,
S. Sutton, B. Vaughn, A. Hinn,
E. Ryan, H. Ritchie, H. Shin
2.058 The POEM Study: Patient
Usage And Satisfaction With An
Online Health Management Platform
For Epilepsy/J. Hixson, D. Barnes,
K. Parko, T. Durgin, S. Van Bebber,
P. Wicks, A. Graham
2.059 Mapping Epilepsy Subspecialty
Care By Physician Networks/H. Hamid,
J. Bates, M. Pugh, J. Neil, C. Brandt
2.060 Developing An Effective
Vocational Rehabilitation Model For
Individuals With Epilepsy And
Comorbid Disabilities In Japan: A New
Hospital-Based Service Delivery
System/Y. Namihisa, M. Sakata,
M. Ohshima, M. Osako, M. Fujikawa
Practice Resources
2.061 Characteristics Of Pediatric
Inpatients In Whom Clinical Decision
Making Is Changed By Continuous
Video EEG Monitoring/
M. C. Spiciarich, K. Ballaban-Gil,
J. C. Beal
2.062 Utility, Applications, Validity
And Reliability Of The Inventory Of
Neppe of Symptoms of Epilepsy and
the Temporal Lobe (INSET) Compared
With Ambulatory
Electroencephalographic Parameters,
Longitudinal Clinical Features,
Anticonvulsant Responsiveness/
V. M. Neppe
2.063 Frequency, Findings, And
Comparisons Of Seizure Montage
Polysomnography/A. Slansky,
S. Manganaro, R. Ribot, L. Tornes
2.064 Designing And Assessing
Digital Patient Education Materials In
An Outpatient Epilepsy Practice
Setting/F. Blezin, H. Quinn,
L. Ponticello, J. Richardson,
J. Stribling
2.065 SUDEP: What Do Patients
Want To Know?/R. RamachandranNair,
A. Rama Madhava, S. M. Jack,
M. J. Shapiro
2.066 Pregnancy And Seizures:
Review Of Practice At George
Washington University In The Past 5
Years/G. T. Que, C. Agha, U. Menon,
R. Aly
Epidemiology
2.067 Epilepsy In The Elderly: A
Distinct Entity?/C. Josephson,
N. Jette, Y. Aghakhani, P. Federico,
A. Hanson, W. Murphy, N. Pillay,
S. Wiebe
2.068 Mortality In Adult Epilepsy
Patients Decreased Over 3 Decades:
A Hospital-Based Cohort/
C. Granbichler, W. Oberaigner,
G. Kuchukhidze, G. Bauer, J.
Ndayisaba, K. Seppi, E. Trinka
2.069 Research Project Management
In Multi-Centre Long-Term Follow-Up
Studies: Meeting The Challenges/
J. Terhaerdt, K. Speechley
2.070 A Survey Of Medical Examiner
Death Certification Of Vignettes On
Death In Epilepsy: Gaps In Identifying
SUDEP/D. Atherton, G. G. Davis,
C. Wright, D. Hesdorffer
2.071 Quality Of Life In Persons With
Epilepsy/N. Jette, S. Patten,
S. Wiebe, A. G. Bulloch,
S. Macrodimitris, K. Fiest
2.072 Epilepsy In Young Children: A
Nationwide Population-Based Study/
K. Aaberg, P. Suren, C. Soraas,
I. Bakken, M. Lossius, C. Stoltenberg,
R. Chin
2.073 Mortality In Patients With
Epilepsy And Psychogenic
Nonepileptic Seizures/
C. Garcia Gracia, K. Unnwongse,
K. Shea, R. Burgess, I. Najm, L. Jehi
2.074 Cause-Specific Mortality
Among Children And Young Adults
With Epilepsy: Results From The
United States National Child Death
Review Case Reporting System/
N. Tian, E. C. Shaw, M. Zack,
R. Kobau, H. Dykstra, D. Thurman,
T. M. Covington
2.075 The Epidemiology, Management
And Outcome Of Convulsive Status
Epilepticus In Children/M. Uzun
2.076 TBI Study In Moscow
Predictors Of Seizures And
Outcomes/A. Guekht, V. Krylov,
N. Gulyaeva, E. Gusev, I. Kaimovsky,
I. Trifonov, A. Talypov, S. Asratyan,
A. Yakovlev, A. Lebedeva, A. Hauser
2.077 Creation Of An Epilepsy
Registry In The Veterans Health
Administration/R. Rehman, P. Kelly,
A. Husain
2.078 A Community-Based Study Of
The Sociodemographic Risk Factors Of
Epilepsy Among Adults In The Province
Of Alicante (Spain)/S. Palao-Duarte

Sunday December 7, 2014
2.079 Prevalence And Risk Factors
Of Peri-Ictal Autonomic Changes In
Children With Temporal And
Frontotemporal Lobe Seizures/
M. A. Whealy, E. Wirrell,
L. Wong-Kisiel, K. Nickels
2.080 Epileptic Seizures In Japanese
Patients With Lacunar Infarction And
Branch Atheromatous Disease/
K. Obata, M. Kinoshita, K. Sato,
M. Chin, S. Yamagata, K. Shindo
2.081 Evidence Mesial TLE Is Not
Always Medically Refractory/P. Tseng,
M. Liu, N. Fountain
2.082 Resective Focal Epilepsy
Surgery Has Selection Of
Candidates Changed?/C. Kwon,
J. Neal, J. Tellez-Zenteno,
A. Metcalfe, W. Hader, S. Wiebe,
N. Jett
2.083 The Clinical Characteristics Of
Preschool-Aged Children Visited
Emergency Room By Epileptic
Seizures/B. Cha, G. Noh
Public Health
2.084 Effects Of Epilepsy In ADHD
And Quality Of Life/M. Salam,
K. Works
2.085 A Mobile Health-Intensive
Comprehensive Care Delivery Model
For Amplifying Outreach For
Refractory Epilepsy And Comorbid
Mood Disorders/M. A. Rossi,
N. Monica, K. Babiarz, L. Cendejas,
R. Hanson, M. Tshionyi, J. Endres,
M. Jain
2.086 Attitude Of Neurologists In
The United Arab Emirates Towards
Epilepsy And Motor Vehicle
Accidents/A. Shatila, O. Khaddam,
N. O. Al Matrooshi, T. Alsaadi
2.087 Trends In Healthcare Charges
And Length Of Stay For People With
Epilepsy, South Carolina, 2000-
2011/D. A. Wilson, A. Selassie
2.088 Engaging Primary Care
Providers In Epilepsy Quality
Measures/S. T. Arnold, R. R. Said,
D. Sirsi, E. A. Burch
2.089 BE- Beyond Epilepsy,
Education, Awareness And Advocacy
Program For Frontline Healthcare
Providers In Tanzania/L. Jurasek,
S. Mbelwa
2.090 Premature Mortality In Poor
Health And Low Income Adults With
Epilepsy/K. Kaiboriboon, N. Schiltz,
P. Bakaki, S. Lhatoo, S. Koroukian
2.091 What Affects The Self-Stigma
And Self-Esteem Of Persons With
Epilepsy?/A. Tabata, K. Hara, S.
Tohma, S. Tanaka, M. Hara, K. Ohta,
M. Matsuura, M. Inaji, T. Maehara,
Y. Sumi
2.092 Do Drivers With Epilepsy Have
Higher Rates Of Motor Vehicle
Accidents Than Those Without
Epilepsy?/P. Naik, M. Fleming,
P. Bhatia, C. Harden
2.093 The Effects Of Reports Of Car
Accidents Caused By Persons With
Epilepsy On Its Stigma In Japan/
K. Hara, S. Tanaka, Y. Hirose,
S. Tohma, M. Matsuura, K. Ohta,
M. Inaji, M. Hara, T. Maehara, Y. Sumi
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.094 Antiepileptic Drug And
Cardiovascular Risk In Patients With
Epilepsy/C. Huang, C. Hsieh,
Y. Yang Kao
2.095 Epilepsy Transition: Challenges
Of Caring For Adults With Childhood-
Onset Seizures/F. Borlot,
J. Tellez-Zenteno, A. Allen, A. Ali,
O. Snead III, D. Andrade
2.096 Epilepsy Knowledge And
Understanding Among
Parents/Caregivers Of Children With
Epilepsy/L. Sanchez-Ortiz,
R. Rios-Motta, M. Rios-Motta
2.097 Implicit Attitudes Toward
Epilepsy In Japan/S. Tohma, K. Hara,
A. Tabata, S. Tanaka, M. Hara,
M. Matsuura, K. Ohta, M. Inaji,
T. Maehara, Y. Sumi
History of Epilepsy
2.098 Diet And Epilepsy A
Historical Review 1875-1938/
S. Goswami, S. P. Singh
2.099 Otto Lwenstein (1889-
1995): The Forgotten Pioneer Of
Video-Monitoring In Epilepsy/
G. Kraemer
2.100 The Birth Of Stigma In
Antiquity: Phaedrus As Disabling
Text/A. Swenson
Case Studies
2.101 Refractory Partial Seizures As
Manifestation Of Polymerase Gamma
(POLG) Mutation In Pediatric
Patients/N. Dalvi, L. Vargas,
S. Karkare
2.102 Pre- And Post-Ictal Body
Positions In Patients With Generalized
Convulsive Seizures/S. Graf, S. Wu,
J. Liebenthal, S. Rose, J. Tao
2.103 Alexia Without Agraphia In A
Child An Unusual Complication Of
Epilepsy Surgical Resection In The
Left Posterior Head Region/
G. Wilkening, N. Stence, M. Handler,
P. Laoprasert
2.104 Resolution Of Seizures And
Normalization Of EEG After Initiation
Of CBD In A Patient With Doose
Syndrome/J. Gold, S. Sattar,
S. Wang, M. Nespeca
2.105 EEG-Based Identification Of
Command-Following After Cardiac
Arrest In The Minimally Conscious
State/P. B. Forgacs, N. Schiff
2.106 Prolonged Propofol Infusion In
Pregnant Women With Refractory
Status Epileptics/N. O. Al Matrooshi,
N. Ali, S. Sinha
2.107 Super Refractory Status
Epilepticus In An 8 Year Old Female
With Congenital Brain Anomalies,
Metabolic Myopathy, And Progressive
Epilepsy Brain Autopsy And Genetic
Testing Correlates/F. Khan, E. Ramsay,
H. Dave, V. Sabharwal, L. Finger
2.108 Photosensitive Epilepsy With
OCD Type Behavior: A Case Series
Report/N. Olney, R. Rajaraman,
R. Sankar, S. A. Hussain
2.109 Case Report: Seizure As The
First Clinical Presentation In Adult
With Childhood Genetic Disorder
(Tuberous Sclerosis Complex)/T. Aung
2.110 Use Of Nicotine Patch For
Drug-Resistant ADNFLE In Children:
A Case Study/C. Gonsalves, K. Lee,
J. Seo, B. Pullum, J. L. Norman
2.111 Surgical Treatment Of
Recurrent Super-Refractory Status
Epilepticus: A Case Report/U. Uysal,
M. Mittal, N. Hammond
2.112 Eye Closure Sensitivity In An
Adult With Suspected Temporal Lobe
Epilepsy/B. Chapman, J. Vidaurre
2.113 Ischemic Epilepsia Partialis
Continua And Age Of Onset: A Tale Of
Two Patients And Review Of The
Literature/T. Gholipour, M. Ng
2.114 Baclofen Induced Non-
Convulsive Status Epilepticus/
R. C. Martinez, W. Richeh, E. Mader
2.115 Bizarre Visual Hallucinations In
A Child With PRES Syndrome/
P. Maertens, M. Bramhall, M. Cobia
2.116 Child Youth Epilepsy (CYE)
TeleECHO Innovative Tele-Mentoring
Clinic For Child & Youth Epilepsy
Care/M. Yamada
2.117 Small Temporal Encephaloceles:
An Under-Recognized Cause Of Non-
Lesional Temporal Lobe Epilepsy/
SUNDAY
R. Azzam, P. Singh, A. Arain,
V. Morgan, J. Neimat, B. Abou-Khalil
2.118 The Ictal Guardian Angel: A
Case Report Of An Ictal Spiritual
Visual Hallucination/M. A. Kellogg,
V. S. Wong
2.119 Hemimegalencephaly In
Tuberous Sclerosis Complex: Is
Surgery The Only Treatment?/
P. B. Cerqueira, E. V. Caetano,
M. G. Manreza, U. C. Reed,
L. B. Sampaio, E. C. Miotto,
F. A. Costa, P. S. Mendes, B. J. Correa
2.120 Asynchronous Leg Jerking
With Normal Sensorium As A
Presentation Of Frontal Lobe
Seizures/L. Vargas, N. Dalvi,
S. Karkare
2.121 Case Report Of A 24-Year-Old
Patient Suffering From Seizures With
G13513A Mutation In The ND5 Gene
Of Mitochondrial DNA/M. Prieschl,
W. Nachbauer, P. Lackner,
B. Matosevic, I. Unterberger,
U. Athing, G. Luef, B. Frauscher
2.122 Are Interictal Epileptiform
Discharges Always Subclinical? A
Study Of Cognitive Function During
Interictal Epileptiform Discharges/
A. Serafini, M. Gubernale, M. Da Rold,
S. Negrin, P. Bonanni
2.123 WITHDRAWN
2.124 A Case Of Neonatal Epilepsy
With KCNQ2 And SCN1A Mutations/
F. Baumer, L. Rodan, J. Heath,
D. Harris, J. Soul
2.125 Sudden Onset Alexia Without
Agraphia Caused By A Reversible
Splenial Lesion (RSL); Two Cases Of
RSL In Non Epileptic Patients On
Lamotrigine And Topomax/R. K. Gupta,
P. Sofat, P. Li, T. Guttuso, R. Sawer, Jr.
2.126 Lesion Negative Anterior
Cingulate Epilepsy/N. Lacuey
Lecumberri, J. Chapa Davila,
M. Pelayo, S. Amina, J. Turnbull,
J. Miller, H. Luders, S. Lhatoo
53

Sunday December 7, 2014
2.127 Refractory Focal-Onset
Seizures As A Consequence Of
Cerebral Amyloid Angiopathy-Related
Inflammation: A Case Study/
B. Appavu, H. Seif Eddeine
2.128 Desmoplastic Infantile
Ganglioglioma Presenting With
Neonatal Status Epilepticus/E. Ng,
S. Karkare, M. Laureta, J. Maytal,
S. Schneider
2.129 Seizure After Laminectomy
Associated With Pneumocephalus/
N. Cinar, M. Cakmak, S. Sahin,
B. Kelten, S. Karsidag
2.130 Insight Into The Precuneus: A
Novel Seizure Semiology In A Child
With Epilepsy Arising From The Mesial
Parietal Region/J. A. Mailo
Professionals in Epilepsy Care
Nursing
2.131 Quality Assurance In The
Epilepsy Monitoring Unit: Time To
Seizure Recognition And
Intervention/D. Nelson, D. Briggs,
J. Shen, K. Lovell, E. Harrell,
E. Wedberg, P. Modur
2.132 Seizure-Related Falls In The
Epilepsy Monitoring Unit/E. Yagiri,
H. Arai, H. Suzuki, K. Jin, M. Fujikawa,
K. Kato, Y. Kakisaka, M. Iwasaki,
K. Yamauchi, N. Nakasato
2.133 Role Of A Nurse Program
Coordinator: Comprehensive Epilepsy
Clinic/M. Gustafson, K. Gugler
2.134 To Coordinate Or Not To
Coordinate?/K. Orton, G. R. Nelson,
C. Van Orman
2.135 Improving Quality Of Care
Following EMU Discharge/R. Mealey,
J. Pollard, K. Davis, C. Kohler,
R. Shmuts, S. Chen, B. Oommen,
C. Hill
2.136 Creating A Standard Of Care
For Epilepsy Patients: Starting with
Nursing Staff in the Adult Epilepsy
Monitoring Unit/R. Ward-Mitchell,
M. Bensalem-Owen, G. Plank,
R. Woodward
2.137 Epilepsy Nurse Led Vagus
Nerve Stimulator Program:
Comprehensive Epilepsy Center/
K. J. Gugler, M. Gustafson
Psychosocial
2.138 Perception Of Happiness In
Adults With Epilepsy/J. Cohen,
D. F. Tovar Quiroga
2.139 Driving Safety In People With
Non-Epileptic Events/K. S. Ziemba,
J. F. Drazkowski
Education
2.140 A Case Report - Importance
Of Early Treatment In Anti-NMDA
Receptor Encephalitis/T. Aung
2.141 Whats In A Year? EEGs
Encountered In An ACGME-Accredited
Clinical Neurophysiology Fellowship/
E. C. Lewis
2.142 SUDEP Experience And
Practice In A Large Group Of Child
Neurologists/J. Reese, Jr,
D. Friedman, W. Gaillard
54
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.143 A Single Center Survery Of
Pediatric Neurologists Views On
Epilepsy Surgery And Medically
Refractory Epilepsy/J. Bolton,
G. Dabscheck
Neurophysiology
Video EEG Epilepsy-Monitoring
2.144 Spread Of The Ictal Discharge
From Hippocampus And Cortex To
Scalp EEG Electrodes In Temporal
Lobe Epilepsy/D. G. Vossler, A. J. Bell,
D. L. Kraemer
2.145 WITHDRAWN
2.146 The Prognostic Value Of Early
EEG Background During Hypothermia
On MRI And Neurodevelopmental
Outcome In Neonates With Hypoxic-
Ischemic Encephalopathy/M. Balestri,
M. Lispi, S. Pro, D. Longo,
F. Vigevano, M. Cilio
2.147 Microseizures Recorded With
Clinical EEG Acquisition System/
L. Higdon, G. Ghearing,
M. Richardson, C. Plummer
2.148 Prevalence Of Ictal Infraslow
Potentials (IISPs) In Scalp EEG/
N. Dorland, J. Lavingia, C. Carlson,
M. Raghavan
2.149 Right Temporal Lobe Seizure
Frequently Induces Precipitous Heart
Rate Increase/K. Kato, K. Jin,
Y. Kakisaka, M. Iwasaki, M. Fujikawa,
M. Aoki, N. Nakasato
2.150 Intracranial Ictal EEG Patterns
And Seizure Onset Zone: A
Systematic Review/S. SINGH,
S. Sandy, Y. Aghakhani, N. Pillay,
S. Wiebe
2.151 Evidence For A Multi-Night
Improving Trend In Sleep During
Intracranial EEG Monitoring/R. Joshi,
N. Gaspard, I. Goncharova,
M. Pavlova, R. Duckrow, J. Gerrard,
D. Spencer, L. Hirsch, H. Zaveri
2.152 Interictal Epileptiform
Discharges Before And After A
Generalized Tonic Clonic Seizure In A
Patient With Generalized Epilepsy
Case Report/D. Sabau, D. W. Harvey,
M. Mehrizi
2.153 Semiological Characterization
And Clinical Profile Of Patients With
Psychogenic Non-Epileptic Seizures/
S. Cieza, P. Amaro, I. Marcotegui,
C. Viteri Torres, M. Alegre, J. Iriarte,
E. Urrestarazu
2.154 Cardiac Sympathetic Nerve
Activity Is Abnormally Suppressed
During Wakefulness In Patients With
Epilepsy/N. Suzuki, K. Jin, K. Kato,
Y. Kakisaka, M. Iwasaki, N. Nakasato
2.155 Texting in Epilepsy: Activation
or Distraction?/B. DiCaccio,
K. H. Yelvington, W. Tatum
ICU EEG
2.156 High Frequency Oscillations
Are Associated With Cognitive
Processing In Human Recognition
Memory/M. T. Kucewicz, J. Cimbalnik,
J. Matsumoto, B. Brinkmann,
M. Bower, V. Vasoli, V. Sulc, F. Meyer,
R. Marsh, M. Stead, G. Worrell
2.157 Misleading EEG Lateralization
Associated With Midline Shift/
S. Abramovici, G. Ghearing
2.158 The Adequacy Of Density
Spectral Array (DSA) And Amplitude-
Integrated EEG (aEEG) For Neonatal
And Pediatric Seizure Identification/
H. Yamamoto, J. Natsume,
H. Kidokoro
2.159 The Application Of Conventional
EEG For Early Prognosis In Infants
Born With Hypoxic Ischemic
Encephalopathy Undergoing
Hypothermia/R. Obeid, M. Naik,
M. Painter, R. Telesco, Y. Sogawa,
S. Gedela, V. Lee, J. Wisnowski,
A. Panigrahy
2.160 Inter-Rater Agreement For
Identification Of Electrographic
Seizures And Periodic Discharges In
Critically Ill Patients/D. Shiau,
J. A. Desrochers, J. J. Halford,
B. J. Kolls, G. U. Martz, S. R. Sinha,
K. F. Haas, E. E. Kutluay, N. J. Azar,
R. T. Kern, K. M. Kelly,
J. C. Sackellares, S. M. LaRoche
2.161 EEG Predictors Of
Antiepileptic Drug Adjustments In
Critically Ill Patients A Prospective
Observational Study/G. Wang,
A. M. Khawaja, G. Cutter,
J. Szaflarski
2.162 Skin Breakdown In Patients
Undergoing EEG Monitoring In The
NICU/S. Manganaro, E. Cruz,
M. Andriola, A. Slansky, L. Manganas
2.163 EEG Predictors Of Outcomes
In Critically Ill Patients A
Prospective Observational Study/
A. M. Khawaja, G. Wang, G. Cutter,
J. P. Szaflarski
Clinical Epilepsy
Classification and Syndromes
2.164 Clinical Characteristics Of
Benign Convulsions With Mild
Gastroenteritis/H. Kim, S. Kim,
Y. Kim, J. Kim, W. Kim
2.165 Ictal And Postictal Aphasia Are
Most Common In Temporal Lobe
Epilepsy/A. M. Loesch, H. Steger,
C. Losher, C. Vollmar, J. Remi,
E. Hartl, S. Noachtar
2.166 Comparing EMU Staffing
Models For Spell Classification
Admissions/S. D. Spritzer,
B. D. Pirotte, S. Agostini, K. Noe,
J. Drazkowski
2.167 Seizure Semiology In Pediatric
Posttraumatic Epilepsy/J. T. Park,
H. T. Chugani
2.168 Incidence And Seizure
Characteristics In Autoimmune
Epilepsy Patients/J. Byun, J. Sunwoo,
J. Moon, J. Shin, K. Jung, S. Lee,
K. Jung, S. Lee, K. Chu, J. Jun
2.169 Familial Ring Chromosome 20
Syndrome A Case Report/
I. Unterberger, H. Schober, D. Kotzot,
C. Fauth

Sunday December 7, 2014
2.170 SUDEP Awareness Among
Pediatric Practitioners: A Descriptive
Survey of United States Physicians/
S. Massey, D. Friedman, N. Berberi,
O. Devinsky, S. Kothare
2.171 Epilepsy Syndrome, MRI
Pathologies and Treatment Response
In Patients With First Seizure And
New-Onset Epilepsy A Comparison
Of Patients Of Middle Age (50-60
Years) Versus Elderly Patients
(> Older 60 Years)/B. Pohlmann-Eden,
C. Crocker, K. Legg, M. Schmidt
2.172 Semiology Of Hypermotor
Seizures/K. Alqadi, R. R. Sankaraneni,
U. Thome Costa, P. Kotagal
2.173 Participant Eligibility In The
Human Epilepsy Project/S. Cristofaro,
C. Freyer, V. Mays, O. HEP
Investigators
2.174 Not All But The Most Patients
With CSWS Are Atypical Benign
Partial Epilepsy In Childhood/
H. Shiraishi, K. Egawa, K. Otsuka,
M. Nakajima, T. Ito, M. Narugami,
S. Nakane, K. Takahashi
2.175 Patterns Of Disease
Progression In Epilepsy/D. Ekstein,
M. Nassar, T. Ben Hur, R. Bar Yossef,
M. Benifla, O. Bennett
2.176 Delay To Initiation Of
Treatment: Data From The Human
Epilepsy Project/R. Hennessy,
M. Mendoza, J. French, S. Haut,
J. Hixson, K. Detyniecki, O. HEP
Investigators
Clinical Diagnosis
2.177 Impact Of Specialty Epilepsy
Consultation On Management And
Outcomes Among Veterans/
A. Panduranga, E. Boudreau,
M. Salinsky
2.178 Radiological And Pathological
Discordance Of Mesial Temporal Lobe
Sclerosis In Pediatric Temporal
Lobectomy/J. Kassiri, D. Sinclair,
M. Wheatley
2.179 Left Temporal Lobe Epilepsy
Presenting As Apparent Life-
Threatening Events In Infants/
J. Kassiri, R. Tang-Wai
2.180 Longer Seizure Duration
Terminates A Seizure Cluster During
Epilepsy Monitoring/V. Ferastraoaru,
S. R. Haut, R. B. Lipton,
A. D. Legatt, J. Blumberg,
M. Dumpelmann, A. Schulze-Bonhage
2.181 Initial Involvement Of The
Posterior Orbital Gyrus In Prolonged
Panic Attack Associated With Simple
Partial Status Epilepticus On Depth
Electrodes/J. M. Chung, C. M. Reed,
U. Rutishauser, A. N. Mamelak
2.182 Seizure Types And
Electrographic Patterns Of Angelman
Syndrome In South Indian Children/
V. Puthenveettil, A. G. Roy,
S. Nampoothiri
2.183 Epileptic Pain As A Rare
Symptom Of Seizures/N. Pazarci,
N. Bebek, B. BAYKAN, C. Gurses,
A. Gokyigit
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.184 Bitemporal Epilepsy: Anatomo-
Electro-Clinical Features And
Comparison With Unitemporal
Epilepsy/G. Didato, V. Chiesa, F. Villani,
V. Pelliccia, F. Deleo, F. Gozzo,
M. Canevini, R. Mai, R. Spreafico,
M. Cossu, L. Tassi
2.185 Predictors For Seizure
Recurrence In 228 Developmentally
And Neurologically Normal Children
With A Newly Diagnosed, Unprovoked
Seizure/H. Kim, A. Oh, X. de Grauw,
A. de Grauw
2.186 Drug-Resistant Epilepsy With
Neurocysticercosis And Mesial
Temporal Lobe Sclerosis/
L. M. Espaillat Solano,
A. Martinez-Perez, M. Leon-Vazquez,
J. Perez-Ruiz, R. Carrillo,
M. Alonso-Vanegas, A. Fleury,
I. E. Martinez-Juarez
2.187 TOSCA Tuberous Sclerosis
Registry To Increase Disease
Awareness: First Interim Data On
Epilepsy/R. Nabbout, C. Hertzberg,
P. Curatolo, P. de Vries, M. Feucht,
E. Belousova, M. Dahlin, J. Ferreira,
J. lawson, A. Macaya, F. O Callaghan,
M. Benedik, V. Sander, S. Youroukos,
A. Jansen, S. Jozwiak
2.188 Concordance Between History
And Epilepsy Monitoring Unit
Evaluation For Diagnosing Seizures/
K. Siddiqui, E. Khalid, R. S. Siddiqui,
S. Sinha
2.189 Autoimmune Epilepsy: Clinical
Features, Management And
Outcomes/D. Dubey, R. Hays,
P. Gupta, K. Ding, M. Agostini,
P. Van Ness, S. Vernino
2.190 Electroclinical Correlation Of
Typical Absence In Idiopathic
Generalized Epilepsies (IGE)/
W. S. Sanchez Barrera
2.191 Is Treatment-Resistant Focal
Epilepsy Less Frequent In
Veterans?/M. Lopez, A. Kanner
2.192 New Onset Temporal Lobe
Epilepsy And REM Sleep Behavior
Disorder: Further Demonstration Of A
Possible Association?/M. Junna,
E. St. Louis, E. Duwell
2.193 Rhythmic ictal Nonclonic
Extremity Movements In Temporal
Lobe Epilepsy: A Reappraisal/K. Ding,
M. Agostini, P. Gupta, R. Hays,
P. Van Ness, P. Modur
2.194 Predictors Of Postneonatal
Epilepsy And Sensitivity Of The First
Hour Of EEG Monitoring In Predicting
Risk Of Seizures In The Neonatal
Period/A. J. Hani, K. Cornett,
B. Smith, W. Gallentine
2.195 Improving Long-Term
Management Of Epilepsy Using
Wearable Multi-Modal Seizure
Detection System/S. Sabesan,
K. Rose, G. Carlson, A. Mueller,
R. Sankar, J. Wheless
2.196 Ambulatory EEG In Children:
When Is It Most Helpful?/S. Adhami,
K. Singh, C. Harini
2.197 Siblings with Juvenile
Huntingtons Disease having two
different Seizure Types: A Case
report/C. Srikanth Mysore,
D. Madhavan, D. Mudugal, T. Jasinski
Clinical Treatments
2.198 Surgical Outcomes Of Patients
With Focal Epilepsy Evaluated By
Intracranial EEG Monitoring/S. Sandy,
S. Singh, Y. Agha-Khani, N. Pillay,
S. Wiebe
2.199 Efficacy And Tolerability Of
Intravenous Lacosamide In Daily
Practice Results Of A Large
Independent Registry/N. Lang,
U. Stephani
2.200 Successful Treatment Of
Febrile Illness-Related Epilepsy
Syndrome (FIRES) And New Onset
Refractory Status Epilepticus
(NORSE) With Plasma Exchange And
Rituximab/J. Berkeley, P. Foreman,
A. Foroughi, F. Tirol
2.201 Efficacy And Safety Of
Intravenous Lacosamide In Pediatric
Status Epilepticus/K. Poddar,
R. Sharma, Y. Ng
SUNDAY
2.202 Application Of A EEG To Severe
Motor And Intellectual Disability
(SMID) Utility In Control Of
Seizures/T. Nagasawa, Y. Okoshi,
S. Atsumi, N. Tanuma, M. Fukumizu,
K. Tominaga
2.203 Acetazolamide For Spike-Wave
Index Reduction In Electrical Status
Epilepticus In Slow Wave Sleep/
A. Fine, E. Wirrell, L. Wong-Kisiel,
K. Nickels
2.204 A Double-Blinded, Randomized
Evaluation Of Neuropsychological And
Behavioral Changes In Children With
Benign Epilepsy With Centrotemporal
Spikes Treated Either With
Levetiracetam Or Sulthiame/
I. Borggraefe, M. Bonfert, L. Gerstl,
F. Heinen, B. Neubauer
2.205 Efficacy And Tolerability Of
Modified Atkins Diet (MAD) And Low
Glycemic Index Diet (LGID) Among
Adults With Medically Intractable
Epilepsy/A. Balabanov, K. Roehl
2.206 Glioma Associated Epilepsy/
M. Fiol, M. Qureshi, M. Hunt, A. Malik
2.207 Epilepsy And Bicycle:
Observation In The Epilepsy
Monitoring Unit/J. Kim, K. Hwang,
E. Joo, S. Hong, D. Seo
2.208 Outcomes Of Vagal Nerve
Stimulation (VNS) For Intractable
Epilepsy/V. S. Wasade,
K. Mohanarangan, A. Gaddam,
L. Schultz, J. Schwalb, M. Spanaki
2.209 Responsive Neurostimulation
In Patients With Periventricular
Nodular Heterotopia (PNH)/P. Rutecki,
A. Herekar, P. Van Ness, G. Bergey,
C. Bazil, D. King-Stephens, F. Sun,
R. Kapur, M. Morrell
2.210 High Dose Oral Steroids For
Treatment Of Infantile Spasms: The
Wake Forest Baptist Medical Center
(WFBMC) Experience/I. Khaytin,
M. Silvia, G. Popli, A. Grefe, C. Lee
55

Sunday December 7, 2014
2.211 Evaluation Of Clobazam
Conversion Therapy Replacing
Clonazepam In Patients With Medically
Refractory Epilepsy/S. Marsh,
S. S. Chung
2.212 Responsive Stimulation Of
Eloquent Cortex/R. Kapur, R. Duckrow,
C. Heck, S. Eisenschenk, R. Gwinn,
E. Geller, M. Smith, A. M. Murro,
G. Worrell, R. Wharen, V. Salanova,
G. L. Barkley, R. Gross, B. Jobst,
C. Bazil, D. Nair, D. King-Stevens,
E. Mizrahi, T. Crowder Skarpaas,
M. Morrell
Prognosis
2.213 Electrodermal Activity During
Complex Partial Seizures Is
Dependent Of Age And MRI Lesions/
S. Thome-Souza, J. Klehm, R. Sarkis,
K. kapur, E. Nagarajan, R. Picard,
M. Jackson, C. Doshi, C. Papadelis,
B. Dworetzky, C. Reinsberger,
T. Loddenkemper
2.214 Predictive Risk Factors Of
Seizure-Related Injury And Postictal
Behavioral Changes/C. Maideniuc,
A. Stino, M. Basha
2.215 Outcomes Of Genetic
Generalized Epilepsy At A
Comprehensive Epilepsy Center/
S. Maturu, T. Dayyoub, B. Assaad,
L. Schultz, V. S. Wasade, E. Muma,
T. Howard, J. Snyder, S. Gaddam,
N. Mahmood, J. Constantinou,
G. L. Barkley, M. Spanaki, A. Zillgitt
2.216 Latency To Treatment Of
Status Epilepticus: Long-Term
Outcomes/J. Cheng
2.217 Prognosis Of Idiopathic
Generalized Epilepsy Patients Who
Had At Least 10 Years Follow Up And
Predictors Of At Least 5 Years
Seizure Remission Off Medication/
H. Hosny
2.218 Relationship Between
Biomarkers Of Vascular And Metabolic
Health And Cognition In Aging Persons
With Chronic Epilepsy/B. Hermann,
M. Sager, R. Koscik
2.219 WITHDRAWN
2.220 Comparison Between Febrile
And Afebrile Convulsion With Mild
Gastroenteritis/S. Kim, I. Lee, T. Eom
2.221 Prediction of Future Epilepsy in
Neonates Who Received Selective
Head Cooling for HIE/T. McDonough,
J. Paolicchi, L. A. Heier, N. Das,
M. Engel, J. M. Perlman, Z. Grinspan
2.222 Treatment Resistance
Correlates With ECG Abnormalities In
A Pilot Clinical Surveillance Of Epilepsy
Patients/P. Zohrevand, M. Diaz,
A. Amador, A. Goldman
2.223 Detrimental Impact Of
Convulsive Status Epilepticus On
Health-Related Quality Of Life
Apparent At 24 Months after
Epilepsy Diagnosis In Children: A
Longitudinal Population-Based
Study/M. Ferro, S. Levin, S. Wiebe,
R. Chin, C. Camfield, K. Speechley
56
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.224 How Different Are Patients
With Bilateral Hippocampal Sclerosis
From The Unilateral Ones?/
E. Vanli- Yavuz, B. Baykan, S. Sencer,
Z. Matur, N. Bebek, A. Gokyigit,
O. Oktem, C. Gurses
2.225 N20 Of Median Nerve SSEP Is
An Early Predictor For Developmental
Outcome After Hemispherotomy In
Patients With Ohtahara Syndrome
With Hemimegalencephaly/K. Sugai,
R. Honda, T. Saito, E. Nakagawa,
H. Komaki, M. Sasaki, A. Takahashi,
T. Kaido, Y. Kaneko, T. Otsuki
2.226 Risk Factors Of Postictal
Generalized Electroencephalographic
Suppression In Generalized Convulsive
Seizures/V. Alexandre, B. Mercedes,
L. Valton, L. Maillard, J. Petit,
A. Biraben, F. Chassoux, P. Kahane,
B. De Toffol, F. Bartolomei, P.
Derambure, V. Navarro, E. Hirsch,
A. Crespel, C. Marchal, P. Thomas,
P. Ryvlin, S. Rheims
2.227 Initial EEG Patterns As An
Adjunctive Prognostic Indicator In
Cardiac Arrest Patients Undergoing
Therapeutic Hypothermia/
E. Tsimerinov, D. Maher, H. Tran,
M. Nuno, D. Eliashiv, D. Palestrant,
A. Moheet, W. Yu, J. Chung
Womens Issues
2.228 Improving The Prescription Of
Folic Acid To Women Taking
Antiepileptic Drugs/A. Sharma,
J. Cavitt, M. Privitera, B. D. Moseley
2.229 A Transdisciplinary Professional
Clinic For Pregnant Adolescents And
Young Adults With Epilepsy In A
Midwest Childrens Hospital/M. Turner,
L. Garrity, K. Junger, S. Standridge
2.230 Epilepsy And Reproductive
Issues In Women With Epilepsy:
Survey Of An Unselected Community
Of Women With Epilepsy/
O. Laban-Grant, E. Fertig, M. Malik,
C. B. de la Pena, M. Fleming,
M. E. Lancman, P. Klein, M. Lancman
2.231 Occurrence Of Obstetric
Complications In Women With Epilepsy
Results From The Oppland Perinatal
Database In Norway/A. Farmen,
T. Tomson, K. Nakken, M. Lossius
2.232 Quality Of Life In Women With
Epilepsy In Pregnancy: Experience At
A Tertiary Care Centre/J. Qiang, E. Bui
2.233 Menstrual Cycle Length In
Women With Epilepsy Trying To
Conceive Compared To Healthy
Controls/C. Harden, C. Lau, P. Pennell,
E. Bagliella, J. Huynh, R. Kashambwa,
N. Llewellyn, B. Kaufman, A. Davis,
J. French
2.234 Seizure Control, Acceptability,
And Drug Interactions During Use Of
The Levonorgestrel Intrauterine
System In Women With Epilepsy/
A. Davis, A. Pack, H. Saadatmand
Neuroimaging
Functional Imaging
2.235 MSI/MEG And DTI Tractography
In Tuberous Sclerosis Complex/
W. Zhang, D. Dickens, J. Doescher,
T. Passe, F. Ritter, M. Dunn, M. Frost
2.236 Individual-Subject Frontolimbic
Neurocircuit Activations During
Emotional Processing And Behavioral
Inhibition In Psychogenic Non-Epileptic
Seizures/D. L. Perez, B. A. Dworetzky,
H. Pan, G. Baslet, D. R. Vago, L. Leung,
J. Epstein, D. A. Silbersweig, E. Stern
2.237 The Temporal Instability Of The
Ventral Default Mode Network
Connectivity In Intractable Epilepsy/
L. Robinson, P. Barnett, G. Doucet,
D. Pustina, A. Ghani, J. Tracy
2.238 In Vivo Optical Signal Changes
Observed With Optical Coherence
Tomography In A Focal Cortical
Seizure Model/J. Szu, M. Eberle,
C. Rodriguez, M. Hsu, B. Park,
D. Binder
2.239 Simultaneous EEG-NIRS (Near
InfraRed Spectroscopy) Guided By
MEEG And EEG-fMRI To Assess The
Neurovascular Coupling In Focal
Epilepsy: A New, Non-Invasive,
Multimodal Approach/G. Pellegrino,
A. Machado, S. Watanabe, N. Drouin,
L. Allard, J. Lina, J. Hall,
E. Kobayashi, C. Grova
2.240 Computer-Automated Focus
Lateralization Of Temporal Lobe
Epilepsy Using fMRI/S. Chiang,
H. Levin, Z. Haneef
2.241 Moving Towards New
Techniques In The Evaluation Of The
Ictal Onset Zone: Ratio Ictal SPECT
(RISCOM) Using A 72-Detector
Focused Collimator Ring SPECT
Scanner System/M. Jain, K. Krug,
P. Balaguera, C. M. Millan, A. Jalota,
V. Pylypyuk, R. W. Byrne, M. A. Rossi
2.242 Frequency Dependent Evolution
Of Functional Networks Over Years Of
Duration In Temporal Lobe Epilepsy/
V. L. Morgan, B. Abou-Khalil,
B. P. Rogers
2.243 Classification Of Individuals
With Temporal Lobe Epilepsy Using
Network Analysis Of Resting-State
Functional MRI/D. Vaughan,
M. Pedersen, C. Tailby, G. Jackson
2.244 Components Of Epileptic
Networks Show Pathological Coherent
Fluctuations Even In The Absence Of
Scalp Spikes/F. Pittau, G. Iannotti,
E. Abela, F. Grouiller, M. Seeck,
C. Michel, S. Vulliemoz
2.245 Nonverbal Memory In Patients
With Mesial Temporal Lobe Epilepsy
And Amygdala Lesions/G. Kuchukhidze,
L. Zamarian, E. Schmid,
F. Koppelstaetter, C. Siedentopf,
M. Delazer, H. Jokeit, E. Gizewski,
G. Luef, I. Unterberger, E. Trinka
2.246 Inter-Hemispheric
Asymmetries In Resting-State fMRI
Activity For Identifying Seizure Onset
And Irritative Zones/D. Groppe,
P. Mgevand, Z. Fallil, S. Hwang,
J. Hira, A. Abisogun, C. Yan,
R. C. Craddock, M. Milham, S. Bickel,
C. Harden, A. Mehta

Sunday December 7, 2014
2.247 Brain Graph Theory Topology
Changes Associated With
Antiepileptic Drug Use/Z. Haneef,
H. Levin, S. Chiang
2.248 Real-Time Functional Mapping
(RTFM) Of Language Function In
Patients With Intractable Epilepsy/
B. Edmonds, M. Korostenskaja,
P. Chen, A. Schaal, C. M. Salinas,
M. Westerveld, E. Castillo, G. Schalk,
P. Brunner, J. Baumgartner, K. Lee
2.249 Comparing Four Connectivity
Measures: From Simultaneous Direct
Intracranial Stimulation And fMRI,
EEG, DWI, And rs-fMRI/S. E. Jones,
A. Alexopoulos, J. Bulacio,
J. Gonzalez-Martinez, J. Mosher,
D. Nair, I. Najm, M. Zhang
Other Emerging Techniques
2.250 Impact Of coregistered
Multimodal Neuroimaging On Pediatric
Epilepsy Surgery Planning And
Postoperative Outcome/D. Freedman,
L. Bailey, A. Hernandez, S. Malik,
C. Keator, D. Donahue, M. Perry
2.251 White Matter Compromise
Modulates Verbal Fluency
Performance In Patients With Atypical
Language Dominance/N. Kemmotsu,
K. Leyden, N. Kucukboyaci,
V. Iragui-Madoz, E. Tecoma,
C. McDonald
2.252 Detection Of The Dominant
Brain Network In Bitemporal Lobe
Epilepsy With MEG/S. Bowyer,
A. Zillgitt, M. Spanaki, K. Mason,
V. S. Wasade
2.253 Clinical Validity Of MEG-Guided
Tractography (MEG-GT) To
Characterize Networks Supporting
Word Comprehension/E. Castillo,
T. Kleineschay, C. M. Salinas,
M. Korostenskaja, P. Chen,
J. Baumgartner, J. Seo, K. Lee
2.254 Regional Cerebral
Hypoperfusion From Arterial Spin
Labeling Correlates With EEG
Lateralization In Patients With
Epilepsy/H. Kadiwala, A. Verma,
S. H. Fung
2.255 Predicting Post-Surgical
Language Outcome With ECoG-Based
Real-Time Functional Mapping
(RTFM)/M. Korostenskaja, P. Chen,
C. M. Salinas, M. Westerveld, J. Seo,
E. Castillo, A. Schaal, B. Edmonds,
G. Schalk, P. Brunner, M. Elsayed,
J. Baumgartner, K. Lee
2.256 Stereotactic Laser Ablation:
How Much Hippocampus And
Amygdala Ablation Volume Optimizes
Seizure Freedom?/A. Sharan, C. Wu,
M. Sperling, R. Gross, J. Willie,
D. Labiner, M. Weinand, R. Marsh,
G. Worrell, G. Cascino, G. Popli,
D. Couture, J. J. Shih, W. Tatum,
A. Mehta, C. Harden, R. Patwardhan,
B. Fernald, A. Shetty, A. Gowda
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
Cormorbidity (Somatic and
Psychiatric)
Medical Conditions
2.257 Mortality In Elderly Veterans
With New And Chronic Epilepsy/
P. J. Foreman, A. VanCott, M. Pugh
2.258 Post Ictal Headache Phenotype
In Epileptic Seizures And Non-
Epileptic Spells/S. Kapoor,
A. Swaminathan
2.259 Diagnosis Of Pnes In
Childhood: Is It Possible To Suspect Of
Non Epileptic Seizures In The First
Standard Neurological Interview For
Epilepsy?/R. Alessi, P. Rzezak,
S. Vincentiis, K. Valente
2.260 Delay In Diagnosis Of
Psychogenic Non-Epileptic Seizures In
Children And Adolescents: Age
Matters/K. Valente, R. Alessi,
S. Vincentiis
2.261 Post Ictal Cardiac Asystole In
A Series Of Pediatric Cases With
Epilepsy Refractory To Medical
Treatment/E. Andrade, Z. Liu
2.262 Sleep Disorders And Circadian
Rhythm In Epilepsy Revisited: A
Prospective Controlled Study/G. Luef,
B. Frauscher, D. Gabelia, M. Prieschl,
K. Chea, M. Hofer, B. Hoegl,
I. Unterberger
Psychiatric Conditions
2.263 ADHD In Childhood Epilepsy:
Clinical Determinants Of Severity And
Of Response To Methylphenidate/
S. Rheims, V. Herbillon, M. Milh,
S. Auvin, S. Napuri, C. Cances,
P. Berquin, P. Castelnau, S. N. Guyen,
The Tich, F. Villega, H. Isnard,
R. Nabbout, B. Kassai,
A. Arzimanoglou
2.264 Recognition Of Mood And
Anxiety Disorders In Patients With
Epilepsy By General Neurologists: A
Comedy Of Contradictions/R. Ribot,
A. Kanner
2.265 Does Screening For Major
Depressive Episodes And Generalized
Anxiety Disorder By Epileptologists
Translate In Their Remission?/
A. Kanner, J. Kozupsky
2.266 Comorbidity Between Epilepsy
And Psychiatric Disorders A
Population-Based Study/
J. Christensen, C. Petersen,
M. Vestergaard
2.267 Stigma Is Uncommonly
Reported By Adolescents With
Epilepsy/J. Langer, M. Thompson,
D. Taplinger
2.268 Autism Spectrum Disorder
And Neurocognitive Comorbidities In
Patients With Epilepsy And ESES/
M. El-Hagrassy, R. C. Gunasekara,
K. Mehrotra, C. Mohan, D. Francois,
L. Probst, Y. Eksioglu
2.269 Health Care Utilization
Following Diagnosis Of Psychogenic
Seizures In U.S. Veterans/M. Salinsky,
C. Evrard, D. Storzbach, E. Goy,
E. Boudreau
2.270 Sleep Problems, Risk Factors,
And Clinical Implications Among
Children At A Tertiary Care Epilepsy
Center/K. Fehr, E. Adams, K. Berg,
M. Frost
2.271 Depression Screening In Youth
With Epilepsy: The NDDI-E-Y/
J. Wagner, G. Smith, B. Brooks,
M. Mueller
2.272 Subjective Forgetfullness In
People With Epilepsy/I. Elmenshawi,
M. A. Mohamed, A. Zaher
2.273 Psychiatric Assessment Of
Psychogenic Nonepileptic Seizures:
A Comparison Of Approaches/
X. F. Jimenez, J. Bautista
2.274 Psychosis In Temporal Lobe
Epilepsy With Hippocampal Sclerosis:
Corroborating The Relevance of
Laterality/
K. Rodrigues Ximenes Goldberg,
S. de Vincentiis, S. E. de Melo-Souza,
F. J. Arruda, P. C. Ragazzo,
H. van der Linden Jr.,
K. Dualibi Ramos Valente
2.275 Predictors Of Major
Depression In Multiplex Epilepsy
Families/S. T. Sorge, J. O. Okeke,
SUNDAY
V. Tangel, S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
Antiepileptic Drugs
Clinical Trials
2.276 Review Of Suicidality Events In
Perampanel Clinical Studies/
A. B. Ettinger, C. Dobrinsky, H. Yang,
B. Williams, D. Xing, R. Fain,
A. Laurenza
2.277 Safety Of Levetiracetam
Among Infants Younger Than 12
months Results From A European
Multicenter Observational Study/
A. Arzimanoglou, P. Berquin, C. Lsch,
J. Bentz
2.278 Analysis Of Psychiatric
Adverse Events In Three Phase III
Controlled Trials Of Eslicarbazepine
Acetate As Adjunctive Therapy For
Refractory Partial-Onset Seizures/
V. Biton, B. Shneker, M. Carreo,
E. Ben-Menachem, F. Rocha,
H. Gama, D. Blum, R. Claus
2.279 Perampanel Discontinuation Is
Not Associated With Self-Reported
Withdrawal Symptoms in Patients
Completing Phase III Clinical
Studies/M. A. Rogawski, H. Yang,
R. V. Fant, B. Williams, D. Xing,
C. Dobrinsky, A. Laurenza
2.280 Clinical And Quality Of Life
Assessments Following Long-Term
Treatment With USL255 (Qudexy
XR; Extended-Release Topiramate) In
Patients With Refractory Partial-
Onset Seizures: PREVAIL OLE/
B. Anders, R. Hogan, S. S. Chung,
A. M. Clark, I. Blatt
57

Sunday December 7, 2014
2.281 Long-Term Safety And
Tolerability Of USL255 (Qudexy XR;
Extended-Release Topiramate) In
Patients With Refractory Partial-
Onset Seizures: PREVAIL OLE/I. Blatt,
S. S. Chung, B. Anders, A. M. Clark,
R. Hogan
2.282 High Retention Rate In
Patients With Refractory Epilepsy
Treated With Eslicarbazepine
Acetate/T. Svendsen, E. Brodtkorb,
A. Reimers, E. Stre,
S. Johannessen, C. J. Landmark
2.283 High Predictability Of Plasma
Lacosamide And No Differences By
Different Age And Gender Through
Normalization Processes/C. Schaefer,
W. Cawello, J. Andreas
2.284 Is Half-Life A Clinically Relevant
Measure For Extended-Release
Drugs? Data Comparing IR Vs XR
Topiramate (USL255; Qudexy XR)/
B. Gidal, A. M. Clark, B. Anders
2.285 Patients Reporting Problems
After Generic Antiepileptic Drug
Switches Are Unlikely To Participate In
A Generic Bioequivalence Trial
D. Ficker, M. Berg, P. Bolger, F. Diaz,
B. Dworetzky, E. Elder, B. Gidal,
W. Jiang, R. Krebill, N. McBee,
A. Paige, J. Pollard, M. Privitera,
J. Szaflarski, T. Welty
2.286 Subject-Unrecognized
Medication Adherence Errors In The
Equivalence Among Generic AED
(EQUIGEN) Chronic Dose Trial/
D. Smith, M. Berg, N. Cohen,
N. Llewellyn, M. Lozano,
D. Schwieterman, J. Sieren, P. Bolger,
F. Diaz, B. Dworetzky, E. Elder,
B. Gidal, W. Jiang, R. Krebill,
N. McBee, A. Paige, J. Pollard,
M. Privitera, J. Szaflarski, T. Welty,
D. Ficker
2.287 Equivalence Among Generic
AEDs (EQUIGEN) Single-Dose
Study/M. Berg, F. Diaz, P. Bolger,
B. Dworetzky, E. Elder, B. Gidal,
W. Jiang, R. Krebill, N. McBee,
A. Paige, J. Pollard, J. Szaflarski,
T. Welty, D. Ficker, M. Privitera
2.288 Aggression Adverse Events
With Concomitant Levetiracetam Use
In Perampanel Phase III Partial-Onset
Seizure Clinical Studies/R. Fain,
S. Chung, H. Yang, D. Xing,
B. Williams, A. Laurenza
2.289 Subgroup Analysis By Race In
Perampanel Phase III Clinical
Studies/A. Laurenza, H. Yang,
B. Williams, S. Huang, M. Sperling
2.290 Long-Term Safety And Efficacy
Of Eslicarbazepine Acetate
Monotherapy In Adults With
Refractory Partial-Onset Seizures:
A One-Year Open-Label Extension
Study/M. R. Sperling, J. Rogin,
J. H. Harvey, H. Cheng, D. Blum
2.291 Placebo-Adjusted Estimation
Of Treatment Effect Of Perampanel/
R. T. Wechsler, S. Mintzer, H. Yang,
B. Williams, D. Xing, A. Laurenza
58
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.292 Improvement In Seizure
Control During Conversion To
Eslicarbazepine Acetate Monotherapy:
A Pooled Analysis Of Two Trials In
Adults With Refractory Partial-Onset
Seizures/G. Krauss, V. Biton,
H. Cheng, D. Blum
2.293 Effect Of Adjunctive
Perampanel On Growth And
Development In Adolescents With
Inadequately Controlled Partial-Onset
Seizures/J. E. Pina-Garza, H. Yang,
B. Williams, D. Kumar, A. Laurenza
2.294 Adjunctive Perampanel In
Adolescents With Inadequately
Controlled Partial-Onset Seizures:
Efficacy And Safety Results From
Study 235/B. Renfroe, L. Lagae,
B. Williams, H. Yang, D. Kumar,
A. Laurenza
2.295 Pharmacokinetic,
Pharmacodynamic And Cognitive
Effects Of Adjunctive Perampanel In
Adolescents With Inadequately
Controlled Partial-Onset Seizures/
Z. Hussein, B. E. Gidal, H. Yang,
B. Williams, D. Kumar, A. Laurenza,
J. Ferry, K. J. Meador
Cohort Studies
2.296 Changes In Antiepileptic Drug
Prescribing Patterns In A Large,
Tertiary-Care Epilepsy Center (2000-
2011)/J. Moeller, A. Legge,
K. Detyniecki, L. Hirsch,
R. Buchsbaum, H. Choi
2.297 Lacosamide Monotherapy
Treatment Pathways In Epilepsy
Patients In A U.S. Managed Care
Population/T. Durgin, R. Wade,
C. Chen, D. Hines, C. Makin
2.298 Analysis Of Real-World
Rufinamide Utilization In The
Treatment Of Epilepsy: Demographic
And Socioeconomic Factors/
R. L. Knoth, J. H. Lasley, S. A. Field,
J. Kerrick Walker, S. Mendes
2.299 Beyond Lennox-Gastaut
Syndrome: A Retrospective Study Of
Clobazam In Pediatric Refractory
Epilepsy/S. Reddy, C. Lopez,
M. Messinger, D. Elledge, A. Wilfong
2.300 Experience With Lacosamide In
Galicia, Spain (GALACO Study):
Results At 12 Months/X. Rodriguez
Osorio, F. Lpez Gonzlez, A. Pato,
M. Saavedra Pieiro,
E. Rubio-Nazbal, I. Cabo Lpez,
N. Raa Martnez, M. Sobrido,
M. Aguado Valcrcel
2.301 Efficacy Of Clobazam Add On
Treatment Of Refractory Focal
Epilepsy In Adults/P. Klein, A. Barber,
I. Tyrlikova, J. Janousek, A. Azarion,
L. Goldman, D. Gorelik
2.302 Lacosamide Effectiveness In
Pediatric Epilepsy: Effect Of
Concomitant NA Channel
Medications/E. Robbins, J. W. Cohen,
S. Kessler
2.303 Clinical Outcomes Of
Treatment With Oxtellar XR Or
Immediate-Release Oxcarbazepine
(OXC-IR) In Typical Care Settings:
A Standardized Case Record
Review/W. ONeal, E. E. Hur,
K. Stringer, T. Resnick
2.304 Long-Term Follow-Up Of
Lacosamide As Add-On Therapy In
Refractory Partial Onset Epilepsy In
Adults In Real Clinical Practice Of
University Hospital, Bratislava/
G. Timarova, S. Meheov
2.305 Analysis Of Real-World
Rufinamide Utilization In The
Treatment Of Epilepsy: Dosing,
Titration, And Concomitant
Antiepileptic Drugs/S. Mendes,
S. A. Field, J. H. Lasley,
J. Kerrick Walker, R. L. Knoth
2.306 Valproate And Lamotrigine: Is
Clobazam More Effective Than Other
Drugs As Adjunctive Therapy?/
V. Moraes, S. Vincentiis, K. Valente
Drug Interaction
2.307 Interaction Study Between
Brivaracetam And Ethanol In Healthy
Subjects/A. Stockis, A. C. Kruithof,
J. M. van Gerven, M. L. de Kam,
S. Watanabe, P. A. Peeters
2.308 Pharmacokinetic Variability Of
Clobazam And Its Metabolite
Desmethylclobazam In Clinical
Practice Impact Of Comedication/
M. Burns, S. Johannessen,
C. J. Landmark
2.309 The Effect Of Epidiolex
(Cannabidiol) On Serum Levels Of
Concomitant Anti-Epileptic Drugs In
Children And Young Adults With
Treatment-Resistant Epilepsy In An
Expanded Access Program/
D. Friedman, M. Cilio, N. Tilton,
J. Sullivan, J. Hedlund, E. Rosenberg,
J. Bluvstein, O. Devinsky
2.310 In Vitro Pharmacokinetic
Profile Of Brivaracetam Reveals Low
Risk Of Drug-Drug Interaction And
Unrestricted Brain Permeability/
H. Chanteux, S. Kervyn, B. Gerin,
M. Rosa, N. Latour, A. Stockis,
J. Nicolas
2.311 Seizure Control In Patients
Initiated On Clobazam Who Use
Frequent 1,4-Benzodiazepines/
G. Russo, T. Vollaro, R. Davis, N. Le
Drug Side Effects
2.312 Adverse Visual Side Effects Of
Antiepileptic Drugs In Adults With
Epilepsy/B. Chen, K. Detyniecki,
L. Hirsch, R. Buchsbaum, H. Choi
2.313 Antiepileptic Use And
Dyslipidemia: A Systematic Review/
M. Vyas, J. Costel, L. Escalaya,
J. G. Burneo
2.314 Anti-Epileptic Drugs And
Vitamin D Deficiency In Children With
Epilepsy/J. Yu, S. Lee, J. Koh

Sunday December 7, 2014
2.315 Adverse Drug Reactions To
Antiepileptic Drugs In Children With
Epilepsy/J. Kim, H. Park, W. Kim,
H. Kim, J. Kang, S. Kim, J. Yu, Y. Kim
2.316 The Pediatric Epilepsy Side
Effects Questionnaire: Establishing
Minimal Clinically Important Difference
Scores/K. Junger, D. Morita, A. Modi
2.317 Adverse Effects Of
Antiepileptic Drug Treatment: The
Patients View/V. K. Kjrvik,
M. A. Mevg, A. Villagran,
S. Johannessen, O. Henning,
C. J. Landmark
2.318 Pigmentary Abnormalities
(Discoloration) Associated With
Ezogabine/Retigabine Treatment:
Clinical Aspects/S. Evans,
A. Alio Saenz, C. Harrington, D. Kelly,
N. Walsh, S. McDonald, W. Lee,
N. Brickel
2.319 Unusual Case Of Drug Rash
With Eosinophilia And Systemic
Symptoms (DRESS) With
Ethosuximide/S. Paudel, A. Patel,
P. Kandel, P. Rawal
2.320 Randomized Crossover Study
Comparing Neuropsychological Effects
Of Lacosamide Versus Carbamazepine
Immediate Release In Healthy
Subjects/K. J. Meador, D. W. Loring,
A. Boyd, W. Byrnes, D. Dilley,
E. Webster, S. Borghs, M. De Backer,
T. Story, P. Dedeken
2.321 An Interesting Case Of Sinus
Nodal Dysfunction Following Use Of
Lacosamide/M. Gurme, C. M. Reed,
D. Eliashiv
2.322 Beyond Efficacy: Focus On
Safety And Effectiveness Of
Antiepileptic Drugs (AEDs)/M. Wen,
V. Nguyen, Y. Bukovskaya,
S. Dergalust
2.323 Effect Of Long-Term
Administration Of Low Dose Of
Rapamycin On Development And
Immunity In Young Rats/L. Zeng
2.324 Pigmentary Abnormalities
(Discoloration) Associated With
Ezogabine/Retigabine Treatment:
Nonclinical Aspects/J. S. Prescott,
C. Evans, A. Alio Saenz
Other
2.325 Generic Antiepileptic Drugs,
Mood Disorders And
Pharmacovigilance: Case Analyses And
Literature Review/K. R. Kaufman,
A. M. Zimmerman, S. Wong,
N. D. Kaufman, P. J. Struck
2.326 Adherence Concerning
Antiepileptic Medication: The
Patients View/A. Villagran,
M. A. Mevg, V. Kjrvik,
S. Johannessen, C. J. Landmark,
O. Henning
2.327 Effectiveness And Tolerance Of
Clobazam Used As Adjunctive To A
Sodium-Blocker Antiepileptic Drug In
Maximum Tolerated Doses In Focal
Seizures/E. A. Seraphim,
L. Rodrigues, J. T. Corso, P. Naves,
G. Bienes, E. Yacubian
Poster Session 2
8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4
2.328 An In Vitro Screen For
Antiepileptogenic Compounds Utilizing
Organotypic Hippocampal Slice
Cultures/Y. Saponjian, Y. Berdichevsky,
W. Swiercz, K. Staley
2.329 Topiramate (TPM) And Impaired
Verbal Fluency: Observations From
Three Formulations With Different
Input Rates/S. E. Marino,
S. T. Brittain, S. V. Pakhomov
2.330 Individual Pharmacokinetic
Profile Analysis From An Average
Bioequivalence Study Of Lamotrigine
In Generic-Brittle Patients: What Can
Be Learned About Patients With
Switchability Issues/T. Ting, W. Jiang,
X. Jiang, J. Polli
2.331 Use Of Computer Simulations
To Test The Concept Of Dose
Forgiveness In The Era Of Extended-
Release (XR) Drugs/S. T. Brittain
2.332 Brivaracetam Achieves Brain
SV2A Occupancy Faster Than
Levetiracetam/J. Mercier, D. Holden,
A. K. Deo, K. Fowles, S. Kervyn,
N. Nabulsi, J. Nicolas, H. Klitgaard,
Y. Huang, J. DSouza, R. E. Carson,
J. Hannestad
2.333 Evaluation Of Weight-Based
Dosing Of Fosphenytoin In Obese
Pediatric Patients/M. M. Messinger,
S. J. Bork, B. S. Moffett,
G. G. Burgess, A. Wilfong
Surgery
Adult
2.334 Neurological And Medical
Complications Of Epilepsy Surgery At
A Tertiary Level Hospital In A
Developing Country/M. Leon-Vazquez,
F. Chavez-Hassan, L. M. Espaillat
Solano, J. Villeda Hernandez,
M. Alonso-Vanegas, D. Crail Melendez,
A. Ruiz Chow, I. E. Martinez-Juarez
2.335 Preoperative Evaluation Of
Speech And Memory Dominance
Estimated By Intracarotid Propofol
Test/T. Kunieda, N. Mikuni, T. Kikuchi,
R. Inano, T. Inada, Y. Takahashi,
S. Nishida, T. Nakae, S. Shibata,
Y. Yamao, Y. Arakawa, R. Matsumoto,
A. Ikeda, S. Miyamoto
2.336 Failed Epilepsy Surgery
Deserves A Second Chance/
C. M. Reed, S. Dewar, D. Eliashiv
2.337 Stereotactic Laser Ablation:
How Much Hippocampal Atrophy
Optimizes Seizure Freedom?/G. Popli,
D. Couture, A. Laxton, R. Gross,
J. Willie, A. Sharan, M. Sperling,
D. Labiner, M. Weinand, R. Marsh,
G. Worrell, G. Cascino, J. J. Shih,
R. Wharen, W. Tatum, R. Patwardhan,
B. Fernald, A. Shetty
2.338 Outcomes After Temporal
Lobectomy After Invasive Monitoring
Versus No Monitoring/A. Romeo,
B. Agee, L. Ver Hoef, K. Riley
2.339 Stereotactic Laser Amygdalo-
Hippocampotomy For Mesial Temporal
Lobe Epilepsy: Collective Experience
From Seven Single-Center,
Prospective, Investigator-Initiated
Studies Objectives/R. Gross, J. Willie,
S. Helmers, K. J. Meador, S. Laroche,
R. Faught, E. Gedzelman, A. Sharan,
M. Sperling, R. Marsh, G. Cascino,
G. Worrell, J. J. Shih, R. Wharen,
W. Tatum, G. Popli, A. Laxton,
D. Couture, M. Weinand, D. Labiner,
A. Mehta, C. Harden, D.
2.340 Robotic-Assisted
MRI-Compatible
Stereoelectroencephalography:
Technique And Complications/J. Hall
Pediatrics
2.341 WITHDRAWN
2.342 Pediatric Epilepsy Surgery
Strategy And Complications: Inter-
Center Worldwide Variability/
B. Rydenhag, A. Cukiert, W. Harkness,
I. Panel
2.343 Pediatric Epilepsy Surgery
Techniques General Issues: Inter-
Center Worldwide Variability/
SUNDAY
A. Cukiert, B. Rydenhag,
W. Harkness, T. International
Pediatric Epilepsy Surgery Panel
2.344 Seizure Outcome After
Battery Depletion In Patients With
Secondary Generalized Epilepsy
Submitted To Vagus Nerve
Stimulation/A. M. Lima,
J. A. Burattini, C. M. Cukiert,
A. Cukiert
2.345 Subtotal Hemispherectomy
In Children With Intractable Focal
Epilepsy/H. Chugani, E. Asano,
C. Juhasz, A. Kumar, W. Kupsky,
S. Sood
2.346 MR-Guided Laser Interstitial
Thermal Therapy For Drug-Resistant,
Lesional Epilepsy in Children/
E. C. Lewis, J. Ragheb, M. Duchowny,
I. Miller
2.347 Corpus Callosotomy With
Stereotactic Laser Ablation In A
Pediatric Patient/A. Dolce, D. Curry,
A. Wilfong
2.348 Usefulness Of Intraoperative
Insular Electrocorticography During
Modified Functional Hemispherectomy/
G. Kim, J. Seo, J. Baumgartner,
K. Lee
2.349 The Ultimate Case Of Curative
Focal Heterotopia Resection:
Resolution Of Lennox-Gastaut
Syndrome And Epileptic
Encephalopathy/J. R. Fesler,
S. Kanaan, T. B. Mapstone, Y. Ng
2.350 Surgical Outcome In
Adolescents With Mesial Temporal
Sclerosis (MTS): Is It Different Than
Adults?/P. Farooque, L. Hirsch,
S. Levy, F. Testa, R. Mattson,
H. Zaveri, J. Bonito, D. Spencer
2.351 Repeat Epilepsy Surgery For
Children With Refractory Seizures:
Profiles And Outcomes/J. Ziobro,
D. Depositario-Cabacar, K. Havens,
J. Conry, S. Weinstein, T. Zelleke,
A. Kao, T. Tsuchida, M. Kolodgie,
A. Yaun, C. Oluigbo, W. Gaillard
59
 Poster Session 2
Sunday December 7, 2014 8:00 a.m. 6:00 p.m.
Convention Center Hall 4B, Level 4

2.352 The Spectrum Of Sleep 2.361 Temporal Lobe Epilepsy With

Disorders In Children Undergoing Pre- Bilateral Features: Prognostic
Surgical Evaluation For Refractory Factors And Outcomes/H. Waseem,
Epilepsy/S. Jain, P. Horn, H. Greiner K. E. Eichstaedt, M. Schoenberg,
2.353 REM Sleep EEG Indicates V. Kelley, A. Bozorg, S. Benbadis,
Epileptogenic Hemisphere For F. Vale
Successful Epilepsy Surgery In 2.362 Electrical Stimulation Of The
Children With Generalized Interictal Centromedian Nucleus Of The
Epileptiform Discharges/K. Okanari, Thalamus For The Treatment Of
S. Baba, H. Otsubo, E. Widjaja, Intractable Epilepsy/Y. Shon, S. Lim,
S. Sakuma, C. Go, K. Jones, W. Kim
K. Nishioka, S. Oba, T. Matsui, 2.363 Acute Intraoperative Entropy
M. Ueno, S. Ukitsu, J. Rutka, Rise During Hippocampal Deep Brain
J. Drake, E. Donner, S. Weiss, Stimulation Surgery/A. Marin,
O. Snead, A. Ochi H. Carmona, N. Sinisterra,
2.354 Thermal Ablation For Patients A. Liscano, C. M. Cukiert, A. Cukiert
Who Failed Surgery Or Would Seldom 2.364 Safety And Efficacy Of
Be Considered As Surgical Candidate/ Complete Corpus Callosotomy As A
D. F. Clarke, J. B. Titus, Localization Tool For Catastrophic
N. Nussbaum, F. F. Perkins, Unlocalizing Epilepsy/J. Seo, K. Lee,
K. C. Keough, M. R. Lee J. Baumgartner, B. Pullum
2.355 Complete Resection Of Fast 2.365 Does Seizure Outcome
Ripples Is A Superior Predictor Of Influence Nonseizure Outcome, Long-
Seizure-Freedom After Epilepsy Term Outcome After Surgery For
Surgery In Comparison To MTS/M. Tripathi, K. Garg, A. Garg,
Conventional Intraoperative A. Wadhawan, M. Goel, C. Bal,
Electrocorticography Findings/ C. Sarkar, V. Kumar, P. Madakasira,
S. A. Hussain, G. Mathern, R. Sankar, S. Chandra
J. Wu
Health Services
All Ages 2.366 Incidence And Prevalence Of
2.356 Predictive Power Of Epilepsy In Low-Income Children:
Presurgical Studies For Temporal Preliminary Analysis/A. Chandran Pillai,
Lobectomy Seizure Freedom/ K. Kaiboriboon, S. Koroukian,
O. I. Khan, D. M. Goldenholz, A. Jow, E. Pestana Knight
W. Theodore
2.357 Frameless Image-Guided
Stereotactic Implantation Of Depth
Electrodes Via Craniotomy For
Presurgical Evaluation Of
Pharmacoresistant Epilepsy/H. Khoo,
H. Kishima, S. Oshino, N. Tani,
T. Maruo, T. Yanagisawa, K. Edagawa,
Y. Inoue, M. Hirata, T. Yoshimine
2.358 Surgical Removal Of High
Frequency Oscillations Correlates
With Postsurgical Outcome A
Prospective Multi-Center Study/
J. Jacobs, J. Y. Wu, P. Perucca,
R. Zelmann, M. Mader, F. Dubeau,
A. Schulze-Bonhage, G. Mathern,
J. Gotman
2.359 Appropriating Surgical
Intervention In Mesial Temporal-Lobe
Epilepsy (MTLE) Patients: Comparison
Of Parameters Influencing Timing Of
Surgery In Patients With Epilepsies
With Different Evidence Levels For
Surgery/K. Iida, K. Kagawa,
M. Kartagiri, A. Hashizume, K. Kurisu
2.360 Laser Ablation Therapy For The
Management Of Medically-Resistant
Epilepsy After Age 50/F. Vale,
H. Waseem, M. Schoenberg, V. Kelley,
A. Bozorg, S. Benbadis, D. Cabello

60
 AES 68TH ANNUAL MEETING
MONDAY December 8, 2014
www.AESnet.org
7:00 a.m. 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Ketogenic Diet: Does the Ketogenic Diet Offer a Cure for
Epilepsy?
Convention Center Room 613, Level 6
Coordinators: Susan Masino, Ph.D., Christina A. Bergqvist, M.D.
Speakers: Detlev Boison, Ph.D., Sudha Kessler, M.D., Renee A. Shellhaas, M.D.,
Timothy A. Simeone, Ph.D.
We have an arsenal of treatments for epilepsy, but do we have any cures?
More specifically, could the time-honored treatment of a ketogenic diet also
be an anti-epileptogenic treatment and offer insight into a cure? What proof
do we have that this is, or is not, the case?
This year the discussion will be organized into a pro/con debate of clinical
evidence and basic science evidence with ample time for rebuttal and
audience participation. Our invited speakers are expected to take a side as we
explore this hot topic. We hope to have fun and inspire the community to
share their thoughts, suggest experiments and put forth provocative ideas to
help move the field forward.
Neuropsychology: Can We Spare Memory with Newer
Surgical Approaches for Temporal Lobe Epilepsy? Emergent
Outcome Data from Laser Ablation, Multiple Hippocampal
Transection, and Fornix DBS
Convention Center Room 609, Level 6
Coordinators: Philip S. Fastenau, Ph.D., Gail L. Risse, Ph.D.
Speakers: Daniel L. Drane, Ph.D., Robert Gross, M.D., Philip Fastenau, Ph.D.,
Jonathan P. Miller, M.D.
Emergent neuropsychological outcome data will be presented on three novel
surgical techniques and will be critically evaluated and discussed with the
audience. The topic (neuropsychology, surgery, temporal lobe) and the
neuropsychologist-neurosurgeon paired presentations are expected to draw a
diverse multidisciplinary audience.
NINDS and Non-Profit Research Resources
Convention Center Room 620, Level 6
Coordinators: Brandy Fureman, Ph.D., Randall Stewart, Ph.D.,
William Benzing, Ph.D., Steve Roberds, Ph.D., Ilene Miller, J.D., Seth Wohlberg
Speakers: Abigail Hemani, Scott C. Baraban, Ph.D.
The purpose of this SIG is to generate focused two-way discussion between
government and non-profit funders and basic and clinical researchers
attending the AES annual meeting. This discussion will educate researchers
on how government and non-profits set their priorities and fund research or
make other resources available, and it will educate non-profit leaders on what
else they could do to support basic and clinical researchers in the epilepsies.
The ultimate goal of this group is to accelerate research on the epilepsies by
more effectively making valuable resources available to the research
community.
Nursing
Convention Center Room 608, Level 6
Coordinators: Tara Myers, CPNP, Wendy Miller, Ph.D., RN, CCRN
Speakers: Nurse Travel Award Winners
The Nurse Travel Award winners will present their poster topics in a
10-minute synopsis with audience discussion and question session. In
addition, we will hold a discussion on an epilepsy certificate program and
feasibility of epilepsy certification in nursing.
Seattle, WA
Status Epilepticus: Are We Over-Treating Status Epilepticus,
and Especially, Nonconvulsive Status Epilepticus?
Convention Center Room 612, Level 6
Coordinators: Frank W. Drislane, M.D., Howard Goodkin, M.D., Ph.D.
Speakers: Peter Kaplan, M.B.B.S., Lawrence J. Hirsch, M.D.,
Howard Goodkin, M.D., Ph.D.
Neurologists agree readily that generalized convulsive Status Epilepticus (SE)
is a neurologic emergency and that it should be halted immediately and the
patient kept from having recurrence of seizures. There is no consensus,
however, that all forms of SE (particularly nonconvulsive SE) need be treated
so aggressively. Even after interruption of convulsive SE, there is
disagreement on how long seizures need be suppressed, and on which EEG
abnormalities signify seizures that require re-treatment. Prolongation of
medically-induced coma with highly sedating drugs keeps patients at risk of
prolonged ICU stays and of new medical complications.
Dr. Peter Kaplan, who has written on the risks of overtreatment (including a
paper this year on worsened outcome for aggressively treated SE patients)
will make the case that much of current treatment is excessive.
Dr. Larry Hirsch, who has studied the treatment of ICU patients with refractory
SE, as well as the deleterious consequences of SE itself, will speak in favor of
vigorous seizure suppression. Finally, Dr. Howard Goodkin, with both a clinical
and basic science perspective, will discuss what evidence from basic and
clinical research can guide us in determining how aggressively to treat NCSE.
8:45 a.m. Noon
Merritt-Putnam Symposium: Stress,
Cannabinoids and Epilepsy: The Science
MONDAY
Behind the Buzz
(3.0 CME Credits)
Convention Center Ballroom 6C, Level 6
Presentation: Hans O. Lders, M.D., Ph.D., William G. Lennox Award
Overview
The impact of stress on seizure control has long been recognized but the
neurobiology of stress impact on neurophysiology is not widely known.
Similarly, cannabinoids have been considered as potentially effective adjunctive
treatment for epilepsy as an alternative to traditional medications but here,
too, the neurobiology requires further elucidation. There is evidence of shared
mechanisms between stress impact on neurologic function and the
neurobiology of cannabinoids. These topics will be explored, providing
information necessary for improved management of patients with
pharmacoresistant epilepsy. Presentations on basic science related to stress
and to cannabinoids, and clinical data regarding both will be presented.
Research on how cannabinoid receptors alter the brains immune system will
be presented, as well as progress that has been made in identifying
cannabinoid agents devoid of drug of abuse properties that may provide
treatment for diverse neurological disorders.
Learning Objectives
u Identify a patient for whom stress is contributing to difficulties in
management of seizures and develop treatment strategies to address
the role of stress
u Query patients regarding use of cannabinoids and address the impact of
such use in developing treatment plans
u Identify a patient who is using cannabinoids for treatment of epilepsy and
discuss the impact of the use of cannabinoids
61
 MONDAY December 8, 2014
u Assist clinicians in developing treatment plans that account for the impact
of cannabinoids and their interaction with traditional medications
u Counsel patient regarding the need for stress management in treatment
of epilepsy
u Counsel patients regarding the impact of stress on seizure control and
develop plans for managing stress
u Evaluate the possible adverse effects of cannabinoids on cognitive
function in patients using cannabinoids for seizure treatment.
Target Audience
Basic, Intermediate and Advanced (see page 120 for details)
Program
Chair: Amy Brooks-Kayal, M.D.
9:00 a.m. Introduction
Amy Brooks-Kayal, M.D.
9:15 a.m. The Neurobiology of Stress: How Stress and Epilepsy
Intersect at the Synapse
Tallie Z. Baram, M.D., Ph.D.
9:45 a.m. Stress and Epilepsy: What Are the Clinical Data?
Sheryl Haut, M.D.
10:15 a.m. Stress and Cannabinoids: What Is the Link?
Jaideep Bains, Ph.D.
10:45 a.m. Cannabinoids and Epilepsy: What Are the Clinical Data?
Allen Hauser, M.D.
11:10 a.m. Cannabinoids in Treatment of Neurological and
Psychiatric Disorders: Is There a Potential Role in
Epilepsy?
Nephi Stella, Ph.D.
11:40 a.m. Panel Discussion and Conclusions
Amy Brooks-Kayal, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 3.0 contact hours for this session.
Nurse Practitioners may claim 3.0 hours of pharmacology for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-035-L01-P.
Initial Release Date: 12/8/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Merritt-Putnam Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Professionalism, Medical Knowledge, Practice-based
Learning and Systems-based Practice
Acknowledgment
This program is supported in part by CURE.
62
9:00 a.m. 10:30 a.m.
Special Interest Group Meetings
Location listed under each session
NEW Epilepsy and Aging
Convention Center Room 620, Level 6
Coordinators: Bruce P. Hermann, Ph.D., Kimford J. Meador, M.D.,
Helen E. Scharfman, Ph.D.
Speakers: Carrie McDonald, Ph.D., David Loring, Ph.D., Ilo Leppik, M.D.,
R. Eugene Ramsay, M.D., Helen Scharfman, Ph.D., Manisha Patel, Ph.D.
This SIG will focus on neurological, neuropsychological, imaging and basic
science aspects of the relationship between epilepsy and aging. This includes
the complications of aging with chronic epilepsy and the issue of new onset
epilepsy with advancing chronological age. The initial meeting will include
brief invited presentations and discussants from clinical neurology,
neuropsychology, and basic science.
Surgery: Surgical Failure in Pediatric and Adult Epilepsy:
The Slam Dunk Case That Wasnt!
Convention Center Room 609, Level 6
Coordinators: Saadi Ghatan, M.D., Gerald Grant, M.D.
Speakers: TBA
We will solicit cases from pediatric and adult surgical epilepsy programs and
select 3-5 cases for presentation, reviewing cases in advance and sticking to
a strict timeline. Presenters are asked to provide a case that was predicted to
be an unequivocal success but resulted in a failure to adequately treat the
patients epilepsy or realize the goal of the operation. Audience participation is
then solicited to generate discussion and suggestions about approaches and
recommendations, with moderators polling the audience.
Tuberous Sclerosis: Thinking Outside the Tuber in TSC
Convention Center Room 612, Level 6
Coordinator: Peter E. Crino, M.D., Ph.D.
Speakers: Peter Crino M.D., Ph.D., Delia Talos Ph.D., Juurian Peters M.D.
This SIG will focus on the role of non-tuberal cortex and sub-cortical
structures in epilepsy and neurobehavioral disabilities in TSC.
2:15 p.m. 3:00 p.m.
Lennox and Lombroso Lecture:
Priorities in Pediatric Epilepsy Research
Convention Center Ballroom 6C, Level 6
Presentation: Karen Gale, Ph.D., Extraordinary Contributions Award
Lecturer: Anne Berg, Ph.D.
The past several decades of clinical and epidemiological research have
provided a wealth of knowledge about the diversity within the pediatric
epilepsies and greatly clarified the sometimes reassuring but still too often
devastating prognosis of many of these disorders. The tremendous advances
in neuroimaging, molecular cell biology, and therapeutics hold the promise of
prevention, more effective targeted treatment, and even disease modification
for these epilepsies with the possibility of ameliorating what can otherwise be
moderate to severe lifelong disability. The challenge is to learn how -when
and in whom- to utilize these techniques and therapies in an optimal manner
to assure the best patient outcomes. Stakeholder identified and endorsed
priorities can help develop a series of research priorities for accomplishing
this goal.
 MONDAY December 8, 2014

3:00 p.m. 4:30 p.m. Credit Designation

Investigators Workshop The American Epilepsy Society designates this live activity for a maximum of
This workshop is an AES Research Grant funded study 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Convention Center Room 607, Level 6

Modeling Epilepsies with Patient-Derived Induced ABPN Core Competencies

Pluripotent Stem Cells The American Board of Psychiatry and Neurology has reviewed the Town Hall
FDA Update and has approved this program as part of a comprehensive
Moderator: Jack M. Parent, M.D.
lifelong learning program, which is mandated by the ABMS as a necessary
Speakers: Kevin Ess, M.D., Ph.D., Jack Parent, M.D., Lori Isom, Ph.D. component of maintenance of certification.
Core Competency: Professionalism
3:00 p.m. 5:00 p.m.
FDA Town Hall Update: SUDEP and 3:00 p.m. 5:15 p.m.
Clinical Trials Pediatric Epilepsy Highlights Session
(2.0 CME Credits)
Convention Center Ballroom 6E, Level 6
Convention Center Room 612, Level 6 Note: Number below refers to poster assignment

Overview
In 2011, a meta-analysis published in Lancet Neurology suggested that patients
randomized into placebo-controlled add-on studies of antiepileptic drugs had a
higher likelihood of having SUDEP if they were randomized to the placebo arm
compared to addition of an active drug. This analysis was recently repeated by
the FDA using data requested from the companies performing the trials. This
symposium will discuss the following issues: 1) How do the findings impact the
design of add-on studies of antiepileptic drugs? 2) What do these findings mean
for clinical practice? The session will include a long interactive audience
discussion session, as specifically requested by the FDA, to provide community
input to the regulatory process.
Learning Objectives
u Define patient-specific risk/benefit ratios related to treatment
interventions vs absence of intervention in treatment resistant patients
This session will showcase selected scientific abstracts focused on topics in
clinical care and research in pediatric epilepsy. Authors will present a six-minute
overview of their work. Presentations are chosen from all submitted abstracts.
Participants will be able to view posters and meet the authors at the end of the
program.
1.032 Diminished Antiepileptogenic Effects Of Neurosteroids In Mice
Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/Bryan Clossen
1.052 Early-Life Clonazepam Exposure Leads To Persistent Alteration Of
Seizure Susceptibility/Hana Kubova
1.097 Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of
Cognition?/Soyong Eom

MONDAY
u Counsel patients regarding risks and benefits related to treatment 1.122 Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of
interventions vs absence of intervention in treatment resistant patients 5HT1A and 5HT2A Receptos In Human Epileptogenesis/Kette Valente
u Understand and counsel patients regarding risks and benefits related to 1.365 Surgical Versus Medical Treatment For Children With Epileptic
treatment interventions vs absence of intervention in treatment resistant Encephalopathy In Infancy And Early Childhood An Observational Cohort
patients. Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/
Target Audience Taisuke Otsuki
Intermediate and Advanced (see page 120 for details) 2.023 Psychiatric Comorbidity In Children With Recent-Onset Epilepsy:
Program A 2-Year Prospective Controlled Investigation/Jana Jones
Co-Chairs: Jacqueline A. French, M.D. and Billy Dunn, M.D. 2.169 Familial Ring Chromosome 20 Syndrome A Case Report/
Iris Unterberger
3:00 p.m. Introduction
Billy Dunn, M.D. 2.179 Left Temporal Lobe Epilepsy Presenting As Apparent Life-Threatening
Events In Infants/Richard Tang-Wai
3:05 p.m. Review of 2011 Analysis
Philippe Ryvlin, M.D., Ph.D. 3.013 Inflammatory Mechanisms Of Epileptogenesis In The Genetic
Epilepsy, Tuberous Sclerosis Complex/Bo Zhang
3:20 p.m. Presentation of FDA Analysis
Mary Doi, M.D., M.S. 3.202 A Brain-Machine Interface For Burst Suppression Control in Pediatric
Status Epilepticus/Christos Papadelis
3:40 p.m. Potential Impact on Clinical Trial Design and Practice
Jacqueline A. French, M.D.
4:00 p.m. Interactive Panel/Audience Discussion
Eric Bastings, M.D. Norman Hershkowitz, M.D., Ph.D.
Mary Doi, M.D., M.S. Alice Hughes, M.D.
Billy Dunn, M.D. Sally Jo Yasuda, Pharm.D., M.S.
4:55 p.m. Conclusions
Jacqueline A. French, M.D.

63
 MONDAY December 8, 2014

3:00 p.m. 5:15 p.m. Credit Designation

Platform Sessions: 3 Concurrent Sessions The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
See page 120 for locations
commensurate with the extent of their participation in the activity.
There will be three concurrent sessions consisting of selected key scientific Nurses may claim up to 2.5 contact hours for this session.
abstracts. Authors will present a 10-minute overview of their work followed
by a five-minute Q & A. Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-036-L01-P.
5:30 p.m. 8:00 p.m. Initial Release Date: 12/8/2014.
Pediatric State of the Art Symposium: ABPN Core Competencies
Long-term Outcomes of Neonatal Seizures The American Board of Psychiatry and Neurology has reviewed the Pediatric
(2.5 CME Credits) State of the Art Symposium and has approved this program as part of a
Convention Center Ballroom 6C, Level 6 comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.

Overview Core Competencies: Patient Care and Systems-based Practice

Seizures occur in a significant number of neonates, yet many critical questions Acknowledgment
remain regarding their diagnosis, treatment, and long-term prognosis. Modern This program is supported in part by an educational grant from
neurophysiological monitoring indicates that the scope of the neonatal seizure Mallinckrodt Pharmaceuticals.
problem may be more extensive than previously appreciated. Although
contemporary neuroprotective strategies have led to improved short-term
outcomes, the impact of both seizures and the medications used to treat
them are now being explored more rigorously in both animal models and
humans. There is a need for clinicians who treat infants, children,
adolescents, and even adults to become familiar with the long-term sequelae
of neonatal seizures. Importantly, these sequelae include not only seizures
cognitive, neuropsychological and social outcomes are affected, as well. This
State of the Art Symposium will address the long-term outcomes of neonatal
seizures, with a focus on both epilepsy and non-epilepsy factors.
Learning Objectives
u Recognize long-term sequelae of neonatal seizures from information
provided by outcome studies
u Choose appropriate medications used to treat neonatal seizures based on
information from follow up studies regarding long-term sequelae
u Utilizing information provided regarding long-term sequelae of neonatal
seizures and medications used to treat them, counsel families about
seizure- and development related outcomes after neonatal seizures.
Target Audience
Intermediate and Advanced (see page 120 for details)
Program
Co-Chairs: Adam Hartman, M.D. and Rene A. Shellhaas, M.D., M.S.
5:30 p.m. Introduction and Case Presentation
Adam Hartman, M.D.
5:45 p.m. Introduction to Neonatal Seizures
Geraldine Boylan, Ph.D.
6:10 p.m. Clinical and EEG Predictors of Prognosis
Rene A. Shellhaas, M.D., M.S.
6:35 p.m. Are Neonatal Seizures So Bad? Get Your Annual Meeting
Rodney Scott, M.D.
CME /CE Credit Online
7:00 p.m. Are Seizure Medicines So Bad?
Timothy Benke, M.D., Ph.D.
Go to www.AESnet.org
7:25 p.m. Neonatal Seizure Management 2014
Janet Soul, M.D. See page 120 for details
7:50 p.m. Conclusions
Rene A. Shellhaas, M.D., M.S.

64
 Monday December 8, 2014
A. Clinical
Convention Center Room 608, Level 6
Moderators: Amy Crepeau, M.D., Nicholas Abend, M.D.
3:00 p.m. A.01 The Not So Simple Course Of Childhood
Epilepsies/A. Berg, K. Rychlik
3:15 p.m. A.02 Factors Influencing Driving Impairment In
Persons With Refractory Epilepsy/V. Punia,
P. Farooque, W. Chen, L. Hirsch, A. Berg,
H. Blumenfeld
selected for the Fritz Dreifuss Honor
3:30 p.m. A.03 Terminal Seizure Remission 45 Years After
Onset Of Absence Epilepsies/M. Holtkamp,
A. Kirschbaum, A. Kowski, D. Janz
3:45 p.m. A.04 Children With Epilepsy And Mild
Intellectual Disability Do Not Have A High Risk Of
Long-Term Resistant Epilepsy; However,
Moderate Or Severe/Profound Intellectual
Disability Is Ominous: A Population-Based Study
With >20 Years Of Follow-Up/P. Camfield,
C. Camfield
4:00 p.m. A.05 Management Of Children With Refractory
Epilepsy. A Decision Analysis Comparing Medical
Versus Surgical Treatment/I. Snchez Fernndez,
S. An, T. Loddenkemper
4:15 p.m. A.06 Pulmonary Edema Occurs In Nearly
One-Third Of Monitored Patients With Convulsive
Seizures And Is Directly Associated With The
Duration Of The Preceding Seizure/J. Kennedy,
P. Parikh, K. Hardin, M. Seyal
4:30 p.m. A.07 Temporal Lobe Epilepsy In Patients With
Nonlesional MRI And Normal Memory: An SEEG
Study/J. Miller, J. Sweet, S. Suresh, P. Landazuri,
H. Lders
4:45 p.m. A.08 A Diagnostic Blood Test For Epilepsy:
A Soluble ICAM-5-Based Panel/J. R. Pollard,
P. B. Crino, G. P. Mueller, O. Eidelman, C. Dalgard,
E. Brand, C. T. Anderson, P. Cai, M. Wamil,
M. C. Strauman, E. Burakgazi-Dalkilic, K. A. Davis,
H. B. Pollard
5:00 p.m. A.09 Predictive Model For Early Posttraumatic
Seizures In The PICU/R. Rajaraman, J. Lerner,
D. Arndt, D. McArthur, J. Fischer, M. Zeiger,
M. Choe, C. Giza
The Fritz Dreifuss Honor is awarded to the highest ranking abstract in the outstanding patient care topic category and is sessioned as Platform A.02. The abstract honored is
selected by the Scientific Program Committee from all submitted abstracts.
The Rebecca Goldberg Kaufman Honor is awarded to the highest ranking abstract in the psychiatric topic category and is sessioned as Platform B.08. The abstract honored is
selected by the Scientific Program Committee from all submitted abstracts.
Platform Sessions
3:00 p.m. - 5:15 p.m.
B. Treatment / Imaging
Convention Center Room 609, Level 6
Moderators: Jacquelyn Bainbridge, Pharm.D.,
Jeffrey Ojemann, M.D.
B.01 Neural Mechanism Of Impaired Consciousness
In Typical Childhood Absence Seizures/J. Guo, R. Kim,
W. R. Xiao, E. Feeney, X. Bai, M. Negishi,
M. J. Crowley, L. C. Mayes, T. Constable,
H. Blumenfeld
B.02 Safety And Pharmacokinetics Of IV Loading
Dose Of Lacosamide In The ICU/R. E. Ramsay,
V. Sabharwal, F. Khan, H. Dave
B.03 Field Potential Imaging: A New Paradigm For
Focal Epilepsy/G. P. Kalamangalam, R. E. Gabr,
P. A. Narayana
B.04 Automated Detection Of Cortical Dysplasia In
MRI-Negative Epilepsy: Class II Diagnostic Evidence/
S. Hong, B. Bernhardt, D. Schrader, N. Bernasconi,
A. Bernasconi
B.05 Increased Cerebral Oxygenation Precedes
Generalized Tonic Clonic Seizures/B. D. Moseley,
J. Britton, E. So
B.06 Continuous Infusions In Refractory Convulsive
Status Epilepticus. Results From The Pediatric Status
Epilepticus Research Group (pSERG)./T. Loddenkemper,
I. Snchez Fernndez, N. Abend, R. Arya, R. Basu,
N. Brenton, J. Carpenter, K. Chapman, J. Condie,
N. Dean, W. Gaillard, T. Glauser, J. Goldstein,
H. Goodkin, A. J. Hani, M. Jackson, K. Kapur,
T. Kebede, J. Klehm, M. Mikati, K. Peariso, M. Sacco,
K. Schmidt, A. Topjian, D. Turner, A. Wilfong,
K. Williams, M. Wainwright, R. Tasker
B.07 The Johns Hopkins Hospital Adult Epilepsy Diet
Center: Results And Experience In Four Years/
M. Cervenka, E. Kossoff, B. Henry, J. Barnett,
R. Fisher
B.08 Long-Term Memory And Language Outcomes
With Responsive Cortical Stimulation Do Not Differ By
Stimulation Localization/D. W. Loring, R. Kapur,
K. J. Meador, M. Morrell
selected for Goldberg Kaufman Honor
B.09 Structural Connectivity Of Limbic Brain Regions
In Patients With Psychogenic Non-Epileptic Seizures
(PNES)/K. Hernando, J. Allendorfer, S. Lee,
L. Ver Hoef, J. Szaflarski
C. Translational
Convention Center Room 603, Level 6
Moderators: Suzanne Bausch, Ph.D., Lori Isom, Ph.D.
C.01 Synaptic Impairment Of Frontal Cortical Fast-
Spiking Basket Cells Induces Cognitive And Behavioural
Deficits In Mice With A Cacna1a Loss-Of-Function
Mutation./A. Lupien-Meilleur, I. Riebe, L. Damaj,
C. Vanasse, G. Louise, A. M. Van den Maagdenberg,
J. Lacaille, E. Rossignol
C.02 Dravet Syndrome Patient-Derived Induced
Pluripotent Stem Cell Cardiac Myocytes Have
Increased Sodium Current Density And Increased
Beating Rate/C. R. Frasier, H. Zhang, K. Collon,
J. Parent, L. L. Isom
C.03 Cerebellar Control Of Spontaneous Seizures In
A Mouse Model Of Temporal Lobe Epilepsy/
E. Krook-Magnuson, C. Armstrong, G. G. Szabo,
M. Oijala, I. Soltesz
C.04 (1-3)Insulin-Like Growth Factor 1 Suppresses
Seizures And Hypsarrhythmia In An Animal Model Of
Infantile Spasms./C. L. Lee, J. D. Frost, Jr., J. T. Le,
R. A. Hrachovy, J. W. Swann
C.05 Development Of Glutamatergic Transmission
Onto Transplanted MGE Interneurons/M. Howard,
S. Baraban
MONDAY
C.06 A Novel Mouse Model Of Chromosome
Xq22.1 Deletion Syndrome Displays Epilepsy And
Cortical Circuit Dysfunction/E. M. Goldberg,
J. Zhou, C. Yue, P. Wang, D. Coulter
C.07 Neuron Subset-Specific-PTEN Deletion Induces
Abnormal Skeletal Activity In Mice/J. Lugo,
M. Thompson, P. Huber, G. Smith, A. Holley, S. Bain,
E. Gardiner, R. Kwon
C.08 Hippocampal DBS Affects Disease Development
In The KA Rat Model For TLE/B. Van Nieuwenhuyse,
R. Raedt, J. Delbeke, M. Sprengers, I. Dauwe,
S. Gadeyne, W. Wadman, P. Boon, K. Vonck
C.09 Seizures And SUDEP In A Mouse Knock-In Model
Of SCN8A Related Epileptic Encephalopathy/J. Wagnon,
M. Korn, R. Parent, J. Jones, G. Murphy, J. Parent,
M. Meisler
65

Monday December 8, 2014
Authors Present: Noon 2:00 p.m.
Poster Walking Tours (see page 15 for details)
Translational Research
Mechanisms
3.001 Increase In Dendritic Spines
Correlates With Increased Synapses
In Hippocampal CA1 Following Hypoxia-
Induced Neonatal Seizures/
J. Lippman-Bell, S. Francomacaro,
F. Jensen
3.002 Using CRISPR In Utero
Electroporation To Study The Function
Of PCDH19/Y. Wang, F. Chen,
J. loturco, J. Parent
3.003 Targeting The JAK/STAT
Pathway For Disease Modification In
Epilepsy/A. J. Carrel,
H. L. Grabenstatter, J. Carlsen,
Y. Cruz Del Angel, S. Russek,
M. F. Wempe, A. Brooks-Kayal
3.004 Topology Of Network
Synchronization During Early
Epileptogenesis/K. Lillis, Z. Wang,
G. Q. Zhao, B. Bacskai, K. Staley
3.005 Retrograde Monosynaptic
Tracing Of Inputs To Neonatal- Vs.
Adult-Born Dentate Granule Cells In A
Rodent Temporal Lobe Epilepsy
Model/X. Du, A. L. Althaus, H. Zhang,
E. G. Wolf, J. Parent
3.006 Disabled 1-Deficient Mice
Exhibit Hippocampal Structural
Abnormalities And A Reduced Seizure
Threshold/M. J. Korn, J. Parent
3.007 Hippocampal Metaplasticity
Induced By Early Life Hypoxic Seizures
In Rats/H. Sun, F. E. Jensen
3.008 Extracellular And Intracellular
K+ Accumulation And Buffering
During Focal Cortical Epilepsy: A
Spatiotemporal Study In Vivo/
S. Dufour, P. Bazzigaluppi, O. Levi,
P. Carlen
3.009 Ceftriaxone Treatment In A
Rat Posttraumatic Epilepsy Model
Preserves Cortical Inhibitory
Interneuron Function And Parvalbumin
Expression/M. Q. Hameed, T. Hsieh,
J. Morales-Quezada, G. S. Goodrich,
A. Rotenberg
3.010 Mifepristone Treatment Post-
Status Epilepticus Normalizes Basal
Corticosterone Levels, Increases
Calretinin Positive Cell Number In The
Dentate Gyrus And Reduces Hilar Cell
Proliferation In Mice/A. C. Wulsin,
J. P. Herman, S. Danzer
3.011 ProBDNF Levels Increase
Rapidly After Seizures In The Mouse/
A. X. Thomas, Y. Cruz Del Angel,
S. J. Russek, B. L. Hempstead,
A. R. Brooks-Kayal
3.012 Preventive Effect Of
Levetiracetam Against The
Pathological Changes In Hippocampus
Of Temporal Lobe Epilepsy Model
Mice/T. Higo, H. Sugano, M. Nakajima,
Y. Iimura, H. Arai
3.013 Inflammatory Mechanisms Of
Epileptogenesis In The Genetic
Epilepsy, Tuberous Sclerosis
Complex/B. Zhang, N. Rensing, J. Zou,
M. Yang, M. Wong
66
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.014 Functional Evaluation Of A De
Novo GRIN2A Mutation In A Patient
With CSWSS, Continuous Spike And
Waves During Slow-Wave Sleep
Syndrome/H. Yuan, A. Tankovic,
S. F. Traynelis
3.015 A Juvenile Myoclonic Epilepsy
GABAA Receptor Mutation Causes
The Developmentally-Dependent
Expression Of Seizures And Cortical
Disinhibition/M. Gallagher, F. Arain,
C. Zhou, L. Ding, S. Zaidi
3.016 Mechanisms Of Epilepsy And
Epileptic Encephalopathy Due To
KCNT1 Mutations/I. H. Quraishi,
G. E. Kim, J. K. Kronengold,
R. L. Couture, M. L. Schwartz,
G. Barcia, R. Nabbout, L. K. Kaczmarek
3.017 A KCNQ2/3 Mutation Causing
Severe Epilepsy Disrupts Channel
Targeting To The Axon Initial
Segment/B. Tran, M. Xu, E. C. Cooper
3.018 Prenatal Valproic Acid
Exposure Impairs Interneuron
Proliferation And Migration/
R. F. Martin, E. Powell
3.019 The Effects Of TRPV1 Ligands
On Blood Brain Barrier Permeability In
A Rodent Model Of Experimental
Febrile Seizures/L. Scott, K. B. Rivard,
K. Barrett, S. Nakanishi,
M. Scantlebury
3.020 5-HT6 Receptor Ligands
Modulate Seizure Thresholds And
Inhibitory Synaptic Transmission In
The Dentate Gyrus/G. J. Remigio,
G. W. Saunders, P. J. West
3.021 The Effect Of Vitamin D On The
Pentylenetetrazol-Kindling And The
Seizure-Induced Neuronal Damage In
The Mouse Hippocampus/S. Lim,
Y. Shon, W. Kim
3.022 Modulation Of NKCC1 And
KCC2 Co-Transporters For Control Of
Drug-Resistant Seizures/V. Dzhala,
Y. Saponjian, Y. De Koninck, K. Staley
3.023 Time Course Of The Neuronal
Sodium Concentration In
PosttTraumatic Epileptogenesis In
Vitro/T. Balena, K. Staley
3.024 A Novel Therapy For Status
Epilepticus Using Biodegradable
Immune-Modifying Nanoparticles/
D. Xu, S. Miller, S. Koh
3.025 Hypothalamus On The Horizon
Of The Seizure Control/T. Chachua,
C. Chern, I. Lilja, J. Veliskova,
L. Velisek
Models
3.026 Use Of Ethosuximide To
Improve Outcome In The Kainic Acid
Model Of Temporal Lobe Epilepsy/
S. S. Iyengar, J. J. LaFrancois,
H. E. Scharfman
3.027 Unravelling The EEG Footprints
That Develop Into Spontaneous
Recurrent Seizures (SRS) During
Epileptogenesis In C57BL6/J Mouse
Model Of Temporal Lobe Epilepsy
(TLE)/S. Puttachary, S. Sharma,
T. Thippeswamy
3.028 The Piriform Cortex In The
Intrahippocampal Kainic Acid Model:
Effects Of Lesions And Deep Brain
Stimulation On Spontaneous
Seizures/M. Sprengers, R. Raedt,
R. Siugzdaite, B. Descamps,
B. Van Nieuwenhuyse, I. Dauwe,
J. Delbeke, W. Wadman, P. Boon, K. Vonck
3.029 Effect Of A Conventional
Antiepileptic Strategy On Seizure
Activity And Neuroprotection In A Rat
Model Of Human Cortical Dysplasia:
Data From A Pilot Study/G. Battaglia,
P. Nobili, A. Finardi, F. Colciaghi
3.030 New Model Of Focal Cortical
Dysplasia Associated Epilepsy/
L. S. Hsieh, J. H. Wen, G. Buchanan,
K. Claycomb, H. Zhan, A. Bordey
3.031 Electrographic Spiking And
Frequency Power Analysis In Mouse
CCI Models Of TBI Compared With
Memory And Motor Deficits/J. Carlsen,
D. Raible, L. Frey, A. Brooks-Kayal
3.032 Oxidative Stress-Mediated
Mitochondrial Dysfunction And
Neuronal Loss Contribute To Cognitive
Deficits In Experimental Temporal Lobe
Epilepsy/J. Pearson, S. Rowley,
L. Liang, B. Day, M. Patel
3.033 Aberrant Diurnal And Circadian
Rhythms In Epileptic Mouse Model/
R. Maganti, E. Wallace, J. Williams
3.034 Microelectrode Array Neuronal
Recordings From Intact Larval Zebrafish/
M. Meyer, A. Poduri, A. Rotenberg
3.035 Enhancing KCC2 By Acute TrkB
Inhibition Rescues Phenobarbital-
Resistant Seizures In A Model Of
Neonatal Ischemia/S. Kadam, S. Kang,
M. Johnston
3.036 Cardiac Consequences Of
Repeated Brief Seizures In Chronic
Experimental Temporal Lobe Epilepsy/
J. Jefferys, A. Ashby-Lumsden,
T. Lovick, K. Qing, S. Lee, P. Irazoqui
3.037 Spike-Wave Discharges Before
And After The Induction Of Epilepsy In Rats/
J. LaFrancois, K. Bermudez-Hernandez,
H. E. Scharfman
3.038 Pattern Recognition And
Quantification Of Spike-And-Wave
Discharge In Normal And Brain-Injured
Sprague-Dawley Rats/D. Barth,
F. Dudek, K. Rodgers
3.039 Flupirtine Is More Efficacious
Than Phenobarbital In The Treatment
Of Hypoxia-Ischemia Induced Neonatal
Seizures In A Rodent Model/
D. Sampath, A. White, Y. Raol
3.040 EEG Analysis After Ketamine
Induction Mechanistic Similarities To
Anti-NMDA Receptor Encephalitis/
C. N. Braun, L. UnCheol, S. Glynn,
M. George
3.041 Increased Neuroinflammation
In A Mouse Model Of Tuberous
Sclerosis/A. A. Coley, H. Sun,
S. S. Soldan, F. E. Jensen, D. M. Talos

Monday December 8, 2014
3.042 In Vivo Modulation Of Synaptic
Noise: A Novel Model Of Ictogenesis/
H. Luna-Munguia, P. Starski, W. Stacey
3.043 Lithium-Pilocarpine And DFP-
Induced Status Epilepticus In
Immature Rats: Behavioral,
Electrographic, And Neuropathological
Characteristics/E. A. Scholl,
N. Simon, M. Lehmkuhle, J. Ekstrand,
F. E. Dudek
3.044 Epilepsy In A Novel Tuberous
Sclerosis Mouse Model/S. C. Dhamne,
E. Chadwick, S. Lammers,
M. Q. Hameed, D. Kwiatkowski,
A. Rotenberg, M. Sahin
3.045 First In-Vivo Model For
Electrically Induced Seizures An
Electroclinical Characterization/
A. Y. Kitay, M. Brosch, F. Marquardt,
L. Buentjen, C. Kluge, J. Mylius,
E. Selezneva, K. Kopitzki, J. Voges,
H. Heinze, H. Scheich, F. Schmitt
3.046 Identifying Gene Pathways
Activated After Audiogenic Atimulus
In Wistar Audiogenic Rats/A. Matos,
A. S. Schwambach Vieira, V. Pascoal,
C. S. Rocha, D. Nascimento,
S. Martins, C. Maurer Morelli,
A. Martins, A. Godard,
I. Lopes-Cendes
3.047 Comparison Of Spike-Wave
Discharges And Other Oscillatory
Activity In Normal Animals With
Spontaneous Recurrent Seizures
Across Several Animal Models Of
Acquired Epilepsy/F. Dudek,
K. M. Rodgers, W. A. Pouliot,
S. Kadam, E. H. Bertram, D. S. Barth
3.048 Rapamycin Normalizes Total
EEG Power In Neuron Subset-Specific
PTEN Knock-Out Mice/
A. Regnier-Golanov, L. Nguyen,
A. Brewster, V. Patil, A. Anderson
3.049 Early EKG Changes And
Cardiac Activation Of Intracellular
Signaling Cascades In A Model Of
Acquired Epilepsy/A. Brewster,
A. Anderson, Y. Lai
3.050 Late Inhibition Of mTOR
Suppresses Fully Established Epilepsy
And Associated Neuropathology In The
NS-Pten KO Mouse Model Of Cortical
Dysplasia/L. Nguyen, A. Brewster,
M. Clark, A. Regnier-Golanov,
C. Sunnen, V. Patil, A. Anderson
3.051 Neonatal Stroke And
Phenobarbital Treatment: Improved
T-Maze Function And Impact On Post-
Stroke Hilar Neurogenesis/A. Comi,
M. Mateo, S. George, A. Garson,
K. Fisk, H. Miao
3.052 Gender Differences In
Cerebrospinal Fluid Levels Of
Monamine Metabolites In The
Baboon/M. Patel, J. Rogers, C. Szabo,
M. Leland, M. A. Javors
Human Studies
3.053 Does Valproate Increase Levels
Of Folate Receptor Autoantibodies In
Women?/C. Lau, C. Harden,
A. Palacios, R. Finnell
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.054 Characteristics Of Seizure
Termination In Focal And Generalized
Seizures/M. Borzello, A. Maheshwari,
C. Chu, M. Westover, M. Kramer,
S. Cash
3.055 Looking For Complexity In
Quantitative Semiology Of Frontal And
Temporal Lobe Seizures Using
Neuroethology And Graph Theory/
N. Garcia-Cairasco, P. Bertti,
J. Tejada, A. Pinheiro Martins,
M. Cleto Dal-Cl, V. Terra,
J. Cortes de Oliveira, T. Rodrigues Velasco,
A. Ceiki Sakamotob
3.056 Quantitative Proteomic
Profiling Reveals Repression Of
Epilepsy Risk Genes Due To Aberrant
MicroRNA Activity In Epileptogenic
TSC Tubers/A. A. Dombkowski,
D. Cukovic, N. J. Carruthers,
P. M. Stemmer, H. T. Chugani,
D. C. Chugani
3.057 The North American SUDEP
Registry/B. Kaufman, D. Hesdorffer,
E. Donner, G. Lapham, J. Buchhalter,
D. Friedman, O. Devinsky
3.058 Deep Brain Stimulation For
Focal Epilepsy How Do Changes Of
Interictal Epileptic Discharges
Correspond To Outcome?/H. Lee,
C. Kluge, F. Marquardt, J. Voges,
L. Buentjen, S. Rampp, A. Kowski,
M. Holtkamp, H. Heinze, F. Schmitt
3.059 The Safety, Efficacy And
Dosing Of Barbiturate Coma In
Pediatric Sustained Refractory
Status Epilepticus/E. Payne,
C. Griffiths, H. Frndova, A. Trope,
C. Hahn
3.060 Whole Brain Networks Of
Visual Object Recognition/
C. Kadipasaoglu, C. Conner,
V. Baboyan, N. Tandon
3.061 Ventricular Repolarization
Instability In Children With Epilepsy/
W. Ali, B. Bubolz, A. Anderson, Y. Lai
3.062 Multiple Functions Of The Pre-
Central Frontal Eye Field/E. C. Brown,
O. Muzik, R. Rothermel, C. Juhasz,
A. Shah, D. Fuerst, S. Mittal,
S. Sood, E. Asano
Biomarkers
3.063 Tracking Inflammation In
Epileptogenic Brain Tissue In The Rat
By Nanoparticles/S. Eyal, E. Portnoy,
B. Polyak, D. Inbar, A. Mann, A. Rai,
A. Bishara, M. Shmuel, S. Magdassi,
T. Ben Hur, D. Ekstein
3.064 High Frequency Oscillations
Deviate From Neuronal Avalanche
Dynamics In The Ictal Onset Zone/
E. Gireesh, C. Jouny, N. Crone
3.065 The Role Of Physiologic
Biomarkers During A Taurine Trial For
Succinic Semialdehyde Dehydrogenase
Deficiency/J. Schreiber, P. Pearl,
I. Dustin, E. Wiggs, E. Barrios,
E. Wassermann, K. M. Gibson,
W. Theodore
3.066 Mass Spectrometry-Based
Metabolomics Approach For
Uncovering Epileptogenic Mechanisms
And Biomarker Discovery/
S. Heischmann, L. B. Gano, K. Quinn,
C. Cruickshank-Quinn, N. Reisdorph,
M. Patel
3.067 Generalized, Automated
Algorithm For Detecting HFOs And
The Extent Of The Seizure Onset
Zone/S. Gliske, W. Stacey
3.068 Occurence Of Ictal High
Frequency Oscillations Mirrows
Seizure Strength In Rats/N. Birk,
K. Somerlik-Fuchs, T. Stieglitz,
A. Schulze-Bonhage, J. Jacobs
3.069 How Reliable Are The High-
Frequency Oscillations And Delayed
Responses As Epileptogenicity
Biomarkers? A Study Based On
Intracranial Stimulation/A. Barborica,
C. Donos, M. Maliia, J. Ciurea,
A. Rasina, I. Mindruta
3.070 Early Seizure Detection Using
Relative Gamma And Ripple Band
Phase Decoherence/Z. Nadasdy,
D. Benites, J. Shen, D. Briggs,
D. F. Clarke, R. Buchanan, M. Lee,
D. Nelson, P. Modur
3.071 High Frequency Oscillations In
Patients With Nonlesional Class I
Outcomes In Seizure Onset Channels
Versus Non Seizure Onset Channels
In Temporal And Neocortical
Structures/N. D. Child, J. Cimbalnik,
V. M. Vasoli, V. Svehlik,
B. H. Brinkmann, M. Stead, G. Worrell
3.072 Spectroscopic Imaging In Early
MONDAY
Post-Status Epilepticus In A Rodent
Model/P. S. Pearce, N. de Lanerolle,
A. Rapuano, T. Hitchens, J. W. Pan
3.073 Automated High-Frequency
Oscillation Detection From Tripolar
Concentric Ring Electrode Scalp
Recordings/M. Abtahi,
I. E. Martnez-Jurez, O. Makeyev,
A. Medvedev, J. Gaitanis, R. Fisher,
W. Besio
3.074 Modulating Epileptogenesis In
The Glutamine-Synthetase Deficient
Model Of MTLE/E. Perez, H. Zaveri,
R. Joshi, H. Wang, E. Damisah,
R. Dhaher, T. Eid
Behavior/Neuropsychology/
Language
Adult
3.075 Development And Field-Testing
Of An Epilepsy Self-Management
Instrument For Adults With
Epilepsy/C. Escoffery, Y. Bamps,
W. LaFrance, S. Stoll, R. Shegog,
J. Buelow, P. Shafer, N. Thompson
3.076 Distinct Domains Of Impulsivity
Are Impaired In Juvenile Myoclonic
Epilepsy, But Not In Temporal Lobe
Epilepsy/P. Rzezak, S. Moschetta,
E. Lima, C. X. Castro, A. Coan,
C. Guerreiro, G. Busatto, K. Valente
3.077 Stability And Variability Of
Cognitive Performance In Patients
With Epilepsy/M. T. Lutz, T. Mayer
67

Monday December 8, 2014
3.078 Depression And Isolation In
People With Epilepsy/N. Thompson,
Y. A. Bamps, L. Selwa, S. Stoll,
C. Begley, E. K. Johnson, R. Fraser
3.079 PHQ-9 And GAD-7 As Reliable
Screening Tools For Mood Disorders
In People With Epilepsy (PWE)/
I. Ahmed, S. Nair, A. Riaz, I. Ali
3.080 The Impact Of Disease
Variables And Standard Cognitive
Measures On Social Cognition In
Epilepsy/K. Bujarski, L. Flashman,
R. M. Roth
3.081 Felt Stigma In Families
Containing Multiple Individuals With
Epilepsy/M. Sabatello, S. T. Sorge,
J. O. Okeke, V. Tangel, S. Shostak,
J. C. Phelan, J. Goldsmith,
M. Winawer, D. Hesdorffer,
W. K. Chung, R. Ottman
3.082 Depression And Seizure
Frequency Predicts Worse Social
Functioning In Patients With Juvenile
Myoclonic Epilepsy (JME)/
S. C. Moschetta, C. A. Guerreiro,
C. Lima Castro, A. Coan, P. Rzezak,
K. Valente
3.083 Unique Characteristics Of
Patients With Comorbid Epileptic And
Psychogenic Nonepileptic Seizures/
J. J. Konikkara, J. Pacheco,
P. Van Ness, M. Agostini, R. Hays,
L. Howe-Martin, C. B. Culver,
J. Munoz, K. Ding, P. Modur, P. Gupta
3.084 Preoperative Hippocampal
Volume And Neuropsychological
Outcomes/S. C. Germeyan, E. Wiggs,
L. Sepeta, E. Emery, I. Dustin,
K. zaghloul, S. Inati, W. Theodore
3.085 Comparison Of Common Data
Elements From The Managing Epilepsy
Well (MEW) Integrated Database And
A Well Characterized Sample With
Nonepileptic Seizures/W. LaFrance,
Jr, Y. Bamps, S. Stoll, S. S. Sahoo,
E. Welter, J. Sams, C. Tatsuoka,
M. Sajatovic
Genetics
Human Studies
3.086 Screen For Somatic Mosaic
Mutations In Unexplained Dravet
Syndrome Patients/C. Myers,
J. McMahon, I. Scheffer, H. Mefford
3.087 The Phenotypic Spectrum Of
SCN2A Encephalopathy: A Diagnosis
With Treatment Implications/
K. Howell, J. McMahon, G. L. Carvill,
A. Poduri, M. T. Mackay,
M. V. Rodriguez Casero, R. Webster,
D. Clark, J. L. Freeman, S. Calvert,
S. Mandelstam, H. Mefford,
A. S. Harvey, I. Scheffer
3.088 Are Mutations Of The
Respiratory Control Gene PHOX2B
Associated With Sudden Unexpected
Death In Epilepsy (SUDEP)?/
B. M. Regan, R. D. Bagnall,
D. E. Crompton, C. Cutmore,
S. Berkovic, I. E. Scheffer,
C. Semsarian
68
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.089 Whole-Exome Sequencing In 84
Cases Of Unsolved Progressive
Myoclonus Epilepsy/M. Muona,
S. Berkovic, L. M. Dibbens,
K. L. Oliver, S. Maljevic, T. Joensuu,
M. A. Bayly, S. Petrou, H. Lerche,
A. Palotie, A. Lehesjoki
3.090 Familial Adult Myoclonic
Epilepsy: A New Family Consistent
With Linkage To Chromosome 2/
K. Klein, M. Pendziwiat,
R. Straussberg, I. Blatt, C. E. Kim,
P. S. Reif, S. von Spiczak, A. Korczyn,
H. Muhle, F. Rosenow, H. Hakonarson,
G. Kuhlenbumer, H. Goldberg-Stern,
U. Stephani, Z. Afawi, I. Helbig
3.091 Genetic Determinants Of
Common Epilepsies: A Meta-Analysis
Of Genome-Wide Association
Studies/G. Na
3.092 CHD2 Myoclonic
Encephalopathy: Self-Induced
Seizures, Photosensitivity And
Variable Cognitive Outcome/
R. Thomas, L. Zhang, G. L. Carvill,
J. Archer, S. Mandelstam, D. Craiu,
S. Berkovic, D. Gill, H. Mefford,
I. Scheffer
3.093 Whole-Exome Sequencing And
Targeted Re-Sequencing In Pediatric
Epileptic Encephalopathies/
J. L. Michaud, M. Lachance,
F. F. Hamdan, S. Dobrzeniecka,
H. Mefford, R. G. Lafrenire,
B. Minassian, P. Cossette,
E. Rossignol
3.094 CACNA1A-Related Hemiplegic
Migraine Mimicking Psychogenic
Non-Epileptic Seizures (PNES)/
M. Chadehumbe, M. Mintz, R. Boles
3.095 Epilepsy Genetics Initiative
(EGI)/D. Goldstein, E. Heinzen,
D. Lowenstein, S. Berkovic,
T. Dixon-Salazar, J. Milder, H. White,
O. Devinsky, D. Dlugos, W. Gallentine,
M. Mikati, A. Poduri, I. Scheffer,
J. Sullivan
3.096 Copy Number Variants Are An
Important Cause Of Unexplained
Epilepsy Plus Other Neurological
Abnormalities/S. E. Buerki, E. Sade,
P. Eydoux, M. Connolly, M. Demos
3.097 Severe Multi-Organ
Involvement Including Pancreatic
Neuroendocrine Tumor In A 51-Year-
Old Female With Tuberous Sclerosis
Complex/F. Andermann, D. Amrom,
M. Heshmati Moghaddam, P. Zanelli,
E. Andermann
3.098 Regional Variation Of SLC7A11
Expression In Glioblastoma
Associated Seizures/J. Lee, J. Snyder,
T. Mikkelsen, P. Wen
3.099 Uncovering New Genetic Loci
For Infantile Spasms Syndrome/
E. D. Marsh, J. Glessner, X. Bozarth,
W. Dobyns, H. Hakonarson, I. Helbig
3.100 Utilizing Brain Expression
Networks To Prioritize Candidate
Epileptic Encephalopathy Genes/
K. L. Oliver, V. Lukic, N. P. Thorne,
S. F. Berkovic, I. E. Scheffer, M. Bahlo
3.101 Association Between
Polymorphisms In Genes Involved In
P-Glycoprotein Regulation And
Pharmacoresistance In Childhood-
Onset Epilepsy/J. Montalvo,
M. Rios-Motta, S. Gonzalez-Crespo,
L. Gonzalez-Sepulveda, K. Acevedo,
M. Vazquez, I. Pita
3.102 Whole Exome Sequencing In
Intractable Paediatric Epilepsy
Patients In Calgary/L. Bello-Espinosa
3.103 Copy Number Variants In
Children With Epilepsy/
S. J. Mackenzie, Y. Eksioglu
3.104 Natural History Of Seizures In
Rett Syndrome And MECP2-Related
Disorders/D. Tarquinio, J. B. Lane,
W. Hou, W. Kaufmann, S. A. Skinner,
K. J. Motil, J. L. Neul, D. Glaze,
A. K. Percy
Animal Studies
3.105 Superimposing Status
Epilepticus On NS-PTEN
Haploinsufficient And Wild Type Mice
Results In Long-Term Changes In
Behavior/G. Smith, J. White,
J. Nicoletti, A. Pandian, J. Lugo
3.106 Selective Targeting Of Scn8a
Expression Confers Seizure
Resistance In Two Mouse Models Of
Refractory Epilepsy/J. Wong,
C. Makinson, H. Zafar, A. Escayg
3.107 Scn2a-null Heterozygosity
Improves Survival And Modifies
Neurocardiac Interaction In The
Kcna1-Null Mouse Model Of SUDEP/
E. Glasscock, N. Gautier, B. Karumuri,
R. Liu, I. Vlachos, L. Iasemidis
Neuropathology of Epilepsy
Human Studies
3.108 Oligodenderoglia-Like Cells In
White Matter Recruiting The
Extensive Epileptogenic Zones In
Pediatric Intractable Focal Epilepsy/
S. Sakuma, W. Halliday, K. Okanari,
S. Baba, M. Nakajima, Y. Sato,
A. Ochi, H. Otsubo
3.109 Hippocampal Changes In
Refractory Status Epilepticus:
Autopsy Findings/K. M. Ikeda, L. Ang,
G. Young
3.110 Neuroinflammatory Processes,
Acute Neuronal Injury And Blood Brain
Barrier In SUDEP/Z. Michalak,
D. Obari, M. Thom, S. Sisodiya
3.111 Cerebral Glucose
Hypometabolism Is Associated With
Mitochondrial Dysfunction In Patients
With Intractable Epilepsy And Cortical
Dysplasia/J. Tenney, L. Rozhkov,
P. Horn, L. Miles, M. Miles
3.112 The Serum Levels Of Sodium
And Uric Acid In Children With Benign
Convulsion With Mild Gastroenteritis/
S. Kim, J. Kang, H. Bang, T. Kim,
H. Kim, J. Kang, J. Kim, Y. Kim

Monday December 8, 2014
3.113 Gene Expression Profiling In
Dentate Granule Cells Of Mesial
Temporal Lobe Epilepsy Patients With
And Without Hippocampal Sclerosis/
N. G. Griffin, Y. Wang, L. Hong,
C. Hulette, M. Haglund, R. Radtke,
P. Skene, S. Sinha, E. Heinzen
3.114 A Case Of Glioneuronal Tumor
With Focal Cortical Dysplasia Type
IIb/T. Saito, S. Sukigara, S. Hanai,
A. Takahashi, M. Sasaki, T. Otsuki,
M. Itoh
Animal Studies
3.115 NMDA Receptor Activation
Contributes To Benzodiazepine
Refractoriness By Enhancing Ampa
Receptor Mediated Transmission
During Status Epilepticus/S. Joshi,
K. Rajasekaran, J. Williamson,
J. Kapur
3.116 Circulating Ccr2+ Monocytes
Display Delayed Brain Infiltration After
Chemoconvulsant-Induced Status
Epilepticus/N. Varvel, J. J. Neher,
R. J. Miller, M. Jucker, R. Dingledine
3.117 Deletion Of Micro-RNA-146a
Leads To Fewer Animals Developing
Acute Behavioral Seizures Following
Viral Encephalitis/M. F. Cusick,
J. E. Libbey, R. M. OConnell,
R. S. Fujinami
3.118 Effects Of Neuronal Nitric
Oxide Synthase Inhibition In A
Neonatal Mouse Model Of Acute
Hypoxic Seizures/S. A. Zanelli,
P. Wagley, J. Kapur
3.119 Regulation Of Hippocampal
Glutamate Transporter-1 (GLT1)
Expression In The Intrahippocampal
Kainic Acid Model Of Epileptogenesis/
J. A. Hubbard, J. Szu, D. Binder
3.120 Impact Of Targeted Ablation Of
Developing Dentate Granule Cells On
Temporal Lobe Epileptogenesis/
B. Hosford, J. Liska, S. Danzer
3.121 Do Ripples Change After
Pilocarpine-Induced Status
Epilepticus?/C. Behr, M. Lvesque,
C. Pack, J. Gotman, M. Avoli
3.122 Sex- And Brain Region-Specific
Regulation Of Brd2 In GABAergic
Neurons In A Juvenile Myoclonic
Epilepsy Mouse Model/J. A. Miller,
F. Mohammad, D. S. Chandler,
J. Veliskova, L. Velisek,
D. A. Greenberg
3.123 Evaluation Of The Inflammatory
Process In Focal Cortical Dysplasia
Model By Freeze Lesion/A. Donatti,
A. Fernandes, N. Garcia-Cairasco
3.124 Effects Of Postnatal
Inflammation On Brain Excitability In A
Mouse Model Of Autism Spectrum
Disorder/M. L. Lewis, L. Qulu,
S. A. Candy, J. M. Rho, Q. J. Pittman
In Vitro Studies
3.125 Laser Scanning
Photostimulation Reveals Altered
Astrocyte Maturation In A Model Of
Developmental Cortical Malformation/
M. Armbruster, C. Dulla
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
Epidemiology
3.126 Real-World Assessment Of The
Burden Of Epilepsy In Tuberous
Sclerosis Complex (TSC) Patients In
The United Kingdom (UK)/P. Crawford,
C. Shepherd, D. Demuth, P. Nasuti,
L. Lucchese, Z. Haider, E. Gray,
M. Magestro
3.127 Managing Information Well:
Towards An Ontology-Driven
Informatics Platform For Data
Sharing And Secondary Use In
Epilepsy Self-Management Research
Centers/S. D. Lhatoo, S. S. Sahoo,
G. Zhang, Y. Bamps, R. Fraser,
S. Stoll, C. Tatsuoka, E. Welter,
M. Sajatovic
3.128 Sudden Unexpected Death In
Epilepsy. A Population-Based Study/
A. Einarsdottir, O. Sveinsson,
E. Olafsson
3.129 Using Routine Data To
Investigate Secular Trends In Hospital
Admission Amongst Children With
Epilepsy: A Nationwide Study/
O. Ajetunmobi, C. Weir, R. Wood,
R. Chin
3.130 A Study Of Epilepsy Prevalence
And Incidence In The U.S. Using
Administrative Claims Data/
S. Helmers, D. Thurman, T. Durgin,
A. Kalsanka Pai, A. Patel, E. Faught
3.131 Epidemiology Study Of
Association Between Onset Of
Chronic Headache And Epilepsy/
T. Chen
3.132 Long QT Mutations And QT
Prolongation Are Linked With An
Increased Risk Of Seizures/
D. S. Auerbach, M. Ruwald,
M. Andrews, A. Moss
3.133 Retrospective Review Of
Seizures Associated With Posterior
Reversible Encephalopathy Syndrome
(PRES)/N. Dike, S. Rana
3.134 Trajectories Of Emotional
Well-Being In Children With Newly
Diagnosed Epilepsy/S. W. Goodwin,
P. Wilk, M. Campbell, K. N. Speechley
3.135 Fertility In Epilepsy: Effects Of
Estimated Offspring Risk And Genetic
Attribution/V. Tangel, S. T. Sorge,
J. O. Okeke, S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
3.136 Defining The Prevalence And
Characteristics Of Seizure Clusters/
T. Choezom, S. Zhang,
S. Radhakrishna, J. Bonito, H. Zaveri,
R. Joshi, L. Hirsch, K. Detyniecki
3.137 Sudden Unexpected Death In
Dravet Syndrome: A Case-Control
Study/E. Donner, D. Friedman,
B. Kaufman, D. Hesdorffer,
G. Lapham, J. Buchhalter, J. Thaler,
S. Rai, A. Thaler, O. Devinsky
3.138 Predictors Of Seizure
Clusters/B. Chen, H. Choi, L. Hirsch,
R. Buchsbaum, K. Kato, A. Legge,
K. Detyniecki
3.139 The Clinical And Social Impact
Of The Post-Ictal State/C. Josephson,
N. Jette, Y. Aghakhani, P. Federico,
A. Hanson, W. Murphy, N. Pillay,
S. Wiebe
3.140 The Elixhauser Index In Incident
Epilepsy And First Unprovoked
Seizure: Means And Reliability Of
Patient Or Parent Report And
Hospital Medical Record/E. Leaffer,
A. Hauser, A. Pack, E. Baldin,
C. I. Akman, D. Hesdorffer
3.141 How Do Caregivers Determine
Seizure Severity In Their Child With
Epilepsy?/S. Shih, M. Ardini,
B. Kroner, W. Gaillard,
S. Cushner-Weinstein, J. Salpekar,
K. Havens, A. Kao, T. Zelleke,
D. Depositario-Cabacar
3.142 Patterns Of Comorbidity In
Pregnant Women with Epilepsy/
A. M. Malek, D. A. Wilson,
B. Wannamaker, R. B. Newman,
J. E. Vena, A. Selassie
3.143 Tuberous Sclerosis Does
Regional Differences In Clinical
Features Exist?/E. V. Caetano,
P. B. Cerqueira, M. G. Manreza,
U. C. Reed, L. B. Sampaio,
E. C. Miotto, F. A. Costa,
P. S. Mendes, B. J. Correa
3.144 Parental Worry About
Nocturnal Seizures And Utilization Of
Methods For Monitoring/B. Kroner,
S. Shih, M. A. Ardini, W. Gaillard
3.145 Etiologies And Yield Of
Investigations For Infantile Spasms:
Results Of A U.S. Multicenter,
MONDAY
Prospective Study/E. Wirrell, C. Joshi,
R. Shellhaas, C. Keator, S. Kumar,
W. Mitchell
Neurophysiology
Other Clinical EEG
3.146 Pharmacologically Induced
Burst Suppression In Pediatric And
Adult Patients Varying But
Predictable Pattern?/L. M. Sorin,
B. Jabo, T. Losey
3.147 Completely Lateralized Vertex
Waves Of Sleep Are A Normal
Phenomenon: A Retrospective,
Blinded, Case Control Study/
J. N. Brenton, J. R. Mytinger
3.148 Posterior Rhythmic Delta
Activity In Patients With Absence
Epilepsy/R. Fabris, L. Wong-Kisiel,
K. Nickels
3.149 Multifocal Electrographic
Seizures Recorded By 128 Channel
Dense Array High-Resolution EEG In
Outpatient EEG LAB/H. Hasegawa
3.150 EEG Focal Interictal
Epileptiform Transients (FIET) & Their
Correlation With Clinical Diagnosis/
F. Matsuo
3.151 How Much Does Sleep
Deprivation EEG Useful For Detecting
Epileptiform Abnormalities?/D. Ozbek,
I. Midi, K. Agan
69

Monday December 8, 2014
3.152 Generalized Onset Seizures
With Focal Evolution Should Be
Recognized As A Seizure Type/
A. Linane, B. Abou-Khalil, A. Lagrange
3.153 Preictal Failure Of Post-Spike
Slow Waves To Control Spike-Related
High-Frequency Oscillations Is
Associated With Seizure Initiation In
Focal Cortical Dysplasia Type II/
Y. Sato, S. M. Doesburg, S. M. Wong,
A. Ochi, H. Otsubo
3.154 Correlation Between
Bispectral Index And
Electrocorticography During Epilepsy
Surgery/D. San Juan Orta,
M. Gmez Ramrez,
L. R. Rodrguez Arias,
A. Osorio Santiago, A. Lpez Pizano,
R. Llerenas Zamora,
R. Vzquez Gregorio,
A. Espinoza Lpez,
C. Trenado, A. Hernandez Ruiz,
J. Delgado-delaMora,
M. Alonso-Vanegas, D. Anschel
3.155 Diagnostic Utility And Yield Of
Routine Electroencephalogram Study
In Patients Referred By
Epileptologists And Carrying A
Diagnosis Of Epilepsy/A. Gudlavalleti,
B. B. Allen, N. K. Sethi, G. Solomon
3.156 Diagnosis Of Electrical Status
Epilepticus In Sleep Made By A
Clinician Versus Computerized Spike
Detection Software: A Comparison/
T. Bryant, M. Guess, L. Wenzel,
D. Tadlock, C. Joshi
3.157 Validation Of The M-Score, An
EEG Grading Scale For Infantile
Spasms/J. R. Mytinger, S. A. Hussain,
J. J. Millichap, N. Ryan, G. L. Heyer
3.158 30 Minute Versus Extended
Outpatient Eeg For The Detection Of
Epileptiform Abnormalities In New
Referrals/D. Burkholder, J. Britton,
V. Rajasekaran, R. Fabris,
J. C. Perumpillichira, K. Kelly, E. So,
K. Nickels, L. Wong-Kisiel,
T. Lagerlund, G. Cascino, G. Worrell,
E. Wirrell
3.159 High-Rate REM Sleep High
Frequency Oscillations (HFOs) Are
Specific To Epileptogenicity/
R. Sakuraba, M. Iwasaki, E. Okumura,
K. Jin, Y. Kakisaka, K. Kato,
T. Tominaga, N. Nakasato
3.160 The Dynamic Changes Of Ictal
High Frequency Oscillations During
Temporal Lobe Seizures Recorded By
Stereo-Electroencephalography/
S. Wu, J. Tao, S. Rose, S. Lhatoo,
H. Lders
3.161 Detectability Of Fast Ripples
On The Scalp EEG: A Preliminary
Study With Subdermal Electrodes/
F. Pizzo, B. Frauscher,
T. Ferrari-Marinho, F. Dubeau,
J. Gotman
3.162 Fixation-Off Sensitivity (FOS)-
Like Phenomenon After Embolic
Strokes Of The Parietal And Occipital
Regions/F. Tirol, A. Foroughi,
P. Foreman
70
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.163 The Intracerebral EEG Pattern
Of Focal Cortical Dysplasia Changes
During The Different Stages Of
Sleep/I. Menezes Cordeiro,
N. von Ellenrieder, F. Dubeau,
J. Gotman, B. Frauscher
3.164 Changes In Scalp EEG Spectral
Content During Deep Temporal Lobe
Seizures Lacking A Scalp Ictal
Correlate/A. D. Lam, S. S. Cash
3.165 Quantitative Analysis Of
Interictal Discharges In Mesial
Temporal Lobe Epilepsy/L. A. Oliveira,
A. D. Borges, S. Yamashita,
L. Betting
3.166 The Epileptiform Abnormalities
In Pediatric Autoimmune
Neuropsychiatric Disorders
Associated With Streptococcus
(PANDAS) Patients/X. Zhou,
A. Buckley, S. Swedo, S. Inati
3.167 How High Is High Enough? Do
Faster EEG Sampling Rates Lead To
Improved Seizure Onset Localization?/
S. P. DeVries, K. A. Davis,
J. B. Wagenaar, W. C. Stacey
3.168 Changes In Intracranial
Electroencephalography (iEEG) In Five
Patients During WADA/S. Le,
K. J. Meador
3.169 Increased Left Hemisphere
Interictal Epileptiform Discharges Are
Associated With Language Based
Knowledge And Learning In Benign
Rolandic Epilepsy/M. Takeoka,
J. Girard, C. Harini, C. Vega, K. Boyer
3.170 EEG Photic Driving: Clinical
Significance Of Asymmetric
Responses/M. T. Kendirli, H. Tekeli,
E. Togrol, F. Ozdag
3.171 The Utility Of Ambulatory
Electroencephalography (aEEG)/
K. AbdeleRahman, R. Mahajan,
M. Grigg-Damberger
3.172 Prevalence Of Epileptiform
Activity In Children Less Than 1 Year
Of Age Referred For Polysomnography/
A. W. Ho, A. Adeleye, A. Nettel-Aguirre,
V. Kirk, J. Buchhalter
3.173 Differences In The Yield Of
Routine EEG Studies In Patients 60
Years Or Older As Compared To
Patients Less Than 60-Years-Old
Presenting With Transient Loss Of
Consciousness/N. Gupta,
C. Christodoulou, J. Miller-Horn
3.174 Broadband Intracranial Ictal
EEG Analysis In Lesional And Non-
Lesional Pharmacoresistant
Epilepsy/M. Dhakar, A. Shah
3.175 Characteristic Electrographic
Findings In Fraternal Twins With
Sialidosis/A. Sheikh, J. Menon,
V. Ramsey-Williams, D. Cameron, H. Li
3.176 Fun Finding Artifacts This Is
An Interactive Poster Showing Some
Common And Uncommon Artifacts.
The Goal Is To Challenge All Levels Of
EEG Knowledge. See The Artifact And
You Guess What You Think That It Is,
Once You Have An Idea You Can Check
Your Answer/C. L. Riley
3.177 Intracranial Recording: A
Glimpse On White Grey Matter
Differences/M. Mercier, S. Bickel,
P. Megevand, D. Groppe, A. Mehta,
F. Lado
3.178 Visual-Evoked Responses As A
Biomarker For Neural Hyper-
Excitability In Childhood Absence
Epilepsy/R. Holt, F. Pei, B. Porter,
J. Tsai, A. Norcia
3.179 Eletroencephalographic Profile
Of Outpatients Presenting Seizures
During Routine EEG on a Tertiary
Teaching Hospital/R. Alessi,
C. N. Alencar, P. B. Lima,
M. R. Silveira, J. Q. Andrade,
E. Garzon
3.180 Photic Stimulation: Get More
Information From An Old Test; Can We
Do Better? Utility Of Change In SPR
As A Marker Of Chronc Efficacy/
P. Timmings
Computational Analysis & Modeling
Of EEG
3.181 Accuracy Of EEG
Interpretation Without A Reference
Standard/J. Slater, A. C. Grant,
A. Omurtag
3.182 On Seizure Dynamics And
Propagation/C. Bernard, V. Jirsa,
W. Stacey, F. Bartolomei, T. Proix
3.183 Spectral Analysis Of
Intracranial Interictal Bursts May
Localize Seizure Onset/H. Ung,
K. Davis, D. Wulsin, B. Litt
3.184 Epileptic Spikes And High
Frequency Oscillations Are More
Frequent During Generalized Slow
Oscillations Than During The Rest Of
NREM Sleep/B. Frauscher,
N. von Ellenrieder, T. Ferrari-Marinho,
F. Dubeau, M. Avoli, J. Gotman
3.185 Ripple (80-250Hz)
Characterization In Nonepileptic
Brain Regions/N. von Ellenrieder,
B. Frauscher, T. Ferrari-Marinho,
F. Dubeau, J. Gotman
3.186 Interictal Localization Of The
Seizure Onset Zone Using High
Frequency Oscillations And Visibility
Graphs/A. M. Spring, R. A. Bessemer,
D. J. Pittman, Y. Aghakhani, P. Federico
3.187 Interictal Phase Clustering Of
High Frequency Oscillations Derived
From 256-Channel Scalp EEG
Correlates With The Epileptogenic
Zone/M. D. Holmes, C. Ramon
3.188 MRI And Electrical Source
Analysis In Patients With Temporal
Lobe Encephaloceles: Localization And
Clinical Correlation/M. Quach
3.189 Index Of HFO Cross-Frequency
Coupling For Assessing The Seizure
Onset Zone/C. Jouny, U. Malinowska,
M. Cervenka, G. Bergey
3.190 Investigation Of HFO In Human
Intracranial EEG With A Semi-Supervised
X-means Clustering/S. Liu, N. Ince,
A. Abosch, T. Henry, Z. Sha

Monday December 8, 2014
3.191 Co-Occurrence Of High
Frequency Oscillations For
Identification Of The Seizure Onset
Zone/U. Malinowska, G. Bergey,
M. Cervenka, C. Jouny
3.192 Integrating 3D Source
Localization And Connectivity Maps
For Guiding Pre-Surgical Subdural
Grid Placement/A. Pinzon-Ardila,
M. Cabrerizo, N. Rojas, P. Jayakar,
G. Sergio, M. Adjouadi
3.193 Validating Individual Head
Models In Electrical Source Imaging
Of Spikes And Seizures/K. Jenson,
D. Tucker, P. Luu, M. D. Holmes
3.194 Source Localization Techniques
Are Essential In More Accurate
Determination Of Target Tuber
Conglomerates For MRI-Guided Laser-
Induced Thermal Ablation For
Treatment Of Intractable Epilepsy And
Neurocognitive Comorbidities In
Pediatric Tuberous Sclerosis/
Y. Eksioglu, Z. Tovar-Spinoza, F. Duffy
3.195 Frequency-Frequency Coupling
Of Brain Oscillations In Studying Ictal
EEG Activity/Y. Hsin
Clinical Epilepsy
Clinical Diagnosis
3.196 Clinical Manifestations Of The
Patients With Caspr2 Encephalitis/
J. Sunwoo, J. Byun, J. Moon, J. Shin,
J. Jun, S. Lee, K. Jung, K. Jung,
K. Chu, S. Lee
3.197 Asystole In The Epilepsy
Unit/A. Honig, S. Chen, F. Benninger,
R. Bar Yossef, R. Eichel,
S. Kipervasser, I. Blatt, M. Neufeld,
D. Ekstein
3.198 Electroclinical Features Of
Ring Chromosome 20 Syndrome In
Children/H. Ikeda, H. Ikeda, K. Imai,
Y. Takahashi, Y. Inoue
3.199 Referral Delay For Epilepsy
Surgery Centers In Patients With
Temporal Lobe Epilepsy And
Hippocampal Sclerosis: Why We
Should Educate Neurologists In First
And Secondary Care Centers/
S. de Vincentiis, K. Rodrigues
Ximenes Goldberg,
S. E. de Melo-Souza, F. J. Arruda,
P. C. Ragazzo, H. van der Linden J.r.,
K. Dualibi Ramos Valente
3.200 Increased Cerebrovascular
Reactivity In The Epileptogenic
Temporal Lobe In Mesial Temporal Lobe
Epilepsy Patients/K. Alhadid,
O. Sobczyk, G. Montandon,
J. Poublanc, L. Venkatraghavan,
A. Crawley, J. Fisher, D. Mikulis,
T. Valiante
3.201 Ictal EEG Yield In Newly-
Treated Focal Epilepsy: Interim
Findings From The Human Epilepsy
Project (HEP)/R. Singh, M. Hegde,
V. Mays, D. Dlugos, on behalf of the
HEP EEG Core and HEP Investigators
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.202 A Brain-Machine Interface For
Burst Suppression Control In
Pediatric Status Epilepticus/
C. Papadelis, C. Doshi,
S. Thome-Souza, E. Grant, R. Tasker,
T. Loddenkemper
3.203 New-Onset Refractory Status
Epilepticus: Etiology And Outcome In
A Retrospective Series Of 121
Cases/N. Gaspard, B. Foreman,
V. Alvarez, C. M. Cabrera Kang,
J. Probasco, A. Jongeling, E. Meyers,
K. Haas, A. Espinera, S. Schmitt,
E. Gerard, T. Gofton, P. Kaplan,
J. Lee, B. Legros, J. Szaflarski,
M. Westover, S. Laroche, L. Hirsch
3.204 Clinical Correlates And
Outcome Of Cyclic Seizures In
Critically Ill Patients: A Case-Control
Study/L. F. Pinto, E. Gilmore,
O. Petroff, N. Rampal, L. Hirsch,
N. Gaspard
3.205 Eyewitnesses Of Seizures Are
More Accurate Historians Than The
Patients/M. Spitz, S. Moreland,
K. Horiuchi, K. Lervik, P. Korb,
C. Drees, R. DeBello, L. Strom,
L. Frey, A. Shrestha, C. OBrien
3.206 Automated EMG Based
Seizure Detection And Quantification
For The Home And The EMU, A
Prospective Multicenter Study/
J. Cavazos, M. Girouard, L. Whitmire
3.207 Jeavons Syndrome: Seizing The
Light A Compulsive Epilepsy
Disorder?/A. Yadav, I. Tuxhorn
3.208 The Proportion Of Time Spent
In The Tonic Phase Of A Convulsive
Seizure Predicts Postictal
Hypopnea/E. Acton, A. Thaler,
A. Krause, C. Anderson,
A. Esfahanizadeh, J. Pollard
3.209 Associated Cardiac Findings In
Children With Down Syndrome And
Infantile Spasms/D. Daniels, K. Knupp,
T. Benke, F. Hickey,
K. Wolter-Warmerdam, D. L. Cohen
3.210 KCNQ2-Deficiency: Clinical
Spectrum Of Epilepsy,
Encephalopathy, And Response To
Ezogabine/K. Park, J. Millichap,
E. C. Cooper
3.211 Temporal IEDs In
Extratemporal Lobe Epilepsy Are
Associated With Temporal
Hypometabolism On PET Imaging/
E. Hartl, J. Rmi, A. Loesch,
C. Vollmar, S. Noachtar
3.212 Co-Oscillation Of Spikes,
Spindles And K Complexes: A Useful
Biomarker Of Epileptogenicity And
Outcome In Children With Epilepsy?/
A. Zrik, I. Tuxhorn, A. Yadav, P. Rai
3.213 Clinical And Intracranial EEG
Features After Secondarily
Generalized Seizures/L. M. Bateman,
C. Schevon
3.214 Characteristics Of Other
Seizure Types Associated With
Infantile Spasms/J. Millichap,
L. Wong-Kisiel, E. Yozawitz, J. Sullivan
3.215 Electrographic And
Hemodynamic Changes In Patients With
Focal Seizures/K. Hecox, J. Zemblis,
C. Sauer, H. Whalen, P. Monrad
3.216 Clinical Course of Seizures In
Ring Chromosome 20 Syndrome/
H. Ikeda, H. Ikeda, T. Hiyoshi,
E. Yamazaki, K. Yoshimura, Y. Inoue
Clinical Treatments
3.217 The Application Of An
Explanatory Model Of Treatment
Decision- Making In A Patient With
Medically Refractory Focal Epilepsy/
S. Dewar, H. Pieters
3.218 Protective Effects Of Vagus
Nerve Stimulation On Cardiac
Electrical Instability In Patients With
Drug-Resistant Epilepsy/A. Schomer,
B. D. Nearing, S. Schachter,
E. Bachman, P. Shafer, D. Sundstrom,
R. L. Verrier
3.219 Pyridoxine Deficiency In Adult
Status Epilepticus Patients/H. Dave,
R. Ramsay, F. Khan, V. Sabharwal,
I. Iwuchukwu
3.220 Outpatient Initiation Of The
Ketogenic Diet: The BC Childrens
Hospital Experience/A. Michoulas,
M. Connolly, K. Selby, E. Anghelina,
A. Ferguson, C. Simonson, F. Zanotto,
K. Farrell
3.221 Electrical Stimulation Of The
Hippocampus For Medically Refractory
Mesial Temporal Lobe Epilepsy: A
Long-Term Follow-Up Study/S. N. Lim,
C. Y. Lee, S. T. Lee, P. H. Tu,
B. L. Chang, C. H. Lee, C. W. Chang,
MONDAY
W. E. Tseng, T. Wu
3.222 A Lack Of Clinically Significant
Vision Loss Among Vigabatrin-Treated
Patients With Infantile Spasms: The
UCLA Experience/M. Schwarz, M. Li,
J. Tsao, R. Zhou, Y. W. Wu,
S. A. Hussain
3.223 The National Infantile Spasms
Consortium (NISC): Moving Towards
Standardization Of Care And Improved
Treatment And Outcomes In Infantile
Spasms/N. Ryan, J. Coryell,
J. R. Mytinger, K. Nickels, K. Knupp
3.224 Improving Efficiency In
Management Of Status Epilepticus
Using A Specific EMR Order Set/
J. Boggs, R. Bolen, L. Bishop,
M. Bailey, M. Bennett
3.225 Management Of Super
Refractory Status Epilepticus With
Ketamine And/Or Propofol/V.
Sabharwal, H. Dave, R. Lancaster,
M. Almualim, F. Khan, H. McGrade,
E. Ramsay
3.226 New-Onset Refractory Status
Epilepticus: Immune Modulatory
Therapy And Outcome/C. M. Cabrera
Kang, S. M. Laroche, B. Foreman,
V. Alvarez, J. Probasco, A. Jongeling,
E. Meyers, K. Haas, S. E. Schmitt,
E. Gerard, T. Gofton, P. W. Kaplan,
J. Lee, B. Legros, J. P. Szaflarski,
M. Westover, L. J. Hirsch, N. Gaspard
71

Monday December 8, 2014
3.227 Lightning Strike Induced Vagus
Nerve Stimulator Malfunction/P. Shah,
G. Ghearing
3.228 Ketamine In Refractory Status
Epilepticus A Two Year
Retrospective Study On 26
Patients/J. Hfler, A. Zerbs,
J. Dobesberger, G. Pilz, M. Leitinger,
H. Novak, E. Trinka
3.229 Frequency And Predictors Of
Rescue Medication Use In Children
Admitted To The Epilepsy Monitoring
Unit/L. AHMADI, K. Nickels,
L. Wong-Kisiel, E. Wirrell
3.230 Use Of Clobazam In Pediatric
Epilepsy At A Tertiary Care Center/
N. McNamara, S. Joshi
3.231 Clinical Characterization Of The
Pre-Ictal State In The Pediatric
Population: A Caretakers Perspective
On Seizure Prediction/P. Patel,
R. Jehle, D. Gold, S. Haut
3.232 Spectrum Of Autoimmune
Epilepsy With Glutamic Acid
Decarboxylase Antibody/A. Shah,
M. Dhakar
3.233 Early Complications Of
Subdural Electrode Placement In
Pediatric Epilepsy Surgery/
P. Pojomovsky, A. Mandel, D. McBrian,
M. Giordano, L. Goldenstein,
N. Feldstein, G. McKhann, C. Akman
3.234 Efficacy Of Ketogenic Diet: An
Experience Of King Fahd Specialist
Hospital-Dammam (KFSH-D)/
R. S. Al-Baradie
Prognosis
3.235 Electrodermal Sleep Storm
Activity As A Biomarker In Epilepsy
Patient/K. Kapur, S. Thome-Souza,
J. Klehm, R. Sarkis, E. Nagarajan,
M. Jackson, R. Picard, C. Doshi,
C. Papadelis, B. Dworetzky,
C. Reinsberger, T. Loddenkemper
3.236 Mortality In Children Evaluated
For Epileptic Spasms At A Tertiary
Care Center/C. Harini, E. Nagarajan,
A. Bergin, K. Kapur, C. Marti,
M. Takeoka, T. Loddenkemper,
M. Libenson
3.237 Predictors Of Refractory
Status Epilepticus/M. Gonzalez,
E. Santamarina, M. Toledo, S. Sarria,
M. Sueiras, L. Guzman, J. Salas Puig
3.238 Ictal Vital Signs In Epilepsy/
W. O. Tatum, M. L. Langston,
E. Acton, K. H. Yelvington,
C. Bowman, J. J. Shih, W. Cheshire
3.239 EEG Prior To Weaning
Antiepileptic Therapy In Seizure-Free
Children: A Cost-Effectiveness
Analysis/B. McCoy, E. Donner
3.240 Correlation Of EEG Findings
And Prognosis In Patients On
Therapeutic Hypothermia After
Cardiac Arrest/Y. Krutoshinskaya,
S. Manganaro, R. Krel, L. Bello
3.241 Outcome Of Early Successful
Seizure Control Or Aggressive
Seizure Management In Presumed
Childhood Encephalitis/N. Rismanchi,
J. Gold, S. Sattar, C. Glaser,
H. Sheriff, A. Mower, J. Crawford,
M. Nespeca, S. Wang
72
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.242 Clinical Phenotypes Within
Patients With Non-Lesional Temporal
Lobe Epilepsy Based On Response To
Antiepileptic Drugs/J. Kim
3.243 Epilepsy With Onset Within 3
Years Of Age: Electro-Clinical
Characterization And Long-Term
Outcome/A. Vignoli, G. F. Scornavacca,
F. La Briola, K. Turner, V. Chiesa,
E. Zambrelli, V. Fergnani, M. Canevini
3.244 Adaptive Function In Dravet
Syndrome/S. Kim, D. Nordli, L. Laux
3.245 Diagnosis, Treatment, And
Outcomes Of Infantile Spasms In The
Trisomy 21 Population/C. Beatty,
J. Wrede, H. Blume
3.246 Clinical And
Electroencephalographic
Characteristics Of Neonates Who
Underwent Continuous
Electroencephalographic Monitoring/
A. J. Sansevere, I. Snchez
Fernndez, J. Klehm, E. Nagarajan,
L. St. Louis, P. Pearl, J. Neil,
T. Loddenkemper
3.247 Long-Term Seizure Outcome In
Response To Carbamazepine In
Children With Newly Diagnosed Partial
Onset Epilepsy/G. Aungaroon,
S. Standridge, K. Holland
3.248 Sudden Unexpected Death In
Epilepsy, Peri-ictal Physiology And The
SUDEP-7 Inventory/N. Odom
3.249 Interictal Background Is
Associated With Survival And
Neurodevelopmental Outcome In Term
Infants Undergoing Hypothermia For
Hypoxic-Ischemic Encephalopathy/
L. Rao, J. Wu, T. Chanlaw, H. Wang,
M. Garg
3.250 EEG Monitoring In Patients
With Hypothermia Post Cardiac
Arrest A Comparison Of Evolving Analyses Of Hippocampal Subfields In
Patterns And Outcomes/K. Suchdev,
S. Rao, L. Avedian, S. Thadur,
D. Zutshi
3.251 Praxis Induction In Juvenile
Myoclonic Epilepsy. Significance In
Prognosis/C. P. Uchida, K. Carvalho,
M. B. Guaranha, L. M. Guilhoto,
E. Yacubian
3.252 Sudden Unexpected Death In
Epilepsy (SUDEP) Vanderbilt
University Experience/
S. Bandyopadhyay, N. Azar, A. Arain
3.253 Seizure Outcomes After
Glioma Resection/A. C. Jongeling,
P. D. Canoll, C. Schevon, S. Srinivasan
Neuroimaging
Structural Imaging
3.254 Relationship Between Cortical
Thickness And Sulcal Depth In
Pediatric Focal Epilepsy/S. Gurbani,
P. Siddarth, D. Tosun, J. Levitt,
R. Caplan
3.255 MRI Characterization Of
Cerebellar Tubers In Tuberous
Sclerosis Complex: Longitudinal Follow
Up And Associations With Clinical
Manifestations/A. Yogi, Y. Hirata,
J. Wu, P. Pan, G. Mathern,
N. Salamon
3.256 Brain Morphometry On Multi-
Modal Imaging For The Detection Of
Epileptogenic Cortical Dysplasias/
L. Kini, S. Das, K. Davis, B. Litt
3.257 Transient Focal Lesion In
Corpus Callosum After First Episode
Of Generalized Seizure: A Case
Report/R. Vakili, M. M. Donohue,
T. Emch
3.258 Are There Neuroanatomical
Differences In New Onset Focal
Epilepsy? Preliminary Results From
The Human Epilepsy Project/
H. R. Pardoe, R. Kuzniecky,
A. HEP MRI Core
3.259 Disrupted Modular
Architecture Of Brain Structural
Network In Temporal Lobe Epilepsy/
Z. Chen, C. Yasuda, G. C. Beltramini,
T. M. Lopes, M. Morita, A. Coan,
F. Bergo, F. Cendes, C. Beaulieu,
D. Gross
3.260 Disrupted Brain Volumetric
Network In Temporal Lobe Epilepsy/
C. Yasuda, C. Zhang, G. C. Beltramini,
M. Morita, A. Coan, P. Araujo,
F. Bergo, C. Beaulieu, F. Cendes,
D. Gross
3.261 Contralateral Hippocampal
Atrophy Following Temporal Lobe
Surgery For Temporal Lobe Epilepsy/
C. A. Elliott, C. Yasuda, L. Concha,
M. Liu, D. Gross, T. Sankar,
M. Wheatley, C. Beaulieu
3.262 Correlation Between
Brainstem Rotation After
Hemispherectomy And The
Occurrence Of Clinical Symptoms In
Hemimegalencephaly Patients/A. Yogi,
Y. Hirata, J. Wu, P. Pan, G. Mathern,
N. Salamon
3.263 Volumetric And Shape
Temporal Lobe Epilepsy With
Hippocampal Sclerosis/J. Kim
3.264 Reduced Right Hippocampal
Volume In Patients With Left
Hippocampal Atrophy Is Associated
With Anxiety And Depression/
T. Stoub, C. L. Grote, A. Kanner
3.265 Biometric Correlations With
Diffusion Tensor Data Of Temporal
Lobe Epilepsy Mcd Patients At
3.0T/S. Nikolova, R. Nikolov,
R. Bartha, J. G. Burneo
3.266 Reversible Brain MRI Changes
Associated With Periodic Lateralized
Epileptiform Discharges (PLEDs)/
A. B. Memon, A. Shah, M. Basha
3.267 Cortical Thickness And
Cognition In Children With ECTS: A
Longitudinal Study/D. Jackson,
C. Garcia-Ramos, K. Dabbs, J. Jones,
D. Hsu, C. Stafstrom, L. Zawadzki,
M. Koehn, M. Seidenberg, B. Hermann
3.268 Hippocampal Subregion
Analysis In Adults With Mesial
Temporal Lobe Epilepsy/L. Sepeta,
S. C. Germeyan, M. Berl, J. Ostuni,
W. Gaillard, W. Theodore

Monday December 8, 2014
3.269 Magnetic Resonance Imaging
Abnormalities Associated With
Status Epilepticus: A Case Report
And Literature Review/A. M. Feyissa,
L. Ponce Mejia, T. Masel
3.270 Disrupted Brain Network
Topology In New-Onset Pediatric
Epilepsy: A Controlled Prospective
Study/J. Lin, R. Rajyaguru, J. Riley,
G. Gulsen, K. Dabbs, J. Jones,
D. Jackson, D. Hsu, C. Stafstrom,
M. Seidenberg, L. Bonilha,
B. Hermann
3.271 To Evaluate Original Diffusion
Properties Of Neural Pathways Of
Patients With Partial Seizures And
Secondary Generalization By Individual
Anatomic Reference Atlases/S. Peng,
T. Harnod, C. Huang, Y. Hsin
3.272 Increased Fractional
Anisotropy In Children With
Epilepsy/M. Berl, V. Terwilliger,
L. Sepeta, W. Gaillard
3.273 Quantitative Analysis Of Fiber
Density From Diffusion Tensor Imaging
Identifies Structural Changes In
Cryptogenic Focal Epilepsy/J. Joc,
N. Khalilieh, E. Hartl, S. Noachtar,
C. Vollmar
Functional Imaging
3.274 EEG-fMRI Study Of Operculo-
Insular Epilepsy/P. Pouliot, T. Tran,
M. robert, A. Bouthillier, D. Nguyen
3.275 Decreased Functional
Interactivity In Patients With Temporal
Lobe Epilepsy And Normal MRI/
A. Coan, B. M. Campos, F. Cendes
3.276 Additive Potential Of Real-Time
Functional Mapping (RTFM) To
Electrical Stimulation Mapping (ESM)
Results For Epilepsy Surgery
Candidates/M. Elsayed,
M. Korostenskaja, E. Castillo, P. Chen,
A. Schaal, B. Edmonds, C. M. Salinas,
M. Westerveld, J. Seo, G. Schalk,
P. Brunner, J. Baumgartner, K. Lee
3.277 7T Mrs In Medically Refractory
Temporal Lobe Epilepsy Patients With
Normal 1.5T/M. jones, S. Nikolova,
J. G. Burneo, R. Bartha
3.278 Language fMRI And Post-
Operative Language Decline/E. Emery,
S. C. Germeyan, L. Sepeta, E. Wiggs,
M. Berl, I. Dustin, D. Goldenholz,
W. Gaillard, W. Theodore
3.279 Significance Of FDG-PET
Hypermetabolism In Focal Cortical
Dysplasia (FCD)/P. Laoprasert,
R. W. Dudley, S. Koh, M. Handler,
N. Stence, D. Mirsky, A. White
3.280 Voxel-Mirrored Homotopic
Connectivity Analysis Of Pediatric
Epilepsy Patients With Mesial
Temporal Sclerosis/A. V. Poliakov,
E. J. Novotny, S. L. Poliachik,
S. D. Friedman, G. E. Ishak,
J. N. Nixon, D. W. Shaw,
J. G. Ojemann
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.281 Identification Of A Pre-Spike
Network In Mesial Temporal Lobe
Epilepsy/N. L. Faizo, H. Burianov,
M. Gray, J. Hocking, G. Galloway,
D. Reutens
3.282 FMRI Mesial Temporal
Activation Paradigm For Children With
Epilepsy/H. Shurtleff, J. Nixon,
M. Warner, A. V. Poliakov, D. W. Shaw,
E. Novotny, J. Ojemann
3.283 Altered Functional Connectome
For Fearful Face Processing In
Temporal Lobe Epilepsy/J. Riley,
R. Rajyaguru, G. Gulsen, J. Lin
3.284 Resting State fMRI Lateralizes
Seizure Onset But Fails To Predict
Cognitive Change After Anterior
Temporal Lobectomy In Temporal Lobe
Epilepsy/M. Gelfand, K. Davis
3.285 Altered Resting-State
Networks In Psychogenic
Nonepileptic Seizures And Idiopathic
Generalized Epilepsy/D. An, C. Luo,
S. Chen, B. Yan, D. yao, D. Zhou
3.286 Ictal Perfusion Pattern With
And Without Secondarily Generalized
Tonic-Clonic Seizure: A Voxel-Based
ECD-SPECT Analysis In Temporal Lobe
Epilepsy/X. Chen, C. H. Wong,
R. McCredie, M. L. Bartley,
D. C. Farlow, Z. Zhao, E. Somerville,
A. Bleasel
3.287 Abnormal Functional
Organisation Of Default-Mode And
Task-Positive Networks In Lennox-
Gastaut Syndrome/A. Warren,
J. Archer, D. Abbott, G. Jackson
Antiepileptic Drugs
Clinical Trials
3.288 FDA OGDs Post-Marketing
Studies To Ensure Therapeutic
Equivalence Of Generic Antiepileptic
Drugs In Epilepsy Patients/X. Jiang,
N. Zheng, T. Ting, J. Polli,
M. Privitera, M. Berg, W. Jiang
3.289 Open Label Trial Of Add-On
Lacosamide Versus High Dose
Monotherapy In Patients With
Breakthrough Seizures/J. Alam,
N. Llewellyn, B. Dworetzky, R. Sarkis,
P. Pennell, E. Bubrick, J. Lee
3.290 Immediate Steady State
Concentrations In Plasma After Oral
Or Intravenous Lacosamide Loading
Dose/W. Cawello, J. Andreas,
C. Schaefer
3.291 Focal Seizure Frequency By
Study Phase And Seizure Type In
Conversion To Lacosamide
Monotherapy Study: A Post-Hoc
Analysis/J. Stern, M. Sperling,
S. S. Chung, P. Ryvlin, R. Wechsler,
S. Dimova, M. De Backer, T. Story,
M. Brock, C. McShea, K. J. Werhahn
3.292 Conversion To Lacosamide
Monotherapy: Post-Hoc Analysis On
Responder And Seizure Freedom
Rates/P. Ryvlin, M. Sperling,
S. S. Chung, J. Stern, R. Wechsler,
S. Dimova, M. De Backer, T. Story,
M. Brock, C. McShea, K. J. Werhahn
3.293 Lacosamide Added To A
Baseline Monotherapy In Patients
With Partial-Onset Seizures (POS):
Efficacy And Safety Across Center
Types In The VITOBA Study/C. Brandt,
M. Noack-Rink, T. Mayer, U. Runge, F.
Ramirez, T. Lauterbach, P. Dedeken
3.294 Safety And Tolerability Of
Lacosamide Monotherapy In Elderly: A
Subgroup Analysis From Lacosamide
Trials In Diabetic Neuropathic Pain/
J. Sirven, E. Faught, M. De Backer,
K. Eckhardt, F. Tennigkeit, S. Bongardt,
D. Rudd, D. Sen, K. Werhahn
3.295 Efficacy and Safety Of
Lacosamide As Adjunctive Treatment
For Partial-Onset Seizures In
Hispanic/Latino Patients From Mexico:
Post Hoc Analysis Of An Open-Label
Trial/H. Ceja Moreno, P. Tzvetanov,
W. Waldman Zadeh, A. Escartin,
I. Wild, W. Byrnes, F. Tennigkeit,
S. Borghs, C. McShea, P. Dedeken,
M. De Backer
3.296 WITHDRAWN
3.297 Lacosamide Added To An
Existing Monotherapy In Epilepsy
Patients With Partial-Onset Seizures:
A Subgroup Analysis Of The Elderly
Population In The VITOBA Study
(VImpat Added To One Baseline
AED)/U. Runge, T. Mayer,
M. Noack - Rink, F. Ramirez,
M. De Backer, F. Tennigkeit,
K. Werhahn
3.298 An Open-Label Trial Evaluating
The Efficacy And Safety Of
Lacosamide As First Add-On
MONDAY
Treatment Of Partial-Onset
Seizures/P. Tzvetanov, W. Waldman,
A. Escartin, W. Byrnes, F. Tennigkeit,
P. Dedeken, M. De Backer, S. Borghs,
T. Li
3.299 Tolerability Of Lacosamide 200
Mg/Day Starting Dose: Post-Hoc
Analysis Of Conversion To Lacosamide
Monotherapy Study/K. J. Werhahn,
S. Dimova, C. McShea, M. Brock,
W. Byrnes, M. De Backer, E. Faught
3.300 Reduction Of Treatment-
Limiting Non-Psychotic Behavioral
Adverse Events Associated With
Levetiracetam: An Open-Label,
Prospective Study Of Patients With
Epilepsy Switching From
Levetiracetam To Brivaracetam
Treatment/S. Yates, T. Fakhoury,
W. Liang, K. Eckhardt, J. DSouza
3.301 Impact Of Adding Perampanel
To Existing Anti-Epileptic Drug (AED)
Therapy On Health-Related Quality Of
Life (HRQL) As Measured By The
Quality Of Life In Epilepsy Inventory
(QOLIE-31-P) In A Pooled Population
Of Patients With Partial-Onset
Seizures (POS) f/W. Tsong,
S. Hudgens, A. Forsythe, R. Muniz
3.302 Vigabatrin For Treatment Of
Complex Partial-Onset Seizures In
Patients With Tuberous Sclerosis:
Prospective Trial And Retrospective
Case Series/B. Oommen, E. Brand,
A. Volpe, A. Krause, P. Crino,
J. Pollard
73

Monday December 8, 2014
3.303 Efficacy And Safety Of
Epidiolex (Cannabidiol) In Children And
Young Adults With Treatment-
Resistant Epilepsy: Initial Data From
An Expanded Access Program/
O. Devinsky, J. Sullivan, D. Friedman,
E. Thiele, E. Marsh, L. Laux,
J. Hedlund, N. Tilton, J. Bluvstein,
M. Cilio
3.304 Retrospective Study Of
Lacosamide In The Elderly (> 60 years
Of Age)/J. Bainbridge, P. Wong,
M. Spitz, L. Frey, C. Drees,
C. OBrien, L. Strom, A. Shrestha,
J. Sirven, S. Benbadis, E. Maa,
S. S. Chung, B. Phillips
3.305 The Initial Results Of
Adjunctive Lacosamide For
Uncontrolled Partial-Onset Seizures in
Eskisehir, Turkey/O. O. Erdinc,
G. Akdag, G. Uzuner, D. Ilhan Algin
3.306 Vigabatrin In The First Line
Treatment Of Infantile Spasms/
K. Jones, J. Boyd, C. Go, A. Ochi,
B. McCoy, K. Puka, O. Snead
3.307 Prospective, Controlled Trial Of
Cannabadiol In A Case Of FIRES/
C. Lopez, A. Wilfong, T. P. Ngo,
M. R. Jenner
3.308 Initial Therapy Outcomes In
Absence Epilepsy : Ethosuximide,
Valproic Acid, Lamotrigine And The
Combination Of Valproic Acid And
Lamotrigine/B. Eun
Other
3.309 Efficacy And Tolerability Of
Lacosamide As An Adjunctive
Treatment In Vascular Epilepsy: 3
Months Study/F. L. Gonzalez,
X. Rodriguez Osorio, M. Toledo,
M. Saavedra Pieiro, E. Santamarina,
I. Lopez Dequit, A. Pato,
D. Campos Blance, P. Bellas,
J. Salas Puig, J. Poza Aldea
3.310 Classification Of Phenytoin As
A Narrow Therapeutic Index Drug/
N. Zheng, L. Fang, W. Jiang
3.311 A Preliminary Analysis Of The
Effect Of Lacosamide On Seizure
Control And Neuropsychological
Performance: Anxiety, Depression And
Quality Of Life/M. Romero Acebal,
C. Snchez Ortiz, F. Villalobos Chvez,
G. Rubio Esteban, L. Redondo Verge,
J. Romero-Godoy, E. Calzado Rivas,
P. Quiroga Subirana, R. Hervas
Navidad, P. Martnez Agredano,
C. Pedraza Benitez
3.312 Efficacy And Tolerability Of
Lacosamide In The Treatment Of
Children With Refractory Generalized
Epilepsy/C. Miskin, D. Khurana,
I. Valencia, A. Legido, D. Hasbani,
K. Carvalho
3.313 Therapeutic Use Of
Lacosamide Does Not Alter Its
Distribution Between Serum And
Cerebrospinal Fluid/A. Shah,
S. Michelhaugh, S. Mittal
74
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.314 VPA Retains Suppressive Ppr
Effect At Steady-State With Less
Variability Than CBZ: Retrospective
Analysis Of 239 Photosensitive Clinic
Patients/D. G. Kasteleijn-Nolst
Trenite, R. Reed
3.315 Efficacy Of Clobazam On
Patients With Failed Resective
Surgery Aparna Sarma DO,
Carolina Restrepo, Janice Jordan,
C. Akos Szabo M.D./A. Sarma,
C. Restrepo, J. Jordan, C. Szabo
3.316 Resistance To Rectal Diazepam
In Dravets Syndrome/P. McGoldrick,
S. Wolf
3.317 Commonly Prescribed
Antiepilepsy Drugs In Nursing Home
Residents/A. Birnbaum, S. Bathena,
I. Leppik
Non-AED / Non-Surgical
Treatments (Hormonal,
Ketogenic, Alternative, Etc.)
Adult
3.318 An Evaluation Of Catamenial
Seizure Patterns And The Relationship
Between The Menstrual Cycle,
Seizures, And Ketosis In Women On
The Modified Atkins Diet For
Treatment For Epilepsy/E. Felton,
E. Kossoff, B. Henry, M. Cervenka
3.319 Auricular Acupuncture For The
Treatment Of Nonepileptic Seizures:
NADA4NES Pilot Study/E. Maa
3.320 LORETA z-Score Neurofeedback
Training In Patients With Drug-
Refractory Epilepsy/L. Frey, C. OBrien
3.321 The Impact Of An Art Therapy
Program On Self-Esteem And Quality
Of Life In People With Epilepsy/
J. M. Buelow, L. R. Vitko,
J. M. Gattone, J. R. Kakacek
Pediatrics
3.322 Predictors Of Ketogenic Diet
Efficacy In Children Based On The
Electroencephalogram/I. M. Walker,
R. Said
3.323 Intravenous
Methylprednisolone For Intractable
Childhood Epilepsy/M. M. Jan
3.324 Therapeutic Plasma Exchange
(TPE) In Children With Antibody-
Mediated Neurologic Disease/
M. Oldham, M. Sweeney, P. Horn,
L. Peglar, E. Rompies,
K. Wesselkamper, B. Hallinan,
S. Goldstein
3.325 Preliminary Overview Of Social
Stressors And Social Work Support
Of Patients And Caregivers In The
Ketogenic Diet Program At Boston
Childrens Hospital/C. Ryan, F. Chris,
K. Costas, S. Tarrant, P. Lora,
P. Pearl, A. Bergin
3.326 Ketogenic Diet Initiation: Step
By Step For Sweet Success/L. Pixley,
S. Tarrant, K. Costas, K. Kapur,
A. Bergin
3.327 Blood Beta-Hydroxybutyrate
Levels Correlate With Seizure
Frequency In Epileptic Patients
Treated With The Ketogenic Diet/
J. Buchhalter, J. D. Smith,
S. DAlfonso, R. Singer, M. Connolly,
A. Michoulas, E. Fung, D. Sinasac,
J. M. Rho
3.328 Evaluation Of Patients Right
And Left Ventricular Functions Who
Treated With Ketogenic Diet/
O. Dokgoz, K. celegen, O. Guzel,
U. Yilmaz, R. Isgder, M. Celegen,
T. Mese
3.329 A Chef Educators Role In The
Ketogenic Diet Program At Childrens
Mercy Hospital/R. Finn
3.330 Lack Of Efficacy Of The
Ketogenic Diet In The Treatment Of
Highly Refractory Infantile Spasms/
J. Shin, K. Murata, J. Matsumoto,
S. A. Hussain
3.331 Complications Of Vagus Nerve
Stimulation For Epilepsy In Children:
How Can We Do Better?/B. Sitwat,
S. Williams, C. Patterson, S. Gedela,
E. Tyler-Kabara, M. Tamber, Y. Sogawa
3.332 New Onset Super-Refractory
Tonic Status Epilepticus In Child With
Down Syndrome: Successful
Treatment With Ketogenic Diet/
L. P. Sampaio, C. L. Moreira,
L. Caboclo
3.333 Clinical Characteristics Of
Children Less Than 3 Years Of Age
Who Elected Vns As An Adjunctive
Therapy For Medically Intractable
Epilepsy/L. D. Fernandez, S. Gedela,
Y. Sogawa
3.334 Pentobarbital, Propylene
Glycol, And Ketosis In Refractory
Status Epilepticus/K. Costas,
R. Tasker, J. Soul, N. Lamb, L. Li,
A. Bergin
3.335 Use Of The Ketogenic Diet In
The Neonatal Intensive Care Unit
Safety and Tolerability/A. Hall,
M. Gustafson, L. Thompson
All Ages
3.336 Benefits Of Exercise in
Patients With Epilepsy: A Literature
Review/F. Gilliam, R. Hogan, G. Gilmet
3.337 Safety And Tolerability Of 1 Hz
Deep Repetitive Transcranial Magnetic
Stimulation (rTMS) For Treatment Of
Temporal Lobe Epilepsy/L. Oberman,
R. Gersner, A. Zangen, A. Rotenberg
Animal
3.338 Antidepressants Have
Different Effects On The Vesicular
Glutamate Transporter 1 And EEG
Spectrum In The Rat Hippocampus/
D. Shin, H. Song
3.339 Non-Invasive Low Frequency
Sensory Stimulation Suppresses
Seizures In Two Rodent Models Of
Epilepsy/N. Couturier

Monday December 8, 2014
3.340 Beta-hydroxybutyrate And
Docosahexaenic Acid Suppress
Seizures And Hippocampal Network
Hyperexcitability In A Mouse Model Of
Dravet Syndrome/Y. Abdulkadir,
T. Scheuer, W. Catterall, F. Kalume
3.341 Regulation Of Brain PPAR
Mediates Ketogenic Diet Anti-Seizure
Efficacy/T. A. Simeone,
S. A. Matthews, K. K. Samson,
K. Simeone
3.342 A 35% Triheptanoin Diet
Reduces Spontaneous Electrographic
Seizures in Pilocarpine-Induced
Epileptic Mice/A. Fernandez, J. Stoll
Surgery
Adult
3.343 Super-Selective
Amygdalohippocampotomy Using Real-
Time Magnetic Resonance Guided
Laser Ablation In Patients With
Mesial Temporal Lobe Epilepsy/
J. W. Yoon, W. Tatum, J. J. Shih,
V. Gupta, P. Vibhute, R. Wharen
3.344 Cognitive Outcome Of Patients
Undergoing Stereotactic Laser
Ablation Of Cavernous Malformations
To Control Chronic Seizures/
D. L. Drane, J. Willie, D. W. Loring,
N. Voets, A. M. Saindane,
M. Ivanisevic, R. Brewster, R. Jayakar,
R. Faught, K. J. Meador, R. Gross
3.345 A Case Report Of A Patient
With Refractory Temporal Lobe
Epilepsy Suffered Ischemic Stroke
After The Wada Test Had Good
Outcome/H. Gong, M. Kim-Tenser,
D. Ko
3.346 Modulating Cortico-Cortical
Evoked Potentials And Their
Connectivity Maps With Differing
Stimulation Parameters/S. Bickel,
M. Mercier, P. Megevand, D. Groppe,
A. Mehta, F. Lado
3.347 Frontal Topectomy May Be
Palliative In Difficult To Localize
Intractable And Disabling Frontal
Epilepsy/J. Oster
3.348 Assessment Of Driving
Outcomes After Epilepsy Surgery/
R. Dawkins, N. Omar, B. Agee,
B. Walters, K. Riley
3.349 Stimulation Of Ncl. Accumbens
In Intractable Partial Epilepsy
Possible Candidates/F. C. Schmitt,
A. Kowski, L. Buentjen, H. Stefan,
H. B. Straub, T. Mayer, T. Zaehle,
F. Oltmanns, H. Heinze, M. Holtkamp,
J. Voges
Pediatrics
3.350 Pediatric Epilepsy Surgery
Techniques Specific Issues: Inter-
Center Worldwide Variability/
W. Harkness, B. Rydenhag, A.
Cukiert, I. Panel
3.351 Epilepsy Related
Characteristics Of Children Less Than
Five Years Of Age Who Underwent
Epilepsy Surgery/E. Thompson,
J. Walker, W. Chlon, S. LeSure,
D. F. Clarke
Poster Session 3
8:00 a.m. 3:00 p.m.
Convention Center Hall 4B, Level 4
3.352 Surgical Treatment Of Patients
With Rasmussen Encephalitis
(34 Cases)/Y. Guan, G. Luan
3.353 SEEG-Based Tailored Laser
Ablation For Lesional Epilepsy/
T. P. Ngo, C. Lopez, D. Curry,
A. Wilfong
3.354 Review Of Extended Multi-lobar
Epilepsy Surgery In Pediatric
Patients/R. Yu, H. Kang, J. Lee,
D. Kim, H. Kim
3.355 Follow Up EEG, MRI And
Frequency Of Relapse In Children
Status Post Resection Of Focal
Cortical Dysplasia/K. Havens,
C. Oluigbo, S. Magge, W. Gaillard,
G. Vezina, D. Depositario-Cabacar
3.356 Special Needs Of Autistic
Patients Undergoing Epilepsy Surgery:
Review Of Inpatient Management In
57 Cases/S. Ghatan, M. Kokoszka,
P. McGoldrick, M. La Vega-Talbott,
H. Raynes, R. Prince, J. Kim, H. Kang,
S. Wolf
3.357 Acute, Mid-And Long-Term
Outcomes Of Medically Refractory
Epilepsy And Neurocognitive
Difficulties Following Staged MRI-
Guided Thermal Laser Ablation In
Pediatric Patients With Tuberous
Sclerosis Complex/Y. Eksioglu,
Z. Tovar-Spinoza
3.358 Outcomes Of Stereotactic
Laser Ablation For Treatment-
Resistant Epilepsy In The Pediatric
Population With 1-Year Follow-Up/
D. Curry, A. Shetty, A. Wilfong
3.359 MEG In Pediatric Presurgical
Evaluation: Comparative Study With
Intracranial EEG Recordings In
Children With Focal Cortical
Dysplasia/U. Thome, N. Agarwal,
Z. I. Wang, H. Murakami, B. Krishnan,
R. Burgess, A. Alexopoulos, A. Gupta
3.360 Acute Intralesional Recording
In Hypothalamic Hamartoma:
Description Of 4 Cases/N. Specchio,
M. Rizzi, M. Trivisano, L. Fusco,
E. Rebessi, S. Cappelletti, F. Villani,
A. Savioli, A. De Benedictis,
C. Marras, O. Delalande, F. Vigevano
3.361 PET And SPECT Concordance
With EEG And MRI In Pre-Surgical
Evaluation For Pediatric Epilepsy/
C. Moufawad El Achkar, M. Takeoka
3.362 Surgical Management Of
Patients With CSWS: The Detroit
Experience/R. Agarwal, A. Kumar,
E. Asano, R. Rothermel, S. Sood,
H. Chugani
3.363 MRI-Guided Laser-Induced
Thermal Ablation: A Promising Tool
With Favorable Acute, Mid And Long-
Term Outcomes For Intractable
Seizures And Neurocognitive
Comorbidities In Cortical Dysplasias/
Y. Eksioglu, K. Ogden, S. Huckins,
Z. Tovar-Spinoza
3.364 Deep Focal Cortical Dysplasia
And Surgical Outcomes In Children/
D. Depositario-Cabacar, K. Havens,
C. Oluigbo, S. Magge, G. Vezina,
W. Gaillard
All Ages
3.365 VNS (Vagus Nerve Stimulation)
Is A Useful Tool To Promote The
Epilepsy Surgery/I. Takumi, T. Nozaki,
Y. Kishi, A. Morita
3.366 Epilepsy Surgery In Or Close To
Eloquent Cortex New Methods Open
For Surgery In More Patients/A. Egge,
M. Stanisic, P. Larsson
3.367 Spontaneous Improvement In
Seizure Control After Intracranial
Electrode Implantation/C. Morris,
J. Boggs, V. Woodard, C. ODonovan,
G. Popli
3.368 Radiographic Changes
Following Laser Interstitial Thermal
Therapy For Medically Intractable
Epilepsy/R. Buckley, J. Ojemann
3.369 Temporopolar Grey/White
Matter Abnormalities In Temporal
Lobe Epilepsy With Hippocampal
Sclerosis And Long-Term Prognosis
After Epilepsy Surgery/P. V. Naves,
L. Caboclo, H. Carrete. Jr.,
R. Centeno, B. V. Kelmann, E. Yacubian
3.370 Magnetoencephalography
Localization Can Guide Reoperation
After Unsuccessful Neocortical
Epilepsy Surgery/I. Mohamed,
A. Pooladian, Y. T. Tran, M. Robert,
A. Bouthillier, D. Nguyen
3.371 Stereotactic Laser Ablation
For Epilepsy: An Analysis Of The
Safety Profile From Peer-Reviewed
Reports/A. Wilfong, A. Shetty,
D. Curry
3.372 Seizure Outcome After
Battery Depletion In Patients
MONDAY
Submitted To Deep Brain Stimulation
For Epilepsy./J. A. Burattini,
A. M. Lima, C. M. Cukiert, A. Cukiert
3.373 Epilepsy Surgical Outcomes
2004-2013: The USC Experience
With Standard Temporal Lobectomy
And Selective Amygdalohippocampectomy/
Y. Marquez, M. N. Zubair, B. Lee,
D. Millett, L. Kalayjian, D. Ko,
S. Shaw, C. Heck, C. Liu
3.374 Results Of A Drug Withdrawal
Protocol After Temporal Lobe Epilepsy
Surgery/R. S. Centeno,
M. D. Guimaraes, L. Caboclo
3.375 Speed And Precision Of
Robotic Depth Electrode Placement
For Stereotactic EEG/N. Tandon,
G. Kalamangalam, B. Seignot
75
 THE EPILEPSY RESEARCH BENCHMARKS

2014 NINDS Benchmarks for Epilepsy Research

Beginning in 2000, the National Institute of Neurological Disorders and Stroke (NINDS) has hosted a series of Curing the
Epilepsies conferences in partnership with epilepsy advocacy and professional organizations to assess progress in epilepsy
research and help set an agenda for future years. As an outcome, these conferences have led to the development of
Benchmarks for Epilepsy Research, which reflect shared priorities across the epilepsy community. The current 2014
Benchmarks are:
I. Understand the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic
conditions
A. Identify new genes and pathways associated with epilepsies and epilepsy-related conditions.
B. Identify new infectious, immune, age-related, environmental, or other causes and risk factors associated with the
epilepsies and epilepsy-related conditions.
C. Determine whether factors related to age, gender, race / ethnicity, socioeconomic status, and other features of
specific populations affect risk and mechanisms of epilepsy and epilepsy-related conditions.
D. Determine whether the bi-directional relationships that exist between the epilepsies and several co-occurring
conditions (e.g., neuropsychiatric or neurodevelopmental disorders) result from the same underlying causal
mechanisms, interacting mechanisms, or are a consequence of the first presenting condition.
II. Prevent epilepsy and its progression
A. Understand epileptogenic processes involved in epilepsies with neurodevelopmental origins, including those due to
genetic or presumed genetic causes.
B. Understand epileptogenic processes involved in the development of epilepsy following traumatic brain injury, stroke,
brain tumor, infections, neurodegeneration, or other insults to the brain.
C. Identify biomarkers that will aid in identifying, predicting, and monitoring epileptogenesis and disease progression,
including markers early after injury / insult that identify those people at risk for epilepsy.
D. Develop or refine models aligned with the etiologies of human epilepsies to enable improved understanding of
epileptogenesis and rigorous preclinical therapy development for epilepsy prevention or disease modification.
E. Identify new targets and develop interventions to prevent or modify epileptogenesis and the progression of epilepsy
and epilepsy-related conditions.
III. Improve treatment options for controlling seizures and epilepsy-related conditions without side effects
A. Understand the initiation, propagation, and termination of seizures at the network level in different forms of epilepsy.
B. Identify biomarkers for assessing or predicting treatment response, including markers that may identify specific
populations that are likely to have good outcomes or develop adverse responses.
C. Develop or refine models that are aligned with etiologies and clinical features of human epilepsies, especially
treatment resistant forms, to enable improved understanding of ictogenesis and preclinical development to improve
seizure control with fewer side effects. Establish the sensitivity and specificity of these models with regard to current
therapies.
D. Identify, develop, and improve interventions to detect, predict, prevent, or terminate seizures, including approaches
suitable for use in the home and other non-medical settings.
E. Identify, develop, and improve anti-seizure therapies that target (either alone, or in combination) novel or multiple
seizure mechanisms.
F. Develop, improve, and implement interventions for effective self-management, including treatment adherence.
G.Develop and validate objective patient-centered outcome metrics for clinical studies.
IV. Limit or prevent adverse consequences of seizures and their treatment across the lifespan
A. Understand and limit adverse impacts of seizures on quality of life, including effects on neurodevelopment, mental
health, intellectual abilities, and other neurological and non-neurological functions.
B. Understand and limit adverse impacts of anti-seizure treatments (medical, surgical, or other interventions) on quality
of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and
non-neurological functions.
C. Understand risk factors and mechanisms involved in non-epileptic seizures (NES). Develop effective approaches for
earlier and accurate diagnosis and treatment.
D. Identify causes, risk factors, and potential preventive strategies for sudden unexpected death in epilepsy (SUDEP) and
other epilepsy-related mortality (for example, suicide) in people with epilepsy.
E. Identify the impact of pharmacological treatment of the epilepsies on fetal and neonatal development. Develop
strategies to control seizures in pregnancy without causing harm to either the mother or child.

Walter Koroshetz, M.D. Daniel H. Lowenstein, M.D. Raymond J. Dingledine, Ph.D. Brandy Fureman, Ph.D.
Acting Director, NINDS Chair, Benchmarks Stewards Vice-Chair, Benchmarks Stewards Co-Chair, Benchmark Stewards
University of California, Emory University NINDS
San Francisco

For more information about the Benchmarks and to view Stewards previous reports, please visit:
http://www.ninds.nih.gov/research/epilepsyweb/2014benchmarks.htm
76
 AES 68TH ANNUAL MEETING
TUESDAY December 9, 2014
www.AESnet.org
7:00 a.m. 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Critical Care (ICU EEG Monitoring) Controversies in ICU
EEG Interpretation and Management
Convention Center Room 612, Level 6
Coordinators: Suzette M. LaRoche, M.D., Cecil Hahn, M.D.
Speakers: Tammy Tsuchida, M.D., Ph.D., Courtney Wusthoff, M.D.,
William Gallentine, D.O., Eric Payne, M.D., M.P.H., FRCPC, Sarah Schmitt, M.D.,
Lawrence J. Hirsch, M.D.
We will present three controversial cases (one neonatal, one pediatric, one adult)
that demonstrate controversial EEG patterns and approach to management.
Speakers will utilize a pro / con format, debating the merits of aggressive vs.
non-aggressive treatment.
Genetics: Personalized Epilepsy Diagnosis and Treatment
Convention Center Room 613, Level 6
Coordinators: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D.
Speakers: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D.,
Stephen Traynelis, Ph.D., Elizabeth K. Ruzzo, Ph.D.
This SIG will discuss the use of genome sequencing for individual diagnosis
and its implication for treatment. The speakers will review exome application
on an individual level, present cases that highlight the possibilities and
limitations of personalized genetic medicine, and then discuss how to apply
genetic data for individualized therapeutics.
NEW Global Health in Epilepsy: How Can You Get Involved?
Convention Center Room 603, Level 6
Coordinator: Sheryl Haut, M.D.
Speakers: Jose Cavazos., M.D., Ph.D., Lionel Carmant, M.D.
Participation in epilepsy-related global health projects is exciting, productive
and important! Many people are still unaware of the possible avenues to
pursue global health. This SIG will focus on opportunities for international
collaborations, professorships and partnerships around the world, both in
person and via telemedicine. The speakers will discuss challenges across
different regions, successes and lessons learned. Areas to be highlighted as
examples include ILAE supported activities such as the PECA (Partnering
Epilepsy Centers in the Americas) program of the North American
Commission of the ILAE and visiting professorship programs in Africa, and the
ILAE/WFN supported epilepsy demonstration project in Haiti.
Practice Management
Convention Center Room 618, Level 6
Coordinator: Gregory Barkley, M.D.
Annual update on ICD and CPT coding plus an open forum to discuss
Electronic Health Record (EHR) issues, tips, and tricks. Participants are
encouraged to submit suggestions of problems or tips from their own
practices ahead of time. Submit to barkley@neuro.hfh.edu.
Sleep and Epilepsy: Sleep Polygraphy Monitoring in the
EMU: Are We Missing a Diagnostic / Therapeutic
Opportunity?
Convention Center Room 606, Level 6
Coordinators: Mark S. Quigg, M.D., Erik K. St. Louis, M.D.
Speakers: Milena Pavlova, Terence J. OBrien, M.D., FRACP,
Erik K. St. Louis, M.D.
Comorbid sleep disturbances such as obstructive sleep apnea, insomnia, and
restless legs syndrome are frequent in persons with epilepsy, and
epileptologists are increasingly recognizing the importance and value of
Seattle, WA
diagnosing and treating sleep comorbidities in epilepsy patients.
Approximately 15-40% of patients with refractory epilepsy have comorbid
sleep apnea, and treatment of sleep apnea in epilepsy patients may improve
seizure burden, in addition to improving alertness and well-being and
modifying future health risk. However, identification of sleep apnea remains
challenging, and most epilepsy centers have separate clinical infrastructures
for the evaluation of epilepsy and sleep disorders, despite obvious intuitive,
practical, and logistical advantages of employing sleep polygraphy techniques
directly in the epilepsy monitoring setting. This years Sleep and Epilepsy SIG
will feature three expert epileptologists addressing the timely issue of utilizing
polysomnography in the differential diagnosis of epilepsy and spells, and the
importance of identifying sleep apnea in epilepsy monitoring inpatients.
Temporal Lobe Club: The Thalamus in Epilepsy Player or
Bystander?
Convention Center Room 620, Level 6
Coordinators: John Huguenard, Ph.D., Robert S. Fisher, M.D., Ph.D.
Speakers: Robert S. Fisher, M.D., Ph.D., John Huguenard, Ph.D.,
Hal Blumenfeld, M.D., Ph.D.
The thalamus has been called the gateway to the cortex. Do seizures travel
through the gate, and if so, in which direction? The role of the thalamus in
seizures has been debated for decades. In this temporal lobe club session, we
will consider whether the thalamus is a player or bystander in epilepsy. Time
is set aside for a lively group discussion.
Tumor Induced Epilepsy Meningiomas
Convention Center Room 604, Level 6
Coordinators: Jeffrey Politsky, M.D., FRCP(C), Theodore Schwartz, M.D., FACS
Speakers: Sandeep Mittal, M.D., Jeffrey Politsky, M.D., FRCP(C),
Jeffrey G. Ojemann, M.D.
The focus of the 2014 Tumor-Related Epilepsy SIG will be meningiomas.
Dr. Sandeep Mittal and Dr. Jeffrey Politsky will be present clinical data. There
will be a third presenter to discuss pathologic basis of meningioma-related
epilepsy. We will also invite members to submit cases in advance and will
reserve the final 20-30 minutes of the SIG for an open forum discussion.
Womens Issues: Controversies in Caring for Women with
Epilepsy
Convention Center Room 615, Level 6
TUESDAY
Coordinators: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D.
Speakers: Samuel F. Berkovic, M.D., Terence J. O'Brien, M.D., FRACP,
Andrew G. Herzog, M.D., M.Sc., Sanjeev V. Thomas, M.D., D.M.
Caring for women with epilepsy poses significant challenges to healthcare
professionals. Despite a growing wealth of knowledge, many issues remain
controversial and we lack evidence-based guidelines and consensus for many
difficult management issues in this field. This SIG targets four major
controversial issues in counseling and caring for women with epilepsy and
intends to bring together expert opinion and best available evidence in
addressing these difficult areas.
1. Controversies about inheritance of epilepsy
2. Controversies about teratogenicity of new AEDs and prenatal counseling
3. Controversies regarding contraception and epilepsy
4. Controversies in hormonal and non-hormonal treatment of catamenial
epilepsy.
77
 TUESDAY December 9, 2014

8:45 a.m. 10:45 a.m. ABPN Core Competencies

Hot Topics Symposium: Epilepsy Updates
(2.0 CME Credits)
Convention Center Ballroom 6C, Level 6
Overview
The Hot Topics symposium will present information about newly developed
approaches to epilepsy diagnosis and management. Faculty will discuss how
MRI can be used to facilitate understanding the pathophysiology of epilepsy
and interictal functional disturbances through study of the default mode
network. In addition, new MRI analyses evaluate disease progression with
important implications for both diagnosis and treatment. How generic drug
use impacts seizure control will be discussed, presenting data from a new
study. Lastly, a new less invasive surgical treatment for epilepsy, thermal
ablation, will be discussed. This potpourri of topics covers the most recent
advances in epilepsy, and should be valuable to both clinicians and basic
scientists.
Learning Objectives
u Recognize when to use generic anticonvulsant drugs when appropriate,
based on the potential impact on treatment efficacy and tolerability and
assists patients in understanding the pros and cons of utilizing generic
medications
u Utilizing current understanding of the pathophysiology of epilepsy,
including progression of disease, learner utilizes new diagnostic and
treatment approaches
The American Board of Psychiatry and Neurology has reviewed the Hot Topics
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competency: Medical Knowledge
8:45 a.m. 10:45 a.m.
Scientific Symposium: The Epidemiology,
Pathophysiology & Prevention of SUDEP
(2.0 CME Credits)
Convention Center Ballroom 6E, Level 6
Overview
This symposium will review the basic and clinical science of Sudden
Unexpected Death in Epilepsy (SUDEP). Specific areas that will be addressed
include epidemiology, clinical risk factors, potential role of preventive strategies,
gaps in how physicians educate patients and families, current biomarkers of
SUDEP and the evidence for the role of devices in seizure detection and their
potential role in preventing SUDEP. In addition, two leading models used to
understand the mechanisms underlying SUDEP in animals and humans will be
discussed: the role of the serotonergic system and respiration and insights into
human SUDEP from a mouse model of Dravet syndrome.

u Educate patients on how new diagnostic and treatment approaches can Learning Objectives
be used to manage refractory epilepsy. u Apply understanding of the clinical risk factors, epidemiology, educational
Target Audience gaps, and basic mechanisms of SUDEP, to developing treatment plans
Intermediate (see page 120 for details) focused on potential role of preventive strategies

Program u Counsel patients and families regarding utility of devices to detect

Co-Chairs: R. Edward Hogan, M.D. and Michael R. Sperling, M.D. seizures
u Counsel patients / families regarding clinical risk factors, epidemiology,
8:45 8:50 a.m. Introduction educational gaps, and potential role of preventive strategies underlying
Michael R. Sperling, M.D. SUDEP
8:50 9:15 a.m. The Default Mode and Networks in Epilepsy u Understand and advice practitioners and patients / families regarding
Jean Gotman, Ph.D. issues of medication adherence and therapeutic levels as prevention
strategy for SUDEP prevention
9:15 9:40 a.m. Progression of Disease in Epilepsy
Andrea Bernasconi, M.D. u Assist patients / families to develop cognitive skills and strategies to
improve medication adherence that could be life saving for some patients.
9:40 10:05 a.m. Generic Drug Update Target Audience
Michael D. Privitera, M.D. Basic, Intermediate, and Advanced (see page 120 for details)
10:05 10:30 a.m. Thermal Ablation Program
Robert Gross, M.D., Ph.D. Chair: Orrin Devinsky, M.D.

10:30 10:45 a.m. Conclusions 8:45 a.m. Introduction

R. Edward Hogan, M.D. Orrin Devinsky, M.D.
8:55 a.m. Risk Factors and Prevention of SUDEP
Credit Designation Dale C. Hesdorffer, Ph.D.
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit 9:15 a.m. Serotonin, Adeonsine and Respiration
commensurate with the extent of their participation in the activity. George B. Richerson, M.D., Ph.D.
Nurses may claim up to 2.0 contact hours for this session. 9:35 a.m. Insights from Dravet Syndrome
Pharmacy Credit William A. Catterall, Ph.D.
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
9:55 a.m. Biomarkers of SUDEP and the Role of Devices
activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-038-L01-P.
Initial Release Date: 12/9/2014. Daniel Friedman, M.D.

78
 TUESDAY December 9, 2014

10:15 a.m. Pediatric SUDEP and Patient / Family Education

Elizabeth J. Donner, M.D.
10:35 a.m. Conclusions
Orrin Devinsky, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.0 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-037-L01-P.
Initial Release Date: 12/9/2014.

ABPN Core Competencies

The American Board of Psychiatry and Neurology has reviewed the Scientific
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competencies: Patient Care, Practice-based Learning, Interpersonal and
Communication Skills

Seven on-demand audio webinars introducing the core

elements of seizures, epilepsy, and epilepsy care. This program
will assist nurses and other health care professionals to provide

TUESDAY
appropriate care and support to patients and families in any
health care setting.

Audio Webinars include:

l Basics of Epilepsy
l Recognition and Care of Seizures and Emergencies: Parts 1-2
l Overview of Treatment Options: Parts 1-2
l Patient and Family Education and Self-Management Approaches

https://www.AESnet.org/epilepsy_101

79
 See you in
Philadelphia!

2015 ANNUAL
MEETING
December 4 - 8

PHILADELPHIA, PA
Pennsylvania Convention Center

CME Symposia and Lectures

Platform Sessions
Informative Exhibitors
Special Interest Group Meetings
Skills Workshops

FUTURE ANNUAL 2016 2018

MEETING DATES Houston, TX New Orleans, LA
George R. Brown Convention Center Ernest N. Morial Convention Center
December 2 - 6 November 30 - December 4

2017 2019
Washington, D.C. Baltimore, MD
Washington Convention Center Baltimore Convention Center
December 1 - 5 December 6 - 10

80
 POSTER BOARDS

PAVILION PAVILION
A B

MEDIA WALL
137 236 239 339
336
135 234 237 337 737 836 837 936
PAVILION PAVILION FOOD & FOOD &
235 334 335 C D BEVERAGE 735 834 835 BEVERAGE
133 232 932
233 332 333 733 832 833

Poster Information Table*

OFFICE 125 726 727 927
#1 625 824
WF AES 223 724 725 823 925
EPILEPSY
LOUNGE
EXHIBITOR

723 822
Exhibit RESOURCE 921
519
220 CENTER 721 820
Manager 119
OFFICE 219
Office #2 617 818 919
216 316 717 817
GES

Poster 117 217 816 917

Session 915

CYBER CAFE
Entrance
513 612 713 913
When 811
Exhibits 511 610 911

Exhibit Hall Hours:

are 105 205 305 405 605 909
Closed 606
505 705
805 905

Elevators
101 200 202 201 300 301 400 501 600 800 801 900 902 901
PE PE MAIN
1 2 ENTRANCE
Elevators
EXHIBITOR FLOOR PLAN

6 7 WF
ESCALATOR
PE PE

Saturday, December 6 ..................................................Noon - 6:00 p.m.

Monday, December 8 ......................................10:00 a.m. - 3:00 p.m.

Sunday, December 7 ........................................10:00 a.m. - 6:00 p.m.
UP TO
LEVEL 6
ESCALATOR
DOWN TO BAG DISTRIBUTION
LEVEL 3

*Poster Walking Tours begin at the Poster Information Table

REGISTRATION
Coat
Check EXIT
EXIT

SOUTH GALLERIA

SOUTH LOBBY - LEVEL 4

81
 EXHIBITOR LOCATIONS
Booth
ABRET Neurodiagnostic Credentialing & Accreditation* .....3
Ad-Tech Medical Instrument Corp.................................505
AED Pregnancy Registry .............................................733
Ambry Genetics .........................................................233
Ambu Inc. ..................................................................911
American Board of Clinical Neurophysiology, Inc. (ABCN)* ..2
American Board of Psychiatry and Neurology ................837
American Clinical Magnetoencephalography Society*
(ACMEGS) ...................................................................5
American Clinical Neurophysiology Society (ACNS)* ...........4
American Epilepsy Society ..........................................125
Angel Wings Foundation* ..............................................16
Anita Kaufmann Foundation, The* ...................................1
ANT North America ....................................................236
Ark Diagnostics, Inc. ..................................................820
ASET The Neurodiagnostic Society* ............................15
Athena Diagnostics, Inc. .............................................612
Aurora Health Care ....................................................235
B. Braun CeGat, LLC ..................................................915
BIOPAC Systems, Inc..................................................836
Blackrock NeuroMed...................................................817
Brain Vision LLC.........................................................835
Cadwell Laboratories, Inc. ...........................................811
captureproof..............................................................919
Charlie Foundation, The and Ice Epilepsy* ......................19
Child Neurology Foundation .........................................832
Clever Sys, Inc. ..........................................................927
Compumedics Limited .................................................805
Courtagen Diagnostics Lab .........................................936
CorTechs Lab, Inc .......................................................334
CURE (Citizens United for Research in Epilepsy)*..............6
Cyberonics, Inc. .........................................................223
Department of Veterans Affairs, Epilepsy Centers of
Excellence*..................................................................9
DigiTrace EEG Services ...............................................727
Dravet Syndrome Foundation* .......................................11
Eisai Inc. ...................................................................305
Electrical Geodesics, Inc.....................................717, 816
ELEKTA......................................................................519
Elsevier, Inc. ..............................................................901
Emfit Corp. ................................................................909
emka TECHNOLOGIES Inc............................................701
Emory Genetics Laboratory.........................................202
Epilepsy Foundation*...............................................8, 513
GeneDx .....................................................................822
GlaxoSmithKline .........................................................336
GW Pharmaceuticals ..................................................133
IEEG.org* ....................................................................17
International Epilepsy Congress...................................234
INSYS Therapeutics....................................................200
Jack Pribaz Foundation, The .......................................332
John Libbey EUROTEXT ...............................................301
82 *Please see Epilepsy Resource Center Participants on page 83
Booth
LGS (Lennox-Gastaut Syndrome) Foundation*.................10
Lifelines Neurodiagnostic Systems, Inc. .......................921
Lundbeck ...........................................................405, 511
Mallinckrodt Pharmaceuticals..............................217, 316
Medical Neurogenetics, LLC........................................216
MediKidz....................................................................232
Medtech Surgical .......................................................800
Medtronic..................................................................932
Moberg Research.......................................................239
Monteris Medical .......................................................905
Multi Channel Systems ...............................................300
National Association of Epilepsy Centers......................723
National Institute of Neurological Disorders &
Stroke (NINDS)........................................................725
Natus Neurology Incorporated.....................................705
Neuralynx, Inc ............................................................713
Neurology Reviews .....................................................101
NeuroPace, Inc...........................................................824
NeuroQuest LLC ........................................................834
Neurotech .................................................................610
Nexstim ....................................................................119
Nihon Kohden America, Inc. .........................................617
Novartis Pharmaceuticals ...........................................137
Optima Neuroscience, Inc. ..........................................833
Oxford University Press ..............................................219
PCDH19 Alliance*...........................................................7
Persyst Development Corporation ...............................925
Physicians Insurance ..................................................220
Pinnacle Technology, Inc...............................................737
PMT Corporation ........................................................606
PreventionGenetics ....................................................902
Rhythmlink International, LLC ......................................721
Ring14 USA Outreach*.................................................12
Ripple LLC .................................................................724
Rogue Research Inc....................................................900
RosmanSearch, Inc. ...................................................726
SeizureTracker.com* .....................................................21
Smart Monitor Corp. ..................................................917
SUDEP Aware* ............................................................20
Sunovion Pharmaceuticals Inc. ....................................105
Supernus Pharmaceuticals, Inc. ..................................605
Texas Childrens Hospital.............................................201
Transgenomic, Inc.......................................................801
Triangle BioSystems, Inc. ............................................735
Tuberous Sclerosis Alliance* ..........................................22
UCB, Inc............................................................135, 205
UCSF Medical Center .................................................913
Upsher-Smith Laboratories, Inc ..........................625, 823
Vitaflo USA ................................................................117
Wiley .........................................................................818
Wolters Kluwer Health................................................400
 Stop by the EPILEPSY RESOURCE CENTER
at the Entrance of the Exhibit Hall

2014 Epilepsy Resource Center

Participants
Table # ERC Participants:
1 The Anita Kaufmann Foundation
2 American Board of Clinical Neurophysiology,
ENTRANCE Inc. (ABCN)
3 The American Board of Registration of EEG
and EP Technologies (ABRET)
4 American Clinical Neurophysiology Society
(ACNS)
5 American Clinical MEG Society (ACMEGS)
6 CURE (Citizens United for Research in
Epilepsy)
7 PCDH19 Alliance
8 Epilepsy Foundation
9 Epilepsy Centers of Excellence, Department of
Veterans Affairs
10 LGS Foundation
ENTRANCE

ENTRANCE

11 Dravet Syndrome Foundation

12 Ring14 USA Outreach
14 North American SUDEP Registry
15 ASET The Neurodiagnostic Society
Presentation Area
16 Angel Wings Foundation
17 IEEG.org
18 British Paediatric Neurology Association
19 The Charlie Foundation and ICE Epilepsy
20 SUDEP Aware
21 SeizureTracker.com
ENTRANCE 22 Tuberous Sclerosis Alliance

Many of the ERC participants will be offering mini-workshops dedicated to the education, awareness
and research for people with epilepsy worldwide. All participants of AES, including exhibitors, are invited to
attend the mini-workshops. The schedule will be posted daily outside the ERC.
The Epilepsy Resource Center is a comprehensive one-stop resource for patients, researchers and clinicians
specializing in the area of epilepsy.

83

Saturday, December 6: Noon-6:00 p.m.
Lunch: Noon-1:00 p.m.
Symposia Break: 5:00 p.m.-6:00 p.m.
Prize Drawing: 5:30 p.m.
ABRET Neurodiagnostic Credentialing &
Accreditation
Booth #3
2908 Greenbriar Dr - Ste A
Springfield IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: abreteo@att.net
Website: www.abret.org
Contact: Ms. Janice Walbert
ABRET Neurodiagnostic Credentialing &
Accreditation offers five credentials (R. EEG
T., R. EP T., CNIM, CLTM, CAP) and
manages three laboratory accreditation
programs, LAB-EEG, LAB-NIOM, and LAB-
LTM. Learn more about laboratory
accreditation, view resources for
technologists and receive assistance in
recruiting neurodiagnostic technologists.
Ad-Tech Medical Instrument Corp.
Booth #505
1901 William St
Racine WI 53404
Phone: 262-634-1555
Fax: 262-634-5668
Email: abouwma@adtechmedical.com
Website: www.adtechmedical.com
Contact: Ms. Angie Bouwma
For over 25 years, Epilepsy Centers have
made Ad-Tech their choice for invasive
electrodes for brain mapping and epilepsy
monitoring. We offer a large variety of
electrodes and accessories to meet you and
your patients needs. Visit our Booth to
discover why Ad-Tech is your best choice.
AED Pregnancy Registry
Booth #733
121 Innerbelt Rd - Ste 220
Massachusetts General Hospital
Somerville MA 02143
Phone: 888-233-2334
Fax: 617-724-8307
Email: crsmith1@partners.org
Website: www.aedpregnancyregistry.org
Contact: Ms. Caitlin Smith
The North American AED Pregnancy Registry in Epilepsy Monitoring or Neurophysiologic
is dedicated to determine the safety of
anticonvulsant medications that can be taken Neurophysiology Track is also available. A
by women during pregnancy. The primary goal Critical Care EEG Track will be offered in fall neurophysiology and furthering the
is to determine the frequency of major
malformations in the infants exposed during
pregnancy to anticonvulsant drugs. Please
visit our booth to learn more about our
findings, and to obtain materials for use in
your office.
84
EXHIBITORS
as of October 21, 2014
Exhibit Schedule
Sunday, December 7:10:00 a.m.-6:00 p.m. Monday, December 8: 10:00 a.m.-3:00 p.m.
Lunch: Noon-1:00 p.m. Lunch: Noon-1:00 p.m.
Suds for Science: 5:00 p.m.-6:00 p.m. Prize Drawing & Grand Prize Drawing:
Prize Drawing: 5:30 p.m. 2:30 p.m.
Ambry Genetics American Board of Psychiatry and Neurology
Booth #233 Booth #837
15 Argonaught 2150 E Lake Cook Rd - #900
Aliso Viejo CA 92656 Buffalo Grove IL 60089
Website: www.ambrygen.com Phone: 847-229-6500
Contact: Colleen Garcia Fax: 847-229-6600
Email: questions@abpn.com
Ambry Genetics is a College of American Website: www.abpn.com
Pathologists (CAP)-accredited and Clinical Contact: Ms. Karen Back
Laboratory Improvement Amendments (CLIA)-
certified commercial clinical laboratory with The American Board of Psychiatry and
headquarters in Orange County, California. Neurology serves the public interest and the
Ambry is a leader in providing genetic professions of psychiatry and neurology by
services focused on clinical diagnostics and promoting excellence in practice through its
genomic services, and has established a certification and maintenance of certification
reputation for unparalleled customer processes. ABPN also oversees the
satisfaction. certification process for physicians seeking
certification in child and adolescent psychiatry.
Ambu Inc.
Booth #911 American Clinical Magnetoencephalography
6740 Baymeadow Dr Society (ACMEGS)
Glen Burnie MD 21060 Booth #5
Phone: 800-262-8462 555 E. Wells Street Ste 1100
Email: meha@ambu.com Milwaukee WI 53202
Website: www.ambuusa.com Phone: 414-918-9804
Contact: Megan Hasson Email: mkelley@acmegs.org
Website: www.acmegs.org
Ambu is dedicated to the development of Contact: Ms. Megan Kelley
innovative products that help save lives and
simplify workflow of the anesthetists to theACMEGS is a non-profit association whose
benefit of the patients.Within the field of membership includes clinical MEG facilities in
anesthesia Ambu offers a wide range of the U.S. Founded by physicians committed to
products from resuscitators, face masks and high-quality care of patients with epilepsy,
laryngeal masks to the highly innovative ACMEGS now advocates for patients with
single use flexible intubation scope. neurological conditions who may benefit from
MEG by educating policymakers about
American Board of Clinical Neurophysiology, recommended standards of care,
Inc. (ABCN) reimbursement, and provider regulations.
Booth #2
2908 Greenbriar Dr Ste A American Clinical Neurophysiology Society
Springfield IL 62704 (ACNS)
Phone: 217-726-7980 Booth #4
Fax: 217-726-7989 555 E. Wells Street Ste 1100
Email: abcn@att.net Milwaukee WI 53202
Website: www.abcn.org Phone: 414-918-9803
Contact: Ms. Janice Walbert Fax: 414-276-3349
Email: info@acns.org
The ABCN has a 65 year history of promoting Website: www.acns.org
excellence in Clinical Neurophysiology and Contact: Ms. Megan Kelley
offers examinations with added competency
The American Clinical Neurophysiology Society
Intraoperative Monitoring. A General Clinical (ACNS) is a professional association dedicated
to fostering excellence in clinical
2015. International testing is available. understanding of central and peripheral
nervous system function in health and disease
through education, research, and the provision
of a forum for discussion and interaction.

American Epilepsy Society
Booth #125
342 N Main St
West Hartford CT 06117-2507
Phone: 860-586-7505
Fax: 860-586-7550
Email: ctubby@AESnet.org
Website: www.AESnet.org
Contact: Ms. Cheryl-Ann Tubby
Visit the AES booth for information on
membership, publications, and research
funding opportunities. Stop by to watch
interviews being taped with member experts
on some of the hottest topics at the meeting.
Recognize a mentor or colleague by
purchasing a Community of Caring pin, and
support AES research and awareness
programs. Get a personal tour of AES online
resources including the Epilepsy Learning
Institute, EMU Caring, and the AES website.
AES logo scarves, ties and bowties will also
be available for purchase.
Angel Wings Foundation
Booth #16
2134 Baldwin Ct
Hanover Park IL 60133
Phone: 630-550-1049
Email: dflader@angelwingsfoundation.net
Website: www.angelwingsfoundation.net
Contact: Ms. Debbie Flader
Angel Wings Foundation is dedicated to
enhancing the lives of adults with epilepsy,
allowing them to reach their full potential
through independent living in the community.
Angel Wings will create home where adults
with epilepsy can lead person-centered lives,
with supports in place. Angel Wings will offer
recreational, vocational and educational
opportunities for adults with epilepsy.
Anita Kaufmann Foundation, The
Booth #1
PO Box 751
Livingston NJ 07039
Phone: 201-655-0420
Email: debra@akfus.org
Website: www.akfus.org
Contact: Ms. Debra Josephs
AKF, global sponsor of Purple Day, is a
501(c)(3) public charity with a grassroots
mission to educate the public not to fear
people with epilepsy. Visit
purpledayeveryday.org and akfus.org to learn
about our Heads Up For Vets and Lace Up For
Epilepsy Programs, or to register for our
Purple Day Mall of America Walk for Epilepsy in
conjunction with the CNF Brain Carnival on
3/21/15.
ANT North America
Booth #236
437 S. Yellowstone Dr #216
Madison WI 53719
Phone: 608-204-0878
Email: myuchtman@ant-neuro.com
Website: www.ant-neuro.com
Contact: Moshe Yuchtman
EXHIBITORS
Ark Diagnostics, Inc.
Booth #820
48089 Fremont Blvd
Fremont CA 94538
Phone: 510-270-6270
Fax: 510-270-6298
Email: ryan@ark-tdm.com
Website: www.ark-tdm.com
Contact: Mr. Ryan Olandria
Ark Diagnostics Inc. designs, manufactures,
and distributes in vitro diagnostic products.
ARKs proprietary assays accurately measure
drug levels in biological fluids. Clinicians use
these measurements to guide dosing
decisions for safe, effective, and personalized
drug therapy. Anti-epileptic drug assays (FDA
510k Cleared): Levetiracetam, Lamotrigine,
Topiramate, Gabapentin, and Zonisamide.
ASET The Neurodiagnostic Society
Booth #15
402 E Bannister Rd Ste A
Kansas City MO 64131-3019
Phone: 816-931-1120
Fax: 816-931-1145
Email: sarah@aset.org
Website: www.aset.org
Contact: Ms. Sarah Ecker
ASET The Neurodiagnostic Society
represents more than 4,500 allied health
professionals who perform neurodiagnostic
procedures. ASET provides education and
advocacy, creates greater awareness of the
profession, and establishes standards and
best practices to ensure quality patient care.
Stop by the ASET booth to see our newest
publications and educational offerings.
Athena Diagnostics, Inc.
Booth #612
Ms. Lorri Harrell
200 Forest Street 2nd Floor
Marlborough MA 01752
Phone: 800-394-4493
Email: lorri.l.harrell@questdiagnositics.com
Website: www.athenadiagnostics.com
Athena Diagnostics is a leader in diagnostics
testing for neurological diseases. Our
comprehensive test menu includes over 400
tests for epilepsy, muscular dystrophy,
peripheral neuropathy, stroke, and other
neuromuscular and developmental disorders.
Aurora Health Care
Booth #235
3305 West Forest Home Ave
Milwaukee WI 53215
Phone: 414-389-2696
Email: chris.mccarrier@aurora.org
Website: www.aurora.org/doctor
Contact: Christine McCarrier
Aurora Health Care is the largest healthcare
system in eastern Wisconsin and extends into
northern Illinois. Our integrated delivery model
helps us coordinate and simplify quality care,
minimize costs and improve our patients
overall health care experience. Our 15
hospitals and 90+ clinics support
neurologists who believe that better health
care leads to stronger communities.
B. Braun CeGat, LLC
Booth #915
824 Twelfth Ave
Bethlehem PA 18018
Phone: 844-692-3428
Email: genetics.us@bbraun.com
Website: www.bbrauncegat.com
Contact: Mitch Nemcek
B. Braun CeGaT is a genetic diagnostic
laboratory that offers an extensive menu
of single-gene sequencing tests and over
150 multi-gene diagnostic panels for a
wide variety of genetic diseases, including
19 panels that analyze 400+ genes
associated with epilepsies, migraines, and
related disorders.
BIOPAC Systems, Inc.
Booth #836
42 Aero Camino
Goleta CA 93117
Phone: 805-685-0066
Fax: 805-685-0067
Email: frontdesk@biopac.com
Website: www.biopac.com
Human and animal wireless EEG systems
with AcqKnowledge analysis automation &
scoring: small animal seizure detection,
EPOCH 2-ch long-term wireless
EEG/neural signals, B-Alert X10 wireless
EEG & Cognitive State Metrics, Mobita
32-ch wireless EEG system with water
electrodes, BioNomadix Wireless
Physiology amplifiers, Stellar telemetry
interface for multiple animals, Developer
Scripting, and more!
Blackrock NeuroMed
Booth #817
630 Komas Dr - Ste 200
Salt Lake City UT 84108
Phone: 801-994-5661
Fax: 801-582-1509
Email: sryan@blackrockneuromed.com
Website: www.blackrockneuromed.com
Contact: Ms. Shanna Ryan
Blackrock NeuroMeds Cervello EEG/LTM
systems provide physicians and clinicians
an advanced EEG monitoring system with
up to 256 channels, remote monitoring
capabilities, Bluetooth wireless
connectivity and a full HD 1080 PTZ video
camera. All systems include
comprehensive service and support with
start to finish integration and IT
consultation.
EXHIBITORS
Brain Vision LLC
Booth #835
2500 Gateway Centre Blvd Ste 100
Morrisville NC 27560
Phone: 919-460-2510
Fax: 214-224-0829
Email: travel@brainvision.com
Website: www.brainvision.com
Brain Vision LLC offers full service
solutions for customized
neurophysiological related research
including epilepsy related on infants and
adults that include EEG/ERP as well as
fNIRS software and hardware, fMRI
85

compatible equipment, stimulation devices
(TMS, tDCS, tACS), wireless system
applications for passive, active, dry
electrodes and accessories.
Cadwell Laboratories, Inc.
Booth #811
909 N Kellogg St
Kennewick WA 99336
Phone: 509-735-6481
Fax: 509-783-6503
Email: lorik@cadwell.com
Website: www.cadwell.com
Contact: Ms. Lori Kaufman
Cadwell introduces a new concept in
Ambulatory and Clinical EEG. Come byBooth
811 to see the new ARC Alterna EEG
system. Completely new software designed
with the EEG specialist in mind, you will
appreciate the clean, simple look and feel of
this new system. The addition of an all new
Photic Stimulator allows for clinical EEGs
with the Ambulatory hardware while still
providing Ambulatory EEGs.
captureproof
Booth #919
190 7th St. Ste 4
San Francisco CA 94103
Phone: 415-770-2020
Email: info@captureproof.com
Website: www.captureproof.com
Do your patients send you videos?
CaptureProof is the HIPAA secure photo and
video solution that organizes events
chronologically. Videos are uploaded by the
patient and shown at the next appointment
or shared online. You can also share images
with peers for consults. See-and-know what
your patients are talking about. Sign-up free
at captureproof.com using invite code:
AES2014.
Charlie Foundation, The and Ice Epilepsy
Booth #19
1325 Victoria Circle S
Elm Grove WI 53122
Phone: 262-271-3479
Fax: 262-754-1369
Email: ketogenicseminars@wi.rr.com
Website: www.charliefoundation.org
Contact: Ms. Beth Zupec-Kania
The Charlie Foundation advocates ketogenic
diet therapies through education programs
and offers KetoCalculator, a web-based diet
tool designed to manage ketogenic therapies.
ICE Alliance provides drug information,
advocacy support for appropriate medical
treatment and education, a patient registry
and funding of research for intractable
childhood epilepsies:ice-epilepsy.org
Child Neurology Foundation
Booth #832
201 Chicago Ave - Ste 200
Minneapolis MN 55431
Phone: 612-928-6326
Fax: 612-454-2744
Email: amiller@cnsmail.org
Website: www.childneurologyfoundation.org
Contact: Ms. Amy Brin Miller
86
EXHIBITORS
CNF improves lives of families battling one or
more of the 450+ childhood neurologic
disorders through our web resources, by
supporting affiliate organizations, public
policy initiatives, and the hope derived from
our annual scholarships and awards.
Clever Sys, Inc.
Booth #927
11425 Isaac Newton Sq - Ste 202
Reston VA 20190
Phone: 703-787-6946
Fax: 703-757-7467
Email: nzhang@cleversysinc.com
Website: www.cleversysinc.com
Contact: Ms. Naili Zhang
Headquartered in the metropolitan D.C. area,
Clever Sys. Inc. sells products and services for
lab animal behavior analysis including rodents,
drosophila, zebra fish, primates, etc.. Our
products utilize information of animal full body
as well as animal body parts, providing
measurements of novel behavioral paradigms
and new parameters, which are more revealing
of the intrinsic of animal behaviors.
Compumedics Limited
Booth #805
6605 W WT Harris Blvd - Ste F
Charlotte NC 28269
Phone: 704-749-3200
Fax: 704-749-3299
Email: marketing@compumedicsusa.com
Website: www.compumedics.com.au
Contact: Ms. Marjie Cummings
Compumedics provides solutions for Epilepsy
monitoring. NEUVO LTM and Grael EEG
Systems with CURRY 7 Neuroimaging Suite
meet requirements for routine and
ambulatory recordings as well as LTM /
Neuro-ICU monitoring. Compumedics
addresses ultra-high density recordings,
source localization and source imaging. See
more and do more with Compumedics.
CorTechs Labs, Inc.
Booth # 334
4690 Executive Dr - Ste 250
San Diego CA 92121
Phone: 858-459-9700
Fax: 858-459-9705
Email: sadams@cortechslabs.com
Website: www.cortechslabs.com
Contact: Ms. Shelly Adams
Courtagen Diagnostics Lab
Booth #936
12 Gill St - Ste 3700
Woburn MA 01801
Phone: 617-999-4122
Fax: 617-892-7191
Email: john.geanacopoulos@courtagen.com
Website: www.courtagen.com
Contact: Mr. John Geanacopoulos
Courtagen is a diagnostic sequencing and
molecular information company that converts
NGS sequencing data into actionable clinical
information for neurological and metabolic
disorders such as mitochondrial disorders
(mtSEEK and nucSEEK), epilepsy
(epiSEEK), and intellectual disability,
including autism spectrum disorders
(devACT and devSEEK).
CURE (Citizens United for Research
in Epilepsy)
Booth #6
430 W Erie Ste 210
Chicago IL 60654
Phone: 312-255-1801
Fax: 312-255-1809
Email: liz@cureepilepsy.org
Website: www.cureepilepsy.org
Contact: Ms. Tracy Dixon-Salazar
CURE (Citizens United for Research in
Epilepsy) is a nonprofit organization
dedicated to finding a cure for epilepsy by
raising funds for research and by increasing
awareness of the prevalence and devastation
of the disease. Since its inception in 1998,
CURE has raised over $28 million to fund
epilepsy research and other initiatives that
will lead the way to a cure.
Cyberonics, Inc.
Booth #223
100 Cyberonics Blvd
Houston TX 77058
Phone: 281-228-7200
Fax: 281-218-9332
Email: renee.adams@cyberonics.com
Website: www.vnstherapy.com
Contact: Ms. Renee Adams
Cyberonics, Inc. is the leader in device
solutions for epilepsy and is committed to
consistently delivering innovative and
effective solutions for physicians, caregivers
and people with epilepsy. Cyberonics VNS
Therapy is available in more than 70
countries for the treatment of drug-
resistant epilepsy, with more than 80,000
patients implanted worldwide.
Department of Veterans Affairs, Epilepsy
Centers of Excellence
Booth #9
4150 Clement St (127E)
San Francisco CA 94121
Phone: 415-221-4810
Fax: 415-379-5666
Email: ryan.rieger@va.gov
Website: www.epilepsy.va.gov
Contact: Mr. Ryan Rieger
The Department of Veterans Affairs, Epilepsy
Centers of Excellence's mission is to improve
the health and well-being of Veteran patients
with epilepsy and other seizure disorders
through the integration of clinical care,
outreach, research, and education.

DigiTrace EEG Services
Booth #727
200 Corporate Pl - Ste 5B
Peabody MA 01960
Phone: 978-536-7400
Fax: 978-535-9778
Email: dmartin@sleepmedinc.com
Website: www.sleepmed.md
Contact: Mr. Dan Martin
DigiTrace EEG products and services are used
by dozens of comprehensive epilepsy centers
throughout the U.S. In addition, there are
over 40 SleepMed Service Centers around the
country where physicians can refer their
patients for ambulatory EEG testing. We are
noted for unique capabilities including our
lightweight head-mounted preamplifier that
minimizes motion artifact.
Dravet Syndrome Foundation
Booth #11
PO Box 16536
West Haven CT 06516
Phone: 203-392-1950
Fax: 203-907-1940
Email: maryanne.m@dravetfoundation.org
Website: www.dravetfoundation.org
Contact: Ms. Mary Anne Meskis
The mission of Dravet Syndrome Foundation
(DSF) is to aggressively raise research funds
for Dravet syndrome and related epilepsies;
to increase awareness of these catastrophic
conditions; and to provide support to affected
individuals and families.
Eisai Inc.
Booth #305
100 Tice Blvd
Woodcliff Lake NJ 07677
Phone: 201-692-1100
Fax: 201-692-1804
Email: shirley_hunt@eisai.com
Website: www.eisai.com/US
Contact: Ms. Shirley Hunt
As the U.S. pharmaceutical subsidiary of
Tokyo-based Eisai Co., Ltd., we are a fully
integrated pharmaceutical business with
discovery, clinical, manufacturing and
marketing capabilities. Our key areas of
commercial focus include oncology and
specialty care (Alzheimers disease, epilepsy
and metabolic disorders).
Electrical Geodesics, Inc.
Booth #717, 816
500 East 4th Ave Ste 200
Eugene OR 97401
Phone: 541-687-7962
Fax: 541-687-7963
Email: daguilar@egi.com
Website: www.egi.com
Contact: Ms. Diana Aguilar
EGI brings next-generation clinical EEG
systems, tools, and workflows to hospitals
and clinics worldwide. EEG Systems feature
EGIs Geodesic Sensor Net for rapid
application and unprecedented comfort.
Your choice of routine EEG systems or dense
array systems for source estimation. Visit
EGIs booth to see this in action!
EXHIBITORS
ELEKTA
Booth #519
400 Perimeter Center Terrace
Suite 50
Atlanta GA 30346
Phone: 770-670-2592
Fax: 770-448-6338
Email: doris.aubuchon@elekta.com
Contact: Doris AuBuchon
Elekta is the global leader in advanced
magnetoencephalography (MEG)
instrumentation. MEG is a highly sensitive and
completely non-invasive technology increasingly
used for localizing the epileptogenic zone(s)
and adjacent eloquent cortex in pre-surgical
evaluation of epileptic patients.
Elsevier, Inc.
Booth #901
1600 JKF Blvd - Ste 1800
Philadelphia PA 19103
Phone: 215-239-3491
Fax: 215-239-3494
Email: j.francis@elsevier.com
Website: www.elsevierhealth.com
Contact: Mr. Jeffrey Francis
Elsevier is a world-leading provider of
information solutions that enhance the
performance of science, health, and
technology professionals, empowering them
to make better decisions, deliver better care,
and sometimes make groundbreaking
discoveries, that advance the boundaries of
knowledge and human progress. Visit our
booth to find out about our Neurology
journals.
Emfit Corp.
Booth #909
PO Box 342394
Austin TX 78734
Phone: 512-266-6950
Fax: 512-266-7203
Email: christine.ocean@emfit.com
Website: www.emfit.com
Contact: Ms. Christine Ocean
Emfit is a pioneer and world-leading
manufacturer of movement activity and
discreet vitals monitoring systems. We will be
demonstrating the Emfit Movement Monitor
for monitoring and detecting abnormal,
nighttime movements, along with the newly
released Emfit QS Sleep Monitor
for tracking and recording essential sleep
statistics, including heart rate, respiration
rate, and movement activity.
emka TECHNOLOGIES Inc.
Booth #701
307 Annandale Rd - Ste 203
Falls Church VA 22042
Phone: 703-237-9001
Fax: 703-237-9006
Email: vb@emkatech.com
Website: www.emkatech.com
Contact: Ms. Virginie Brechet
Stop by booth#701 to discover the all new
non-invasive and tether-less monitoring
system: rodentPACK v2. An affordable, head-
mounted, radio-telemetry device for
recording EEG, EMG, ECG, temperature,
and/or activity from up to 32 subjects
simultaneously! Weighs only 4.5g with
batteries, 5 meters transmission range,
150 hours continuous recording, no
refurbishment, just replace batteries.
Emory Genetics Laboratory
Booth #202
2165 N Decatur Rd
Decatur GA 30033
Phone: 404-778-8500
Fax: 404-778-8559
Email: derek.stevens@emory.edu
Website: www.genetics.emory.edu
Contact: Mr. Derek Stevens
Emory Genetics Laboratory (EGL) features
fully integrated molecular genetics,
cytogenetics, and biochemical genetics
laboratories, making it a "one-stop shop"
for genetic testing. EGL benefits from its
affiliation with Emory University, but EGL
is not the typical, highly specialized
academic laboratory. EGL offers a full
range of test options, with more than
900 tests available.
Epilepsy Foundation
Booths #8, 513
8301 Professional Pl
Ardmore MD 20785
Phone: 301-918-3739
Email: taregbesola@efa.org
Website: www.epilepsy.com
Contact: Ms. Temi Aregbesola
The Epilepsy Foundation is a community-
based, family-led organization dedicated
to improving the lives of people impacted
by seizures. We provide programs,
services, support, and encourage
innovation in accelerating new treatments
and therapies.We educate about proper
seizure awareness, recognition and first
aid.We advocate for improved rights and
regulations involving people living with
epilepsy.
GeneDx
Booth #822
481 Edward H Ross Dr
Elmwood Park NJ 07407
Phone: 301-519-2100
Fax: 301-519-2892
Email: msansing@bioreference.com
Website: www.genedx.com
EXHIBITORS
Contact: Ms. Marianne Sansing
GeneDx is highly respected laboratory,
specializing in genetic testing for rare
Mendelian disorders. GeneDx offers
sequencing and deletion/duplication
testing for inherited cardiac disorders,
mitochondrial disorders, neurological
disorders, inherited cancer disorders,
prenatal disorders and other rare genetic
disorders. GeneDx also offers whole
exome sequencing, next-generation and
microarray-based testing.
87

GlaxoSmithKline
Booth #336
Ms. Laura Byrne
Five Moore Dr
Research Triangle Park NC 27709
Phone: 800-366-8900
Email: lbyrne@lynchexhibits.com
Website: www.gsk.com
GlaxoSmithKline is a leading research-based
pharmaceutical company with a powerful
combination of skills to discover and deliver
innovative medicines. We offer a number of
program resources to support effective
health management strategies and improve
patient care. Please visit our exhibit to learn
more about our products and resources.
GW Pharmaceuticals
Booth #133
1 Cavendish Pl
London W1G 0QF
United Kingdom
Phone: 917-280-2424
Email: sschultz@gwpharm.com
Website: www.gwpharm.com
Contact: Kelly Simontacchi
With 15 years of cannabinoid research
experience, GW is the world leader in
development of novel cannabinoid prescription
medicines to address unmet patient needs
across a range of therapeutic areas. Our
portfolio includes the worlds first plant-
derived cannabinoid prescription drug,
Sativex, as well as Epidiolex, currently in
development for treatment of Dravet and
Lennox-Gastaut syndromes.
IEEG.org
Booth #17
Room 301 Hayden Hall, 240 S. 33rd St
Philadelphia PA 19104
Phone: 215-746-4850
Email: wilkinsc@seas.upenn.edu
Website: eeg.org
Contact: Carolyn Wilkinson
IEEG.org: A Scientific Platform for
collaborative science. The International
Epilepsy Electrophysiology Portal is a
collaborative initiative funded by the
NIH/NINDS. This initiative seeks to advance
research towards the understanding of
epilepsy by providing a platform for sharing
data, tools and expertise between
researchers. ( NIH Grant #1 U24
NS063930-01)
International Epilepsy Congress
Booth #234
7 Priory Office Park, Stillorgan Rd
Co. Dublin 18
Ireland
Phone: 353-1-2056720
Fax: 353-1-2123576
Website: www.epilepsycongress.org
Contact: Mr. Fergus Egan
The ILAE is the world's preeminent
association of physicians and other health
professionals working towards a world where
no persons life is limited by epilepsy. The IBE
88
EXHIBITORS
exists to improve the quality of life of people
with epilepsy and their families and carers
through national epilepsy organizations
around the world.
INSYS Therapeutics
Booth #200
1333 S Spectrum #100
Chandler AZ 85286
Phone: 602-910-2617
Email: amarzahl@insysrx.com
Website: www.insysrx.com
Contact: Anna Marzahl
INSYS Therapeutics is a specialty
pharmaceutical company that develops and
commercializes innovative drugs and novel
drug delivery systems of therapeutic
molecules, including its proprietary sublingual
spray technology, to help improve patient
quality of life. Focused on pharmaceutical
cannabinoids development, the company is
evaluating its pharmaceutical cannabidiol
(CBD) for epilepsy treatment.
Jack Pribaz Foundation, The
Booth #332
PO Box 813
Wheaton IL 60187
Phone: 630-485-9986
Email: angelacherry86@gmail.com
Website: www.jacksarmy.org
Contact: Angela Cherry
hosted solution. Stop by booth #921 to see
The Jack Pribaz Foundation is a 501(c)(3)
charity established in Illinois in 2011. Named
for a boy diagnosed with one of the first
known cases of KCNQ2 epileptic
encephalopathy in North America, its mission
is to support research for this condition by
raising funds and awareness. To learn more
visit www.kcnq2.org and.
John Libbey EUROTEXT
Booth #301
127 Avenue de la Republique
92120 Montrouge
France
Phone: 330-146-7306-79
Fax: 330-140-8409-99
Email: gilles.cahn@jle.com
Website: www.jle.com
Contact: Mr. Gilles Cahn
For decades, JOHN LIBBEY EUROTEXT
has been THE Publisher of both world-
renowned specialists and new authors
in Epilepsy. Through Epileptic Disorders,
the Educational Journal of the ILAE, and
moreover through our huge book series,
we provide first-class knowledge in the field
of Epilepsy. Visit www.epilepticdisorders.com,
The Real Forum for The Worldwide Epilepsy
Community.
segment includes branded and specialty
LGS (Lennox-Gastaut Syndrome) Foundation
Booth #10
192 Lexington Ave Ste 216
New York NY 10150
Phone: 718-374-3800
Email: christina@lgsfoundation.org
Website: www.lgsfoundation.org
Contact: Ms. Christina San Inocencio
The LGS Foundation is a non-profit
organization dedicated to providing
information about Lennox-Gastaut Syndrome
while raising funds for research, programs
and services for individuals living with LGS,
and their families.
Lifelines Neurodiagnostic Systems, Inc.
Booth #921
411 Edwardsville Rd Ste A
Troy IL 62294
Phone: 618-667-6445
Fax: 618-667-1982
Email: sales@lifelinesneuro.com
Website: www.lifelinesneuro.com
Cloud-based technology is the next step in
the evolution of EEG, and LifeLines
Neurodiagnostic Systems is leading the
industry with innovative, new products. iEEG
Cloud is a complete, home video solution.
Record and upload the EEG/video data to the
Cloud for review over the Internet in near-
real time. We maintain servers with our
how EEG is evolving!
Lundbeck
Booth #405, 511
Four Parkway North
Deerfield IL 60015
Phone: 847-282-1000
Fax: 847-282-1001
Email: lerr@lundbeck.com
Website: www.lundbeck.com/us
Contact: Ms. Lisa Berry
Headquartered in Deerfield, Illinois, with a
portfolio specialty central nervous system
(CNS) therapies and a robust pipeline of
promising CNS compounds, Lundbeck is
committed to providing innovative therapies
that fulfill unmet medical needs of people
with CNS disorders, including rare diseases,
for which few, if any, effective treatments
are available.
Mallinckrodt Pharmaceuticals
Booth #217, 316
26118 Research Rd
Hayward CA 94545
Phone: 510-400-0721
Fax: 510-400-0710
Email: jt.thomas@mallinckrodt.com
Website: www.mallinckrodt.com/ard
Contact: J.T. Thomas
Mallinckrodt is a global specialty
pharmaceutical and medical imaging business
that develops, manufactures, markets and
distributes specialty pharmaceutical
products and medical imaging agents. The
company's Specialty Pharmaceuticals
generic drugs and active pharmaceutical
ingredients, and a Global Medical Imaging
segment.

Medical Neurogenetics, LLC
Booth #216
5424 Glenridge Dr NE
Atlanta GA 30342
Phone: 678-225-0222
Fax: 678-225-0212
Website: www.mnglab.com
Contact: Juliann Kowalski
MNG provides expert diagnostics through
clinical services, biochemical testing and Next
Generation Sequencing. Our panels are the
most cost effective and comprehensive
available, particularly for cellular energetics,
muscular dystrophies, and epilepsy. A major
focus is to provide rapid sequencing
/metabolic diagnostics. Now available is an
Anticonvulsant-Resistant Epilepsy Rapid
Evaluation Kit.
MediKidz
Booth #232
21 West 46th St
New York City NY 10036
Phone: 718-808-5144
Email: ryanmulcock@medikidz.com
Website: www.medikidz.com
Contact: Ryan Mulcock
Medikidz is an exciting initiative in childrens
health education, which aims to provide
accurate and relevant medical information for
young people. Medikidz believes that every
child deserves access to medical information
they can understand. We are creating a
global community of young people that are
informed, empowered and health-aware.
Medtech Surgical
Booth #800
211 Warren St - Ste 306
Newark NJ 07103
Phone: 612-251-6698
Fax: 855-329-7672
Email: e.caille@medtechsurgical.com
Website: www.medtechsurgical.com
Contact: Mr. Eric Caille
ROSA is a FDA approved Neurosurgery
robot to offer a touchless Laser Registration
that has been in use for several years in
leading Epilepsy programs in North America
and abroad. With over 1600 procedures to
date ROSA is on the forefront of SEEG
Invasive monitoring. We offer a complete
program including training, case observations, Multi Channel Systems develop precision
consultation and innovative webinars and
referral programs.
Medtronic
Booth #932
8058 El Rio St
Houston TX 77054
Phone: 713-275-2063
Fax: 713-741-0122
Email: amarquette@visualaseinc.com
Website: www.visualaseinc.com
Contact: Mr. Andre Marquette
The Visualase Thermal Therapy System is an
MRI-guided, minimally invasive laser ablation
system which allows for continuous
monitoring of an ablation in real-time. The
system is FDA-cleared for the ablation of
EXHIBITORS
soft tissue, including for use in neurosurgical
procedures. More than 45 U.S. centers have
performed more than 900 neurosurgical
cases.
Moberg Research
Booth #239
224 S Maple Way
Ambler PA 19002
Phone: 215-283-0860
Fax: 215-283-0859
Email: kfitzgerald@moberg.com
Website: www.moberg.com
Contact: Ms. Kathleen Fitzgerald
The Moberg CNS Monitor continuously
records EEG and processed EEG trends,
time-synchronized with other physiology.
Multimodal monitoring with integrated video,
EEG trends and physiology helps you evaluate
patients' neurological statuses. View
correlations between EEG and parameters
from other devices including vital signs, ICP,
brain oxygen, cerebral blood flow, and more.
Monteris Medical
Booth #905
16305 36th Ave N - Ste 200
Plymouth MN 55446
Phone: 719-487-9558
Fax: 763-746-0084
Email: marketing@monteris.com
Website: www.monteris.com
Contact: Ms. Lisa Bichsel
Monteris Medical manufactures minimally-
invasive devices for MR-guided neurosurgery
including: The NeuroBlate System for precise
controlled laser ablation therapy of epilepsy
and brain lesion targets; AxiiiS Stereotactic
Miniframe skull-mounted platform for image-
guided trajectory alignment; AtamA System,
an MR-compatible transport and head
stabilization system.
Multi Channel Systems
Booth #300
60 Marine St
Farmingdale NY 11763
Phone: 631-393-6401
Fax: 631-393-6407
Email: margaret@alascience.com
Website: www.multichannelsystems.com
Contact: Ms. Margaret Badon
scientific measuring instrumentation &
equipment for research groups at universities
& the pharmaceutical industry, in the field of
electrophysiology. We provide solutions for
extracellular recordings with microelectrode
arrays in vitro & in vivo with the MEA-System
& the ME-System as well as for electrical
stimulation with the STG series.
National Association of Epilepsy Centers
Booth #723
600 Maryland Ave SW - Ste 835W
Washington DC 20024
Phone: 202-524-6767
Email: jgray@dc-crd.com
Website: www.naec-epilepsy.org
Contact: Ms. Johanna Gray
The National Association of Epilepsy Centers
is a non-profit 501(c)(6) trade association
with a membership of more than 210
specialized epilepsy centers in the United
States. With the goal of no seizures and no
side effects, NAEC strives to make high
quality healthcare available to and affordable
for epilepsy patients across the country.
National Institute of Neurological
Disorders & Stroke (NINDS)
Booth #725
31 Center Dr - Bldg 31 - Rm 8A07
Bethesda MD 20892-2540
Phone: 301-496-5751
Fax: 301-402-2186
Email: frazinn@ninds.nih.gov
Website: www.ninds.nih.gov
Contact: Ms. Natalie Frazin
The National Institute of Neurological
Disorders and Stroke (NINDS) supports
basic, translational, and patient-oriented
research on epilepsy prevention, diagnosis
and treatment, including mechanisms
underlying seizures and epileptogenesis,
gene discovery and targeted therapeutics,
epidemiology, psychosocial and behavioral
consequences, and development of new
therapies. Free patient information.
Natus Neurology Incorporated
Booth #705
3150 Pleasant View Road
Middleton WI 53562
Phone: 608-829-8500
Fax: 847-949-8615
Email: madison.info@natus.com
Website: www.natus.com
Neuralynx, Inc
Booth #713
105 Commercial Dr
Bozeman MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: sales@neuralynx.com
Website: www.neuralynx.com
Contact: Ms. Kathy Walsh
Neuralynx ATLAS systems record the entire
range of human electrophysiology from
surface EEG to single units via micro-wires.
Features include DC capability, flexible
referencing, and 40 KHz acquisition across
all channels. ATLAS provides complete
integration with Nihon Kohden EEG systems
for a seamless clinical workflow. This
functionality makes ATLAS the logical choice
EXHIBITORS
for clinical research.
Neurology Reviews
Booth #101
7 Century Dr - Ste 302
Parsippany NJ 07054
Phone: 973-290-8228
Fax: 973-206-9178
Email: lkalish@frontlinemedcom.com
Website: www.frontlinemedcom.com
Contact: Ms. Lynne Kalish
89

NEUROLOGY REVIEWS is a clinical news
publication with articles and timely
department features that keep neurologists,
primary care physicians, and other healthcare
professionals informed of the latest news
affecting their practice. NEUROLOGY
REVIEWS covers major medical conferences
and monitors the peer review literature to
report the latest research findings.
NeuroPace, Inc.
Booth #824
455 N. Bernardo Ave
Mountain View CA 94043
Phone: 650-237-2700
Fax: 650-237-2701
Email: info@neuropace.com
Website: www.neuropace.com
Contact: Ms. Kathy Miller
NeuroPace, Inc. develops and produces
medical device solutions for the treatment of
neurological disorders. NeuroPace, Inc. has
FDA approval for the RNS System, the
worlds first and only neurostimulator that
provides targeted, responsive therapy for
patients with medically refractory epilepsy.
NeuroQuest LLC
Booth #834
S75 W17317 Janesville Rd
Muskego WI 53150
Phone: 262-679-7100
Fax: 855-777-8378
Email: mgersonde@neuroquestllc.com
Website: www.neuroquestllc.com
Contact: Ms. Mindy Gersonde
There's no place like home to have your
EEG(SM), especially since we make house
calls. NeuroQuest LLC is the premiere
provider of extended ambulatory video EEGs.
Our technologists travel into your patient's
home, a clinic, office or institution to meet
the goal of providing the highest quality, most
convenient, cost-effective EEGs.
Neurotech
Booth #610
15285 Watertown Plank Rd Ste 2
Elm Grove WI 53122
Phone: 262-754-0895
Email: vwolfe@neurotecheeg.com
Website: www.neurotecheeg.com
Contact: Vickie Wolfe
Neurotech EEG Telemedicine In Home Tests,
24/7 Remote Monitoring Neurotech
provides 24+ hour EEG tests to diagnose
seizures. With prompt scheduling,
technologists hookup patients in their homes.
R EEG T remotely monitors patients
continuously, any problems resolved by
technologist returning to patient if
necessary; ensuring quality test results.
Physicians have live online access to data.
90
EXHIBITORS
Nexstim
Booth #119
1360 Union Hill Rd Ste 5B
Alpharetta GA 30004
Phone: 770-664-1000
Website: www.nexstim.com
Contact: Sydney Bridger
Nexstims Navigated Brain Stimulation (NBS)
System integrates TMS, EMG, & MRI guided
navigation to noninvasively map the motor
cortex with the accuracy of DCS. Nexstim
holds FDA clearances for (NBS) Pre-
Procedural Planning and (NexSpeech) for
Mapping Language Function. Future FDA
applications: Stroke Rehabilitation*,
Depression, and TBI. *currently in clinical
trials.
Nihon Kohden America, Inc.
Booth #617
15353 Barranca Pkwy
Irvine CA 92618
Phone: 949-580-1555
Fax: 949-580-1550
Email: jeannie_callahan@nkusa.com
Website: www.nkusa.com
Contact: Ms. Jeannie Callahan
For over 60 years Nihon Kohden has been
the trusted Neurology solution for Epilepsy
Monitoring, Electroencephalography, EEG &
PSG Wireless & Ambulatory Recording,
Polysomnography, Out of Center Sleep
Testing/PSG, Electromyography, Evoked
Potentials, Intra-operative and cEEG ICU
monitoring. Serving the Best Minds in
Neurology for Over Sixty Years.
Novartis Pharmaceuticals
Booth #137
One Health Plaza
East Hanover NJ 07936
Phone: 862-778-2159
Website: www.novartisoncology.com
Contact: Marianne LaRosa
Novartis Oncology has emerged as a global
leader in oncology through targeted research
and open partnership in the pursuit of new
therapies capable of transforming outcomes
for people with cancer. Our research is driven
by a distinctive scientific and clinical strategy,
focusing on unmet medical needs and disease
pathways.
Optima Neuroscience, Inc.
Booth #833
11930 Research Circle
Alachua FL 32615
Phone: 386-462-9622
Fax: 386-462-5365
Email: rrojas@tdt.com
Website: www.optimaneuro.com
Optima Neuroscience is a medical device
company developing innovative technologies
for the diagnosis and treatment of
neurological disorders. Optima's initial
product lines feature neurological status
monitoring technologies designed to directly
address these needs.
Oxford University Press
Booth #219
198 Madison Ave
New York NY 10016
Phone: 212-726-6000
Fax: 212-726-6494
Email: meagan.burnett@oup.com
Website: www.oup.com/us
Contact: Ms. Meagan Burnett
PCDH19 Alliance
Booth #7
6 Wisteria Ct
Novato CA 94945
Phone: 415-892-5794
Email: julie@pcdh19info.org
Website: www.pcdh19info.org
Contact: Ms. Julie Walters
The PCDH19 Alliance focuses on raising and
directing funds to scientific research with the
goal of finding better, more effective
treatments and, ultimately, a cure; providing
information and support to affected families;
and assisting the efforts of the medical
community, so that no family suffers without
a diagnosis and the most appropriate medical
treatment.
Persyst Development Corporation
Booth #925
12625 High Bluff Dr - Ste 213
San Diego CA 92130
Phone: 858-461-4542
Fax: 858-461-4531
Email: sales@persyst.com
Website: www.persyst.com
For more than twenty years Persyst has
produced the most trusted and innovative
EEG analysis products. Today, Persyst is the
worlds leading supplier of artifact reduction,
seizure detection, spike detection, and
quantitative analysis software to every
leading EEG manufacturer for continuous EEG
monitoring, LTM and ambulatory EEG.
Physicians Insurance
Booth #220
1301 Second Ave Ste 2700
Seattle WA 98101
Phone: 206-343-7300
Fax: 206-343-7100
Email: Liz@phyins.com
Website: www.phyins.com
Contact: Catherine Kunkel
Physicians Insurance A Mutual Company is
the largest medical professional liability
insurance company in the Northwest, with
7,000 members in Oregon, Washington,
Idaho, and Wyoming. Owned and operated by
its insured physicians and clinics, Physicians
Insurance offers broad protection at a
reasonable cost, focusing on patient safety
and claims management.

Pinnacle Technology, Inc.
Booth #737
2721 Oregon St
Lawrence KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Email: llane@pinnaclet.com
Website: www.pinnaclet.com
Contact: Ms. Linda Lane
Pinnacle provides preclinical research tools.
New this year is optogenetics technology
integrated into our seizure monitoring
systems. Biosensors can be added to the
core EEG/EMG units to measure
neurotransmitters along with seizure activity.
Our analysis software finds, identifies, marks
and analyzes seizure events. Synchronized
video and precision timing can be added to
any system.
PMT Corporation
Booth #606
1500 Park Rd
Chanhassen MN 55317
Phone: 952-470-0866
Fax: 952-470-0865
Email: abammert@pmtcorp.com
Website: www.pmtcorp.com
Contact: Ms. Amanda Bammert
PMT Corporation is the premier supplier of an software is cross platform, and can be run
extensive line of neurosurgical products,
offering Cortac, cortical surface electrodes,
Depthalon, depth electrodes and sEEG depth Rogue Research Inc.
electrodes for epilepsy monitoring and
microsurgical instruments. PMT also offers
high-end neck braces, including halo systems Montreal QC H2W 1Z5 Canada
and orthotic vests for cervical, thoracic and Phone: 514-284-3888
lumbar spinal immobilization.
PreventionGenetics
Booth #902
3800 South Business Park Ave
Marshfield WI 54449
Phone: 715-387-0484
Email: danielle.krohn@preventiongenetics.com
Website: www.preventiongenetics.com
Contact: Danielle Krohn
PreventionGenetics is a leader in providing
comprehensive clinical DNA testing offering
NextGen Sequencing, Sanger sequencing and
deletion/duplication testing via array CGH for
over 1000 genes. Our highly experienced
team of geneticists provide fast turnaround
times, outstanding personalized service, and
the highest quality testing at the lowest
prices possible. We are CLIA/CAP accredited.
Rhythmlink International, LLC
Booth #721
1140 First St S
Columbia SC 29202
Phone: 816-429-5931
Fax: 803-252-1111
Email: gbutler@rhythmlink.com
Website: www.rhythmlink.com
Contact: Mr. Garrett Butler
Rhythmlink International is a medical device
manufacturing company specializing in devices
that help connect patients to machines to
record or elicit physiologic information.
EXHIBITORS
Rhythmlink offers an array of monitoring
devices including the first and only FDA
cleared disposable MR Conditional EEG
products on the market.
Ring14 USA Outreach
Booth #12
4313 Wood Dr.
Midland TX 79707
Phone: 765-491-6910
Email: yssa@ring14usa.org
Website: www.ring14usa.org
Contact: Yssa DeWoody
Ripple LLC
Booth #724
2015 S 1100 E
Salt Lake City UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Email: mitch@rppl.com
Website: www.rppl.com
Contact: Mr. Mitch Frankel
Ripple provides high performance
electrophysiology data acquisition systems
for neuromuscular recording and stimulation.
Our systems are compact, portable, and
heavily optimized for real-time, closed-loop
control applications with up to 512 channels
of EMG, EEG and microelectrode data. Our
on Windows, Mac OS X, and Linux.
Booth #900
4398 St-Laurent Ste 206
Fax: 514-284-6750
Email: diane@rogue-research.com
Website: www.rogue-research.com
Contact: Mrs. Diane Gariepy
Rogue Research develops the Brainsight
family of neuronavigation products, including
Brainsight TMS, the first and most popular
neuronavigation system designed specifically
for TMS. Brainsight NIRS is a unique fNIRS
system designed specifically for multimodality Contact: Ms. Tamzin Jeffs
applications, allowing fNIRS acquisition during
TMS and simultaneous fNIRS acquisition along SUDEP Aware is a not-for-profit organization
with EEG, fMRI or MEG.
RosmanSearch, Inc.
Booth #726
30799 Pinetree Rd Ste 250
Pepper Pike OH 44124
Phone: 216-287-2302
Fax: 216-803-6672
Email: bdery@rosmansearch.com
Website: www.rosmansearch.com
Contact: Mrs. Beth Dery
RosmanSearch is a dual-specialty, truly
expert, high integrity neurosurgical and
neurology recruiting service you can trust.
We specialize exclusively in neurosciences
permanent placement, and our recruitment
methodology is data driven and unique in the
industry.
SeizureTracker.com
Booth #21
PO Box 10738
Alexandria VA 22310
Phone: 703-339-8448
Fax: 703-339-8430
Email: rob@seizuretracker.com
Website: www.seizuretracker.com
Contact: Mr. Robert Moss
Seizure Tracker provides free tools to help
patients and doctors better understand
seizure activity and surrounding treatments.
The site provides patients with resources to
log their seizures along with medication, diet,
VNS settings and much more. Reports
generated on SeizureTracker.com include
graphs that illustrate trending in treatment
efficacy and can be easily shared with care
providers.
Smart Monitor Corp.
Booth #917
6203 San Ignacio Ave #112
San Jose CA 95119
Phone: 408-505-1976
Fax: 408-351-0154
Email: sheri.becker@smart-monitor.com
Website: www.smart-monitor.com
Contact: Ms. Sheri Becker
Smart Monitor provides monitoring solutions
for people with chronic health conditions.
Founded in 2009 and headquartered in San
Jose, CA, Smart Monitor fuses together
sensor, mobile and cloud technologies with
big-data analytics in a seamless environment.
Our patent protected solutions foster
autonomy and enhance safety,while offering
significant peace-of mind to their families and
care providers.
SUDEP Aware
Booth #20
283 Danforth Ave Ste 350
Toronto ON M4K 1N2 Canada
Phone: 416-556-8770
Email: tcjeffs@gmail.com
Website: www.sudepaware.org
that has worked since 2007 to bring more
awareness and better understanding to
Sudden Unexpected Death in EPilepsy
(SUDEP). It provides support to families and
researchers through its co-founder
partnership between Dr Elizabeth Donner
(Pediatric Neurologist at Sick Kids Hospital,
EXHIBITORS
Toronto) & Tamzin Jeffs (who has epilepsy
and lost her sister to SUDEP).
Sunovion Pharmaceuticals Inc.
Booth #105
84 Waterford Dr
Marlborough MA 01752
Phone: 508-481-6700
Fax: 508-357-7490
Email: susan.mahoney@sunovion.com
Website: www.sunovion.com
Contact: Ms. Susan Mahoney
91

Sunovion is a leading pharmaceutical company
dedicated to discovering, developing and
commercializing therapeutic products that
advance the science of medicine in the
Psychiatry, Neurology and Respiratory
disease areas and improve the lives of
patients and their families. Sunovion is a
subsidiary of Sumitomo Dianippon Pharma
Co., Ltd.
Supernus Pharmaceuticals, Inc.
Booth #605
1550 E Gude Dr
Rockville MD 20850
Phone: 301-838-2500
Email: tconner@supernus.com
Website: www.supernuspharma.com
Contact: Mr. Tilton Conner
Supernus Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on
developing and commercializing products for
the treatment of CNS diseases. The company
has two marketed products for epilepsy,
Oxtellar XR (oxcarbazepine) extended-
release tablets and Trokendi XR (topiramate)
extended-release capsules.
Texas Childrens Hospital
Booth #201
1919 S Braeswood Ste 6226
Houston TX 77030
Phone: 832-824-2143
Fax: 832-825-2624
Email: kcwilkin@texaschildrens.org
Website: www.texaschildrens.org
Contact: Ms. Karen Wilkinson
The Neuroscience Center at Texas Childrens
Hospital, located in Houston, Texas is
committed to creating a healthier future for
children and women by leading in patient
care, education and research. Utilizing
Neurology, Neurosurgery and the Jan and Dan
Duncan Neurological Research Institute, we
are able to identify, monitor and surgically
correct the full continuum of neurological
conditions.
Transgenomic, Inc.
Booth #801
12325 Emmet St
Omaha NE 68164
Phone: 402-452-5400
Fax: 402-452-5401
Email: sstremick@transgenomic.com
Website: www.transgenomic.com
Contact: Mr. Scott Stremick
Transgenomic, Inc. specializes in genetic
testing for cardiology (FAMILION), neurology,
mitochondrial disorders and oncology.
Transgenomic develops assays and offers
testing with the goal to overall improve
medical diagnosis and outcomes for patients.
92
EXHIBITORS
Triangle BioSystems, Inc.
Booth #735
2224 Page Rd Ste 108
Durham NC 27703
Phone: 919-361-2663
Fax: 919-544-3061
Email: jmorizio@trianglebiosystems.com
Website: www.trianglebiosystems.com
Contact: Mr. James Morizio
Miniaturized stimulation and recording
solutions for rodent and other animal models.
Wireless Stim headstage (2-16ch). Recording
headstages for single unit, EEG and other
signals: tethered, multiplexed or signature
wireless headstages (5128Ch). Software:
Neuroware acquisition, Optimap video
tracking, StimWare. Custom
electrophysiology engineering solutions.
Tuberous Sclerosis Alliance
Booth #22
801 Roeder Rd Ste 750
Silver Spring MD 20910-4467
Phone: 301-562-9890
Fax: 301-562-9870
Email: info@tsalliance.org
Website: www.tsalliance.org
Contact: Ms. Katie Smith
Founded in 1974, the TS Alliance is the only
national voluntary health agency dedicated to
finding a cure for TSC, while improving the
lives of those affected. TSC is a genetic
disorder characterized by seizures and tumor
growth in vital organs such as the brain,
heart, kidneys, lungs and skin.
UCB, Inc.
Booth #135, 205
1950 Lake Park Dr
Smyrna GA 30080
Phone: 770-970-7500
Fax: 770-970-8917
Email: dave.tappan@ucb.com
Website: www.ucb-group.com
Contact: Mr. Dave Tappan
At UCB, we have a passionate, long-term
commitment to discovering and developing
innovative medicines that transform the lives
of people living with severe immunological
diseases and central nervous system
disorders. With 8,500 employees in 40
countries, we invest more than 25% of
revenue in cutting-edge scientific research
to meet unmet patient needs.
UCSF Medical Center
Booth #913
3360 Geary Blvd Ste 301
San Francisco CA 94118
Phone: 415-353-7703
Email: Cheryl.Hardin@ucsfmedctr.org
Website: jobs.ucsfmedicalcenter.org
Contact: Cheryl Hardin
If you are looking to take your career in the
END field to the next level then UCSF Medical
Center Neurodiagnostics Program is for you!
UCSF has one of the largest, most
comprehensive epilepsy surgery programs
in the western United States.
Upsher-Smith Laboratories, Inc
Booth #625, 823
6701 Evenstad Dr
Maple Grove MN 55369
Phone: 763-315-2000
Fax: 763-315-2244
Email: becky.bouley@upsher-smith.com
Website: www.upsher-smith.com
Contact: Ms. Becky Bouley
Upsher-Smith Laboratories, Inc., founded in
1919, is a growing pharmaceutical company
dedicated to its mission of Advancing
Pharmacotherapy. Improving Life. With
capabilities ranging from early-stage research
to delivering on-market products, Upsher-
Smith is committed to developing quality
products that enable people to live life to its
greatest potential.
Vitaflo USA
Booth #117
316 Montgomery St
Alexandria VA 22314
Phone: 631-897-6939
Email: katrina.bellan@vitaflousa.com
Website: www.vitaflousa.com
Contact: Ms. Katrina Bellan
Vitaflo is at the forefront of developing
innovative specialized medical foods for
Metabolic Disorders, Nutrition Support and
other areas of disease specific nutrition. Our
aim is to create nutritional products that
combine the best of cutting edge research
with the lifestyle demands of modern living,
ensuring the most acceptable products are
available for the patient.
Wiley
Booth #818
111 River Street
Hoboken NJ 07030
Phone: 201-748-6000
Fax: 201-748-6617
Email: info@wiley.com
Website: www.wiley.com
Wiley is the leading society publisher. We
publish on behalf of more societies and
membership associations than anybody else,
and offer libraries and individuals 1,250 online
journals, thousands of books and e-books,
reviews, reference works, databases, and
more. For more information, or our online
resource: onlinelibrary.wiley.com.
Wolters Kluwer Health
Booth #400
Two Commerce Sq 2001 Market St
Philadelphia PA 19103
Phone: 215-521-8300
Fax: 215-521-8493
Email: customerservice@wolterskluwer.com
Website: www.lww.com
Contact: Ms. Joey-Rose Jester
Wolters Kluwer Health is a leading global
provider of information, business intelligence
and point-of-care solutions for the healthcare
industry. Clinicians rely on Wolters Kluwer
Healths market leading information-enabled
tools and software solutions throughout their
professional careers from training to
research to practice.
 ABSTRACT AUTHOR INDEX

A Alegre, M. 2.153 Appavu, B. 2.127 Bakaki, P. 2.052, 2.090

Aaberg, K. 2.072 Alencar, C.N. 3.179 Appleton, R. 1.109 Baker, D. 1.140
Abbott, D. 3.287 Alessi, R. 2.259, 2.260, 3.179 Aracri, P. 1.108 Baker, E. 1.184
Abdel-Latief, O. 1.066 Alexandre, F.P. 1.086 Arai, H. 1.116, 1.363, 1.370, 2.132, Baker, M. 1.327
AbdeleRahman, K. 3.171 Alexandre, V. 2.226 3.012 Baker, S. 1.043
Abdulkadir, Y. 3.340 Alexopoulos, A. 1.040, 1.144, 1.149, Arain, A. 1.327, 2.117, 3.252 Bakken, I. 2.072
Abel, T.J. 1.079 1.240, 2.249, 3.359 Arain, F. 3.015 Bal, C. 2.365
Abela, E. 2.244 Alhadid, K. 3.200 Arakawa, Y. 1.350, 2.335 Balabanov, A. 2.037, 2.205
Abend, N. 1.136, 1.182, B.06 Alhashem, A. 1.104 Araujo, P. 3.260 Balaguera, P. 2.241
Abibullaev, B. 1.130 Alhusaini, S. 1.248 Archer, J. 3.092, 3.287 Baldeweg, T. 1.190
Abisogun, A. 2.246 Ali, A. 2.095 Ardini, M. 3.141, 3.144 Baldin, E. 3.140
Abosch, A. 3.190 Ali, I. 1.321, 3.079 Arican, N. 1.053 Balena, T. 1.021, 3.023
Abou-Khalil, B. 1.186, 1.280, 1.321, Ali, N. 1.239, 2.106 Arita, K. 1.265, 2.002 Balestri, M. 2.146
1.327, 1.338, 2.117, 2.242, 3.152 Ali, W. 3.061 Arkilo, D. 1.123 Ball, T. 1.167
Abramovici, S. 2.157 Alio Saenz, A. 2.318, 2.324 Armbruster, M. 3.125 Ballaban-Gil, K. 2.061
Abramson, E.L. 2.043 Alkawadri, R. 1.156 Armstrong, C. C.03 Bamps, Y. 3.075, 3.078, 3.085, 3.127
Abtahi, M. 3.073 Allard, L. 2.239 Arndt, D. 1.182, A.09 Bandt, S. 1.376
Abu Abthan, M. 1.223 Allen, A. 2.095 Arnedo, V. 1.085 Bandyopadhyay, S. 3.252
Abubakr, A. 1.183 Allen, B.B. 3.155 Arnett, A. 1.090, 1.091 Bang, H. 3.112
Acevedo, K. 3.101 Allen, V. 1.267 Arnold, S.T. 2.088 Banks, G. 1.057
Aceves, J. 1.341 Allendorfer, J. 1.236, 1.257, B.09 Arrigoni, E. 1.162 Bar Yossef, R. 2.175, 3.197
Ackley, M. 1.296, 1.303 Almane, D. 2.023 Arruda, F.J. 2.274, 3.199 Baraban, S. C.05
Acton, E. 3.208, 3.238 Almualim, M. 3.225 Arya, R. 1.353, B.06 Baram, T. 1.009,
Adams, E. 1.094, 2.021, 2.270 Almutairi, F. 1.104 Arzimanoglou, A. 2.263, 2.277 Barba, C. 1.348
Adeleye, A. 3.172 Alonso-Vanegas, M. 2.186, 2.334, Asadi-Pooya, A. 1.311 Barber, A. 2.301
Adhami, S. 2.196 3.154 Asano, E. 1.251, 2.345, 3.062, 3.362 Barber, J. 2.039
Adjouadi, M. 3.192 Alqadi, K. 2.172 Ashby-Lumsden, A. 3.036 Barborica, A. 1.191, 3.069
Adkins, A. 1.066 Alsaadi, T. 2.086 Asratyan, S. 2.076 Barbosa-Nunez, C. 1.294
Afawi, Z. 3.090 Alshafai, L. 1.189 Assaad, B. 1.151, 2.215 Barcia, G. 3.016
Afra, P. 1.068 Althaus, A.L. 3.005 Ates, N. 1.053 Barisic, N. 1.107, 1.118
Agadi, S. 1.215, 1.341 Altura, C. 1.285 Atherton, D. 2.070 Barker-Haliski, M. 1.050
Agan, K. 3.151 Alvarez, V. 3.203, 3.226 Athing, U. 2.121 Barkley, G.L. 1.151, 2.212, 2.215
Agarwal, M. 1.275 Aly, R. 2.066 Atsumi, S. 2.202 Barnard, M.E. 1.154
Agarwal, N. 1.144, 3.359 Amador, A. 2.222 Auerbach, D.S. 3.132 Barnes, D. 2.058
Agarwal, R. 3.362 Amaro, P. 2.153 Auguste, K.I. 1.369 Barnett, J. B.07
Agee, B. 2.338, 3.348 Amina, S. 2.126 Aung, T. 2.109, 2.140 Barnett, P. 1.255, 2.237
Agha, C. 2.066 Amiri, M. 1.171 Aungaroon, G. 3.247 Barrett, K. 1.025, 3.019
Agha-Khani, Y. 2.198 Amrom, D. 1.121, 3.097 Auvin, S. 1.055, 1.056, 2.263 Barrios, E. 3.065
Aghakhani, Y. 1.264, 2.067, 2.150, An, D. 3.285 Avallone, J. 1.133 Barritt, S.E. 1.278
3.139, 3.186 An, S. 2.035, A.05 Avedian, L. 3.250 Barth, D. 3.038, 3.047
Agostini, M. 2.038, 2.189, 2.193, Anastassopoulos, K.P. 1.273, 1.287 Avoli, M. 1.301, 3.121, 3.184 Bartha, R. 3.265, 3.277
3.083 Andermann, E. 1.121, 1.317, 1.319, Ayasoufi, K. 1.008 Bartley, M.L. 3.286
Agostini, S. 2.166 3.097 Azar, N. 1.187, 1.327, 2.160, 3.252 Bartolomei, F. 1.377, 2.226, 3.182
Agrawal, S. 2.041 Andermann, F. 1.121, 3.097 Azarion, A. 2.301 Basha, M. 2.214, 3.266
Aguado Valcrcel, M. 2.300 Anders, B. 1.307, 1.308, 2.280, Azuma, J. 1.116
2.281, 2.284 Baslet, G. 2.236
Ahishali, B. 1.053 Azuma, Y. 1.224, 1.235, 1.243 Bastar, J. 1.161
Ahmadi, L. 3.229 Anderson, A. 1.139, 3.048, 3.049,
3.050, 3.061 Azzam, R. 1.280, 2.117 Basu, I. 1.064
Ahmed, I. 3.079 Basu, R. B.06
Anderson, C. 3.208
Ahmed, O.J. 1.018 B Bateman, L. 1.057, 3.213
ABSTRACT AUTHOR INDEX
Anderson, C.T. A.08
Ajetunmobi, O. 3.129 Baba, H. 1.359, 1.361, 1.365 Bates, J. 2.059
Anderson, M. 1.290
Akasaka, N. 1.116 Baba, K. 1.365 Bathena, S. 3.317
Anderson, W. 1.045, 1.061, 2.025
Akdag, G. 3.305 Baba, S. 1.127, 1.145, 2.353, 3.108 Battaglia, G. 3.029
Anderson, W.S. 1.064
Akiyama, M. 1.172 Babiarz, K. 2.085 Baudry, M. 1.039
Ando, N. 1.224, 1.243
Akiyama, T. 1.172 Baboyan, V. 3.060 Bauer, G. 2.068
Ando, T. 1.079
Akman, C. 3.233 Babtain, F. 1.223 Baulac, M. 3.296
Andrade, D. 1.112, 2.095
Akman, C.I. 3.140 Bachman, E. 1.188, 3.218 Baumer, F. 2.124
Andrade, E. 2.261
Al Ghamdi, S. 1.223 Backofen-Wehrhahn, B. 1.069 Baumgartner, J. 1.179, 2.014, 2.248,
Andrade, J.Q. 3.179
Al Jarrah, S.A. 2.001 Bacskai, B. 1.021, 3.004 2.253, 2.255, 2.348, 2.364, 3.276
Andreas, J. 2.283, 3.290
Al Matrooshi, N.O. 2.086 Badesch, B. 1.267 Bautista, J. 2.273
Andrews, J. 1.164
Al matrooshi, N.O. 2.106 Bagliella, E. 2.233 Baxter, R. 1.194
Andrews, M. 3.132
Al-Baradie, R.S. 3.234 Bagnall, R.D. 3.088 Baykan, B. 1.128, 2.183
Andriola, M. 1.132, 1.142, 2.162
Alagapan, S. 1.159 Bahlo, M. 3.100 Baykan, B. 2.224
Ang, L. 3.109
Alam, J. 3.289 Bai, X. B.01 Baykara, Y. 1.076
Anghelina, E. 3.220
Alareddy, A. 1.062 Bailey, L. 2.022, 2.250 Bayly, M.A. 3.089
Anschel, D. 3.154
Albert, J. 2.052 Bailey, M. 3.224 Baysal Kirac, L. 1.128
Antony, A. 1.073
Alberts, G. 2.016 Bain, S. C.07 Bazil, C. 2.209, 2.212
Aoki, M. 2.149
Aldenkamp, A. 2.018 Bainbridge, J. 3.304

93
 ABSTRACT AUTHOR INDEX

Bazzigaluppi, P. 1.016, 3.008 Bhatia, P. 2.092 Boyer, K. 2.017, 3.169 Burgess, R. 1.063, 1.144, 1.149,
Beal, J.C. 2.061 Bickel, S. 1.157, 2.246, 3.177, 3.346 Boyle, M. 1.100 1.240, 2.073, 3.359
Beatty, C. 3.245 Bienes, G. 2.327 Bozarth, X. 3.099 Burgos, J. 1.333
Beaulieu, C. 3.259, 3.260, 3.261 Bilir, E. 1.207 Bozorg, A. 2.360, 2.361 Burianov, H. 3.281
Bebek, N. 1.128, 2.183, 2.224 Binder, D. 2.238, 3.119 Braesch, C.T. 1.278 Burkholder, D. 1.374, 3.158
Becchetti, A. 1.108 Bingaman, W. 1.058, 1.093, 1.099, Bragin, A. 1.177 Burn, S. 1.109
Bechstedt, S. 1.121 1.240, 1.347, 1.362, 1.377 Bramhall, M. 2.115 Burneo, J.G. 1.185, 2.032, 2.054,
Becker, D. 2.007 Biraben, A. 1.317, 2.226 Brand, E. 3.302, A.08 2.313, 3.265, 3.277
Beers, C. 1.264 Birk, N. 3.068 Brandt, C. 2.059, 3.293 Burns, M. 2.308
Begley, C. 2.009, 2.047, 3.078 Birnbaum, A. 1.272, 3.317 Braun, C.N. 3.040 Burns, S. 1.061
Behr, C. 1.301, 3.121 Birney, K.A. 2.042 Brazdil, M. 2.003 Buroker, J. 1.353
Beimer, N.J. 2.030 Bishara, A. 3.063 Brennan, G.P. 1.009 Busatto, G. 3.076
Belfort, G. 1.296, 1.303 Bishop, L. 3.224 Brenton, J.N. 3.147 Busch, R.M. 1.093, 1.099, 1.347
Bell, A.J. 2.144 Biton, V. 2.278, 2.292 Brenton, N. B.06 Butler, C. 1.027
Bellas, P. 3.309 Blatt, I. 1.307, 1.308, 2.280, 2.281, Brewster, A. 3.048, 3.049, 3.050 Byars, A.W. 1.353
Bello, L. 1.132, 1.142, 3.240 3.090, 3.197 Brewster, R. 3.344 Byerman, B. 1.066
Bello-Espinosa, L. 1.360, 3.102 Bleasel, A. 3.286 Brickel, N. 2.318 Byrne, R.W. 2.241
Belousova, E. 2.187 Blezin, F. 2.064 Briggs, D. 2.131, 3.070 Byrnes, W. 2.320, 3.295, 3.296,
Block, S.C. 1.186 3.298, 3.299
Beltramini, G.C. 3.259, 3.260 Brima, T. 1.305
Blum, D. 1.273, 1.287, 1.312, 1.314, Byun, J. 2.168, 3.196
Ben Hur, T. 2.175, 3.063 Brinkmann, B. 1.175, 2.156, 3.071
1.315, 1.316, 1.317, 1.318, 1.319, Bzymek, K. 1.017
Ben Salem, Z. 1.051 1.320, 1.321, 1.322, 1.323, 1.342, Brittain, S.T. 1.337, 1.343, 2.329,
Ben-Menachem, E. 2.278 2.278, 2.290, 2.292 2.331
Britton, J. 1.374, 3.158, B.05 C
Benbadis, S. 1.101, 1.315, 1.317, Blumberg, J. 2.180
1.322, 1.340, 2.360, 2.361, 3.304 Brock, M. 3.291, 3.292, 3.299 Cabello, D. 2.360
Blumcke, I. 1.346 Cabo Lpez, I. 2.300
Bendrups, N. 1.279 Blume, H. 3.245 Brodie, M. 1.331, 1.334, 1.335,
Benedik, M. 2.187 1.336 Caboclo, L. 3.332, 3.369, 3.374
Blumenfeld, H. 1.044, 1.062, 1.076, Cabrera Kang, C.M. 3.203, 3.226
Beniczky, S. 1.118 1.164, A.02, B.01, Brodtkorb, E. 2.282
Benifla, M. 2.175 Brooks, B. 2.271 Cabrerizo, M. 3.192
Blumenfeld, J. 1.076
Benites, D. 3.070 Brooks-Kayal, A. 1.003, 3.003, 3.011, Caetano, E.V. 2.119, 3.143
Blumenthal, H. 2.022
Benke, T. 3.209 3.031 Cai, P. A.08
Bluvstein, J. 2.309, 3.303
Bennett, M. 3.224 Brosch, M. 3.045 Cakmak, M. 2.129
Boada, R. 2.012
Bennett, O. 2.175 Brouhard, G. 1.121 Caller, T. 1.086, 1.286, 2.042
Boals, A. 2.022
Benninger, F. 3.197 Brown, E.C. 3.062 Calvert, S. 3.087
Boelman, C. 1.145, 1.172
Bensalem-Owen, M. 1.323, 2.136 Brown, M. 1.266 Calzado Rivas, E. 3.311
Bogaarts, G. 1.138
Bentz, J. 2.277 Brown, S. 1.209, 2.054 Cameron, D. 3.175
Boggs, J. 3.224, 3.367
Berberi, N. 2.170 Brunner, P. 2.248, 2.255, 3.276 Cameron, J. 1.073
Bolen, R. 3.224
Berdichevsky, Y. 2.328 Brusco, S. 1.108 Camfield, C. 1.203, 2.223, A.04
Boles, R. 3.094
Berg, A. 1.097, 1.206, 2.035, A.01, Bryant, T. 3.156 Camfield, P. 1.203, A.04
Bolger, P. 1.324, 2.285, 2.286, 2.287
A.02 Bubolz, B. 3.061 Campbell, M. 3.134
Bollu, V. 1.342, 2.044
Berg, K. 2.021, 2.270 Bubrick, E. 3.289 Campos, B.M. 3.275
Bolton, J. 2.143
Berg, M. 1.324, 2.285, 2.286, 2.287, Buchanan, G. 1.049, 1.164, 3.030, Campos Blance, D. 1.332, 3.309
Bonanni, P. 2.122
3.288 Buchanan, R. 3.070 Cances, C. 2.263
Bond, T.C. 1.273, 1.287
Berg, R. 1.182 Buchfelder, M. 1.146, 1.346 Candy, S.A. 3.124
Bonfert, M. 2.204
Bergey, G. 1.174, 1.216, 2.209, Buchhalter, J. 1.276, 3.057, 3.137, Canevini, M. 2.184, 3.243
3.189, 3.191 Bongardt, S. 3.294 3.172, 3.327 Canoll, P.D. 3.253
Bergin, A. 3.236, 3.325, 3.326, 3.334 Bonilha, L. 1.352, 2.004, 3.270 Buchsbaum, R. 2.296, 2.312, 3.138 Caplan, R. 1.097, 1.252, 1.254,
Bergo, F. 3.259, 3.260 Bonito, J. 2.350, 3.136 Buchtel, H. 2.030 2.018, 3.254
Berkeley, J. 2.200 Bonno, D.M. 1.125 Buckley, A. 3.166 Cappelletti, S. 3.360
Berkovic, S. 1.120, 3.088, 3.089, Boon, P. 1.017, 1.067, 3.028, C.08 Buckley, R. 3.368 Cara, L. 1.168
3.092, 3.095, 3.100 Bordey, A. 3.030 Buckley, S. 1.228 Carbone, L. 1.096
Berl, M. 2.019, 3.268, 3.272, 3.278 Borges, A.D. 3.165 Buckmaster, P. 1.014 Carlen, P. 1.010, 1.016, 3.008
Bermudez-Hernandez, K. 3.037 Borggraefe, I. 2.204 Budech, C.B. 1.241 Carlsen, J. 3.003, 3.031
Bernard, C. 3.182 Borghs, S. 2.219, 2.320, 3.295, Buelow, J. 3.075, 3.321 Carlson, C. 2.148
Bernardo,, D. 1.159 3.298
Buentjen, L. 3.045, 3.058, 3.349 Carlson, G. 1.075, 2.195
Bernasconi, A. 1.237, 1.244, B.04 Bork, S.J. 2.333
Buerki, S.E. 3.096 Carlson, H. 1.360
Bernasconi, N. 1.237, 1.244, B.04 Borlot, F. 1.112, 2.095
Bui, E. 2.232 Carmona, H. 2.363
Bernhardt, B. 1.237, 1.244, B.04 Borzello, M. 3.054
Bujarski, K. 1.246, 1.286, 2.042, Carpenter, J. 1.182, B.06
Berquin, P. 2.263, 2.277 Bosler Walton, C. 2.006 3.080 Carrel, A.J. 3.003
Berrios-Siervo, G. 2.012 Boudreau, E. 2.177, 2.269 Bukovskaya, Y. 2.322 Carrete Jr., H. 3.369
Bertram, E.H. 3.047 Bouthillier, A. 2.123, 3.274, 3.370 Bulacio, J. 1.063, 2.249 Carreo, M. 1.322, 2.278
Bertti, P. 3.055 Bowden, S.C. 1.279 Bulloch, A.G. 1.285, 2.071 CarrilloCarrillo, R. 2.186
Besag, F. 2.018 Bower, M. 2.156 Bunker, M.T. 1.375 Carruthers, N.J. 3.056
Besio, W. 3.073 Bower Baca, C. 1.357 Bunnenberg, A. 1.263 Carson, R.E. 2.332
Bessemer, R.A. 3.186 Bowman, C. 3.238 Burakgazi-Dalkilic, E. A.08 Carvalho, K. 3.251
Betting, L. 3.165 Bowyer, S. 1.151, 2.252 Burattini, J.A. 2.344, 3.372 Carvalho, K. 3.312
Betts, K. 1.342 Boychuk, J. 1.027 Burch, E.A. 2.088 Carver, C. 1.033
Bevot, A. 1.118 Boyd, A. 2.320 Burdette, D. 1.151 Carvill, G.L. 1.103, 3.087, 3.092
Bhatia, H. 1.223 Boyd, J. 3.306 Burgess, G.G. 2.333 Cascino, G. 2.256, 2.337, 2.339,
3.158
94
 ABSTRACT AUTHOR INDEX

Cash, S. 3.054 Chen, H. 1.013 Clark, A.M. 1.307, 1.308, 2.280, Crawford, P. 3.126
Cash, S.S. 1.018, 3.164 Chen, J.J. 1.286, 2.042 2.281, 2.284 Crawley, A. 3.200
Castelnau, P. 2.263 Chen, P. 1.179, 2.014, 2.248, 2.253, Clark, C. 2.033, 2.047 Crespel, A. 2.226
Castillo, A. 1.332 2.255, 3.276 Clark, D. 3.087 Crino, P. 3.302,
Castillo, E. 1.179, 2.014, 2.248, Chen, S. 1.242, 2.135, 3.197, 3.285 Clark, M. 3.050 Crino, P.B. A.08
2.253, 2.255, 3.276 Chen, T. 3.131 Clark, S. 2.050 Cristofaro, S. 2.173
Castillo, R. 1.341 Chen, W. 1.062, 1.076, 1.164, A.02 Clarke, D.F. 2.354, 3.070, 3.351 Crocker, C. 2.171
Castro, C. 1.295 Chen, X. 3.286 Claus, R. 1.315, 1.316, 1.317, 1.323, Crompton, D.E. 1.120, 3.088
Castro, C.X. 3.076 Chen, Y. 1.009 2.278 Crone, N. 1.174, 1.353, 2.025, 3.064
Catterall, W. 3.340 Chen, Z. 3.259 Claycomb, K. 1.049, 3.030 Cross, J. 1.190
Cavalleri, G. 1.248 Cheng, H. 1.318, 1.322, 2.290, 2.292 Cleto Dal-Cl, M. 3.055 Crowder Skarpaas, T. 1.216, 2.212
Cavaretta, J. 1.234 Cheng, J. 2.216 Clossen, B. 1.032 Crowley, M.J. B.01
Cavazos, J. 3.206 Chern, C. 3.025 Coan, A. 3.076, 3.082, 3.259, 3.260, Cruickshank-Quinn, C. 3.066
Cavitt, J. 2.228 Cheshire, W. 3.238 3.275
Cruz, E. 1.132, 1.142, 2.162
Cawello, W. 2.283, 3.290 Chevalier-Riffard, C. 1.190 Cobia, M. 2.115
Cruz Del Angel, Y. 1.003, 3.003, 3.011
Caylor, L. 2.039 Chez, M. 1.368 Cohen, D.L. 2.012, 3.209
Cukier, Y. 2.011, 2.029
Ceiki Sakamotob, A. 3.055 Chiang, S. 2.240, 2.247 Cohen, G. 2.031
Cukiert, A. 2.342, 2.343, 2.344,
Ceja Moreno, H. 3.295 Chiba, Y. 1.300 Cohen, J. 2.138 2.363, 3.350, 3.372
Celegen, K. 3.328 Chiesa, V. 2.184, 3.243 Cohen, J.W. 2.302 Cukiert, C.M. 2.344, 2.363, 3.372
Celegen, M. 3.328 Chikako, O. 1.235 Cohen, M.S. 1.278 Cukovic, D. 3.056
Cendejas, L. 1.074, 2.085 Child, N.D. 3.071 Cohen, N. 1.257, 2.286 Culver, C.B. 2.038, 3.083
Cendes, F. 1.319, 1.377, 3.259, Chin, M. 2.080 Colciaghi, F. 3.029 Cummins, T.R. 1.294
3.260, 3.275 Chin, R. 2.015, 2.072, 2.223, 3.129 Cole, A.J. 1.314 Cunningham, C. 1.076
Centeno, R. 3.369, 3.374 Chin, R.F. 1.092 Coleman, M. 1.085 Cunningham, C.E. 1.100
Cerqueira, P.B. 2.119, 3.143 Chiti, L. 1.108 Coley, A.A. 3.041 Curatolo, P. 2.187
Cerven, S. 1.198, 1.199, 1.200, Chiyonobu, T. 1.116 Collon, K. C.02 Curry, D. 2.347, 3.353, 3.358, 3.371
1.201 Chlon, W. 3.351 Coln-Zimmermann, K. 1.084 Cushner-Weinstein, S. 3.141
Cervenka, M. 1.174, 3.189, 3.191, Cho, K. 1.230 Coman, D. 1.041 Cusick, M.F. 3.117
3.318, B.07 Comi, A. 3.051
Cho, S. 1.087 Cutmore, C. 3.088
Cha, B. 2.083 Concha, L. 3.261
Cho, Y. 1.202, 1.218, 1.230 Cutter, G. 2.161, 2.163
Chabardes, S. 1.191, 1.348 Condie, J. B.06
Choe, M. A.09 Czech, T. 1.137
Chabrol, T. 1.039 Congedo, B.A. 1.284
Choezom, T. 3.136
Chachua, T. 3.025 Conner, C. 3.060
Chadehumbe, M. 2.016, 3.094
Choi, H. 2.296, 2.312, 3.138 D
Choi, J. 1.195 Connolly, M. 2.040, 3.096, 3.220, DAlfonso, S. 1.276, 3.327
Chadwick, E. 3.044 3.327
Choi, S. 1.117 DAmbrosio, R. 1.372
Chae, J. 1.119, 1.195 Connors, R. 1.057
Choi, Y. 1.219 DSouza, J. 2.219, 2.332, 3.300
Chagin, K. 1.377 Conry, J. 2.351
Chow, E. 1.066 DSouza, W. 1.227, 1.232, 1.279
Chan, S. 1.190 Constable, T. B.01
Chrastina, J. 2.003 Da Rold, M. 2.122
Chan, V. 1.208 Constantinou, J. 1.151, 2.215
Chris, F. 3.325 Dabbs, K. 1.169, 3.267, 3.270
Chandler, D.S. 3.122 Conti, V. 1.108
Christensen, J. 2.266 Dabscheck, G. 2.143
Chandra, S. 2.365 Cook, M. 1.227, 1.232
Christian, E. 1.303 Dagam, J. 1.333
Chang, B.L. 3.221 Cooper, E.C. 3.017, 3.210
Christodoulou, C. 3.173 Dahlin, M. 2.187
Chang, B.S. 1.154 Corallo, K. 1.082
Christodoulou, J. 1.154 Dalgard, C. A.08
Chang, C.W. 3.221 Cordeiro, M. 1.137
Chu, C. 3.054, Dalvi, N. 2.101, 2.120
Chang, E. 1.369 Cornett, K. 2.194
Chu, J. 1.232 Damaj, L. C.01
Chang, T. 1.136, 1.137 Correa, B.J. 2.119, 3.143
Chu, K. 2.168, 3.196 Damera, S. 2.010
Chanlaw, T. 3.249 Corso, J.T. 2.327
Chuang, S. 1.172 Damiano, J.A. 1.120
Chansard, M. 1.030 Cortes de Oliveira, J. 3.055
Chugani, D.C. 3.056 Damisah, E. 3.074
Chanteux, H. 2.310 Coryell, J. 3.223
Chugani, H. 1.251, 2.167, 2.345, Daniels, D. 3.209

ABSTRACT AUTHOR INDEX

Chapa Davila, J. 2.126 3.056, 3.362 Cossette, P. 3.093,
Danny, L. 1.231
Chapman, B. 2.112 Chung, H. 1.234 Cossu, M. 2.184
Danzer, S. 3.010, 3.120
Chapman, K. 1.098, 1.182, 1.326, Chung, J. 1.126, 2.227 Costa, F.A. 2.119, 3.143
1.345, B.06 Danzer, S.C. 1.048
Chung, J.M. 2.181 Costas, K. 3.325, 3.326, 3.334
Charpier, S. 1.039 Das, N. 2.221
Chung, S. 1.111, 1.316, 1.319, 2.288 Costel, J. 2.313
Chassoux, F. 2.226 Das, S. 3.256
Chung, S.S. 1.198, 1.199, 1.200, Cothros, N. 2.054
Chauvel, P. 1.377 Dauwe, I. 3.028, C.08
1.201, 1.307, 1.308, 1.334, 1.335, Cotten, J. 1.023
Chavez, G. 1.155 Dave, H. 2.107, 3.219, 3.225, B.02
1.336, 2.211, 2.280, 2.281, 3.291, Coulter, D. C.06
Chavez-Hassan, F. 2.334 3.292, 3.304 Davis, A. 2.233, 2.234
Couture, D. 2.256, 2.337, 2.339
Chaytor, N. 2.039 Chung, W.K. 2.275, 3.081, 3.135 Davis, A.M. 1.100
Couture, R.L. 3.016
Chea, K. 2.262 Ciechanowski, P. 2.039 Davis, E.C. 1.278
Couturier, N. 3.339
Chekhovtsov, I. 1.075 Cieza, S. 2.153 Davis, G.G. 2.070
Covington, T.M. 2.074
Chemali, Z. 2.008 Cilio, M. 2.146, 2.309, 3.303 Davis, K. 1.242, 2.135, 3.183, 3.256,
Craddock, R.C. 2.246 3.284
Chen, B. 1.262, 2.312, 3.138 Cimbalnik, J. 1.175, 2.156, 3.071 Crail Melendez, D. 2.334 Davis, K.A. 1.266, 3.167, A.08
Chen, C. 2.297 Cinar, N. 2.129 Craiu, D. 3.092 Davis, R. 2.057, 2.311
Chen, D.K. 1.089 Ciricillo, S. 1.368 Cramer, J.A. 1.273, 1.287 Dawe, R. 1.074
Chen, E. 1.076 Ciurea, J. 1.191, 3.069 Crawford, J. 3.241 Dawkins, R. 3.348
Chen, F. 3.002

95
 ABSTRACT AUTHOR INDEX

Day, B. 3.032 Didato, G. 2.184 Durand, D. 1.019, Espaillat Solano, L.M. 2.186
Dayyoub, T. 2.215 Diehl, B. 1.057 Durgin, T. 2.058, 2.297, 3.130 Espaillat Solano, L.M. 2.334
Dazzo, E. 1.113 Dike, N. 3.133 Dustin, I. 1.002, 3.065, 3.084, 3.278 Espinera, A. 3.203
De, G. 1.342 Dilley, C. 2.033, 2.047 Duveau, V. 1.039 Espinoza Lpez, D.A. 3.154
De Backer, M. 2.320, 3.291, 3.292, Dilley, D. 2.320 Duwell, E. 2.192 Ess, K.
3.294, 3.295, 3.296, 3.297, 3.298, Dimova, S. 3.291, 3.292, 3.299 Dworetzky, B. 1.281, 1.324, 2.213, Ettinger, A.B. 2.276
3.299 Ding, K. 2.038, 2.189, 2.193, 3.083 2.236, 2.285, 2.286, 2.287, 3.235, Eun, B. 3.308
De Benedictis, A. 3.360 Ding, L. 3.015 3.289 Euroepinomics-Res, C. 1.114
de Grauw, A. 2.185 Ding, Y.S. 1.262 Dykstra, H. 2.074 Evans, C. 2.324
de Grauw, X. 2.185 Dingledine, R. 3.116 Dzhala, V. 1.021, 3.022 Evans, J. 1.255
De Jonghe, P. 1.115 Dionisio, A. 1.058, 1.153 Evans, S. 2.318
de Kam, M.L. 2.307 Divino, V. 2.044 E Evrard, C. 2.269
De Koninck, Y. 3.022 Dixon-Salazar, T. 3.095 Eb, A. 1.275 Eyal, S. 3.063
de la Pena, C.B. 2.230 Dlugos, D. 1.182, 3.095, 3.201, Eberle, M. 2.238 Eydoux, P. 3.096
de Lanerolle, N. 3.072 Dobesberger, J. 3.228 Eberly, L.E. 1.272
de Melo-Souza, S.E. 2.274, 3.199 Dobrinsky, C. 2.276, 2.279 Ebril, M. 1.188 F
de Paula, V.D. 1.122 Dobrzeniecka, S. 3.093 Eckhardt, K. 3.294, 3.300 Faber, A. 2.040
De Toffol, B. 2.226 Dobyns, W. 1.043, 3.099 Edagawa, K. 2.357 Fabo, D. 1.157
de Vincentiis, S. 2.274, 3.199 Doesburg, S. 1.145 Edakawa, K. 1.060 Fabris, R. 3.148, 3.158
de Vries, P. 2.187 Doesburg, S.M. 3.153 Edmonds, B. 2.248, 2.255, 3.276 Fain, R. 2.276, 2.288
Dean, N. B.06 Doescher, J. 2.235 Egawa, K. 1.021, 2.174 Faingold, C. 1.023, 1.034,
DeBello, R. 2.053, 3.205 Doggett, K. 3.296 Egge, A. 3.366 Faizo, N.L. 3.281
DeCoster, C. 2.051 Doherty, C. 1.248 Eichel, R. 3.197 Fakhoury, T. 1.312, 3.300
Dedeken, P. 2.320, 3.293, 3.295, Doherty, J. 1.296, 1.303 Eichstaedt, K.E. 2.361 Fallil, Z. 1.157, 2.246
3.296, 3.298 Eid, T. 1.041, 3.074
Dokgoz, O. 1.229, 3.328 Fang, L. 3.310
del Prete, A. 1.020 Eidelman, O. A.08
Dolce, A. 2.347 Fant, R.V. 2.279
Delalande, O. 3.360 Einarsdottir, A. 3.128
Dombkowski, A.A. 3.056 Farah, J. 1.109
Delanty, N. 1.248 Eisenschenk, S. 2.212
Donahue, D. 2.250 Faria, L. 1.299
Delazer, M. 2.245 Eksioglu, Y. 2.268, 3.103, 3.194,
Donatti, A. 3.123 Farlow, D.C. 3.286
Delbeke, J. 3.028, C.08 3.357, 3.363
Donner, E. 2.353, 3.057, 3.137, 3.239 Farmen, A. 2.231
Deleo, F. 2.184 Ekstein, D. 1.302, 2.175, 3.063,
Donner, E.J. 1.208 3.197 Farooque, P. 2.350, A.02
Delgado-delaMora, J. 3.154
Donohue, K.D. 1.071 Ekstrand, J. 3.043 Farrell, K. 3.220
DeLorenzo, R. 1.026
Donohue, M.M. 3.257 Ekstrom, A. 1.078 Farwell Gonzalez, K.D. 1.194
Demos, M. 3.096
Donos, C. 3.069 El Tahry, R. 1.067 Fasano, A. 1.112
Demuth, D. 3.126
Dorland, N. 2.148 El-Hagrassy, M. 2.268 Faught, E. 2.047, 2.219, 3.130,
Denny, D. 1.198, 1.199, 1.200, 1.201 3.294, 3.299
Doshi, C. 2.213, 3.202, 3.235 Elder, E. 1.324, 2.285, 2.286, 2.287
Deo, A.K. 2.332 Faught, R. 2.339, 3.344
Doss, J. 1.094, 2.021 Elger, C. 1.067, 1.316, 1.320
Depaulis, A. 1.039 Faulkner, M. 2.041
Doss, R. 1.080, 2.026, 2.046 Eliashiv, D. 2.227, 2.321, 2.336
Depienne, C. 1.118 Fauth, C. 2.169
Doucet, G. 1.255, 2.237 Eliassen, J.C. 1.257
Depondt, C. 1.141 Fayed, N. 1.100
Dove, C. 1.185 Elledge, D. 2.299
Depositario-Cabacar, D. 1.354, 2.351, Federico, P. 1.264, 2.067, 3.139,
3.141, 3.355, 3.364 Drake, J. 1.172, 2.353 Ellingson, B. 1.238, 1.245, 1.261
Drane, D. 1.352, 3.344 3.186
Derambure, P. 2.226 Elliott, C.A. 3.261 Feeney, E. B.01
Dergalust, S. 2.322 Drazkowski, J. 2.139, 2.166 Elmenshawi, I. 2.272
Drees, C. 2.053, 3.205, 3.304 Fehr, K. 2.270
Derry, R. 1.096 Elmoufti, S. 2.219 Feldstein, N. 3.233
Descamps, B. 3.028 Drouin, N. 2.239 Elsayed, M. 2.255, 3.276
Du, X. 3.005 Felton, E. 3.318
Deshpande, L. 1.026 Emch, T. 3.257 Feng, H. 1.023
Desnous, B. 1.055, 1.056 du Plessis, D. 1.109 Emerson, R. 1.057,
Dualibi Ramos Valente, K. 2.274, 3.199 Feoli, E. 1.131
Desrochers, J.A. 2.160 Emery, E. 3.084, 3.278 Ferastraoaru, V. 2.180
DeStefino, V. 1.073 Dubeau, F. 1.121, 1.259, 2.358, Enatsu, R. 1.063
3.161, 3.163, 3.184, 3.185 Fergnani, V. 3.243
Detyniecki, K. 2.176, 2.296, 2.312, Endres, J. 2.085 Ferguson, A. 3.220
3.136, 3.138, Dubey, D. 2.189
Engel, J. 1.278 Ferguson, L. 1.093, 1.099, 1.347
Devinsky, O. 1.123, 1.133, 1.262, Dubroff, J.G. 1.266
Engel, M. 2.221 Ferguson, R.J. 1.086
2.007, 2.033, 2.170, 2.309, 3.057, Duchowny, M. 2.346
Englot, D.J. 1.369 Fernald, B. 2.256, 2.337
3.095, 3.137, 3.303, Duckrow, R. 1.062, 1.156, 1.216,
2.151, 2.212 Enoki, H. 1.371 Fernandes, A. 3.123
DeVries, S.P. 3.167
Dudek, F. 1.161, 1.166, 3.038, 3.043, Entz, L. 1.157 Fernandez, A. 1.062, 3.342
Dewar, S. 2.336, 3.217
3.047 Eom, S. 1.097 Fernandez, G. 1.106
Dhaher, R. 1.041, 3.074
Dudley, R.W. 1.267, 3.279 Eom, T. 2.220 Fernandez, L.D. 3.333
Dhakar, M. 3.174, 3.232
Duempelmann, M. 1.129, 1.167 Epi4K/EPGP, C. 1.114 Ferrari-Marinho, T. 3.161, 3.184,
Dhamne, S.C. 3.044
Duffy, F. 3.194 Epstein, J. 2.236 3.185
Diaz, F. 1.324, 2.285, 2.286, 2.287
Dufour, S. 1.016, 3.008 Erdinc, O.O. 3.305 Ferrazzano, P. 1.169
Diaz, M. 2.222
Dulla, C. 3.125, Escalaya, L. 2.313 Ferreira, J. 1.101, 2.187
Diaz-Medina, G. 1.139
Dumpelmann, M. 2.180 Escartin, A. 3.295, 3.298 Ferro, M. 2.223
Dibbens, L.M. 3.089
Duncan, R. 1.109 Escayg, A. 1.046, 3.106 Ferrrari, L. 1.162
DiCaccio, B. 2.155
Dunn, D. 2.018 Escoffery, C. 3.075 Ferry, J. 2.295
Dickens, D. 2.235
Dunn, M. 2.235 Esfahanizadeh, A. 3.208 Fertig, E. 1.131, 1.140, 2.230
Dickerson, B. 2.008
Dupuis, N. 1.055, 1.056 Eskandar, E.N. 1.018 Fesler, J.R. 2.349
Dickstein, L. 1.002
Eslamy, H. 1.250 Fessler, A. 1.125
96
 ABSTRACT AUTHOR INDEX

Feucht, M. 2.187 Frost, Jr., J.D. C.04 Gaxiola Valdez, I. 1.264 Goldman, A. 2.222
Feyissa, A.M. 3.269 Fu, A. 1.198, 1.199, 1.200, 1.201 Gebre, R. 1.076 Goldman, L. 2.301
Ficker, D. 2.285, 2.286, 2.287 Fuerst, D. 3.062 Gedela, S. 2.159, 3.331, 3.333 Goldschmidt, Y. 2.033
Fiedler-Kelly, J. 1.312, 1.314, 1.319, Fujikawa, M. 2.060, 2.132, 2.149 Gedzelman, E. 2.339 Goldsmith, J. 2.275, 3.081, 3.135
1.320, 1.321 Fujimoto, A. 1.371 Gelfand, M. 3.284 Goldstein, D. 3.095
Field, S.A. 2.298, 2.305 Fujinami, R.S. 3.117 Geller, E. 2.212 Goldstein, J. 1.182, B.06
Fiest, K. 2.071 Fujita, K. 1.220 Geng, B. 1.062 Goldstein, S. 3.324
Fiest, K.M. 1.285 Fujita, M. 1.002 Genov, R. 1.010 Gmez Ramrez, M. 3.154
Filippi, C. 1.057 Fujita, S. 1.014 George, M. 3.040 Gommer, E. 1.138
Finardi, A. 3.029 Fujiwara, H. 1.152, 1.353 George, S. 3.051 Goncharova, I. 2.151
Fine, A. 2.203 Fukasawa, T. 1.243 Gerard, E. 3.203, 3.226 Gong, H. 3.345
Finger, L. 2.107 Fukumizu, M. 2.202 Gerin, B. 2.310 Gonsalves, C. 2.110
Finn, C. 1.286 Fuller, P.M. 1.162 Germeyan, S.C. 3.084, 3.268, 3.278 Gonzales, E. 1.274, 1.356
Finn, R. 3.329 Funck, V. 1.295 Gernert, M. 1.069, 1.070 Gonzalez, F.L. 3.309
Finnell, R. 3.053 Fung, E. 3.327 Gerrard, J. 1.156, 2.151 Gonzalez, M. 3.237
Fiol, M. 2.206 Fung, S.H. 2.254 Gersner, R. 1.158, 1.302, 3.337 Gonzalez-Crespo, S. 3.101
Fischer, J. A.09 Furman, M. 1.164 Gerstl, L. 2.204 Gonzalez-Martinez, J. 1.058, 1.063,
Fisher, E. 2.019 Fusco, L. 3.360 Gey, L. 1.070 1.153, 1.240, 1.347, 1.362, 1.377,
Fisher, J. 3.200 Ghani, A. 1.255, 2.237 2.249
Fisher, R. 1.068, 3.073, B.07 G Ghassemi, A. 1.368 Gonzalez-Sepulveda, L. 3.101
Fishman, J. 2.031 Gabelia, D. 2.262 Ghatan, S. 3.356 Gonzlez de la Aleja, J. 1.332
Fisk, K. 3.051 Gabr, R.E. B.03 Ghearing, G. 2.147, 2.157, 3.227 Good, L. 1.054
Fitzsimons, M. 1.248 Gabrieli, J.D. 1.154 Gholipour, T. 2.113 Goodkin, H. 1.028, B.06
Flanagan, P. 1.153 Gaddam, A. 2.208 Giarratano, M. 1.340 Goodrich, G.S. 3.009
Flashman, L. 3.080 Gaddam, S. 2.215 Gibson, K.M. 3.065 Goodwin, S.W. 3.134
Fleming, M. 2.092, 2.230 Gadeyne, S. C.08 Gibson, M. 1.225 Gordon, C.M. 1.375
Fletcher, L. 2.050 Gadhoumi, K. 1.178 Gidal, B. 1.324, 2.284, 2.285, 2.286, Gorelik, D. 2.301
Fleury, A. 2.186 Gaik-Siew, C. 1.105 2.287 Gospe, S.M. 1.241
Flores, J. 1.332 Gaillard, W. 1.354, 2.142, 2.351, Gidal, B.E. 2.295 Goswami, S. 2.041, 2.098
Fonseca, N. 1.122 3.141, 3.144, 3.268, 3.272, 3.278, Gilbert, T. 1.263 Gotman, J. 1.171, 1.178, 1.259,
Ford, L. 1.309 3.355, 3.364, B.06 Gilby, K. 1.047 2.358, 3.121, 3.161, 3.163, 3.184,
Gaitanis, J. 3.073 3.185,
Foreman, B. 3.203, 3.226 Gill, D. 3.092
Galanopoulou, A.S. 1.304, 1.305, Gowda, A. 2.256
Foreman, P. 2.200, 3.162 Gilliam, F. 3.336
Galimberti, C. 1.316 Goy, E. 2.269
Foreman, P.J. 2.257 Gilmet, G. 3.336
Gallagher, M. 3.015 Goyal, A. 1.022
Forgacs, P.B. 2.105 Gilmore, E. 1.135, 3.204
Gallentine, W. 1.182, 2.194, 3.095 Gozzo, F. 2.184
Forman, S. 1.023 Giordano, M. 3.233
Galloway, G. 3.281 Grabenstatter, H.L. 1.003, 3.003
Forman, S.D. 1.284 Girard, J. 2.017, 3.169
Gama, H. 1.315, 1.316, 1.317, 1.323, Graf, S. 2.102
Foroughi, A. 2.200, 3.162 Gireesh, E. 3.064
2.278 Graham, A. 2.058
Forsythe, A. 3.301 Girouard, M. 3.206
Gandomi, S. 1.194 Granbichler, C. 2.068
Fountain, N. 1.209, 2.081 Giza, C. 1.182, A.09
Gangisetty, O. 1.033 Grant, A.C. 1.085, 3.181
Fowles, K. 2.332 Gizewski, E. 2.245
Gano, L.B. 3.066 Grant, E. 3.202
Franaszczuk, P. 1.174 Glaser, C. 3.241
Gao, J. 1.155 Gray, E. 3.126
Francois, D. 2.268 Glass, H.C. 1.136
Garces, M. 1.332 Gray, M. 3.281
Francomacaro, S. 3.001 Glasscock, E. 3.107
Garcia, P. 1.369 Greenberg, D.A. 3.122
Franois, C. 1.334, 1.335, 1.336 Glauser, T. 2.024, B.06
Garcia, R. 1.295 Grefe, A. 2.210
Fraser, R. 3.078, 3.127 Glaze, D. 3.104
Garcia Gracia, C. 2.073 Greiner, H. 1.152, 1.353, 2.352
Fraser, R.T. 2.039 Glessner, J. 3.099
Garcia-Cairasco, N. 3.055, 3.123 Griffin, N.G. 3.113
Frasier, C.R. C.02 Glielmi, C. 1.262
Garcia-Ramos, C. 3.267 Griffiths, C. 3.059
Frauscher, B. 2.121, 2.262, 3.161, Gliske, S. 3.067

ABSTRACT AUTHOR INDEX

3.163, 3.184, 3.185 Gardella, E. 1.118 Grigg-Damberger, M. 3.171
Glykys, J. 1.021
Freedman, D. 2.250 Gardiner, E. C.07 Grinspan, Z. 2.043, 2.055, 2.221
Glynn, S. 2.030, 3.040
Freeman, J.L. 3.087 Garg, A. 2.032, 2.365 Groomes, L. 2.025
Go, C. 1.127, 1.172, 1.189, 2.353,
French, C. 1.231 Garg, K. 2.365 3.306 Groppe, D. 1.157, 2.246, 3.177,
Garg, M. 3.249 3.346
French, J. 1.318, 2.007, 2.176, 2.233 Gobbi, G. 2.018
Garrido, E. 1.295 Gross, D. 3.259, 3.260, 3.261
Frey, L. 2.053, 3.031, 3.205, 3.304, Godard, A. 3.046
3.320 Garrity, L. 2.229 Gross, D.W. 1.253
Goel, M. 2.365
Freyer, C. 2.173 Garson, A. 3.051 Gross, R. 1.349, 2.212, 2.256, 2.337,
Gofton, T. 3.203, 3.226 2.339, 3.344
Fried, I. 1.177 Garzon, E. 3.179 Gokyigit, A. 1.128, 2.183, 2.224 Grote, C.L. 3.264
Friedman, D. 2.007, 2.142, 2.170, Gaspard, N. 1.135, 2.151, 3.203, Golby, A. 2.025
2.309, 3.057, 3.137, 3.303 3.204, 3.226 Grouiller, F. 2.244
Gold, D. 3.231 Grova, C. 2.239,
Friedman, K. 1.262 Gaston, T. 1.236 Gold, J. 2.104, 3.241
Friedman, S.D. 1.241, 3.280 Gaston, T.E. 1.247, 1.249 Gu, B. 1.006
Goldberg, E.M. C.06 Gu, F. 1.299
Frigerio, F. 1.020 Gattaz, W.F. 1.122 Goldberg-Stern, H. 3.090
Fritz, P. 2.033, 2.047 Gattone, J.M. 3.321 Guan, Y. 3.352
Goldenholz, D. 1.065, 3.278 Guaranha, M.B. 3.251
Frndova, H. 3.059 Gautier, N. 3.107 Goldenholz, D.M. 2.356
Frohlich, F. 1.159 Gavrilovici, C. 1.030 Gubernale, M. 2.122
Goldenstein, L. 3.233 Gudbranson, E. 1.062, 1.076
Frost, M. 2.235, 2.270 Goldie, J. 1.158 Gudlavalleti, A. 3.155

97
 ABSTRACT AUTHOR INDEX

Guekht, A. 2.076 Hanai, S. 3.114 Helmers, S. 2.047, 2.339, 3.130 Holden, D. 2.332
Guenot, M. 1.348 Hanaya, R. 1.265, 2.002 Helmstaedter, C. 1.283 Holland, K. 1.353, 3.247
Guerreiro, C. 3.076, 3.082 Handler, M. 1.267, 2.103, 3.279 Hempstead, B.L. 3.011 Hollen, C. 2.034
Guerrini, R. 1.108 Handreck, A. 1.069 Hemza, J. 2.003 Holley, A. 1.292, C.07
Guess, M. 3.156 Haneef, Z. 2.240, 2.247 Henegan, P.L. 1.086 Holmes, M.D. 1.180, 3.187, 3.193
Gugler, K. 2.133, 2.137 Hani, A.J. 2.194, B.06 Hennessy, R. 2.176 Holt, R. 3.178
Guilfoyle, S. 1.090, 1.091 Hannestad, J. 2.332 Henning, O. 2.317, 2.326 Holtkamp, M. 3.058, 3.349, A.03
Guilhoto, L.M. 3.251 Hanson, A. 2.067, 3.139 Henry, B. 3.318, B.07 Homa, K.A. 1.286
Guimaraes, M.D. 3.374 Hanson, M. 1.333 Henry, T. 3.190 Honda, R. 1.147, 1.359, 1.361,
Guiraud-Diawara, A. 1.334, 1.335, Hanson, R. 2.085 Heo, K. 1.218, 1.230 2.225, 2.341
1.336 Hanusa, B.H. 1.284 HEP Investigators 2.173, 2.176, 3.201 Hong, J. 1.002
Gulsen, G. 3.270, 3.283 Hankov, H. 1.051 HEP MRI Core 3.258 Hong, L. 3.113
Gulyaeva, N. 2.076 Haque, O. 1.355 Herbillon, V. 2.263 Hong, S. 1.087
Gummadavelli, A. 1.044, 1.164 Hara, K. 2.091, 2.093, 2.097 Herekar, A. 1.216, 2.209 Hong, S. 1.130, 1.365, 2.207, B.04
Gunasekara, R.C. 2.268 Hara, M. 2.091, 2.093, 2.097 Herman, J.P. 3.010 Honig, A. 3.197
Guo, A. 1.213 Harada, Y. 1.370 Herman, S. 1.205 Hope, C. 1.111
Guo, D. 1.024 Harden, C. 1.157, 2.011, 2.029, Hermann, B. 1.169, 2.004, 2.023, Hope, O. 2.037
Guo, J. B.01 2.092, 2.233, 2.246, 2.256, 2.339, 2.218, 3.267, 3.270 Hori, J.M. 1.278
Gupta, A. 1.144, 1.362, 3.359 3.053 Hernandez, A. 2.250 Horiuchi, K. 3.205
Gupta, N. 3.173 Hardin, K. A.06 Hernandez Ronquillo, L. 1.228 Horn, P. 2.352, 3.111, 3.324
Gupta, P. 2.038, 2.189, 2.193, 3.083 Haridas, B. 2.055 Hernandez Ruiz, A. 3.154 Hosain, S.A. 1.134
Gupta, R.K. 2.125 Harini, C. 1.098, 2.196, 3.169, 3.236 Hernando, K. 1.236, B.09 Hosford, B. 3.120
Gupta, V. 3.343 Harkness, W. 2.342, 2.343, 3.350 Hertzberg, C. 2.187 Hosny, H. 2.217
Gupta, Y.K. 1.022 Harnod, T. 3.271 Hervas Navidad, R. 3.311 Hosoyama, H. 2.002
Gurbani, S. 1.252, 1.254, 3.254 Harrell, E. 2.131 Hesdorffer, D. 2.070, 2.275, 3.057, Hou, W. 3.104
Gurkoff, G. 1.078 Harrington, C. 2.318 3.081, 3.135, 3.137, 3.140 Howard, M. 1.079, C.05
Gurme, M. 2.321 Harrington, J. 1.086, 2.033, 2.042 Heshmati Moghaddam, M. 3.097 Howard, T. 2.215
Gurses, C. 1.053, 1.128, 2.183, Harris, D. 2.124 Hevner, R. 1.250 Howe-Martin, L. 2.038, 3.083
2.224 Harris, K. 1.137 Heyer, G.L. 3.157 Howell, K. 3.087
Gusev, E. 2.076 Harris, R. 1.238, 1.261 Heyse, H. 1.257 Hrachovy, R.A. C.04
Gustafson, M. 2.133, 2.137, 3.335 Hart, S. 1.306 Hibbard, K. 2.024 Hsieh, C. 2.094
Guttuso, T. 2.125 Hartl, E. 2.165, 3.211, 3.273 Hickey, F. 3.209 Hsieh, L.S. 3.030
Guzel, O. 3.328 Hartman, A. Higdon, L. 2.147 Hsieh, T. 3.009
Guzman, L. 3.237 Harvey, A.S. 3.087 Higo, T. 1.363, 1.370, 3.012 Hsin, Y. 3.195, 3.271
Gwinn, R. 2.212 Harvey, D.W. 2.152 Hildebrand, M.S. 1.120 Hsu, D. 1.169, 2.023, 3.267, 3.270
Harvey, J. 1.068, 1.312, 1.319, 2.290 Hilkman, D. 1.138 Hsu, M. 1.169, 2.238
H Harward, S.C. 1.269 Hill, C. 2.135, Hsu, S. 1.351
Haas, K. 1.327, 2.160, 3.203, 3.226 Hasbani, D. 3.312 Hines, D. 2.297 Huang, C. 2.094, 3.271
Hader, W. 1.360, 2.082 Hasegawa, H. 3.149 Hinn, A. 2.057 Huang, S. 2.289
Haginoya, K. 1.367 Hashizume, A. 1.265, 2.359 Hino-Fukuyo, N. 1.367 Huang, Y. 1.006, 1.041, 1.253, 2.332
Haglund, M. 3.113 Hastings, W. 1.341 Hira, J. 2.246 Hubbard, J.A. 3.119
Hahn, C. 1.182, 3.059 Hauser, A. 2.076, 3.140 Hirai, S. 1.116 Huber, P. C.07
Haider, Z. 3.126 Haut, J. 1.093, 1.099 Hirata, M. 1.060, 2.357 Huckins, S. 3.363
Hajek, M.A. 1.049 Haut, S. 2.176, 3.231 Hirata, Y. 1.238, 1.245, 1.261, 3.255, Hudgens, S. 3.301
Hakami, T. 1.231 Haut, S.R. 2.180 3.262 Huiskamp, F. 2.145
Hakimi, A. 2.034 Havens, K. 2.351, 3.141, 3.355, Hirose, S. 1.365 Hulette, C. 3.113
Hakonarson, H. 3.090, 3.099 3.364 Hirose, Y. 2.093 Hummelova, Z. 2.003
Halford, J.J. 2.160 Hawasli, A.H. 1.376 Hirsch, E. 2.226 Hunt, M. 2.206
Hall, A. 3.335 Hawkins, C. 1.189 Hirsch, L. 1.062, 1.135, 1.156, 2.151, Hunter, M. 1.092, 2.015
Hall, J. 2.239, 2.340 Hays, R. 2.038, 2.189, 2.193, 3.083 2.296, 2.312, 2.350, 3.136, 3.138,
3.203, 3.204, 3.226, A.02 Hur, E.E. 2.303
Halliday, W. 3.108 He, B. 1.268 Husain, A. 2.036, 2.048, 2.077
Heath, J. 2.124 Hirvonen, J. 1.002
Hallinan, B. 3.324 Hussain, S.A. 2.108, 2.355, 3.157,
Heck, C. 1.216, 2.212, 3.373 Hitchens, T. 3.072
Halvorsen, M.B. 1.307, 1.308 3.222, 3.330
Hecox, K. 1.173, 3.215 Hixson, J. 2.058, 2.176
Hamano, S. 1.365 Hussein, Z. 2.295
Hedlund, J. 2.309, 3.303 Hiyoshi, T. 3.216
Hamberger, M.J. 2.027 Huynh, J. 2.233
Hedrick, N.G. 1.269 Hjalgrim, H. 1.118
Hamdan, F.F. 3.093 Hwang, D. 2.029
Heers, M. 1.167 Ho, A.W. 3.172
Hameed, M.Q. 3.009, 3.044 Hwang, E.S. 1.278
Hegde, M. 3.201 Hoang, K. 2.034
Hamer, H. 1.146, 1.346 Hwang, H. 1.119, 1.195, 1.212
Heier, L.A. 2.221 Hoch, D. 2.045
Hamid, H. 2.059 Hwang, K. 1.087, 2.207
Heinen, F. 2.204 Hochberg, L.R. 1.018
Hammond, N. 2.111 Hwang, S. 1.157, 2.011, 2.246
Heinze, H. 3.045, 3.058, 3.349 Hocking, J. 3.281
Hammond, R. 1.296, 1.303 Hwang, Y. 1.119, 1.195, 1.212
Heinzen, E. 3.095, 3.113 Hoegl, B. 2.262
Han, H. 1.218 Hyder, F. 1.041
Heischmann, S. 3.066 Hoerth, M. 1.082
Han, J. 1.313
Heiss, J. 1.150 Hofer, M. 2.262
Han, R. 1.372
Helbig, I. 1.115, 3.090, 3.099 Hfler, J. 3.228
Han, S. 1.218
Hoffmann, D. 1.191, 1.348
Hogan, R. 1.307, 1.308, 1.376,
2.280, 2.281, 3.336

98
 ABSTRACT AUTHOR INDEX

I Jacobson, M. 1.318 Jongeling, A. 3.203 Karavaeva, E. 1.245, 1.261

Iannotti, G. 2.244 Jaffe, D.B. 1.165 Joo, E. 1.087, 1.130, 1.218, 2.207 Karkar, K. 2.028
Iasemidis, L. 3.107 Jhn, J. 1.115 Jordan, J. 3.315 Karkare, S. 2.101, 2.120, 2.128
Iida, K. 1.265, 2.002, 2.359 Jain, M. 2.085, 2.241 Jordan, S. 2.050 Karsidag, S. 2.129
Iijima, K. 1.220 Jain, S. 2.352 Jorgensen, A. 1.109 Kartagiri, M. 1.265, 2.359
Iimura, Y. 1.363, 1.370, 3.012 Jaisani, Z. 1.240 Josan, V. 1.109 Karumuri, B. 3.107
Ikeda, A. 1.110, 1.350, 2.335 Jalota, A. 2.241 Josephson, C. 2.067, 3.139 Kashambwa, R. 2.233
Ikeda, H. 3.198, 3.216 Jan, M.M. 3.323 Joshi, C. 1.206, 2.035, 3.145, 3.156 Kashida, Y. 2.002
Ikeda, K.M. 3.109 Jang, S. 1.163 Joshi, R. 2.151, 3.074, 3.136 Kassab, A. 1.072
Ikeda, T. 1.116 Janio, E.A. 1.278 Joshi, S. 1.037, 2.050, 3.115, 3.230 Kassai, B. 2.263
Ikegaya, N. 2.341 Janke, K. 2.011, 2.029 Jouny, C. 1.174, 3.064, 3.189, 3.191 Kassiri, J. 2.178, 2.179
Ilhan Algin, D. 3.305 Janousek, J. 2.301 Jow, A. 2.356 Kasteleijn-Nolst Trenite, D.G. 3.314
Imai, K. 3.198 Jansen, A. 2.187 Jozwiak, S. 2.187 Kato, K. 2.132, 2.149, 2.154, 3.138,
Inaba, Y. 1.116 Janz, D. A.03 Jucker, M. 3.116 3.159
Inada, T. 2.335 Jasinski, T. 2.197 Juhasz, C. 1.251, 2.345, 3.062 Kato, M. 1.105, 1.116
Inaji, M. 2.091, 2.093, 2.097 Javors, M.A. 3.052 Jun, J. 2.168, 3.196 Kattan, M. 1.377
Inano, R. 1.350, 2.335 Jayabal, V. 1.148 Jung, D. 1.222 Katus, L. 1.271
Inati, S. 1.002, 1.150, 3.084, 3.166 Jayakar, P. 3.192 Jung, H. 2.043 Kaufman, B. 2.233, 3.057, 3.137
Inati, S.K. 2.010 Jayakar, R. 3.344 Jung, K. 2.168, 3.196 Kaufman, K.R. 2.325
Inbar, D. 3.063 Jefferys, J. 3.036 Jung, S. 1.170 Kaufman, N.D. 2.325
Ince, N. 3.190 Jehi, L. 1.226, 1.347, 1.362, 1.377, Junger, K. 1.090, 1.091, 2.229, 2.316 Kaufmann, W. 3.104
Innis, R. 1.002 2.073 Junna, M. 2.192 Kaushal, R. 2.043
Inoue, N. 1.233 Jehle, R. 3.231 Jurasek, L. 2.089 Kavak, K. 1.214
Inoue, Y. 1.060, 1.365, 2.357, 3.198, Jenko, K. 1.002 Jurd, R. 2.007 Kawasaki, H. 1.079
3.216 Jenner, M.R. 3.307 Kaya, M. 1.053
International Pediatric Epilepsy Surgery Jensen, F. 3.001, 3.007, 3.041 K Kayani, S. 1.054
Panel, T. 2.343 Jensen, J. 1.352 Kaczmarek, L.K. 3.016 Keating, J. 2.016
Iragui-Madoz, V. 2.251 Jenson, K. 1.180, 3.193 Kadam, S. 3.035, 3.047 Keating, R. 1.354
Irazoqui, P. 3.036 Jeon, J. 1.202 Kadipasaoglu, C. 3.060 Keator, C. 2.250, 3.145
Iriarte, J. 2.153 Jeong, J. 1.251 Kadish, N.E. 1.329 Kebede, T. B.06
Isaacs Lebeau, K. 1.083 Jepsen, B. 1.118 Kadiwala, H. 2.254 Keller, C. 1.157
Iseki, H. 1.373 Jett, N. 1.285, 2.051, 2.067, 2.071, Kagawa, K. 1.265, 2.359 Kellermann, T. 2.004
Isgder, R. 3.328 2.082, 3.139 Kahane, P. 1.191, 1.348, 2.226, Kelley, V. 2.360, 2.361
Ishak, G. 1.250 Ji, K. 1.218 Kahle, K.T. 1.021 Kellogg, M.A. 2.118
Ishak, G.E. 1.241, 3.280 Jiang, W. 1.324, 2.285, 2.286, 2.287, Kaiboriboon, K. 2.052, 2.090 Kelly, D. 1.054, 2.318
Ishihara, N. 1.224, 1.235, 1.243 2.330, 3.288, 3.310 Kelly, K. 1.331, 3.158
Kaido, T. 1.147, 1.365, 2.225, 2.341
Ishihara, Y. 1.300 Jiang, X. 2.330, 3.288 Kelly, K.M. 2.160
Kaimovsky, I. 2.076
Isnard, H. 2.263 Jiang, Y. 1.030 Kelly, P. 2.036, 2.048, 2.077
Kakacek, J.R. 3.321
Isnard, J. 1.348 Jih, J. 1.306 Kelmann, B.V. 3.369
Kakisaka, Y. 2.132, 2.149, 2.154,
Isojarvi, J. 1.334, 1.335, 1.336 Jimenez, X.F. 2.273 3.159 Kelten, B. 2.129
Isom, L.L. C.02, Jin, K. 1.367, 2.132, 2.149, 2.154, Kalamangalam, G. 1.160, 1.168, Kemmotsu, N. 2.005, 2.251
3.159 3.375, B.03
Ito, T. 2.174 Kempapura, M. 1.341
Jin, X. 1.155 Kalayjian, L. 3.373
Ito, Y. 1.224, 1.235, 1.243 Kendirli, M.T. 3.170
Jirsa, V. 3.182 Kalsanka Pai, A. 3.130
Itoh, K. 1.300 Kennedy, J. A.06
Joachim, K.C. 2.056 Kalume, F. 1.043, 3.340
Itoh, M. 3.114 Keough, K.C. 2.354
Joaquim, H.P. 1.122 Kameyama, S. 1.365
Ivanisevic, M. 3.344 Kern, L.M. 2.043
Job, A. 1.191 Kaminski, R. 1.020
Iwaki, T. 1.357 Kern, R.T. 2.160
Jobst, B. 1.086, 1.209, 1.286, 2.042, Kamson, D. 1.251
Iwasaki, K. 1.373 2.212 Kerr, M.S. 2.010
Iwasaki, M. 1.367, 2.132, 2.149, Kanaan, S. 2.349 Kerr, W.T. 1.278
Joc, J. 3.273
ABSTRACT AUTHOR INDEX
2.154, 3.159 Kandel, P. 2.319 Kerrick Walker, J. 2.298, 2.305
Joensuu, T. 3.089
Iwasaki, T. 1.116 Kaneko, Y. 1.147, 2.225, 2.341 Kervyn, S. 2.310, 2.332
Johannessen, S. 2.282, 2.308, 2.317,
Iwuchukwu, I. 3.219 2.326 Kang, H. 1.211, 3.354, 3.356 Kessler, S. 2.302
Iyengar, S.S. 3.026 Johnson, E.K. 2.039, 3.078 Kang, J. 2.315, 3.112 Khaddam, O. 2.086
Iyer, S. 1.133 Johnson, J.K. 1.337, 1.343 Kang, K. 1.219 Khalid, E. 2.188
Izadi, A. 1.078 Johnson, M. 1.076 Kang, S. 3.035 Khalilieh, N. 3.273
Johnston, L.A. 1.047 Kankirawatana, P. 1.268 Khan, F. 2.107, 3.219, 3.225, B.02
J Johnston, M. 3.035 Kanner, A. 2.191, 2.264, 2.265, 3.264 Khan, I. 1.181
Jabo, B. 3.146 Jokeit, H. 2.245 Kao, A. 2.351, 3.141 Khan, O. 1.341
Jack, S.M. 2.065 Jones, A. 1.066 Kaplan, L.R. 1.106 Khan, O.I. 2.356
Jackson, D. 1.169, 2.023, 3.267, Jones, D. 1.334, 1.335, 1.336 Kaplan, P. 3.203 Khawaja, A.M. 2.161, 2.163
3.270 Kaplan, P.W. 3.226 Khaytin, I. 2.210
Jones, J. 1.169, 2.023, 3.267, 3.270,
Jackson, G. 2.243, 3.287 C.09 Kapoor, S. 2.258 Khoo, H. 1.060, 2.357
Jackson, G.D. 1.120 Jones, K. 2.353, 3.306 Kapur, J. 1.037, 3.115, 3.118 Khurana, D. 3.312
Jackson, M. 1.329, 2.213, 3.235, Jones, M. 3.277 Kapur, K. 2.213, 3.235, 3.236, 3.326, Khusiwilai, K. 1.137
B.06 B.06
Jones, S.E. 1.240, 2.249 Kidokoro, H. 1.224, 1.235, 1.243,
Jacobs, J. 1.129, 1.167, 2.358, 3.068 Kapur, R. 2.209, 2.212, B.08 2.158
Jongeling, A. 3.226
Jongeling, A.C. 3.253 Karaarslan, U. 1.229 Kikuchi, T. 1.350, 2.335
Kim, B. 1.218
99
 ABSTRACT AUTHOR INDEX

Kim, C.E. 3.090 Koh, E. 1.218 Kumar, A. 2.345, 3.362 Lapham, G. 3.057, 3.137
Kim, D. 1.130, 1.204, 1.218, 3.354 Koh, J. 2.314 Kumar, D. 2.293, 2.294, 2.295 Lapointe, V. 1.017
Kim, E. 1.313, 1.328 Koh, S. 1.218, 1.222, 1.267, 3.024, Kumar, R. 1.022 Laroche, S. 2.339, 3.203
Kim, G. 1.218, 2.348 3.279 Kumar, S. 3.145 LaRoche, S.M. 2.160, 3.226
Kim, G.E. 3.016 Kohler, C. 2.135 Kumar, U. 1.289 Larsen, J. 1.118
Kim, H. 1.119, 1.195, 1.211, 1.212, Kohli, S. 1.214 Kumar, V. 2.365 Larsson, P. 3.366
1.244, 1.365, 2.164, 2.185, 2.315, Kokoszka, M. 3.356 Kunieda, T. 1.350, 2.335 LaSarge, C.L. 1.048
3.112, 3.354 Kolls, B.J. 2.160 Kunnakkat, S.D. 1.085 Lashley, S. 2.039
Kim, J. 1.087 Kolodgie, M. 2.351 Kuo, C. 1.180 Lasley, J.H. 2.298, 2.305
Kim, J. 1.211, 1.218, 2.164, 2.207, Komaki, H. 2.225 Kupsky, W. 2.345 Latour, N. 2.310
2.315, 3.112, 3.242, 3.263, 3.356 Kommajosyula, S.P. 1.034 Kuratani, J. 1.250 Lau, C. 2.233, 3.053
Kim, K. 1.093, 1.119, 1.195, 1.212, Kondo, T. 1.110
1.218 Kurisu, K. 1.265, 2.359 Laura, W. 1.139
Konikkara, J.J. 2.038, 3.083 Kurlemann, G. 1.115 Laurenza, A. 1.325, 2.276, 2.279,
Kim, M. 1.117, 1.218, 1.219
Kopitzki, K. 3.045 Kuruba, R. 1.029, 1.031 2.288, 2.289, 2.291, 2.293, 2.294,
Kim, R. B.01 2.295
Koppelstaetter, F. 2.245 Kutluay, E.E. 2.160
Kim, S. 1.081, 1.218, 1.221, 2.164, Laureta, M. 2.128
2.220, 2.315, 3.112, 3.244 Korb, P. 2.053, 3.205 Kuzniecky, R. 1.352, 3.258
Korczyn, A. 3.090 Kwan, P. 1.231 Lauterbach, T. 3.293
Kim, T. 3.112
Korgaonkar, A.A. 1.007 Kwiatkowski, D. 3.044 Laux, L. 3.244, 3.303
Kim, W. 1.218, 2.164, 2.315, 2.362,
3.021 Korn, M. 3.006, C.09 Kwon, C. 2.082 Lavingia, J. 2.148
Kim, Y. 1.117, 2.164, 2.315, 3.112 Koroma, M. 1.126 Kwon, H. 1.130 Lawson, J. 2.187
Kim-Tenser, M. 3.345 Korostenskaja, M. 1.179, 2.014, Kwon, O. 1.081, 1.170 Laxton, A. 2.337, 2.339
Kimura, S. 1.116 2.248, 2.253, 2.255, 3.276 Kwon, R. C.07 Le, J.M. 1.278
King, J. 2.034 Koroukian, S. 2.052, 2.090 Le, J.T. C.04
King-Stephens, D. 1.216, 2.209 Korzeniewska, A. 1.174 L Le, N. 2.311
King-Stevens, D. 2.212 Koscik, R. 2.218 La Briola, F. 3.243 Le, S. 3.168
Kini, L. 3.256 Kossoff, E. 3.318, B.07 La Vega-Talbott, M. 3.356 Leaffer, E. 3.140
Kinoshita, M. 1.110, 2.080 Kotagal, P. 2.172 Laban-Grant, O. 1.131, 2.230 Leanage, G. 1.035
Kipervasser, S. 3.197 Kothare, S. 2.170 Labiner, D. 1.349, 2.256, 2.337, Lebedeva, A. 2.076
Kirk, V. 3.172 Kotloski, R. 1.038 2.339 Leclercq, K. 1.020
Kirkpatrick, M. 1.118 Kotzot, D. 2.169 Lacaille, J. C.01 Lee, B. 1.230, 3.373
Kirmani, B. 1.341 Kowacs, P. 1.315 Lach, L. 1.100 Lee, C. 2.210
Kirschbaum, A. A.03 Kowski, A. 3.058, 3.349, A.03 Lachance, M. 3.093 Lee, C.H. 3.221
Kishi, Y. 3.365 Kozupsky, J. 2.265 Lachhwani, D. 1.093, 1.099, 1.192 Lee, C.L. C.04
Kishima, H. 1.060, 2.357 Kraemer, D.L. 2.144 Lackner, P. 2.121 Lee, C.Y. 3.221
Kitay, A.Y. 3.045 Kraemer, G. 2.099 Lacuey Lecumberri, N. 2.126 Lee, D. 1.078, 2.005
Kiura, Y. 1.265 Kramer, M. 3.054 Ladino, L.D. 1.228 Lee, E. 1.211, 1.218
Kjrvik, V. 2.317, 2.326 Krause, A. 3.208, 3.302 Lado, F. 3.177, 3.346 Lee, H. 3.058
Klaas, P. 1.093, 1.099 Krauss, G. 1.316, 1.320, 2.292 LaFrance, W. 3.075, 3.085 Lee, I. 1.313, 2.220
Kleen, J. 1.086 Krebill, R. 1.324, 2.285, 2.286, 2.287 LaFrancois, J. 3.026, 3.037 Lee, J. 1.211, 1.218, 3.098, 3.203,
Kreiman, G. 2.025 Lafrenire, R.G. 3.093 3.226, 3.289, 3.354
Klehm, J. 1.098, 1.197, 1.329, 1.345,
2.213, 3.235, 3.246, B.06 Kreisl, W. 1.002 Lagae, L. 2.294 Lee, K. 1.179, 1.196, 1.234, 2.014,
Krel, R. 3.240 2.110, 2.248, 2.253, 2.255, 2.348,
Klein, K. 3.090 Lagerlund, T. 3.158 2.364, 3.276
Klein, P. 1.315, 2.230, 2.301 Krishnan, B. 1.040, 1.144, 1.240, Lagrange, A. 3.152
3.359 Lee, M. 1.036, 3.070
Kleineschay, T. 2.253 Lai, Y. 1.139, 3.049, 3.061 Lee, M.R. 2.354
Kleinfeld, K. 1.187 Krishnan, V. 1.290 Lam, A.D. 3.164
Kronengold, J.K. 3.016 Lee, S. 1.218, 1.219, 1.236, 2.168,
Klitgaard, H. 1.298, 2.332 Lamanna, I. 1.141 2.314, 3.036, 3.196, B.09
Klooster, D. 1.154 Kroner, B. 3.141, 3.144 Lamar, T. 1.046 Lee, S.T. 3.221
Kloosterman, F. 1.017 Krook-Magnuson, E. C.03 Lamartine Sabido Monteiro, M. 1.141 Lee, V. 2.159
Kluge, C. 3.045, 3.058 Krueger, A. 1.270 Lamb, N. 3.334 Lee, W. 2.318
Kluger, D. 1.076 Krug, K. 2.241 Lambrakis, C. 1.131 Lee, Y. 1.130, 1.230, 1.328
Klus, C. 1.129 Kruithof, A.C. 2.307 Lammers, S. 3.044 Lega, B. 1.058, 1.153
Knopf, L. 1.188 Krutoshinskaya, Y. 3.240 Lancaster, R. 3.225 Legatt, A.D. 2.180
Knoth, R.L. 2.298, 2.305 Krylov, V. 1.059, 2.076 Lancman, M. 1.083, 1.131, 2.020, Legendre, A. 1.039
Knowlton, R.C. 1.236, 1.369 Kuba, R. 2.003 2.230 Legg, K. 2.171
Knupp, K. 1.326, 2.035, 3.209, 3.223 Kubikova, R. 2.003 Lancman, M.E. 1.083, 2.020, 2.230 Legge, A. 2.296, 3.138
Ko, D. 3.345, 3.373 Kubota, M. 1.116 Landazuri, P. A.07 Legido, A. 3.312
Ko, T. 1.036, 1.328 Kubota, T. 1.224, 1.243 Landmark, C.J. 2.282, 2.308, 2.317, Legros, B. 1.141, 3.203, 3.226
Kobau, R. 2.074 Kubota, Y. 1.063 2.326
Lehesjoki, A. 3.089
Kobayashi, A. 1.233 Kubova, H. 1.052 Lane, J.B. 3.104
Lehmkuhle, M. 3.043
Kobayashi, E. 2.239 Kucewicz, M.T. 1.175, 2.156 Lang, A.E. 1.112
Leijten, F. 2.145
Kobayashi, J. 1.208 Kuchibhotla, K. 1.021 Lang, N. 2.199
Leitinger, M. 3.228
Kobayashi, K. 1.172, 1.365 Kuchukhidze, G. 2.068, 2.245 Langer, J. 2.267
Leland, M. 3.052
Kobayashi, M. 1.060 Kucuk, M. 1.053 Langston, M.L. 3.238
Lemesiou, A. 1.057
Kobylarz, E. 1.286, 2.042 Kucukboyaci, N. 2.005, 2.251 Lantz, G. 1.263
Lenz, F. 2.025
Koehn, M. 3.267 Kudela, P. 1.045 Lanyon, R. 1.082
Leon, Y.C. 1.101
Kogure, S. 1.233 Kuhlenbumer, G. 3.090 Laoprasert, P. 1.267, 2.012, 2.103,
3.279 Leon-Vazquez, M. 2.186, 2.334
Kumada, S. 1.116
LaPalme-Remis, S. 1.225 Leonard, S. 2.032
Kumada, T. 1.116
100
 ABSTRACT AUTHOR INDEX

Leppik, I. 1.272, 1.325, 3.317 Liu, R. 1.030, 3.107 Macaulay, D. 1.213 Marras, C. 3.360
Lerche, H. 3.089 Liu, S. 3.190 Macaya, A. 2.187 Marsh, E. 3.303
Lerner, J. 1.182, A.09 Liu, Y.C. 1.208 Machado, A. 2.239 Marsh, E.D. 3.099
Lervik, K. 3.205 Liu, Z. 2.261 Maciag, C. 1.303 Marsh, R. 1.175, 1.374, 2.156,
Lesage, F. 1.072, 1.260 Llerenas Zamora, R. 3.154 Mackay, M.T. 3.087 2.256, 2.337, 2.339
LeSure, S. 3.351 Llewellyn, N. 2.233, 2.286, 3.289 Mackenzie, S.J. 3.103 Marsh, S. 2.211
Leung, L. 2.236 Locke, D. 1.082 Mackie, E.J. 1.291 Marsh, S.T. 1.042
Leuthardt, E. 1.376 Loddenkemper, T. 1.098, 1.182, 1.197, Macrodimitris, S. 1.285, 2.071 Marson, A. 1.109
Leventer, R.J. 1.120 1.329, 1.345, 2.035, 2.213, 3.202, Madakasira, P. 2.365 Marti, C. 3.236
Lvesque, M. 1.301, 3.121 3.235, 3.236, 3.246, A.05, B.06 Mader, E. 2.114 Martin, R.F. 3.018
Levi, O. 3.008 Loeb, J. 1.004 Mader, M. 1.129, 2.358 Martinez, G. 1.296
Levin, H. 2.240, 2.247 Loesch, A. 2.165, 3.211 Madhavan, D. 2.197 Martinez, J. 1.295
Levin, S. 2.223 Loi, R.Q. 2.005 Madhavan, R. 2.025 Martinez, R.C. 2.114
Levitt, J. 1.252, 1.254, 3.254 Long, X. 1.023 Madsen, J. 2.025 Martinez-Juarez, I.E. 2.186, 2.334
Levy, S. 2.350 Longo, D. 2.146 Madsen, J.R. 1.366 Martinez-Perez, A. 2.186
Lewis, E. 1.225 Longo, F.M. 1.299 Maehara, T. 2.091, 2.093, 2.097 Martins, A. 3.046
Lewis, E.C. 2.141, 2.346 Lopes, T.M. 3.259 Maertens, P. 2.115 Martins, S. 3.046
Lewis, M.L. 3.124 Lopes-Cendes, I. 3.046 Maganti, R. 3.033 Martz, G.U. 2.160
Leyden, K. 2.005, 2.251 Lopez, C. 2.299, 3.307, 3.353 Magdassi, S. 3.063 Martnez Agredano, P. 3.311
Leymon-Porter, B. 2.031 Lopez, M. 2.191 Magestro, M. 3.126 Martnez-Jurez, I.E. 3.073
Lhatoo, S. 2.090, 2.126, 3.127, 3.160 Lopez Dequit, I. 3.309 Magge, S. 1.354, 3.355, 3.364 Maruo, T. 1.060, 2.357
Li, B. 2.051 Lpez-Gomriz, E. 1.332 Mah, S. 2.051 Maruyama, A. 1.220
Li, H. 3.175 Lpez Gonzlez, F. 1.332, 2.300 Mahajan, R. 3.171 Masel, T. 3.269
Li, L. 3.334 Lpez Pizano, A. 3.154 Maher, D. 2.227 Mason, K. 1.151, 2.252
Li, M. 3.222 Lopez-Trigo Picho, F. 1.332 Maheshwari, A. 3.054 Mason, S. 1.288
Li, N. 1.076 Lora, P. 3.325 Mahmood, N. 2.215 Massaro, A. 1.137
Li, P. 1.214, 2.125 Loring, D.W. 2.320, 3.344, B.08 Mai, R. 2.184 Massey, S. 2.170
Li, S. 1.231 Lsch, C. 2.277 Maideniuc, C. 2.214 Massot-Tarrs, A. 1.185
Li, T. 1.005, 3.298 Loscher, W. 1.070 Maillard, L. 2.226 Matagne, A. 1.298
Li, W. 1.164 Losey, T. 3.146 Mailo, J.A. 2.130 Mateo, M. 3.051
Li, Y. 1.007 Losher, C. 2.165 Majmudar, S. 1.089 Mathern, G. 1.245, 1.357, 2.355,
Liang, L. 3.032 Lossius, M. 2.072, 2.231 Makeyev, O. 3.073 2.358, 3.255, 3.262
Liang, W. 3.300 Loturco, J. 3.002 Makin, C. 2.044, 2.297 Matkovic, Z. 1.231
Libbey, J.E. 3.117 Loughman, A. 1.279 Makinson, C. 3.106 Matos, A. 3.046
Libenson, M. 3.236 Louise, G. C.01 Malek, A.M. 3.142 Matosevic, B. 2.121
Lie, O. 2.028 Love, T.E. 1.347 Maliia, M. 3.069 Matsui, T. 2.353
Liebenthal, J. 2.102 Lovell, K. 2.131 Malik, A. 2.206 Matsumoto, H. 1.116
Ligot, N. 1.141 Lovick, T. 3.036 Malik, M. 2.230 Matsumoto, J. 1.175, 1.182, 2.156,
Lowden, A. 1.210 3.330
Lilja, I. 3.025 Malik, S. 2.250
Lowe, H. 1.208 Matsumoto, N. 1.105, 1.116
Lillis, K. 1.011, 3.004 Malinowska, U. 3.189, 3.191
Lowen, K. 1.338 Matsumoto, R. 1.350, 2.335
Lim, B. 1.119, 1.195, 1.212 Maljevic, S. 3.089
Lowenstein, D. 3.095 Matsuo, F. 3.150
Lim, S. 2.362, 3.021 Mall, E.M. 1.069
Lozano, M. 2.286 Matsuo, T. 1.177
Lim, S.N. 3.221 Maloney, T. 2.024
Lu, Y. 1.268 Matsuura, M. 2.091, 2.093, 2.097
Lima, A.M. 2.344, 3.372 Malykhin, N.V. 1.253
Luan, G. 1.005, 1.365, 3.352 Matthews, S.A. 3.341
Lima, E. 3.076 Mamelak, A. 1.126, 2.181
Lucchese, L. 3.126 Mattson, R. 2.350
Lima, P.B. 3.179 Mandadi, S. 1.025
Luczak, A. 1.017 Matur, Z. 2.224
Lima Castro, C. 3.082 Mandel, A. 3.233
Lin, C. 1.351 Lders, H. 2.126, 3.160, A.07 Mandelstam, S. 3.087, 3.092
Maturu, S. 2.215
Ludmir, E.B. 1.006 Maurer Morelli, C. 3.046
Lin, J. 1.352, 2.004, 2.013, 3.270, Mandrekar, J. 1.374
ABSTRACT AUTHOR INDEX
3.283 Ludwig, E. 1.312, 1.314, 1.319, Mauri, J. 1.332
Manganaro, S. 1.132, 1.142, 2.063,
Lina, J. 1.178, 2.239 1.320, 1.321 2.162, 3.240 Mavroudakis, N. 1.141
Linane, A. 1.280, 3.152 Luef, G. 2.121, 2.245, 2.262 Manganas, L. 1.132, 1.135, 2.162 Maxwell, C. 1.285
Lindsay, K. 1.109 Lugo, J. 1.292, 3.105, C.07 Mangano, F. 1.353 Mayer, T. 3.077, 3.293, 3.297, 3.349
Lineweaver, T. 1.093, 1.099 Lukic, V. 3.100 Manitpisitkul, P. 1.309 Mayes, L.C. B.01
Liow, J. 1.002 Luna-Munguia, H. 3.042 Mann, A. 3.063 Mays, V. 2.173, 3.201
Lippman-Bell, J. 3.001 Lundstrom, B. 1.176 Mann, K. 1.090 Maytal, J. 2.128
Lipski, W.J. 1.073 Luo, C. 3.285 Manreza, M.G. 2.119, 3.143 Mazarati, A. 1.055, 1.056, 1.289
Lipton, R.B. 2.180 Lupien-Meilleur, A. C.01 Mapstone, T.B. 2.349 Mbelwa, S. 2.089
Liscano, A. 2.363 Lushbough, C. 1.085 Marchal, C. 2.226 McArthur, D. A.09
Lisicki, D. 1.101 Lutz, M.T. 3.077 Marcotegui, I. 2.153 McAuley, J. 1.306
Liska, J. 3.120 Luu, P. 1.180, 1.263, 3.193 Mares, P. 1.051, 1.052 McBee, N. 1.324, 2.285, 2.286,
Ly, C. 1.009 2.287
Lispi, M. 2.146 Mari, F. 1.108
Lyons, R. 1.288, 2.026 McBrian, D. 3.233
Litt, B. 3.183, 3.256 Marin, A. 2.363
McCarthy, A. 1.203
Liu, C. 3.373 Marini, C. 1.108, 1.115
Liu, G. 1.038 M Marino, S.E. 2.329
McCarthy, D. 1.184
Ma, Y. 1.299 McCoy, B. 1.189, 3.239, 3.306
Liu, K. 2.032 Mariyappa, N. 1.143
Maa, E. 3.304, 3.319 McCredie, R. 3.286
Liu, M. 1.237, 2.081, 3.261 Marquardt, F. 3.045, 3.058
McDonald, C. 2.005, 2.251
Marquez, Y. 3.373
101

McDonald, S. 2.318
McDonough, T. 2.221
McGoldrick, P. 3.316, 3.356
McGrade, H. 3.225
McGuire, R. 1.067
McIntosh, A. 1.231
McKee, H.R. 1.280
McKhann, II, G.M. 2.027, 3.233
McLachlan, R. 1.185
McLellan, A. 1.092, 2.015
McMahon, J. 1.103, 3.086, 3.087
McNamara, J. 1.006, 1.038, 1.269
McNamara, N. 3.230
McNaughton, B.L. 1.017
McPhillips, M. 1.092
McShea, C. 3.291, 3.292, 3.295,
3.299
Meador, K.J. 2.295, 2.320, 2.339,
3.168, 3.344, B.08,
Mealey, R. 2.135
Mecchella, J.N. 1.286
Medvedev, A. 3.073
Mefford, H. 1.103, 3.086, 3.087,
3.092, 3.093
Megevand, P. 1.157, 3.177, 3.346
Mgevand, P. 2.246
Meheov, S. 2.304
Mehrizi, M. 2.152
Mehrotra, K. 2.268
Mehta, A. 1.157, 2.011, 2.246,
2.256, 2.339, 3.177, 3.346
Mehta, D. 2.029
Meisler, M. C.09
Melaiki, B. 1.104
Melanson, D. 1.121
Memon, A.B. 3.266
Mendes, P.S. 2.119, 3.143
Mendes, S. 2.298, 2.305
Mendez, D. 2.045
Mendoza, L. 1.257, 1.310
Mendoza, M. 2.176
Menezes Cordeiro, I. 3.163
Menon, J. 3.175
Menon, U. 2.066
Mercan, M. 1.207
Mercedes, B. 2.226
Mercier, J. 2.332
Mercier, M. 3.177, 3.346
Mesad, S. 1.131
Mese, T. 1.229, 3.328
Messinger, M. 2.299, 2.333
Metcalfe, A. 2.082
Mevg, M.A. 2.317, 2.326
Meyer, F. 1.175, 1.374, 2.156
Meyer, K. 1.344
Meyer, M. 3.034
Meyers, E. 3.203, 3.226
Miao, H. 3.051
Michalak, Z. 3.110
Michaud, J.L. 3.093
Michel, C. 2.244
Michelhaugh, S. 3.313
Michelucci, R. 1.113
Michoulas, A. 3.220, 3.327
Midi, I. 3.151
Midura, M. 1.062
Mikati, M. 3.095, B.06
Mikkelsen, T. 3.098
102
ABSTRACT AUTHOR INDEX
Mikulis, D. 3.200 Morales-Quezada, J. 3.009 Nachbauer, W. 2.121
Mikuni, N. 2.335 Moran, J. 1.151 Nadasdy, Z. 3.070
Milder, J. 3.095 Morawo, A. 1.076 Naduvil Valappil, A. 1.149, 1.192,
Miles, L. 3.111 Moreira, C.L. 3.332 1.362
Miles, M. 3.111 Moreland, S. 3.205 Naeije, G. 1.141
Milh, M. 2.263 Morgan, L. 2.028 Nagarajan, E. 1.197, 2.035, 2.213,
Milham, M. 2.246 Morgan, V. 2.117 3.235, 3.236, 3.246
Millan, C.M. 2.241 Morgan, V.L. 2.242 Nagasawa, T. 2.202
Millen, K.J. 1.043 Morisada, N. 1.220 Nagase, H. 1.220
Miller, I. 2.346 Morita, A. 3.365 Naik, M. 2.159
Miller, J. 1.372, 2.039, 2.126, A.07 Morita, D. 1.090, 2.024, 2.316 Naik, P. 2.092
Miller, J.A. 3.122 Morita, M. 1.377, 3.259, 3.260 Nair, D. 1.063, 1.153, 1.216, 2.212,
2.249
Miller, R.J. 3.116 Morrell, M. 1.216, 2.209, 2.212, B.08
Nair, S. 3.079
Miller, S. 3.024 Morris, C. 3.367
Najimipour, B. 1.068
Miller-Horn, J. 3.173 Morris, G. 1.333
Najm, I. 1.008, 1.012, 1.040, 1.058,
Millett, D. 3.373 Morse, C. 1.002 1.063, 1.240, 1.362, 1.377, 2.073,
Millichap, J. 3.210, 3.157, 3.214 Moschetta, S. 3.076 2.249
Milligan, C.J. 1.291 Moschetta, S.C. 3.082 Nakae, T. 1.350, 2.335
Minassian, B. 3.093 Moseley, B.D. 2.228, B.05 Nakagawa, E. 1.116, 1.147, 2.225,
Mindruta, I. 1.191, 3.069 Moseley, M. 1.006 2.341
Minotti, L. 1.191, 1.348 Mosher, J. 1.063, 1.149, 2.249 Nakagawa, T. 1.220
Mintz, M. 2.016, 3.094 Mosh, S. 1.305 Nakajima, M. 1.145, 1.363, 1.370,
Mintzer, S. 2.291 Moss, A. 3.132 2.174, 3.012, 3.108
Nakamura, K. 1.116
Miotto, E.C. 2.119, 3.143 Moss, R. 1.065
Nakane, S. 2.174
Miozzo, M. 2.027 Motamedi, G. 1.202
Nakanishi, S. 3.019
Mirchandani, N. 1.181 Motelow, J. 1.044, 1.164
Nakano, H. 1.110
Mirro, E. 1.209 Motika, P. 1.277
Nakasato, N. 1.367, 2.132, 2.149,
Mirsattari, S. 1.185 Motil, K.J. 3.104
2.154, 3.159
Mirsky, D. 1.267, 3.279 Moufawad El Achkar, C. 3.361
Nakashima, M. 1.105, 1.116
Mirza, N. 1.109 Moura, L.V. 2.045
Nakayama, T. 1.367
Misajon, J. 1.133 Moussa, N.A. 2.001
Nakhutina, L. 1.085
Miskin, C. 3.312 Mower, A. 3.241
Nakken, K. 2.231
Misra, S.N. 1.215 Mowrey, W. 1.304, 1.305
Nam, H. 1.218
Mitchell, W. 3.145 Mrelashvili, A. 1.364
Namihisa, Y. 2.060
Mittal, M. 2.111 Mucci, G. 2.013
Nampoothiri, S. 2.182
Mittal, S. 3.062, 3.313 Mudugal, D. 2.197
Napuri, S. 2.263
Miura, K. 1.224, 1.235, 1.243 mueller, A. 2.195
Narayana, P.A. B.03
Miyama, S. 1.116 Mueller, G.P. A.08
Narayanan, M. 1.148
Miyamoto, S. 1.350, 2.335 Mueller, M. 2.271
Narugami, M. 2.174
Mizrahi, E. 2.212 Muhle, H. 1.115, 3.090
Nascimento, D. 3.046
Modi, A. 1.090, 1.091, 2.316 Muhonen, M. 2.013
Nash, K. 1.182
Modur, P. 1.077, 2.038, 2.131, 2.193, Mullatti, N. 1.067
3.070, 3.083 Nassar, M. 2.175
Mullins, J.G. 1.111
Moeller, J. 2.296 Nasuti, P. 3.126
Muma, E. 2.215
Moffett, B.S. 2.333 Natsume, J. 1.224, 1.235, 1.243,
Muniz, R. 3.301
2.158
Mohamadpour, M. 2.016 Munoz, J. 1.210, 3.083
Navarro, V. 2.226
Mohamed, I. 2.123, 3.370 Muona, M. 3.089
Naves, P. 2.327, 3.369
Mohamed, M.A. 2.272 Murakami, H. 1.149, 3.359
Navratilova, Z. 1.017
Mohammad, F. 3.122 Murata, K. 3.330
Ndayisaba, J. 2.068
Mohammadi, M. 1.127 Murphy, G. C.09
Neal, J. 2.082
Mohan, C. 2.268 Murphy, M. 1.232
Nearing, B.D. 3.218
Mohanarangan, K. 2.208 Murphy, W. 2.067, 3.139
Negishi, M. B.01
Mohanraj, R. 1.109 Murro, A.M. 2.212
Negoro, T. 1.224, 1.235, 1.243
Moheet, A. 2.227 Muzik, O. 3.062
Negrin, S. 2.122
Molins, A. 1.332 Myers, C. 3.086
Neher, J.J. 3.116
Mller, R.S. 1.115, 1.118 Myers, L. 1.083, 1.088
Neil, J. 2.059, 3.246
Monica, N. 2.085 Mylius, J. 3.045
Neimat, J. 2.117
Monrad, P. 3.215 Myseros, J. 1.354
Nelson, D. 2.131, 3.070
Montalvo, J. 3.101 Mytinger, J.R. 3.147, 3.157, 3.223
Nelson, E.B. 1.257
Montandon, G. 1.010, 3.200
Nelson, G.R. 2.134
Montoya, J. 1.332 N Nemes, A. 1.008, 1.012, 1.040
Moon, C. 1.196 N Guyen The Tich, S. 2.263
Nemoto, M. 1.233
Moon, H. 1.202 Na, G. 3.091
Neppe, V.M. 2.062
Moon, J. 2.168, 3.196 Nabatame, S. 1.105
Nespeca, M. 2.104, 3.241
Moore, J.L. 2.006 Nabbout, R. 2.187, 2.263, 3.016
Nettel-Aguirre, A. 3.172
Moorley, N. 1.198, 1.199, 1.200, Nabors, L.B. 1.330
1.201 Neubauer, B. 1.115, 2.204
Nabulsi, N. 2.332
Moraes, V. 2.306
 ABSTRACT AUTHOR INDEX

Neufeld, M. 3.197 Obari, D. 3.110 P Patten, S.B. 1.285

Neul, J.L. 3.104 Obata, K. 2.080 Pacheco, J. 3.083 Patterson, C. 3.331
Neumann, A. 1.017 Obeid, R. 2.159 Pacheco, L. 1.295 Patterson, E. 1.372
Neveux, M. 1.020 Oberaigner, W. 2.068 Pacheco-Phillips, J. 2.049 Patterson, K.P. 1.009
Newman, R.B. 3.142 Oberman, L. 3.337 Pack, A. 2.234, 3.140 Patwardhan, R. 2.256, 2.337, 2.339
Ng, E. 2.128 Ochi, A. 1.127, 1.145, 1.172, 1.189, Pack, C. 3.121 Paudel, S. 2.319
Ng, M. 2.113 2.353, 3.108, 3.153, 3.306 Paige, A. 1.324, 2.285, 2.286, 2.287 Pavlova, M. 2.151
Ng, Y. 2.201, 2.349 Odom, N. 2.057, 3.248 Painter, M. 2.159 Payne, E. 1.182, 3.059
Ngo, T.P. 3.307, 3.353 Ogawa, C. 1.243 Pakhomov, S.V. 2.329 Pazarci, N. 2.183
Nguyen, D. 1.072, 3.274, 3.370 Ogden, K. 3.363 Palacios, A. 3.053 Pazdera, L. 1.318
Nguyen, D.K. 1.260, 2.123 Oguni, H. 1.365 Palao-Duarte, S. 2.078 Pearce, P.S. 3.072
Nguyen, D.V. 2.123 Oh, A. 2.185 Palat Chirakkara, S. 1.239 Peariso, K. B.06
Nguyen, L. 3.048, 3.050 Oh, M. 1.221 Palestrant, D. 2.227 Pearl, P. 1.197, 1.225, 3.065, 3.246,
Nguyen, M. 1.030, 2.123 Ohshima, M. 2.060 Palmquist, M. 1.094 3.325
Nguyen, V. 2.322 Ohta, K. 2.091, 2.093, 2.097 Palotie, A. 3.089 Pearson, J. 3.032
Ni, J. 1.043 Oijala, M. C.03 Pan, H. 2.236 Pedersen, M. 2.243
Nick, S. 1.267 Ojemann, J. 1.250, 3.280, 3.282, Pan, J.W. 3.072 Pedersen, N.P. 1.162
Nickels, K. 1.193, 1.355, 1.364, 3.368, Pedraza Benitez, C. 3.311
Pan, P. 3.255, 3.262
2.079, 2.203, 3.148, 3.158, 3.223, Okanari, K. 1.127, 1.145, 2.353, Peeters, P.A. 2.307
3.108 Pan, Y. 2.040
3.229 Peglar, L. 3.324
Okanishi, T. 1.127, 1.172, 1.371 Pandey, R. 1.275
Nicolas, J. 2.310, 2.332 Pei, F. 3.178
Okeke, J.O. 2.275, 3.081, 3.135 Pandian, A. 3.105
Nicoletti, J. 3.105 Peinhof, S. 2.040
Okoshi, Y. 2.202 Panduranga, A. 2.177
Niemann, H. 1.069 Pelayo, M. 2.126
Oktem, O. 2.224 Panel, I. 2.342, 3.350
Nikanorova, M. 1.118 Pella, R. 2.028
Okumura, A. 1.224 Pang, T. 1.188, 1.205
Nikolov, R. 3.265 Pellegrino, G. 2.239
Okumura, E. 3.159 Panigrahy, A. 2.159
Nikolova, S. 3.265, 3.277 Pelliccia, V. 2.184
Olafsson, E. 3.128 Paolicchi, J. 2.221
Nishida, S. 1.350, 2.335 Peltier, A. 1.187
Oldham, M. 3.324 Papadelis, C. 2.213, 3.202, 3.235
Nishioka, K. 2.353 Pendziwiat, M. 1.115, 3.090
Oliveira, L.A. 3.165 Papale, L. 1.046
Nishiyama, M. 1.220 Peng, K. 1.260
Oliver, K.L. 3.089, 3.100 Parada, I. 1.299
Nita, D.A. 1.172 Peng, S. 3.271
Olney, N. 2.108 Pardoe, H.R. 3.258
Nixon, J. 3.280, 3.282 Pennell, P. 2.233, 3.289,
Olson, A. 2.046 Paredes Saenz, C.F. 1.158
Noachtar, S. 1.124, 2.165, 3.211, Penovich, P. 1.288, 1.320, 2.046
3.273 Olson, L. 1.339 Parent, J. 3.002, 3.005, 3.006, C.02,
C.09, Perchyonok, Y. 1.120
Noack - Rink, M. 3.293, 3.297 Oltmanns, F. 3.349 Percy, A.K. 3.104
Parent, R. C.09
Nobile, C. 1.113 Oluigbo, C. 1.354, 2.351, 3.355, Perez, D.L. 2.236
3.364 Parikh, P. A.06
Nobili, P. 3.029 Perez, E. 3.074
Omar, N. 3.348 Park, B. 2.238
Noe, K. 2.166 Perez Velazquez, J. 1.010
Omurtag, A. 3.181 Park, C. 1.130
Noebels, J. Perez-Ruiz, J. 2.186
Ono, T. 1.359, 1.361 Park, E. 1.366
Noh, G. 2.083 Perkins, F.F. 2.354
Onomura, A. 1.373 Park, H. 2.315
Nonoda, Y. 1.116 Perlman, J.M. 2.221
Oommen, B. 2.135, 3.302 Park, J.T. 2.167
Norcia, A. 3.178 Pernot, F. 1.039
Opperman, C. 2.021 Park, K. 1.110, 1.218, 3.210
Nordli, D. 1.222, 3.244 Perry, L. 1.247, 1.249
Orhan, N. 1.053 Park, S. 1.030, 1.081, 1.218, 1.282,
Norman, J.L. 2.110 1.313 Perry, M. 2.022, 2.250
Nourski, K.V. 1.079 Orii, K. 1.116
Parker, P. 1.331 Perucca, P. 2.358
Novak, H. 3.228 Orozco-Suarez, S. 1.001
Parko, K. 2.058 Perumpillichira, J.C. 3.158
Novak, Z. 2.003 Orton, K. 2.134
Parra, M. 1.194 Perven, G. 1.226
Noviawaty, I. 1.192 Osaka, H. 1.116
Parsons, K. 1.030 Perzynski, A.T. 1.084
Novotny, E. 1.250, 3.280, 3.282 Osako, M. 2.060
Parsons, T. 2.022 Peters, J. 1.098
Nowell, M. 1.057 Osawa, S. 1.367
Parthasarathy, S. 1.148 Peters, P.A. 1.175

ABSTRACT AUTHOR INDEX

Nozaki, T. 3.365 Osborn, M. 1.338
Pascoal, V. 3.046 Petersen, B. 1.069
Nuno, M. 2.227 Oshino, S. 1.060, 2.357
Pascual, F.T. 2.034 Petersen, C. 2.266
Nussbaum, N. 2.354 Osorio Santiago, A. 3.154
Pascual, J. 1.054 Petit, J. 2.226
Oster, J. 3.347
Pascual-Leone, A. 1.154, 1.205 Petroff, O. 1.135, 3.204
O Ostuni, J. 3.268
Passarell, J. 1.312, 1.314, 1.319, Petrou, S. 1.291, 3.089
OBrien, C. 2.053, 3.205, 3.304, Otsubo, H. 1.127, 1.145, 1.172, 1.320
1.189, 2.353, 3.108, 3.153 Petty, S.J. 1.291
3.320 Passe, T. 2.235
Otsubo, T. 2.002 Phelan, J.C. 2.275, 3.081, 3.135
OBrien, T. 1.231 Passen, N. 1.306
Otsuka, K. 2.174 Phillips, B. 3.304
OBrien, T.J. 1.047, 1.291 Passmore, C. 1.037
Otsuki, T. 1.147, 1.365, 2.225, 2.341, Phillips, K. 1.026
OCallaghan, F. 2.187 Patel, A. 2.055, 2.319, 3.130
3.114 Picard, R. 2.213, 3.235
OConnell, R.M. 3.117 Patel, A.B. 1.278
Ottman, R. 2.275, 3.081, 3.135 Pickrell, W.O. 1.111
ODay, K. 1.344 Patel, M. 3.032, 3.052, 3.066
Othal, J. 1.051 Pieters, H. 1.357, 3.217
ODonovan, C. 3.367 Patel, P. 1.341, 3.231
Oya, H. 1.079 Pike, V. 1.002
OHara, B.F. 1.071 Patel, R. 1.294
Ozbek, D. 3.151 Pillai, A. 2.366
ONeal, W. 2.303 Pathmanathan, J. 1.184
Ozdag, F. 3.170 Pillay, N. 2.067, 2.150, 2.198, 3.139
ONeill, B. 1.267 Patil, V. 3.048, 3.050 Pilli, V. 1.251
Oba, S. 2.353 Pato, A. 2.300, 3.309 Pilz, G. 3.228
Patten, S. 2.071 Pina-Garza, J.E. 2.293
Ping, X. 1.155
103
 ABSTRACT AUTHOR INDEX

Pinheiro Martins, A. 3.055 Q Redondo Verge, L. 3.311 Rodrigues Ximenes Goldberg, K. 2.274,
Pinto, L.F. 3.204 Qiang, J. 2.232 Reed, C.M. 2.181, 2.321, 2.336 3.199
Pinzon-Ardila, A. 3.192 Qing, K. 3.036 Reed, R. 3.314 Rodriguez, C. 2.238
Pirmohamed, M. 1.109 Quach, M. 3.188 Reed, U.C. 2.119, 3.143 Rodriguez, J. 1.295
Pirotte, B.D. 2.166 Que, G.T. 2.066 Rees, M.I. 1.111 Rodriguez Casero, M.V. 3.087
Pita, I. 3.101 Quelen, C. 1.334, 1.335, 1.336 Reese Jr, J. 2.142 Rodriguez Osorio, X. 2.300, 3.309
Pittau, F. 2.244 Quigg, M. 1.209 Regan, B.M. 3.088 Rodriguez Uranga, J. 1.332
Pittman, D.J. 1.264, 3.186 Quinn, H. 2.064 Regnier-Golanov, A. 3.048, 3.050 Rodriguez-Osorio, X. 1.332
Pittman, Q.J. 3.124 Quinn, K. 3.066 Rehman, R. 2.048, 2.077 Rodrguez Arias, L.R. 3.154
Pixley, L. 3.326 Quiroga Subirana, P. 3.311 Reid, C. Roehl, K. 2.205
Pizzo, F. 3.161 Qulu, L. 3.124 Reif, P.S. 3.090 Roers, E. 1.337
Plank, G. 2.136 Quraishi, I. 1.062 Reimers, A. 2.282 Roessler, K. 1.146, 1.346
Platel, J. 1.039 Quraishi, I.H. 3.016 Reinsberger, C. 2.213, 3.235 Rogawski, M.A. 2.279
Plegue, M. 1.096 Qureshi, M. 2.206 Reisdorph, N. 3.066 Rogers, B.P. 2.242
Plummer, C. 2.147 Rektor, I. 2.003 Rogers, J. 3.052
Poddar, K. 2.201 R Remi, J. 1.124, 2.165 Rogin, J. 1.314, 2.290
Poduri, A. 3.034, 3.087, 3.095 Rabinovitz, B. 2.029 Rmi, J. 3.211 Rojas, N. 3.192
Pohlmann-Eden, B. 2.171 Rabinowicz, A.L. 1.213 Remigio, G.J. 3.020 Romain, J. 2.013
Pojomovsky, P. 3.233 Radhakrishna, S. 3.136 Rener Primec, Z. 1.105 Romatoski, K. 1.154, 1.188
Polack, P. 1.039 Radtke, R. 3.113 Renfroe, B. 2.294 Romeo, A. 2.338
Poliachik, S. 1.241, 1.250, 3.280 Raedt, R. 1.017, 3.028, C.08 Rensing, N. 1.024, 3.013 Romero Acebal, M. 3.311
Poliakov, A.V. 1.241, 1.250, 3.280, Ragazzo, P.C. 2.274, 3.199 Resnick, T. 2.303 Romero-Godoy, J. 3.311
3.282 Raghavan, M. 2.148 Restrepo, C. 3.315 Romigi, A. 1.108
Politsky, J. 1.131, 1.140 Ragheb, J. 2.346 Reutens, D. 1.035, 3.281 Rompies, E. 3.324
Pollard, H.B. A.08 Rai, A. 3.063 Rheims, S. 1.348, 2.226, 2.263 Ronen, G. 1.100
Pollard, J. 1.324, 2.135, 2.285, Rai, P. 3.212 Rho, J.M. 1.030, 3.124, 3.327 Rosa, M. 2.310
2.286, 2.287, 3.208, 3.302 Rhone, A.E. 1.079 Rose, D. 1.152, 1.353
Rai, S. 3.137
Pollard, J.R. A.08 Riaz, A. 3.079 Rose, K. 1.075, 2.195
Raible, D. 3.031
Polli, J. 2.330, 3.288 Ribot, R. 2.063, 2.264 Rose, S. 2.102, 3.160
Rajaraman, R. 2.108, A.09
Polster, T. 1.115 Richards, S. 2.040 Rosenbaum, P.L. 1.100
Rajasekaran, K. 1.054, 3.115
Polyak, B. 3.063 Richardson, J. 2.064 Rosenberg, E. 2.309
Rajasekaran, V. 1.374, 3.158
Ponce Mejia, L. 3.269 Richardson, M. 1.073, 2.147 Rosenfeld, W. 1.315
Rajyaguru, R. 3.270, 3.283
Ponticello, L. 2.064 Richardson, Z. 1.281 Rosenow, F. 3.090
Rama Madhava, A. 2.065
Pooladian, A. 3.370 Richeh, W. 2.114 Rossi, M.A. 1.074, 2.085, 2.241
RamachandranNair, R. 2.065
Popli, G. 2.210, 2.256, 2.337, 2.339, Richerson, G. 1.164 Rossignol, E. 3.093, C.01
3.367 Raman, K.R. 1.278
Ramey, P. 1.338 Riebe, I. C.01 Rotenberg, A. 1.158, 1.302, 3.009,
Porter, B. 3.178 3.034, 3.044, 3.337
Ramirez, C. 1.101 Riley, C.L. 3.176
Portnoy, E. 3.063 Roth, R.M. 1.086, 3.080
Ramirez, F. 3.293, 3.297 Riley, J. 2.013, 3.270, 3.283
Poublanc, J. 3.200 Rothermel, R. 3.062, 3.362
Ramon, C. 3.187 Riley, K. 2.338, 3.348
Pouliot, P. 1.260, 3.274 Rothman, S. 1.372
Rampal, N. 1.135, 3.204 Rios-Motta, M. 2.096, 3.101
Pouliot, W.A. 3.047 Roucard, C. 1.039
Rampp, S. 1.146, 1.346, 3.058 Rios-Motta, R. 2.096
Powell, E. 3.018 Rowley, S. 3.032
Ramsay, E. 2.107, 3.225 Rismanchi, N. 3.241
Powell, K.L. 1.047 Roy, A. 1.043
Ramsay, R. 3.219 Risse, G. 1.080, 2.026
Poza Aldea, J. 1.332, 3.309 Roy, A.G. 2.182
Ramsay, R.E. B.02 Ritacco, D.G. 1.222
Prayson, R. 1.144, 1.240 Rozen-Zvi, M. 2.033
Ramsey, R.K. 1.084 Ritchie, H. 2.057
Prescott, J.S. 2.324 Rozhkov, L. 3.111
Ramsey-Williams, V. 3.175 Ritter, F. 2.021, 2.235
Press, C. 1.326 Rubio Esteban, G. 3.311
Rana, S. 3.133 Rivard, K.B. 1.217, 3.019
Prieschl, M. 2.121, 2.262 Rubio-Nazbal, E. 2.300
Randall, M. 1.034 Rizzi, M. 3.360
Prince, D.A. 1.299 Rudd, D. 3.294
Rankin, S. 1.043 Robbins, E. 2.302
Prince, R. 3.356 Rudoinov, R. 1.057
Ransom, C. 1.015 Robert, M. 3.274, 3.370
Privitera, M. 1.324, 2.228, 2.285, Rueda, C.H. 1.050
2.286, 2.287, 3.288, Rao, L. 3.249 Roberts, H. 1.213
Roberts, J. 1.284 Ruiz Chow, A. 2.334
Pro, S. 2.146 Rao, S. 3.250
Robichaud, A. 1.303 Runge, U. 3.293, 3.297
Probasco, J. 3.226, 3.203 Raol, Y. 3.039
Robichaud, A.J. 1.296 Russek, S. 3.003, 3.011
Probst, L. 2.268 Rappoport, D.A. 1.049
Robinson, L. 2.237 Russo, G. 2.311
Proix, T. 3.182 Rapuano, A. 3.072
Robinson, S. 1.150 Rutecki, P. 2.209
Prusa, C. 1.306 Rasina, A. 3.069
Rocha, C.S. 3.046 Rutishauser, U. 1.126, 2.181
Pugh, M. 2.059, 2.257 Rau, S. 1.096
Rocha, F. 1.273, 1.287, 1.315, 1.316, Rutka, J. 1.172, 1.189, 2.353
Puka, K. 1.095, 3.306 Rawal, P. 1.281, 2.319
1.319, 1.320, 1.322, 2.278 Ruttle-Soon, L. 1.360
Pullum, B. 2.110, 2.364 Rayer, K. 1.169
Rocha, L. 1.001 Ruvalcaba, N. 1.295
Punia, V. A.02 Raygor, K. 1.369
Rodan, L. 2.124 Ruwald, M. 3.132
Pushchinska, G. 1.181 Raynes, H. 3.356
Rodgers, K. 3.038 Ryan, B. 2.056
Pustina, D. 1.255, 2.237 Raa Martnez, N. 2.300
Rodgers, K.M. 3.047 Ryan, C. 3.325
Puthenveettil, V. 2.182 Rebessi, E. 3.360
Rodgers, P. 1.140 Ryan, E. 2.057
Puttachary, S. 3.027 Reck-Peterson, S. 1.121
Rodrigues, L. 2.327 Ryan, N. 3.157, 3.223
Pylypyuk, V. 2.241 Reddy, D. 1.029, 1.031, 1.032, 1.033
Rodrigues Velasco, T. 3.055 Rychlik, K. A.01
Reddy, J. 1.239
Rydenhag, B. 2.342, 2.343, 3.350
Reddy, S. 2.299
Ryu, H. 1.195
104
 ABSTRACT AUTHOR INDEX

Ryvlin, P. 1.348, 2.226, 3.291, 3.292 Santamarina, E. 3.237, 3.309 1.167, 2.180, 2.358, 3.068 Shegog, R. 2.009, 3.075
Rzezak, P. 2.259, 3.076, 3.082 Santana-Gomez, C. 1.001 Schwabe, M.J. 1.173 Sheikh, A. 3.175
Santaniello, S. 1.061 Schwalb, J. 2.208 Shellhaas, R. 1.096, 1.136, 3.145,
S Santhakumar, V. 1.007 Schwambach Vieira, A.S. 3.046 Shen, A. 1.066
Saadatmand, H. 2.234 Santos, V.R. 1.048 Schwartz, M.L. 3.016 Shen, J. 2.131, 3.070
Saavedra Pieiro, M. 2.300, 3.309 Saper, C.B. 1.162 Schwarz, M. 3.222 Shen, S.C. 1.208
Sabatello, M. 3.081 Saponjian, Y. 1.021, 2.328, 3.022 Schwieterman, D. 2.286 Shen, V. 1.334, 1.335, 1.336
Sabau, D. 2.152 Saposnik, G. 2.032 Schnherr, M. 1.146 Shepherd, C. 3.126
Sabesan, S. 1.075, 2.195 Sarkar, C. 2.365 Scornavacca, G.F. 3.243 Sheriff, H. 3.241
Sabharwal, V. 2.107, 3.219, 3.225, Sarkis, R. 2.008, 2.213, 3.235, 3.289 Scott, J. 1.150 Sherman, E. 1.360
B.02 Sarma, A. 3.315 Scott, L. 1.025, 3.019 Shetty, A. 2.256, 2.337, 3.358, 3.371
Sabri, J. 1.131 Sarma, S.V. 1.061, 2.010 Scullion, K. 1.217 Shetty, J. 1.092, 2.015
Sacco, M. B.06 Sarode, A. 1.341 Secore, K. 2.042 Shi, Y. 1.309
Sackellares, J.C. 2.160 Sarria, S. 3.237 Secore, K.L. 1.086 Shiau, D. 2.160
Sade, E. 3.096 Sasaki, M. 1.147, 2.225, 2.341, Seeck, M. 2.244 Shibata, S. 1.350, 2.335
Saenz, J. 1.281 3.114 Seidenberg, M. 2.023, 3.267, 3.270 Shields, D. 1.216
Safi, D. 1.072 Satishchandra, P. 1.143 Seidl, S. 1.078 Shih, J.J. 1.349, 2.256, 2.337, 2.339,
Sager, M. 2.218 Sato, K. 2.080 Seif Eddeine, H. 2.127 3.238, 3.343
Sahin, D. 1.053 Sato, S. 1.150 Seignot, B. 3.375 Shih, S. 3.141, 3.144
Sahin, M. 3.044 Sato, Y. 1.145, 3.108, 3.153 Selassie, A. 2.087, 3.142 Shih, Y. 1.351
Sahin, S. 2.129 Sattar, S. 2.104, 3.241 Selby, K. 3.220 Shimoda, Y. 1.367
Sahoo, S.S. 3.085, 3.127 Sauer, C. 3.215 Selezneva, E. 3.045 Shimono, M. 1.116
Said, R. 1.210, 3.322 Saunders, G.W. 3.020 Selwa, L. 3.078 Shin, D. 1.218, 1.289, 3.338
Said, R.R. 2.088 Sauro, K. 2.051 Semah, F. 2.219 Shin, H. 1.159, 2.057
Saindane, A.M. 3.344 Savioli, A. 3.360 Semsarian, C. 3.088 Shin, J. 3.330, 2.168, 3.196
Sainju, R. 1.062, 1.135 Sawan, M. 1.072, 1.260 Sen, D. 3.294 Shin, W. 1.218
Saito, T. 2.225, 3.114 Sawchuk, T. 1.276 Sencer, S. 2.224 Shindo, K. 2.080
Saito, Y. 1.147 Sawer Jr, R. 2.125 Seneviratne, U. 1.227 Shinpoo, M. 1.116
Saitsu, H. 1.105, 1.116 Scantlebury, M. 1.025, 1.030, 1.217, Seo, D. 1.130, 2.207 Shiraishi, H. 2.174
Saiz-Diaz, R. 1.332 3.019 Seo, J. 1.130, 1.179, 2.014, 2.110, Shmuel, M. 3.063
Sajatovic, M. 1.084, 3.085, 3.127 Schaal, A. 2.248, 2.255, 3.276 2.253, 2.255, 2.348, 2.364, 3.276 Shmuts, R. 2.135
Sakaguchi, Y. 1.235, 1.243 Schachter, S. 1.232, 1.302, 3.218 Sepeta, L. 2.019, 3.084, 3.268, Shneker, B. 1.306, 2.278
Sakata, M. 2.060 Schaefer, C. 2.283, 3.290 3.272, 3.278 Shon, Y. 2.362, 3.021
Sakuma, S. 1.127, 1.145, 2.353, Schaffer, D. 2.029 Seppi, K. 2.068 Shostak, S. 2.275, 3.081, 3.135
3.108 Schaffer, S. 2.011 Serafini, A. 2.122 Shrestha, A. 2.053, 3.205, 3.304
Sakuraba, R. 3.159 Schalk, G. 2.248, 2.255, 3.276 Serafini, R. 1.004 Shults, J. 1.182
Salam, M. 2.084 Scharfman, H.E. 3.026, 3.037 Seraphim, E.A. 2.327 Shurtleff, H. 3.282
Salam, T. 1.010 Scheffer, I. 1.103, 1.115, 1.120, Sergio, G. 3.192 Shutter, L.A. 1.310
Salamon, N. 1.238, 1.245, 1.261, 3.086, 3.087, 3.088, 3.092, 3.095, Serioli, E. 1.113 Si, Y. 1.062, 1.076
1.278, 3.255, 3.262 3.100 Serout, F. 1.164 Siddarth, P. 1.252, 1.254, 3.254
Salanova, V. 2.212 Scheich, H. 3.045 Sethi, N.K. 1.271, 3.155 Siddiqui, K. 2.001, 2.188
Salas Puig, J. 1.332, 3.237, 3.309 Scheuer, T. 3.340 Seyal, M. A.06 Siddiqui, R.S. 2.188
Salinas, C.M. 2.014, 2.248, 2.253, Schevon, C. 1.057, 3.213, 3.253, Sha, Z. 3.190 Sidovar, M. 1.213
2.255, 3.276 Schiemann, J. 2.219 Shafer, P. 3.075, 3.218 Siebert, R. 1.115
Salinsky, M. 2.177, 2.269 Schiff, N. 1.044, 2.105 Shafi, M. 1.154, 1.205 Siedentopf, C. 2.245
Salituro, F. 1.296 Schildt, C. 1.071 Shah, A. 1.317, 1.321, 3.062, 3.174, Sieren, J. 2.286
Salpekar, J. 3.141 Schiltz, N. 2.090 3.232, 3.266, 3.313 Silbersweig, D.A. 2.236
Sampaio, L.B. 2.119, 3.143 Schmid, E. 2.245 Shah, P. 3.227 Sillanpaa, M. 2.018
Sampaio, L.P. 3.332 Schmidt, K. B.06 Shahlaie, K. 1.078 Sills, G. 1.109

ABSTRACT AUTHOR INDEX

Sampath, D. 3.039 Schmidt, M. 2.171 Shallcross, A. 2.007 Silveira, M.R. 3.179
Sams, J. 3.085 Schmidt, S. 1.159 Shandra, O. 1.304 Silvia, M. 2.210
Samson, K.K. 3.341 Schmiedel, G. 1.118 Shapiro, J.S. 2.043 Simeone, K. 1.293, 3.341
San Juan Orta, D. 3.154 Schmitt, F. 3.045, 3.058 Shapiro, M.J. 2.065 Simeone, T. 1.293
Sanchez Barrera, W.S. 2.190 Schmitt, F.C. 3.349 Shapiro, M.S. 1.165 Simeone, T.A. 3.341
Snchez Fernndez, I. 1.098, 1.182, Schmitt, S. 1.242, 3.203 Sharan, A. 1.255, 1.349, 2.256,
1.197, 1.329, 2.035, 3.246, A.05, Simon, N. 3.043
Schmitt, S.E. 3.226 2.337, 2.339
B.06 Simonson, C. 3.220
Schneider, S. 2.128 Shariff, S. 2.032
Snchez Ortiz, C. 3.311 Sinasac, D. 3.327
Schober, H. 2.169 Sharma, A. 2.228
Sanchez-Ortiz, L. 2.096 Sinclair, D. 2.178
Schoedel, K.A. 1.323 Sharma, B. 1.270
Sander, T. 1.115 Singer, R. 3.327
Schoenberg, M. 2.360, 2.361 Sharma, P. 1.047
Sander, V. 2.187 Singh, A. 2.007
Scholl, E.A. 3.043 Sharma, R. 2.201
Sandy, S. 2.150, 2.198 Singh, K. 2.196
Schomer, A. 3.218 Sharma, S. 3.027
Saneto, R. 1.250 Singh, M. 1.275
Schooley, D.E. 1.042 Shatila, A. 2.086
Sankar, R. 1.289, 2.108, 2.195, 2.355 Singh, P. 2.117
Schrader, D. B.04 Shaw, D.W. 1.241, 3.280, 3.282
Sankar, T. 3.261 Singh, R. 3.201
Schreiber, J. 3.065 Shaw, E.C. 2.074
Sankaraneni, R.R. 2.172 Singh, S. 2.150, 2.198
Schultz, L. 2.208, 2.215 Shaw, S. 3.373
Sansevere, A. 1.197 Singh, S.P. 2.041, 2.098
Schulze-Bonhage, A. 1.067, 1.129, Shea, K. 2.073
Sansevere, A.J. 3.246

105
 ABSTRACT AUTHOR INDEX

Sinha, S. 1.143, 1.148, 1.239, 2.106, Spiciarich, M.C. 2.061 Sugano, H. 1.358, 1.363, 1.370, Takumi, I. 3.365
2.188, 3.113 Spitz, A. 1.106 3.012 Talib, L.L. 1.122
Sinha, S.R. 2.160 Spitz, M. 2.053, 3.205, 3.304 Sukigara, S. 3.114 Talos, D.M. 3.041
Sinisterra, N. 2.363 Spreafico, R. 2.184 Sulc, V. 2.156 Talypov, A. 1.059, 2.076
Sirsi, D. 2.088 Sprengers, M. 1.017, 3.028, C.08 Sullivan, J. 1.136, 2.309, 3.095, Tamber, M. 3.331
Sirven, J. 3.294, 3.304 Spring, A.M. 3.186 3.214, 3.303 Tampieri, D. 1.121
Sisodiya, S. 3.110 Spritzer, S.D. 2.166 Suls, A. 1.115 Tan, M. 1.231
Sitwat, B. 3.331 Spruill, T. 2.007 Sumi, Y. 2.091, 2.093, 2.097 Tanaka, N. 1.256, 1.258
Siugzdaite, R. 3.028 Squillacote, D. 1.213 Sumpter, R. 2.015 Tanaka, S. 2.091, 2.093, 2.097
Sivaraju, A. 1.062 Srikanth Mysore, C. 2.197 Sun, F. 1.209, 2.209 Tanaka, T. 1.220
Skene, P. 3.113 Srinivasan, S. 3.253 Sun, H. 1.028, 3.007, 3.041 Tandon, N. 3.060, 3.375
Skibo, J. 1.043 St. Louis, E. 2.192 Sun, P.Y. 1.193 Tang, H. 2.025
Skidmore, C. 1.216, 1.255 St. Louis, L. 1.197, 3.246 Sunderam, S. 1.071, 1.077 Tang-Wai, R. 2.179
Skinner, S.A. 3.104 Staba, R. 1.177 Sundstrom, D. 3.218 Tangel, V. 2.275, 3.135, 3.081
Slansky, A. 2.063, 2.162 Stacey, W. 3.042, 3.067, 3.167, Sunkaraneni, S. 1.312, 1.314, 1.319, Tani, N. 2.357
Slater, J. 1.160, 3.181 3.182 1.320, 1.321
Tankovic, A. 3.014
Slick, D. 1.360 Stafstrom, C. 1.169, 2.023, 3.267, Sunnen, C. 3.050
Tanuma, N. 2.202
Smith, B. 1.027, 2.194 3.270 Sunwoo, J. 2.168, 3.196
Tao, J. 2.102, 3.160
Smith, D. 2.286 Staley, K. 1.011, 1.021, 2.328, 3.004, Suren, P. 2.072
Tao, W. 1.015
Smith, E. 1.057 3.022, 3.023 Suresh, S. A.07
Tapia, M. 2.037
Smith, G. 2.271, 3.105, C.07 Stamatoyannopoulos, J. 1.103 Sutton, S. 2.057
Taplinger, D. 2.267
Smith, J.D. 1.276, 3.327 Stamboulian-Platel, S. 1.039 Suwanpakdee, P. 1.240, 1.362
Tarquinio, D. 3.104
Smith, M. 1.095, 2.212 Standridge, S. 2.229, 3.247 Suzuki, H. 2.132
Tarrant, S. 3.325, 3.326
Smith, N. 1.044 Stanisic, M. 3.366 Suzuki, N. 1.256, 1.258, 2.154
Tasker, R. 1.197, 3.202, 3.334, B.06
Smith, P.E. 1.111 Stanslaski, S. 1.073 Svehlik, V. 1.175, 3.071
Tassi, L. 1.377, 2.184
Smyth, M. 1.372 Stanton, P. 1.295 Sveinsson, O. 3.128
Tatsuoka, C. 3.085, 3.127
Snead, C. 1.172 Starski, P. 3.042 Svendsen, K.H. 1.272
Tatum, W. 1.349, 2.155, 2.256,
Snead, O. 1.189, 2.353, 3.306 Stead, M. 1.175, 2.156, 3.071 Svendsen, T. 2.282 2.337, 2.339, 3.343
Snead III, O.C. 1.127, 2.095 Steenland, H. 1.017 Svenson, L. 2.051 Tatum, W.O. 3.238
Snyder, J. 2.215, 3.098 Stefan, H. 1.346, 3.349, 1.146 Swaminathan, A. 2.258 Tayah, T. 1.260
So, E. 3.158, B.05 Steger, H. 2.165 Swann, J. 1.013, C.04 Taylor, C.T. 1.165
Sobczyk, O. 3.200 Stemmer, P.M. 3.056 Swearingen, R. 2.034 Taylor, D. 1.295
Sobrido, M. 2.300 Stence, N. 2.103, 3.279 Swedo, S. 3.166 Tecoma, E. 2.005, 2.251
Soderblom, E.J. 1.006 Stephani, U. 1.115, 2.199, 3.090 Sweeney, M. 3.324 Tejada, J. 3.055
Sofat, P. 2.125 Stephen, L. 1.331 Sweet, J. A.07 Tekeli, H. 3.170
Sogawa, Y. 2.159, 3.331, 3.333 Stern, E. 2.236 Swenson, A. 2.100 Telecka, S. 2.003
Sohn, Y. 1.218 Stern, J. 1.278, 3.291, 3.292 Swiercz, W. 1.011, 2.328 Telesco, R. 2.159
Sohrabpour, A. 1.268 Steve, T.A. 1.253 Sylvester, C. 1.080 Tellez-Zenteno, J. 1.228, 2.082, 2.095
Soldan, S.S. 3.041 Steven, D. 2.054 Szabo, C. 2.028, 3.052, 3.315 Temkin, N. 2.039
Solomon, G. 3.155 Stieglitz, T. 3.068 Szabo, G.G. C.03 Tenney, J. 1.152, 2.024, 3.111
Solt, K. 1.023 Stino, A. 2.214 Szaflarski, B.A. 1.257 Tennigkeit, F. 3.294, 3.295, 3.297,
Soltesz, I. C.03 Stockis, A. 2.307, 2.310 Szaflarski, J. 1.236, 1.257, 1.281, 3.298
Stocks, J.D. 1.337, 1.343 1.310, 1.324, 1.330, 2.024, 2.161, Terashima, H. 1.116
Somerlik-Fuchs, K. 3.068 2.163, 2.285, 2.286, 2.287, 3.203,
Somerville, E. 3.286 Stoll, J. 3.342 Terhaerdt, J. 2.069
3.226, B.09
Sommer, B. 1.346 Stoll, S. 3.075, 3.078, 3.085, 3.127 Terra, V. 3.055
Szaflarski, M. 1.281, 1.310
Song, H. 3.338 Stoltenberg, C. 2.072 Terrill, M. 1.263
Szklarski, L. 2.016
Soni, N. 1.085 Storrs, J.M. 1.257 Terry, D. 2.049
Szu, J. 2.238, 3.119
Sonmezturk, H. 1.186, 1.327 Story, T. 2.320, 3.291, 3.292 Terwilliger, V. 2.019, 3.272
Stre, E. 2.282
Sood, S. 1.251, 2.345, 3.062, 3.362 Storzbach, D. 2.269 Teskey, G. 1.030, 1.217,
Stoub, T. 3.264 Testa, F. 2.350
Soraas, C. 2.072 T
Sorge, S.T. 2.275, 3.081, 3.135 Straub, H.B. 3.349 Teter, B. 1.214
Tabata, A. 2.091, 2.097
Sorin, L.M. 3.146 Strauman, M.C. A.08 Tezer-Filik, F. 1.124
Taccone, F. 1.141
Soucy, A. 1.270 Straussberg, R. 3.090 Thadani, V. 1.286, 2.042
Tadlock, D. 3.156
Soul, J. 2.124, 3.334 Streiner, D.L. 1.100 Thadur, S. 3.250
Tailby, C. 2.243
Sousa, R. 1.273, 1.287, 1.317, 1.319, Striano, P. 1.113, 1.115 Thaker, A.A. 1.266
Takada, S. 1.220
1.320, 1.322, 1.323 Striano, S. 1.113, 1.320, 1.322 Thakur, D.S. 1.286
Takagi, Y. 1.350
Sozzani, S. 1.020 Stribling, J. 2.064 Thaler, A. 3.137, 3.208
Takahashi, A. 1.147, 1.365, 2.225,
Spain, W. 1.015 Stringer, K. 2.303 2.341, 3.114 Thaler, J. 3.137
Spampanato, J. 1.161, 1.166 Strode, D. 1.003 Takahashi, K. 2.174 Thamattoor, A. 1.014
Spanaki, M. 2.208, 2.215, 2.252 Strom, L. 1.314, 2.053, 3.205, 3.304 Takahashi, R. 1.110, 1.350 Theodore, W. 1.002, 1.065, 1.150,
Specchio, L. 1.315 Struck, P.J. 2.325 Takahashi, Y. 2.335, 3.198 1.225, 2.356, 3.065, 3.084, 3.268,
Specchio, N. 3.360 Stufflebeam, S. 1.256, 1.258 3.278
Takami, Y. 1.116
Speechley, K. 2.056, 2.069, 2.223, Suchdev, K. 3.250 Thibert, R. 1.123
Takeoka, M. 1.098, 2.017, 3.169,
3.134 Sudo, A. 1.116 3.236, 3.361 Thiele, E. 3.303
Spencer, D. 1.156, 1.209, 1.216, Sueiras, M. 3.237 Takeshita, S. 1.116 Thippeswamy, T. 3.027
2.151, 2.350 Sugai, K. 1.147, 1.365, 2.225, 2.341 Takeuchi, T. 1.235, 1.243 Thom, M. 3.110
Sperling, M. 1.255, 1.318, 1.320, Thomas, A.X. 3.011
1.323, 1.349, 2.290, 2.256, 2.289,
2.337, 2.339, 3.291, 3.292,
106
 ABSTRACT AUTHOR INDEX

Thomas, G.P. 1.246 Tripathi, M. 2.365 Valle-Dorado, M. 1.001 Villanueva, V. 1.332

Thomas, P. 2.226 Trivisano, M. 3.360 Valton, L. 2.226 Villeda Hernandez, J. 2.334
Thomas, R. 3.092 Trobliger, R. 2.020 Valujskikh, A. 1.008 Villega, F. 2.263
Thome, U. 3.359 Troncoso, L. 1.118 Van Bebber, S. 2.058 Vincent, J. 1.141
Thome Costa, U. 1.144, 2.172 Troncoso, M. 1.118 Van Cott, A.C. 1.284 Vincentiis, S. 1.122, 2.259, 2.260,
Thome-Souza, S. 1.098, 1.329, 2.213, Trope, A. 3.059 Van den Maagdenberg, A.M. C.01 2.306
3.202, 3.235 Tropea, T. 1.271 van der Linden, Jr., H. 2.274, 3.199 Virta, J. 1.052
Thompson, A.L. 1.139 Tsai, J. 3.178 van Gerven, J.M. 2.307 Viteri Torres, C. 2.153
Thompson, D. 1.066 Tsao, J. 3.222 Van Grunderbeek, W. 1.067 Vitko, L.R. 3.321
Thompson, D.M. 2.034 Tseng, P. 2.081 Van Kampen, A. 1.333 Vitkovskiy, P. 1.062, 1.076, 1.164
Thompson, E. 3.351 Tseng, W.E. 3.221 van Kranen-Mastenbroek, V. 1.138 Vlachos, I. 3.107
Thompson, L. 3.335 Tsenov, G. 1.052 Van Ness, P. 1.316, 2.038, 2.189, Voets, N. 3.344
Thompson, M. 2.267, C.07 Tshionyi, M. 2.085 2.193, 2.209, 3.083 Voges, J. 3.045, 3.058, 3.349
Thompson, N. 3.075, 3.078 Tsimerinov, E. 2.227 Van Nieuwenhuyse, B. 3.028, C.08 Vollaro, T. 2.311
Thomson, J. 1.076 Tsong, W. 3.301 Van Orman, C. 2.134 Vollmar, C. 2.165, 3.211, 3.273
Thomson, K. 1.050 Tsuchida, T. 1.136, 1.137, 2.351 van Rijckevorsel, K. 1.067 Volpe, A. 3.302
Thorne, N.P. 3.100 Tsuchiya, K. 1.233 Van Straten, A.F. 2.042 von Deimling, M. 1.115
Thurman, D. 2.047, 2.074, 3.130 Tsuji, T. 1.224 Vanasse, C. C.01 von Ellenrieder, N. 3.163, 3.184, 3.185
Tian, N. 2.074 Tu, P.H. 3.221 VanCott, A. 2.257 von Spiczak, S. 1.115, 3.090
Tilton, N. 2.309, 3.303 Tucker, D. 1.180, 1.263, 3.193 VanHaerents, S. 1.188, 1.205 Vonck, K. 1.017, 1.067, 3.028, C.08
Timarova, G. 2.304 Turco, L. 2.041 Vanli- Yavuz, E. 2.224 Vossler, D.G. 2.144
Timmings, P. 3.180 Turnbull, J. 2.126 Vannasing, P. 1.072, 1.260 Vulliemoz, S. 2.244
Ting, T. 2.330, 3.288 Turner, D. B.06 Vannest, J. 1.353, 2.024 Vyas, M. 2.313
Tippin Davis, B. 1.194 Turner, K. 3.243 Vargas, L. 2.101, 2.120
Tirol, F. 2.200, 3.162 Turner, M. 2.229 Varni, J. 1.090 W
Titus, J.B. 2.354 Tuxhorn, I. 3.207, 3.212 Varvel, N. 3.116 Waber, D.P. 2.017
Toda, K. 1.359, 1.361 Tyler-Kabara, E. 3.331 Vasoli, V. 1.175, 2.156, 3.071 Wada, T. 1.116
Todaro, M. 1.231, 1.291 Tyrlik, M. 2.003 Vater, I. 1.115 Wade, A.G. 1.334, 1.335, 1.336
Togrol, E. 3.170 Tyrlikova, I. 2.003, 2.301 Vaughan, D. 2.243 Wade, R. 2.297
Tohma, S. 2.091, 2.093, 2.097 Tzvetanov, P. 3.295, 3.298 Vaughn, B. 2.057 Wadhawan, A. 2.365
Tohyama, J. 1.105, 1.116 Vazquez, B. 1.213 Wadman, W. 3.028, C.08
Toledo, M. 1.332, 3.237, 3.309 U Vazquez, M. 3.101 Wagenaar, J.B. 3.167
Toler, J. 1.345 Uchida, C.P. 3.251 Vzquez Gregorio, R. 3.154 Wagley, P. 3.118
Tom, M. 2.046 Uchio, H. 1.116 Veenstra, A. 2.013 Wagner, G. 1.067
Tominaga, K. 2.202 Ueda, Y. 1.297 Vega, C. 1.098, 3.169, 2.017 Wagner, J. 2.271
Tominaga, T. 1.367, 3.159 Uematsu, M. 1.367 Velez, A. 2.028 Wagnon, J. C.09
Tominaga, Y. 1.116 Ueno, M. 1.300, 2.353 Velez, F. 1.342, 1.344, 2.044 Wainwright, M. B.06
Tomson, T. 2.231 Ugorec, I. 1.140 Velez, F.F. 1.273, 1.287 Waldman, W. 3.298
Topjian, A. 1.182, B.06 Ugur Yilmaz, C. 1.053 Velisek, L. 3.025, 3.122 Waldman Zadeh, W. 3.295
Torello, A. 1.020 Ukitsu, S. 2.353 Veliskova, J. 3.025, 3.122 Walker, I.M. 3.322
Tornes, L. 2.063 Ullmann, J. 1.035 Velmurugan, J. 1.143 Walker, J. 3.351
Toropova, K. 1.121 Umezu, M. 1.373 Velmurugan, M. 1.223 Walker, M. 1.057
Torres-Barba, D. 1.278 nalp, A. 1.229 Vena, J.E. 3.142 Wallace, E. 3.033
Torrez-Corzo, J. 1.356 UnCheol, L. 3.040 Venkatesan, C. 1.222 Waller, K. 1.194
Tosun, D. 1.252, 1.254, 3.254 Ung, H. 3.183 Venkatraghavan, L. 3.200 Walsh, N. 2.318
Toth, E. 1.157 Unnwongse, K. 2.073 Venkatraman, K. 1.066 Walters, B. 3.348
Tovar Quiroga, D.F. 2.138 Unterberger, I. 2.121, 2.169, 2.245, Ver Hoef, L. 1.236, 1.247, 1.249, Wambacq, I. 1.183
Tovar-Spinoza, Z. 3.194, 3.357, 3.363 2.262 2.338, B.09 Wamil, M. A.08
Toyoda, I. 1.014 Upchurch, K. 1.184 Verity, K. 2.015 Wang, G. 2.161, 2.163

ABSTRACT AUTHOR INDEX

Toyoshima, D. 1.220 Upreti, C. 1.295 Verma, A. 2.254 Wang, H. 1.041, 1.103, 3.074, 3.249
Tracy, J. 1.255, 2.237 Urrestarazu, E. 2.153 Vernet, M. 1.154 Wang, J.L. 1.162
Tran, B. 3.017 Uysal, U. 2.111 Vernier, E. 1.340 Wang, L. 1.016
Tran, H. 2.227 Uzun, M. 2.075 Vernino, S. 2.189 Wang, P. C.06
Tran, P.T. 2.123 Uzuner, G. 3.305 Verpillat, P. 1.334, 1.335, 1.336 Wang, S. 2.104, 3.241
Tran, T. 3.274 Verrier, R.L. 3.218 Wang, X. 1.167, 1.273, 1.287
Tran, T.T. 2.036 V Vestergaard, M. 2.266 Wang, Y. 3.002, 3.113
Tran, Y.T. 3.370 Vago, D.R. 2.236 Vezina, G. 3.355, 3.364 Wang, Z. 1.240, 3.004
Tranel, D. 1.079 Vajjala, V.S. 1.134 Vezzani, A. 1.020 Wang, Z.I. 1.040, 3.359
Traynelis, S.F. 3.014 Vakili, R. 3.257 Vibhute, P. 3.343 Wannamaker, B. 3.142
Treiman, D.M. 1.042 Vale, F. 2.360, 2.361 Vickrey, B. 1.357, 2.045 Ward-Mitchell, R. 2.136
Treiman, L.J. 1.042 Valencia, I. 1.203, 2.035, 3.312 Vidaurre, J. 2.112 Wark, J.D. 1.291
Tremblay, J. 1.072, 1.260 Valente, K. 1.122, 2.259, 2.260, Vigevano, F. 2.146, 3.360 Warner, M. 3.282
Trenado, C. 3.154 2.306, 3.076, 3.082 Vignoli, A. 3.243 Warren, A. 3.287
Trent, C. 1.054 Valiante, T. 1.016, 3.200 Villagran, A. 2.317, 2.326 Warren, C. 1.066
Trifonov, I. 1.059, 2.076 Villalobos, R. 1.274, 1.356 Warren, P. 1.330
Trinka, E. 1.317, 1.319, 2.068, 2.245, Villalobos Chvez, F. 3.311 Wasade, V.S. 2.208, 2.215, 2.252
3.228 Villani, F. 2.184, 3.360

107
 ABSTRACT AUTHOR INDEX

Waseem, H. 2.360, 2.361 Williams, K. 1.182, B.06 Xu, D. 3.024 Yue, C. C.06
Washington III, J. 1.289 Williams, P. 3.296 Xu, M. 3.017 Yum, M. 1.036, 1.328
Wassermann, E. 3.065 Williams, S. 3.331
Watanabe, K. 1.224, 1.235, 1.243 Williamson, J. 1.037, 3.115 Y Z
Watanabe, S. 1.259, 2.239, 2.307 Willie, J. 1.349, 2.256, 2.337, 2.339, Yacubian, E. 2.327, 3.251, 3.369 Zack, M. 2.074
Watanabe, T. 1.116 3.344 Yadav, A. 3.207, 3.212 Zadeh, N. 1.106
Watson, R. 2.339 Willmore, L. 1.297 Yaffe, R.B. 2.010 Zaehle, T. 3.349
Weaver, K. Wilman, A.H. 1.253 Yaghouby, F. 1.071, 1.077 Zafar, H. 3.106
Weber, Y. 1.115 Wilner, A. 1.270 Yagiri, E. 2.132 Zaghloul, K. 1.150
Webster, E. 2.320, 3.296 Wilson, D.A. 2.087, 3.142 Yakovlev, A. 2.076 zaghloul, K. 3.084
Webster, R. 3.087 Wilson, J.A. 1.353 Yamada, M. 2.116 Zaghloul, K.A. 2.010
Wechsler, R. 3.291, 3.292 Winawer, M. 2.275, 3.081, 3.135 Yamagata, S. 2.080 Zaher, A. 2.272
Wechsler, R.T. 1.312, 2.291 Wirrell, E. 1.193, 1.206, 1.355, Yamaguchi, T. 1.116 Zaidi, S. 3.015
Weckhuysen, S. 1.114 1.364, 2.035, 2.079, 2.203, 3.145, Yamamoto, H. 1.235, 1.243, 1.365, Zak, M. 1.208
3.158, 3.229 2.158
Wedberg, E. 2.131 Zamarian, L. 2.245
Wise, C.A. 1.120 Yamamoto, T. 1.371, 1.373
Wei, S.P. 2.042 Zambrelli, E. 3.243
Wisnowski, J. 2.159 Yamao, Y. 1.350, 2.335
Weinand, M. 1.349, 2.256, 2.337, Zanelli, P. 3.097
2.339 Wlodek, M.E. 1.047 Yamashita, H. 1.110 Zanelli, S.A. 3.118
Weinstein, S. 2.351 Woldoff, S. 2.016 Yamashita, S. 3.165 Zangen, A. 3.337
Weinstock, A. 1.214 Wolf, E.G. 3.005 Yamauchi, K. 2.132 Zanotti-Fregonara, P. 1.002
Weir, C. 3.129 Wolf, S. 3.316, 3.356 Yamazaki, E. 3.216 Zanotto, F. 3.220
Weiss, S. 2.353 Wolff, M. 1.118 Yamazoe, T. 1.371 Zaveri, H. 1.041, 1.156, 2.151, 2.350,
Weiss, S.A. 1.057 Wollack, J.B. 1.134 Yan, B. 3.285 3.074, 3.136
Welter, E. 1.084, 3.085, 3.127 Wolter-Warmerdam, K. 3.209 Yan, C. 2.246 Zawadzki, L. 2.023, 3.267
Welty, T. 1.324, 2.285, 2.286, 2.287 Wong, C.H. 3.286 Yanagisawa, T. 1.060, 2.357 Zeft, A. 1.192
Wempe, M.F. 3.003 Wong, J. 1.046, 3.106 Yang, A. 1.182 Zeiger, M. A.09
Wen, J.H. 3.030 Wong, M. 1.024, 3.013, Yang, G. 1.102 Zelleke, T. 2.351, 3.141
Wen, M. 2.322 Wong, P. 3.304 Yang, H. 1.325, 2.276, 2.279, 2.288, Zelmann, R. 2.358
Wen, P. 3.098 Wong, S. 1.145, 2.325 2.289, 2.291, 2.293, 2.294, 2.295 Zemblis, J. 3.215
Wenzel, L. 3.156 Wong, S.M. 3.153 Yang, M. 3.013 Zeng, C. 1.023
Werhahn, K. 3.294, 3.297 Wong, V.S. 1.209, 1.277, 2.118 Yang, T. 1.170 Zeng, L. 2.323
Werhahn, K.J. 3.291, 3.292, 3.299 Wong-Kisiel, L. 1.193, 1.355, 1.364, Yang, X. 1.372 Zeng, R. 1.088
2.079, 2.203, 3.148, 3.158, 3.214, Yang Kao, Y. 2.094
Wesselkamper, K. 3.324 3.229 Zerbs, A. 3.228
West, P.J. 3.020 Yao, D. 3.285 Zeuthen, T. 1.021
Woo, D. 1.036
Westerveld, M. 2.014, 2.248, 2.255, Yarbrough, C. 1.372 Zhan, H. 3.030
Woo, Y. 1.117
3.276 Yardi, R. 1.226 Zhan, Q. 1.044, 1.164
Wood, R. 3.129
Weston, M. 1.013 Yardi, R. 1.347, 1.377 Zhang, B. 3.013
Woodard, V. 3.367
Westover, M. 1.154, 3.054, 3.203, Yasuda, C. 3.259, 3.260, 3.261 Zhang, C. 3.260
3.226 Woodrum, D. 2.339
Yasuda, R. 1.269 Zhang, G. 3.127
Wetjen, N. 1.355 Woodward, R. 2.136
Yates, S. 3.300 Zhang, H. 3.005, C.02
Whalen, H. 3.215 Works, K. 2.084
Yaun, A. 2.351 Zhang, L. 3.092
Whalley, B.J. Worrell, G. 1.169, 1.175, 1.374,
1.377, 2.156, 2.212, 2.256, 2.337, Ye, S. 1.126 Zhang, M. 2.249
Wharen, R. 1.349, 2.212, 2.337, 2.339, 3.071, 3.158 Yelvington, K.H. 2.155, 3.238 Zhang, S. 3.136
2.339, 3.343 Yeom, J. 1.170
Wrede, J. 3.245 Zhang, W. 2.026, 2.235
Whealy, M.A. 2.079 Yerra, S. 1.231
Wright, C. 2.070 Zhao, B. 1.057
Wheatley, M. 2.178, 3.261 Yildirim Capraz, I. 1.207
Wu, C. 2.256 Zhao, G.Q. 3.004
Whelan, P. 1.025 Yilmaz, C. 1.229
Wu, E. 1.213 Zhao, J. 1.043
Wheless, J. 2.195 Yilmaz, U. 3.328
Wu, J. 1.245, 2.355, 3.249, 3.255, Zhao, Z. 3.286
White, A. 1.267, 3.039, 3.279 3.262 Ying, Z. 1.008, 1.012, 1.040 Zheng, N. 3.288, 3.310
White, H. 1.050, 3.095 Wu, J.Y. 2.358 Yogi, A. 1.238, 1.245, 1.261, 3.255, Zhou, C. 3.015
White, J. 3.105 Wu, R. 1.062 3.262 Zhou, D. 3.285
Whitehead, M. 1.354 Wu, S. 2.102, 3.160 Yokoi, S. 1.235, 1.243 Zhou, J. C.06
Whitfield-Gabrieli, S. 1.154 Wu, T. 3.221 Yokota, T. 1.371 Zhou, R. 3.222
Whitmire, L. 3.206 Wu, X. 1.029, 1.031, 1.033 Yoon, J. 1.211 Zhou, X. 3.166
Wicks, P. 2.058 Wu, Y.W. 3.222 Yoon, J.W. 3.343 Ziemba, K.S. 2.139
Widjaja, E. 1.127, 1.189, 2.353 Wulsin, A.C. 3.010 Yoong, M. 1.092, 2.015 Zillgitt, A. 1.151, 2.215, 2.252
Wiebe, S. 1.285, 2.051, 2.067, 2.071, Wulsin, D. 3.183 Yoshimine, T. 1.060, 2.357
2.082, 2.150, 2.198, 2.223, 3.139 Zimmerman, A.M. 2.325
Wusthoff, C. 1.136, 1.182 Yoshimura, K. 3.216 Ziobro, J. 2.351
Wiggs, E. 3.065, 3.084, 3.278 Young, G. 3.109
Wyatt, K. 1.193 Zoghbi, S. 1.002
Wild, I. 3.295 Youroukos, S. 2.187
Wyllie, E. 1.149, 1.362 Zohrevand, P. 2.222
Wilfong, A. 2.299, 2.333, 2.347, Yozawitz, E. 3.214
3.307, 3.353, 3.358, 3.371, B.06 Zou, J. 3.013
Wilk, P. 2.056, 3.134 X Yu, H. 1.351 Zrik, A. 3.212
Xiao, W.R. B.01 Yu, J. 2.314, 2.315 Zubair, M.N. 3.373
Wilkening, G. 1.098, 2.012, 2.103
Xie, J. 1.017 Yu, R. 3.354 Zupanc, M. 2.013
Williams, B. 1.325, 2.276, 2.279,
2.288, 2.289, 2.291, 2.293, 2.294, Xing, D. 1.325, 2.276, 2.279, 2.288, Yu, W. 2.227 Zutshi, D. 3.250
2.295 2.291 Yuan, H. 3.014
Williams, J. 3.033 Xiong, W. 1.155 Yudovin, S. 1.245

108
COMMERCIAL SUPPORTER RECOGNITION
All as of October 21, 2014

Benefactor Level

Special thanks to:

Sunovion
Pharmaceuticals Inc.
for supporting:
Exhibit Cell Phone Charging Station
(3 days)
Program Book Ad
Networking Massage
Media Wall Spots (3 days)
Lounge (3 days)
Footprints
Airport Baggage Carousel
virtualTote Bag Banner Ad Display AD
virtualTote Bag Insert Passport to Prizes
Suds for Science Reception Door Drops
Lunch in Exhibit Hall Scientific Exhibit
(3 days)
Office Rental in Exhibit Hall
Poster Session Breakfast
Epilepsy Currents Ads
(2 days)
Educational Grant -
Coffee Break in Exhibit Hall
Annual Fundamentals
(3 days) SUPPORTER LEVELS
Symposium, AET Symposium
Innovation Pavilion
AES Fellows / EpiPORT
(Saturday / Sunday)
SIGs (2)
Cyber Caf (3 days)

109
 Leader Level

Special thanks to:

Eisai, Inc.
for supporting:
Exhibit
Program Book Ad
Innovation Pavilion (Monday)
virtualTote Bag Banner Ad
Passport to Prizes
Door Drops
Epilepsy Currents Ads
Named Fellowship (Sustained)
Nurse / Young Investigator Awards
AES Fellows / EpiPORT
Educational Grant Epilepsy Specialist Symposium,
Annual Fundamentals Symposium, AET Symposium,
Professionals in Epilepsy Care Symposium

110
 Leader Level

Special thanks to:

UCB, Inc.
for supporting:
Exhibit
Program Book Ad
Scientific Exhibits
Educational Grant Epilepsy Specialist Symposium,
Annual Fundamentals Symposium, AET Symposium
AES Fellows / EpiPORT
Cyber Caf (3 days)
Media Wall Spot (3 days)
Coffee Break in Exhibit Hall (2 days)

SUPPORTER LEVELS

111
 Partner Level

Special thanks to:

Lundbeck
Pharmaceuticals, Inc.
for supporting:
Exhibit
Program Book Ad
Media Wall spot (2 days)
Innovation Pavilion (Saturday / Sunday)
Passport to Prizes
Door Drops
Scientific Exhibit
Epilepsy Currents Ads
Educational Grant AET Symposium,
Annual Fundamentals Symposium

112
 Partner Level

Special thanks to:

Upsher-Smith
Laboratories, Inc.
for supporting:
Exhibit
Hoyer Lecture
Program Book Ad
Passport to Prizes
Door Drops
Scientific Exhibits
Epilepsy Currents Ads
Seed Grant
AES Fellows / EpiPORT
Year Round Education
SUPPORTER LEVELS

113
 Supporter Level

Special thanks to: for supporting:

Cyberonics, Inc.
Exhibit
Innovation Pavilion
(Saturday / Sunday)
Scientific Exhibit
Named Fellowship (Sustained)
Educational Grant Annual
Fundamentals Symposium

Supporter Level

Special thanks to: for supporting:

Natus Neurology
Exhibit
Auction of XLTEK LTM
System
Incorporated

114
 Supporter Level

Special thanks to: for supporting:

Supernus

Exhibit
Program Book Ad

Pharmaceuticals,

Passport to Prizes
Door Drop

Inc.

AES Fellows / EpiPORT
Educational Grant Annual
Fundamentals Symposium

Supporter Level

Special thanks to: for supporting:

Mallinckrodt
Exhibit
Epilepsy Currents Ads SUPPORTER LEVELS
Educational Grant
Pharmaceuticals Pediatric State of the
Art Symposium

115
 Supporter Level

Special thanks to: for supporting:

Acorda
Investigator Workshop
SIGs (2)

Therapeutics
Program Book Ad
virtualTotebag Banner Ad
Epilepsy Currents Ads
AES Fellows / EpiPORT

116
Contributor Level Contributor Level

Special thanks to: Special thanks to:

Nihon Kohden Cadwell

America, Inc. Laboratories, Inc.
for supporting:
for supporting: Exhibit
Exhibit Media Wall Spot (2 days)
Auction of EEG-1200 Footprints
Passport to Prizes
Epilepsy Currents Ads

Contributor Level Contributor Level

Special thanks to:

Special thanks to:
Compumedics
Limited Pfizer Inc.
for supporting:
for supporting:
SUPPORTER LEVELS
General Conference Grant
Exhibit
Epilepsy Currents Ad

117
 Advocate Level
Special thanks to these companies for supporting:

NeuroPace, Inc. ELEKTA

Exhibit
Exhibit
Innovation Pavilion (Saturday/Sunday)
Epilepsy Currents Ad

Electrical GW Pharmaceuticals
Geodesics, Inc. Exhibit
Exhibit Investigators Workshop (1)
Epilepsy Currents Ad SIG (1)
Educational Grant
Annual Course

Medtronic, Inc. Blackrock

Exhibit
Nurse/Young Investigators Awards
Microsystems, LLC
Exhibit

118
 Patron Level
Special thanks to these
companies for supporting:

Rhythm Link PMT Corporation

Exhibit Exhibit
Epilepsy Currents Ad
Ripple LLC
Ad-Tech Medical Exhibit
Instrument Corp.
Exhibit Lifelines Neurodiagnostics
Systems, Inc.
Monteris Medical, Inc. Exhibit
Exhibit
The Jack Pribaz Foundation
Medical Neurogenetics, Exhibit
LLC Passport to Prizes
Exhibit Media Wall Spot (3 days)

Nexstim, Inc.
Exhibit

Neurolynx, Inc.
Exhibit

SUPPORTER LEVELS

119
 GENERAL INFORMATION
AES 2014 Annual Meeting
The American Epilepsy Society (AES) is one of 108 Chapters of the
International League Against Epilepsy (ILAE). The Annual Meeting of the
American Epilepsy Society is the largest meeting and exhibition in the world
for those who share the common scientific and clinical interests of epilepsy
and clinical neurophysiology. The meeting attracts more than 4,000 attendees
dedicated to improving the quality of life for those dealing with epilepsy. This
meeting is the top forum to examine common concerns and to gain insight
from leading authorities.
Mission Statement
The American Epilepsy Society advances research and education for
professionals dedicated to the prevention, treatment and cure of epilepsy.
Target Audiences
Basic: Those new to epilepsy treatment or whose background is limited, e.g.,
students, residents, general physicians, general neurologists and
neurosurgeons, other professionals in epilepsy care, administrators.
Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons,
and other providers with experience in epilepsy care (e.g., advanced practice
nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic
and translational researchers.
Advanced: Symposia will address highly technical or complex topics
(e.g., neurophysiology, advanced imaging techniques or advanced treatment
modalities, including surgery).
Policy on Commercial Support and Conflict
of Interest
The American Epilepsy Society maintains a policy on the use of commercial
support, which ensures that all educational activities sponsored by the AES
provide in-depth presentations that are fair, balanced, independent and
scientifically rigorous. All faculty, planning committee members, editors,
and other individuals who are in a position to control content are required to
disclose any relevant relationships with any commercial interests related to
the activity. The existence of these interests or relationships is not viewed as
implying bias or decreasing the value of the presentations. All educational
materials are reviewed for fair balance, scientific objectivity and levels of
evidence. This information will also be made available through syllabus
materials and faculty presentations.
Disclosure of Unlabeled / Unapproved Uses
This educational program may include references to the use of products for
indications not approved by the FDA. These discussions are noted on the
facultys disclosure forms as well as during their presentations. Opinions
expressed with regard to unapproved uses of products are solely those of the
faculty and are not endorsed by the American Epilepsy Society or any
manufacturers of pharmaceuticals.
Abstracts
Abstracts from the 2014 Annual Meeting are available on the AES website
and will also be available as an online supplement to Epilepsy Currents.
Accreditation
The American Epilepsy Society is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to offer
continuing medical education for physicians.
Credit Designation
Physicians: The American Epilepsy Society designates this live activity for a
maximum of 32.75 AMA PRA Category 1 CreditsTM. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
Physician Assistant: AAPA accepts certificates of participation for
educational activities certified for AMA PRA Category 1 Credit from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 32.75 hours of Category 1
credit for completing this program.
120
Nursing: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare
and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare
is accredited as a provider of continuing nursing education by the American
Nurses Credentialing Centers Commission on Accreditation.
This activity is awarded 30.75 contact hours.
Nurse Practitioners: Jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in
Healthcare is accredited by the American Association of Nurse Practitioners
as an approved provider of nurse practitioner continuing education. Provider
Number: 030803.
This program is accredited for 30.75 contact hours which includes 7.0 hours
of pharmacology. Program ID #21424
This program was planned in accordance with AANP CE Standards and
Policies and AANP Commercial Support Standards.
Pharmacy: Jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and American Epilepsy Society. AKH Inc., Advancing
Knowledge in Healthcare is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
Select portions of this Annual Meeting are approved for pharmacy CE credit.
Specific hours of credit for approved presentations and Universal Activity
Numbers assigned to those presentations are found elsewhere in program
materials. Criteria for success: Credit is based on documented program
attendance and online completion of a program evaluation / assessment.
If you have any questions about this CE activity, please contact AKH Inc. at
service@akhcme.com.
International Credits: The American Medical Association has determined
that non-U.S. licensed physicians who participate in this CME activity are
eligible for AMA PRA Category 1 Credits TM.
CME / CE Certificates
The Medical Education Evaluator is an online system that allows attendees
to complete course evaluations, track educational credits and print out the
appropriate certificate.
Once you have accessed the Medical Education Evaluator, you will be
asked to enter your myAES number and password that you created. The
certificate(s) are saved to your personal account page and are cumulative.
You may print the certificate(s) at any time.
The following fees apply for obtaining educational credits:
Member Fees: $50 through January 16, 2015
$75 January 17 February 27, 2015
Non-member Fees: $75 through January 16, 2015
$100 January 17 February 27, 2015
The online Evaluator will be open through February 27, 2015. You
must complete the evaluations and credit tracking by that date.
Completing this information online also assists the Council on Education and
Annual Meeting Committee with important needs assessment data so AES
can further plan and address educational gaps to meet the needs of our
learners.
Attendance Certificate / International Attendees
A meeting attendance certificate will be available at the registration desk for
international meeting attendees on Tuesday, December 9.
Handouts
Handouts for the educational symposia will be available
via the virtualTotebag. For instructions: please refer to
the flyer provided in your meeting bag or go to the AES
website for details at www.AESnet.org.
Questions? Please contact virtualTotebag Support Desk at 410.402.1062
Email: support@virtualtotebag.com
 GENERAL INFORMATION

Audience Response System Press Room

AES will be utilizing the Audience Response System (ARS) in several of the Convention Center Room 304, Level 3
symposia. Faculty will have ARS questions throughout their presentations with AES offers meeting information and assistance for journalists reporting on
multiple choice answers. To participate, you will use your cell phone to text epilepsy studies, educational presentations, and special reports at this
your reply. When a question appears in a presentation, simply text your meeting. The AES on-site Press Room staff works with journalists to develop
answer (a 5 or 6 digit code) to 22333. Standard text rates will apply. The stories, research facts and information, and connect with experts and
ARS will allow for interactive audience participation as well as real time, presenters. The on-site Press Room is also available to sponsors and
immediate feedback to enhance the learning environment and ensure that we exhibitors for the display and distribution of relevant press releases and media
are meeting the learning objectives set forth by each symposium. kits. For more information, contact Ellen Cupo at (203) 314-6545 and
ellen@bigvoicecomm.com, or Natalie Judd at (203) 605-9515 and
Commercial Exhibits (page 82) natalie@bigvoicecomm.com.
The Exhibit Hall is an integral part of the learning experience. Meeting
participants will have an ideal opportunity to learn about the latest in Friday, December 5 .................................................. 11:00 a.m. - 6:30 p.m.
pharmaceuticals, publications, scientific equipment, and technology relevant Saturday, December 6 .............................................. 7:30 a.m. - 6:30 p.m.
to the fields of epilepsy and neurophysiology. Please check the AES website Sunday, December 7 ................................................ 7:30 a.m. - 6:30 p.m.
for an updated listing of exhibiting companies and organizations. To ensure Monday, December 8 .............................................. 7:30 a.m. - 6:30 p.m.
safety and security, no children under 12 years of age, strollers, carriages, Tuesday, December 9................................................ 7:30 a.m. - 1:00 p.m.
wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall A series of media briefings on a select number of topics will be held in the
during exhibit hours. press room from Friday, December 5 through Monday, December 8. Details
Saturday, December 6 Noon - 6:00 p.m. will be posted in Room 304, Level 3 at the Washington State Convention
Sunday, December 7 10:00 a.m. - 6:00 p.m. Center and in advance on the AES website Press Room after December 1.
Monday, December 8 10:00 a.m. - 3:00 p.m. Hotel Information
Scientific Exhibits (page 23) Early Departure Policy
AES has approved guidelines for industry-sponsored Scientific Exhibits at the Guests who check out of the hotel prior to their scheduled departure date will
Annual Meeting. Scientific Exhibits differ from traditional poster presentations be charged a penalty of one nights room rate and tax.
in that a broad range of material can be presented as a collection of topics, Sheraton Seattle Hotel (Headquarters Hotel)
such as results of various clinical trials, or a thematic presentation of one 1400 Sixth Avenue, Seattle, Washington 98101
aspect of drug development. Scientific Exhibits will be displayed on Sunday, Telephone: 206.621.9000
December 7 and Monday, December 8. An application to register for a Crown Plaza Hotel Seattle
Scientific Exhibit was emailed to interested companies in June. Reservations 1113 Sixth Avenue, Seattle, WA 98101
will be reviewed and accepted on a first-come, first-served basis until space Telephone: 206.464.1980
is sold out. Send inquiries of interest to JoLynn Amsden at
jamsden@aesnet.org. Grand Hyatt Seattle
721 Pine Street, Seattle, WA 98101
Cyber Caf Telephone: 206.774.1234
Convention Center Exhibit Hall 4B, Level 4 Hyatt at Olive 8 Seattle
Open during Exhibit Hall hours 1635 8th Avenue, Seattle, WA 98101
The Cyber Caf will be available during Exhibit Hall hours at the Convention Telephone: 206.695.1234
Center with email and Internet access. You will also be able to complete the
course evaluations and obtain your CME certificate online. For your convenience, Hilton Seattle
Wi-Fi will also be available in the Convention Center. 1301 Sixth Avenue, Seattle, WA 98101
Telephone: 206.624.0500
Photography and Recording of Programs Mayflower Park Hotel
AES strictly prohibits all photography (flash, digital, or otherwise), audio and / 405 Olive Way, Seattle, WA 98101
or videotaping during the Annual Meeting. Equipment will be confiscated.
Telephone: 206.623.8700
Material presented at the AES Annual Meeting is not to be reproduced in any
Motif Seattle Hotel (formerly the Red Lion)
format without the express written consent of the AES. Attendees acknowledge
1415 Fifth Avenue, Seattle, WA 98101
and agree that commercial or promotional distribution, publishing or
Telephone: 206.971.8000
exploitation of speaker sessions, content, or materials from the AES Annual
Meeting is strictly prohibited unless you have received the express prior Renaissance Seattle Hotel
written permission from AES or the otherwise applicable rights holder. 515 Madison Street, Seattle, WA 98101
Telephone: 206.583.0300
When you attend an approved AES event or program, you enter an area where
The Fairmont Olympic Seattle
photography, audio, and video recording may occur. By entering the event
411 University Street, Seattle, WA 98101
GENERAL INFORMATION
premises, you consent to photography and its release, publication, exhibition,
or reproduction to be used for news, newsletters, promotional purposes, Telephone: 206.621.170
advertising, inclusion on websites, or any other purpose by AES and The Paramount Hotel
representatives. You release AES, its officers and employees, and each and all 724 Pine Street, Seattle, WA 98101
persons involved from any liability connected with the taking, digitizing, or Telephone: 206.292.9500
publication of photographs and computer images. You have been fully informed
The Roosevelt Hotel
of your consent, waiver of liability, and release before entering the event.
1531 7th Avenue, Seattle, WA 98101
Business Centers Telephone: 206.621.1200
Two full-service FedEx Office business centers are conveniently located in Warwick Seattle Hotel
Seattle for Annual Meeting attendees. Both offer a variety of services which
401 Lenora Street, Seattle, WA 98121
include shipping, mailing, faxing and photocopying. Please contact the office
directly for details. Telephone: 206.443.4300

Washington State Convention Center, Level 1 (Suite 11-13) Meeting Location

http://local.fedex.com/wa/seattle/office-5161/ Washington State Convention Center
Phone: 206.467.1767 800 Convention Place, Seattle, WA 98101-2350
Sheraton Seattle Hotel, Level 2
http://local.fedex.com/wa/seattle/office-5539/
Phone: 206.467.5885 121
 GENERAL INFORMATION

Program Changes Safety and Security Information

AES cannot assume liability for any changes in the program due to external or
unforeseen circumstances.
Language
The official language of the Annual Meeting is English.
Meeting Attire
Dress for the Annual Meeting is business casual. Consider bringing a light
jacket or sweater with you since meeting room temperatures and personal
comfort levels vary.
No Smoking Policy
For the comfort and health of all attendees, smoking is not permitted at any
AES function. This includes educational sessions, meetings and all food
functions. Both the Convention Center and the Sheraton Seattle are smoke-
free facilities. Also, smoking is not permitted in public buildings, restaurants
or bars.
Gratuities
Gratuities are not automatically added to the bill, except in some cases for
large groups. Waiters and waitresses are usually given 15% to 20% of the bill.
Taxi drivers usually receive 15% of the fare and doormen and $2 per night for
hotel housekeeping. Skycaps and porters are normally tipped $1 per bag.
Registration & Security
AES is committed to providing a secure meeting environment. A formal
security plan is developed in consultation with the Security Department at the
Convention Center. All meeting attendees will be required to produce
government-issued photo identification prior to receiving their badge and
registration materials. Appropriate badges must be worn at all times while in
attendance at the Annual Meeting and are required for admittance to all
meeting activities. Security procedures will also be in place for exhibition
materials and all deliveries to the Annual Meeting.
Insurance / Liabilities
AES cannot be held responsible for any personal injury, loss, damage,
accident to private property or additional expenses incurred as a result of
delays or changes in air, rail, sea, road, or other services, strikes, sickness,
weather, acts of terrorism and any other cause. All participants are
encouraged to make their own arrangements for health and travel insurance.
Contact Information
American Epilepsy Society
342 North Main Street, Suite 301
West Hartford, CT 06117-2507
The following security measures have been designed to further enhance your
personal and professional safety.
Pick up any Convention Center house phone located in the facility and dial
5127 or 206.694.5127. Uniformed Convention Center employees have
radios and are ready to assist you. Advise the dispatcher of the exact
location within the Convention Center.
We respectfully request that you do NOT call 911 directly.
An EMT will be on duty in the Convention Center throughout the meeting.
A government-issued photo identification is required to receive a badge
and to replace a lost badge.
Convention Center Security may randomly check packages and bags at the
Convention Center entrances, meeting rooms and in the Exhibit Hall.
You will be asked to always clearly display your name badge and to use
only approved Convention Center entrances and exits.
Appropriate badges will be required to enter all educational sessions,
Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire
regulations, doors will be closed to all session rooms that fill to capacity.
Throughout the meeting, you will notice security staff presence to monitor
the safety of all participants.
Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.)
in any area of the Convention Center or hotel.
Please report any suspicious activity to security staff or to the AES
registration desk staff.
General Safety Tips
Remove your badge once you leave the meeting facilities.
Carry important telephone numbers with you.
Do not display or carry large amounts of cash.
Walk in groups, especially at night.
Lock your hotel room door.
Always verify hotel room repair or service calls.
Do not disclose your room number to anyone.
Never give your personal information (credit card, room number, etc.) over
the phone; instead, go to the front desk if the hotel calls with questions.

Phone: 860.586.7505, ext. 512

Meeting Fax: 888.238.7428
Email: info@aesnet.org
Website: www.AESnet.org

Faculty Ready Room and Photos

Location: Convention Center Room 303, Level 3

Faculty need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint
presentations have already been uploaded through the AES Faculty Development Room. All faculty must stop by
to reconfirm their presentation with an audiovisual technician.

Thursday, December 4 .............................. 4:00 p.m. - 8:00 p.m.

Friday, December 5 .................................. 8:00 a.m. - 6:00 p.m.
Saturday, December 6 .............................. 8:00 a.m. - 6:00 p.m.
Sunday, December 7 ................................ 8:00 a.m. - 6:00 p.m.
Monday, December 8 ................................ 8:00 a.m. - 6:00 p.m.
Tuesday, December 9.............................. 8:00 a.m. - 11:00 a.m.

122
 MAP OF SEATTLE, WA
M
MOH AI
A
Aloh
A ohaa St .

1st
1

Warren
W

2nd
2

4 t h Av
2nd
2

Aurora
A

D ex

8th
8
s t Av

n d Av
n d Av

t h Av
a r r e n Av e
L AKE
K

u r o r a Av

xtte
UNION
I

ve
Va
alley St.

ve

err Av
ve

ve
e. N.
ve
PAR
ARK

e. N.
e. N.

e. N.
e. W.
W.Ro
oyy St.

N
N

N
ve

ve
W
Ro
oyy St.

e. N.

e. N .

e. N .
1sstt Av
E . Ro
E. oyy S
Stt.

9th
9 t h Av
Merce
M ercerr St. Merce
M ercer St.
vee. W. E.. M
E Mercer
e rc e r St .

GAT
G

ve
ATE
AT

e. N.
BILL
B
W

ES F

Ea
E
LL & MELIN
Queen
Q

Westlake
W

Terry
T

Boren
Bor

Fairvi
Fa

Min
M

Po
P

Ya
Y
N
W. Rep
publican
u b c a n St .

a
e r r y Av

a
o
FOUN
ueen Anne
Rep
epublican
ub c an St.

es t ake Av
OUN DAT

n
MEL NDA

r v e w Av
.

e n Av e
St
LEGEND

EMP MUSEUM

d
AT ON
ATION

oa
SEAT TLE
A n n e Av

vee. N.
Br
W. Harrison
H a r r s o n St . Harrison
H arr son Stt..

e.
1. Crowne Plaza Hotel Seat tle

ve
CENTER

N
ve

e. N.
e. N.

N
2. Grand Hyat t Seat tle

N
ve

5th
5

Taylor
T

6 t h Av e
W. Thomas
T h o m a s St . Thoma
Th
homass St.
e. N.

a y o r Av
t h Av
3. Hilton Seat tle
N

CHIHULY

vee. N.

e. N
GARDEN
W J o h n St .
W.John
W. JJohn
ohn S
St.
t 4. Motif Seat tle (formerly Red Lion)

ve
JJohn
ohn

N.
& G L A SS

e. N .
PACIFIC
DENN Y 5. Renaissance Seat tle Hotel
M

SCI E N CE
YR

CENTER Denn
D enny Wa
Way
ay PA
ARK Denn
D enn
6. Sheraton Seat tle Hotel
TL

C A L A N D E R SO N
E

.
St
ED

7. The Paramount Hotel

.
St

Bo
e
W

gl

ay

t.

re
.

SC O L
AR

rS
St

PARK
Ea

Cl

8. May ower Park Hotel

A
Te
U YM
d

da
DS

Wes ttllake
1s r
oa

PALPT PIC
.

ry
St
Ce

t 7t
PA

Av 9. The Roosevelt
Br

h 9t Av
RK UR
ne

e. Av h
t.

e
R

.
Vi

E Av
lS

6t
St
K

e.
W 10. The Fairmont Olympic Hotel

ke Ave
h 8t e.
al

es Av h
er
W

te 5t e. Av

lS
tt

rn h e. 11. Hyat t at Olive 8

Ba

el
Av

e.. N
Av
.

w
St

Fe rr y e.
e. 4t

Ho
to V i
ll

c to r i h 12. War wick Seat tle Hotel

Be

a B.C

.
. Av
3r e.12
1

7t
P I E R 69 d
11
1

.
El

hA
St
Av
.

VIC TORIA CLIPPER lio

St

ia
e.
tt
7

ve
U on
Unio
Un n St .
d

in

t.
Av t.
ar

tS

.
rg
WA
WA SHIN
SH N GT
TOON STA
TAT
TA
ATnTSE
ch

e.
Vi

nio
ar
2n
2
.
an

St

CONV
NVE
V NTIOON CCENTER R
ew
d U
8
Bl

Av
9
ra

1s
St

Mi
e.
no

t Av

no
Le

e. WE
W E S TL
LAKE
AK
PIER 67 t.

rA
Al ST St. PA
PARK ke S 6

6t
BELL HARBOR EI e Pi

ve
as N Pi n

hA
CONFERENCE CENTER

Broadway
Br
5t
PA BRU

.
ka St .
PI

hA
4

ve
ca

o a d w ay
KE

PI E R 6 6 W RK E 4t
e
C

.
ay K en

ve
hA
N S t.
PL

BELL S T. CRUISE TERMINAL

3r

gS
.
3S
AC

ve
dA

ri n St
.
Sp
.
y
E

si t

Mi
St .
ve

r on
M

PI E R S 6 2 & 6 3 n e is

no
.

nio niv ad

Bo
AR

U 10
0 a St . 1 M

rA
U
W E
2n

re
KE

Te
PIER 59 ec

ve
nA
n
dA

r
1s

Se
T W

ry
t.

9t

.
SE AT TLE AQUARIUM
gS
t

ve
ve

hA

Av
5
Av

ri n

8t

.
.
.

Sp St
es

e.
hA

ve
e.

WATERFRONT PARK
A
on
te

7t

.
S is

ve
rn

P I E R 57 ad

hA
t. t.

.
M
nS sS
Av

SE AT TLE GRE AT WHEEL

me

ve
V illag e o t.
a ri St . nS
e.

ic u m Ja

.
Fe r r y to T ill PI E R 5 5 M ia so
r
ARGOS Y CRUISES/ TILLICUM VILL AGE
lu mb f fe
Co Je
St .
r ry
C he St . t.
s
me t. rS
Ja S de
on Al
rs
PIER
P R 52
52 f fe
WA S
WA STA
TAT
ATE Je
PIO UA

F e r r y to B a i n b r i d g e I s l a n d FERRIES
F RR ES Yesle
Y
Ye
es er W
Way
ay
SQ
NE R E

SW
Washington
a s h n g to n S t .
ER

n S Main
M a n St .
e r to
B re m
y to
Fe rr S Jackson
J a c k s o n St .
CH
K ng SN
t T
I IN
L ATO
d
S King
sla n
er SDt IS W
on I
1st
1

ash
Occidental
O

to V SW
Weeller
s t Av

i
Ta x TR N /
c c d e n t a Av

ry
Fe r te r
le W
a
I
L a n e St . C T
vee. S

t S Lane
ea t
st S
- We
t tl e CENTURYLINK S Dearborn
D e a r b o r n St .
a
Se
ve

FIELD
e. S

S Charles
C h a r e s St .

SP
Plumme
ummer St.
Pike Place Market to CenturyLink Event Center: 1 mi / 1.6 km
Pike Place Market to Space Needle: 1 mi / 1.6 km CENTURYLINK
EVENT CENTER
Pike Place Market to Convention Center: mi / 800 m DR .
JOSE
Ro
oyya
al B
Brougham
ro u g h a m W
Way
ay R IZ AL
MA JOR AT TR AC TION S . L A K E U N I O N S T R E E TC A R PARK
A
S A F E CO F I E L D
PARK BUS/LIGHT R AIL TUNNEL
4 t h Av

BUS/LIGHT R AIL TUNNEL STAT

TION SE AT TLE CENTER MONOR AIL
ve

Edgar
E dgar Martinez
Ma r t n ez W
Way
ay
e.

CONVENTION HOTEL INFORMAT

TION CENTER

123
 WASHINGTON STATE CONVENTION CENTER

LEVEL 3
n Faculty Ready Room (302)
n Faculty Photo Room (303)
n Press Room (304)

Poster entrance when

exhibit hall is closed

LEVEL 4
n Registration
n Exhibit Hall
n Poster Sessions

124
WASHINGTON STATE CONVENTION CENTER

LEVEL 6
n Ballrooms 6C and 6E
n Session Rooms
n Scientific Exhibits

125
 SHERATON SEATTLE HOTEL

126
Seattle Childrens Epilepsy Program
Offers Unsurpassed Care

Seattle Childrens Epilepsy Program is the largest on the West Coast

dedicated to treating children and young adults up to age 21.
As part of the University of Washingtons Regional Epilepsy Center
and the Northwest Epilepsy Consortium, Seattle Childrens serves
patients in Washington, Alaska, Idaho and Montana.
Our six pediatric epileptologists collaborate with experts in
neurosurgery, neuropsychology and neuroradiology to provide
promising leading-edge options for children with epilepsy like laser
ablation. We have special expertise in neurogenetics, participated
in NIH sponsored EPGP and EPI-4K projects, and mitochondrial
disorders. We are active in epilepsy research and offer clinical trial
and study opportunities.
Learn more at www.seattlechildrens.org/epilepsy

127
127
 THE MOST WIDELY READ AND HIGHLY
The Ofcial Journal of the
CITED PEER-REVIEWED NEUROLOGY JOURNAL American Academy of Neurology

One subscription...four ways to access

Neurology brings you:
   Online Correspondence
Clinical/Scientic Notes in Neurologic Practice 
 Images 

Medical Hypothesis papers)  
   

Enjoy full-text online access, including expedited e-pub, presentation downloads, search functions,
topic alerts, e-TOC service, RSS feeds of current issues and podcasts, mobile device downloads, and a
Resident & Fellow subsite. Plus, access Neurology on your iPad for a print-like reading experience
enhanced with article-sharing features, links, and more!

Neurology.org
Visit Booth #400 for Meeting Discounts
4-R013

128
 Neurology Clinical Practice
An Ofcial Journal of the American Academy of Neurology

Additional Series Sections: 

 Neurology
 Clinical Practice

 
  
 
AAN.com/Membership.


Neurology.org/cp
Visit Booth #400 for Meeting Discounts 

129
  
 

Indexed In: Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine,
EMBASE, Excerpta Medica, Index Medicus, MEDLINE,
Neuroscience Citation Index, Research Alert, Scopus and Scisearch

Seminars in Neurology
Editor-in-Chief: D. Greer
2015/Volume 35/6 issues p.a./ISSN 0271-8235

USA and Canada

Individuals: $316 $253
Institutions: $1,054
Please contact customerservice@thieme.com
For institutional licenses, please contact esales@thieme.com

Mexico, Central and South America

Individuals: $343 $274
Institutions: $1,081
Please contact customerservice@thieme.com
For institutional licenses, please contact esales@thieme.com

Europe, Africa, Asia, Australia, New Zealand

Individuals: 336 269
Institutions: 1,084
(Please add shipping charges: 57.00)
Please contact customerservice@thieme.de
For institutional licenses, please contact eproducts@thieme.de

Bangladesh, Bhutan, India, Nepal,

Pakistan, and Sri Lanka
For subscription rates in INR, please
contact customerservice@thieme.in

SUBSCRIBE NOW AND STAY UP-TO-DATE IN 2015

Visit www.thieme.com/journals in order to subscribe or renew your subscription.
Take full advantage of your individual subscription by registering online at
www.thieme-connect.com/products:
Individual subscribers get free online access to current and back issues of their journal(s)
Advanced online access for select journals via the eFirst service
Up-to-date Alerts via email or RSS-Feed
Advanced search across our entire library of journals

ORDER TODAY http://www.thieme.com

 


 


 
     


 

Become a fan at www.facebook.com/thiemepublishers. Follow us @ThiemeNY

130
 Exploring Critical Advances
in Brain Connection Research
Brain Connectivity is the premier peer-reviewed journal for cutting-edge
research in the expanding area of systems neuroscience.

Critical advancements in the

diagnosis and treatment of
neurodegenerative diseases
and psychiatric disorders

Vital information on brain

mapping, new imaging
modalities, and translating
research discoveries from
lab to clinic

Accepted in MEDLINE
in its rst year

Founding and Co-Editors-in-Chief:

Christopher P. Pawela, PhD
and Bharat B. Biswal, PhD

Subscribe Today!
www.liebertpub.com/brain

131
 Adjunctive therapy for patients ages 12 and up
with partial-onset seizures1

NOVEL TARGET.
NOVEL POTENTIAL.
FYCOMPAthe rst and only non-competitive
AMPA receptor antagonist1-3

GET ON TARGET AT AES

Visit us at Booth #305

Indication
FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures
with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.

AES = American Epilepsy Society

132
Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily
generalized seizures in patients with epilepsy aged 12 years and older.
Important Safety Information
WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS
Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and
threats have been reported in patients taking FYCOMPA
These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated
with hostility and aggression
Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality
that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA
Closely monitor patients particularly during the titration period and at higher doses
FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening
Serious Psychiatric and Behavioral Reactions Hostility- and aggression-related mental alertness, such as operating motor vehicles or dangerous machinery, until the
adverse reactions occurred in 12% and 20% of clinical trial patients randomized to effect of FYCOMPA is known.
receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 6% of Falls Falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at
patients in the placebo group. These effects were dose-related and generally appeared doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients.
within the first 6 weeks of treatment, although new events continued to be observed
through more than 37 weeks. These effects in FYCOMPA-treated patients led to Withdrawal of AEDs A gradual withdrawal is generally recommended with
dose reduction, interruption, and discontinuation more frequently than placebo- antiepileptic drugs to minimize the potential of increased seizure frequency.
treated patients. The combination of alcohol and FYCOMPA significantly worsened mood Most Common Adverse Reactions In clinical trials, the most frequently reported
and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. dose-related adverse reactions in patients receiving FYCOMPA 8 mg or 12 mg vs
Patients, their caregivers, and families should be informed that FYCOMPA may increase placebo (4% and at least 1% higher than the placebo group) included dizziness
the risk of psychiatric events. Patients should be monitored during treatment and for (36% vs 9%), somnolence (16% vs 7%), fatigue (10% vs 5%), irritability (9% vs 3%),
at least one month after the last dose of FYCOMPA, and especially when taking higher falls (7% vs 3%), nausea (7% vs 5%), ataxia (5% vs 0%), balance disorder (4% vs 1%),
doses and during the initial few weeks of drug therapy (titration period) or at other times gait disturbance (4% vs 1%), vertigo (4% vs 1%), and weight gain (4% vs 1%).
of dose increases. Drug Interactions FYCOMPA may decrease the efficacy of contraceptives containing
Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with
FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone carbamazepine, phenytoin and oxcarbazepine. Concomitant use with strong CYP3A
considering prescribing FYCOMPA or any other AED must balance the risk of suicidal inducers such as St. Johns wort and rifampin should be avoided. Multiple dosing of
thoughts or behavior with the risk of untreated illness. Epilepsy and many other FYCOMPA 12 mg/day enhanced the effects of alcohol on vigilance and alertness, and
illnesses for which AEDs are prescribed are themselves associated with morbidity increased levels of anger, confusion, and depression. These effects may also be seen
and mortality and an increased risk of suicidal thoughts and behavior. Patients, their when FYCOMPA is used in combination with other CNS depressants.
caregivers, and families should be informed of the risk and advised to monitor and Pregnancy Category C and Lactation FYCOMPA should be used during pregnancy
immediately report the emergence or worsening of depression, suicidal thoughts or only if the potential benefit justifies the potential risk to the fetus. Physicians are
behavior, thoughts about self-harm, and/or any unusual changes in mood or behavior. advised to recommend that pregnant patients taking FYCOMPA enroll in the North
Should suicidal thoughts or behavior emerge during treatment, consider whether the American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be
emergence of these symptoms in any given patient may be related to the illness exercised when FYCOMPA is administered to a nursing woman.
being treated. Hepatic and Renal Impairment Use in patients with severe hepatic or severe
Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in renal impairment is not recommended. Dosage adjustments are recommended in
events related to dizziness and disturbance in gait or coordination. Dizziness and patients with mild or moderate hepatic impairment. Use with caution in patients
vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at with moderate renal impairment.
doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated Drug Abuse and Dependence FYCOMPA is a Schedule III controlled drug substance
patients. Gait disturbance related events were reported in 12% and 16% of patients and has the potential to be abused or lead to drug dependence.
randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively,
compared to 2% of placebo-treated patients. These adverse reactions occurred
mostly during the titration phase. Please see Brief Summary of full Prescribing
Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence
Information on the next page for Boxed WARNING
and fatigue-related events. Somnolence was reported in 16% and 18% of patients and additional Important Safety Information.
randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared
to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and References: 1. Fycompa Prescribing Information. Woodcliff Lake, NJ: Eisai
15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, Inc.; June 2014. 2. Rogawski MA. Revisiting AMPA receptors as an antiepileptic
drug target. Epilepsy Curr. 2011;11:56-63. 3. Hanada T, Hashizume Y, Tokuhara
respectively, compared to 5% of placebo-treated patients. In the controlled Phase 3 N, et al. Fycompa: a novel, orally active, noncompetitive AMPA-receptor
epilepsy clinical trials, these adverse reactions occurred mostly during the titration antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia.
phase. Patients should be advised against engaging in hazardous activities requiring 2011;52:1331-1340.

FYCOMPA is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc.
Manufactured and marketed by Eisai Inc., Woodcliff Lake, NJ 07677
2014 Eisai Inc. All rights reserved. FYCO0788 September 2014

133
 Table 1. Risk by indication for antiepileptic drugs in the pooled analysis
Relative Risk: Risk Difference:
Placebo Patients Drug Patients Incidence of Additional Drug
Indication with Events Per with Events Per Events in Drug Patients/ Patients with Events
1000 Patients 1000 Patients Incidence in Placebo Per 1000 Patients
Patients
FYCOMPA (perampanel) tablets, for oral use, CIII
Epilepsy 1.0 3.4 3.5 2.4
Initial U.S. Approval: 2012
Psychiatric 5.7 8.5 1.5 2.9
BRIEF SUMMARY-see package insert for full Prescribing Information Other 1.0 1.8 1.9 0.9
WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Total 2.4 4.3 1.8 1.9
Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for
hostility, irritability, anger, and homicidal ideation and threats have been reported in patients psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric
taking FYCOMPA (5.1) indications. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts
These reactions occurred in patients with and without prior psychiatric history, prior aggressive or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are
behavior, or concomitant use of medications associated with hostility and aggression (5.1) themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should
Advise patients and caregivers to contact a healthcare provider immediately if any of these suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence
reactions or changes in mood, behavior, or personality that are not typical for the patient are of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and
observed while taking FYCOMPA or after discontinuing FYCOMPA (5.1) families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of
Closely monitor patients particularly during the titration period and at higher doses (5.1) the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes
in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of
FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if concern should be reported immediately to healthcare providers. Neurologic Effects Dizziness and Gait Disturbance
symptoms are severe or are worsening (5.1) FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination [see
Adverse Reactions (6.1)]. In the controlled Phase 3 epilepsy clinical trials, dizziness and vertigo were reported in 35%
INDICATIONS AND USAGE and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 10%
FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without of placebo-treated patients. The gait disturbance related events (including ataxia, gait disturbance, balance disorder,
secondarily generalized seizures in patients with epilepsy aged 12 years and older. and coordination abnormal) were reported in 12% and 16% of patients randomized to receive FYCOMPA at doses of
DOSAGE AND ADMINISTRATION 8 mg and 12 mg/day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred
Dosing Information In the Absence of Enzyme-Inducing AEDs The recommended starting dosage of FYCOMPA is mostly during the titration phase and led to discontinuation in 3% of perampanel-treated subjects compared to 1%
2 mg once daily taken orally at bedtime. Increase dosage by 2 mg per day increments no more frequently than every of placebo-treated patients. Elderly patients had an increased risk of these adverse reactions compared to younger
week to a dose of 4 mg to 8 mg once daily taken at bedtime. In elderly patients, dosage increases during titration are adults and adolescents. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and
recommended no more frequently than every two weeks. The recommended dose range is 8 mg to 12 mg once daily. fatigue-related events (including fatigue, asthenia, and lethargy). In the controlled Phase 3 epilepsy clinical trials,
A dose of 12 mg once daily resulted in somewhat greater reductions in seizure rates than the dose of 8 mg once daily, 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, reported
but with a substantial increase in adverse reactions. Individual dosing should be adjusted based on clinical response somnolence compared to 7% of placebo patients. In the controlled Phase 3 epilepsy clinical trials, 12% and 15% of
and tolerability [see Clinical Studies (14)]. In the Presence of Enzyme-Inducing AEDs The recommended starting dosage patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, reported fatigue-related
of FYCOMPA in the presence of enzyme-inducing AEDs, including phenytoin, carbamazepine, and oxcarbazepine, is events compared to 5% of placebo patients. Somnolence or fatigue-related events led to discontinuation in 2% of
4 mg and patients should be monitored closely for response. Clinical trials revealed a substantially reduced effect on perampanel-treated patients and 0.5% of placebo-treated patients. Elderly patients had an increased risk of these
seizure rates in these patients. The reduction in seizure frequency was somewhat greater at 12 mg than at 8 mg [see adverse reactions compared to younger adults and adolescents. Risk Amelioration Prescribers should advise patients
Clinical Studies (14)]. When these enzyme-inducing AEDs are introduced or withdrawn from a patients treatment against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous
regimen, patient should be closely monitored for clinical response and tolerability. Dose adjustment of FYCOMPA machinery, until the effect of FYCOMPA is known. In the controlled Phase 3 epilepsy clinical trials these adverse
may be necessary. Dosage Adjustments in Patients with Hepatic Impairment Based on higher exposure and reactions occurred mostly during the titration phase. Falls An increased risk of falls, in some cases leading to serious
the longer half-life of perampanel in patients with mild and moderate hepatic impairment, dosage adjustment is injuries including head injuries and bone fracture, occurred in patients being treated with FYCOMPA (with and without
recommended. Starting dose should be 2 mg per day with weekly increments of 2 mg per day every two weeks until concurrent seizures). In the controlled Phase 3 epilepsy clinical trials, falls were reported in 5% and 10% of patients
target dose is achieved. The maximum recommended daily dose is 6 mg for patients with mild hepatic impairment randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated
and 4 mg for patients with moderate hepatic impairment. Dose increases in patients with mild and moderate hepatic patients. Falls were reported as serious and led to discontinuation more frequently in FYCOMPA-treated patients than
impairment, as with all patients, should be based on clinical response and tolerability. Use in patients with severe placebo-treated patients. Elderly patients had an increased risk of falls compared to younger adults and adolescents.
hepatic impairment is not recommended [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. Patients Withdrawal of Antiepileptic Drugs There is the potential of increased seizure frequency in patients with seizure
with Renal Impairment FYCOMPA can be used in patients with moderate renal impairment with close monitoring. disorders when antiepileptic drugs are withdrawn abruptly. FYCOMPA has a half-life of approximately 105 hours so
A slower titration may be considered based on clinical response and tolerability. Use in patients with severe renal that even after abrupt cessation, blood levels fall gradually. In antiepileptic clinical trials FYCOMPA was withdrawn
impairment or patients undergoing hemodialysis is not recommended [see Use in Specific Populations (8.7), Clinical without down-titration. Although a small number of patients exhibited seizures following discontinuation, the data
Pharmacology (12.3)]. were not sufficient to allow any recommendations regarding appropriate withdrawal regimens. A gradual withdrawal
is generally recommended with antiepileptic drugs, but if withdrawal is a response to adverse events, prompt
CONTRAINDICATIONS withdrawal can be considered.
None. ADVERSE REACTIONS
WARNINGS AND PRECAUTIONS The following adverse reactions are discussed in more detail in other sections of the prescribing information:
Serious Psychiatric and Behavioral Reactions In the controlled Phase 3 epilepsy clinical trials, hostility- and Serious Psychiatric and Behavioral Reactions [see Warnings and Precautions (5.1)]
aggression-related adverse reactions occurred in 12% and 20% of patients randomized to receive FYCOMPA at Suicidal Behavior and Ideation [see Warnings and Precautions (5.2)]
doses of 8 mg and 12 mg/day, respectively, compared to 6% of patients in the placebo group. These effects were Dizziness and Gait Disturbance [see Warnings and Precautions (5.3)]
dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be Somnolence and Fatigue [see Warnings and Precautions (5.3)]
observed through more than 37 weeks. FYCOMPA-treated patients experienced more hostility- and aggression- Falls [see Warnings and Precautions (5.4)]
related adverse reactions that were serious, severe, and led to dose reduction, interruption, and discontinuation more Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction
frequently than placebo-treated patients. In general, in placebo-controlled Phase 3 epilepsy trials, neuropsychiatric rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug
events were reported more frequently in patients being treated with FYCOMPA than in patients taking placebo. These and may not reflect the rates observed in clinical practice. A total of 1,038 patients on perampanel (2, 4, 8, or 12 mg
events included irritability, aggression, anger, and anxiety which occurred in 2% or greater of perampanel treated once daily) constituted the safety population in the pooled analysis of Phase 3 placebo controlled studies (Studies 1,
patients and twice as frequently as in placebo-treated patients. Other symptoms that were observed with perampanel 2, and 3) in patients with partial onset seizures. Approximately 51% of patients were female and the mean age was
treatment and more commonly than with placebo, included belligerence, affect lability, agitation, and physical assault. 35 years. Adverse Reactions Leading to Discontinuation In controlled Phase 3 clinical trials (Studies 1, 2, and 3), the
Some of these events were reported as serious and life-threatening. Homicidal ideation and/or threat were exhibited rate of discontinuation as a result of an adverse reaction was 3%, 8% and 19% in patients randomized to receive
in 0.1% of 4,368 perampanel treated patients in controlled and open label studies, including non-epilepsy studies. In FYCOMPA at the recommended doses of 4 mg, 8 mg and 12 mg/day, respectively, and 5% in patients randomized
the Phase 3 epilepsy trials these events occurred in patients with and without prior psychiatric history, prior aggressive to receive placebo [see Clinical Studies (14)]. The adverse events most commonly leading to discontinuation (1%
behavior, or concomitant use of medications associated with hostility and aggression. Some patients experienced in the 8 mg or 12 mg FYCOMPA group and greater than placebo) were dizziness, somnolence, vertigo, aggression,
worsening of their pre-existing psychiatric conditions. Patients with active psychotic disorders and unstable recurrent anger, ataxia, blurred vision, irritability, and dysarthria [see Warnings and Precautions (5.1 and 5.3)]. Most Common
affective disorders were excluded from the clinical trials. The combination of alcohol and perampanel significantly Adverse Reactions Table 2 gives the incidence in the Phase 3 controlled trials (Studies 1, 2, and 3) of the adverse
worsened mood and increased anger [see Drug Interactions (7.3)]. Patients taking FYCOMPA should avoid the reactions that occurred in 2% of patients with partial-onset seizures in any FYCOMPA dose group. Overall, the most
use of alcohol. In healthy volunteers taking FYCOMPA, observed psychiatric events included paranoia, euphoric frequently reported dose-related adverse reactions in patients receiving FYCOMPA at doses of 8 mg or 12 mg (4%
mood, agitation, anger, mental status changes, and disorientation/confusional state. In the non-epilepsy trials, and occurring at least 1% higher than the placebo group) included dizziness (36%), somnolence (16%), fatigue (10%),
psychiatric events that occurred in perampanel-treated subjects more often than placebo-treated subjects included irritability (9%), falls (7%), nausea (7%), ataxia (5%), balance disorder (4%), gait disturbance (4%), vertigo (4%), and
disorientation, delusion, and paranoia. Patients, their caregivers, and families should be informed that FYCOMPA may weight gain (4%). For almost every adverse reaction, rates were higher on 12 mg and more often led to dose reduction
increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after or discontinuation.
the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy
(titration period) or at other times of dose increases. Dose of FYCOMPA should be reduced if these symptoms occur. Table 2. Adverse Reactions in Pooled Double-blind Trials in Patients with Partial-Onset Seizures
Permanently discontinue FYCOMPA for persistent severe or worsening psychiatric symptoms or behaviors and refer (Reactions 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo)
for psychiatric evaluation. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase
the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED Placebo FYCOMPA
for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior,
and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and 4 mg 8 mg 12 mg
adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice n=442 n=172 n=431 n=255
the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized % % % %
to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal Ear and Labyrinth Disorders
behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-
treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 Vertigo 1 4 3 5
patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, Eye Disorders
but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal
thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and Diplopia 1 1 1 3
persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond Blurred vision 1 1 3 4
24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal
thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with Gastrointestinal Disorders
AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used Constipation 2 2 2 3
for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 1 shows
absolute and relative risk by indication for all evaluated AEDs. Nausea 5 3 6 8
Vomiting 3 2 3 4
Infections and Infestations
Upper respiratory tract infection 3 3 3 4
Injury, Poisoning and Procedural Complications
134
Table 2. Adverse Reactions in Pooled Double-blind Trials in Patients with Partial-Onset Seizures embryo-fetal developmental toxicity in rabbit (1 mg/kg/day) is approximately 2 times a human dose of 8 mg/day based
(Reactions 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) (cont.) on body surface area (mg/m2). Oral administration of perampanel (1, 3, or 10 mg/kg/day) to rats throughout gestation
and lactation resulted in fetal and pup deaths at the mid and high doses and delayed sexual maturation in males and
Contusion 1 0 2 2 females at the highest dose tested. No effects were observed on measures of neurobehavioral or reproductive function
Falls 3 2 5 10 in the offspring. The no-effect dose for pre- and postnatal developmental toxicity in rat (1 mg/kg/day) is similar
to a human dose of 8 mg/day based on body surface area (mg/m2). Pregnancy Registry To provide information
Head injury 1 1 1 3 regarding the effects of in utero exposure to FYCOMPA, physicians are advised to recommend that pregnant patients
Limb injury <1 1 1 2 taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by
calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry
Skin laceration 1 0 2 2 can also be found at the website: http://www.aedpregnancyregistry.org. Nursing Mothers Perampanel and/or its
Investigations metabolites are excreted in rat milk, and are detected at concentrations higher than that in maternal plasma. It is
not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution
Weight gain 1 4 4 4 should be exercised when FYCOMPA is administered to a nursing woman. Pediatric Use The safety and efficacy of
Metabolism & Nutrition disorders FYCOMPA for the adjunctive therapy of partial-onset seizures was established by three randomized double blind,
placebo-controlled, multicenter studies which included 72 pediatric patients between 12 and 16 years old exposed
Hyponatremia <1 0 0 2 to perampanel [see Clinical Studies (14.1), Clinical Pharmacology (12.3)]. The safety and effectiveness of FYCOMPA in
Musculoskeletal and Connective Tissue disorders pediatric patients <12 years old have not been established. Juvenile Animal Data Oral administration of perampanel
(1, 3, 3/10/30 mg/kg/day; high dose increased on postnatal days [PND] 28 and 56) to young rats for 12 weeks starting
Arthralgia 1 0 3 2 on PND 7 resulted in reduced body weight, reduced growth, neurobehavioral impairment (water maze performance
Back pain 2 2 2 5 and auditory startle habituation) at the mid and high doses, and delayed sexual maturation at the high doses. CNS
signs (reduced activity, incoordination, excessive grooming/scratching), pup death, decreased hindlimb splay, and
Musculoskeletal pain 1 1 1 2 decreased hindlimb grip strength were observed at all doses. Effects on pup body weight, pup growth, hindlimb splay,
Myalgia 2 1 1 3 impairment in the water maze performance and auditory startle persisted after dosing was stopped. A no-effect
dose for postnatal developmental toxicity was not identified in this study. Oral administration of perampanel (1, 5,
Pain in extremity 1 0 2 3 5/10 mg/kg/day; high dose increased on PND 56) to juvenile dogs for 33 weeks, starting on PND 42, resulted in
Peripheral edema 1 1 1 2 CNS signs (incoordination, excessive grooming/licking/scratching, spatial disorientation, and/or ataxic gait) at
all doses tested. Geriatric Use Clinical studies of FYCOMPA did not include sufficient numbers of patients aged
Nervous system disorders 65 and over to determine the safety and efficacy of FYCOMPA in the elderly population. Because of increased
Asthenia 1 1 2 2 likelihood for adverse reactions in the elderly dosing titration should proceed slowly in patients aged 65 years and
older [see Dosage and Administration (2.1)]. Patients with Hepatic Impairment Use of FYCOMPA in patients with
Ataxia 0 1 3 8 severe hepatic impairment is not recommended and dosage adjustments are recommended in patients with mild
Balance disorder 1 0 5 3 or moderate hepatic impairment [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)]. Patients with
Renal Impairment Dose adjustment is not required in patients with mild renal impairment. FYCOMPA should be used
Coordination abnormal 0 1 <1 2 with caution in patients with moderate renal impairment and slower titration may be considered. Use in patients with
Dizziness 9 16 32 43 severe renal impairment or patients undergoing hemodialysis is not recommended [see Dosage and Administration
(2.3), Clinical Pharmacology (12.3)].
Dysarthria 0 1 3 4
DRUG ABUSE AND DEPENDENCE
Fatigue 5 8 8 12 Controlled Substance FYCOMPA contains perampanel and is listed as a Schedule III controlled substance. Abuse
Gait disturbance 1 1 4 4 Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or
physiological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire
Headache 11 11 11 13 to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than
Hypersomnia 0 1 2 3 to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate
and distinct from physical dependence (for example, abuse may not be accompanied by physical dependence) [see
Hypoaesthesia 1 0 0 3 Drug Abuse and Dependence (9.3)]. Studies of human abuse potential were performed to evaluate the abuse potential
Memory impairment 1 0 1 2 of FYCOMPA (8 mg, 24 mg, and 36 mg) as compared to alprazolam C-IV (1.5 mg and 3 mg), and oral ketamine C-III
(100 mg) in recreational polydrug users. Supra-therapeutic doses of FYCOMPA 24 and 36 mg produced responses
Paraesthesia 1 0 1 2 for Euphoria that were similar to ketamine 100 mg and alprazolam 3 mg. For High, FYCOMPA 24 mg and 36
Somnolence 7 9 16 18 mg produced responses comparable to ketamine 100 mg and significantly higher than both doses of alprazolam
on a visual analog scale (VAS). Drug Liking, Overall Drug Liking, and Take Drug Again for FYCOMPA were
Psychiatric disorders each statistically lower than ketamine 100 mg. In addition, for Bad Drug Effects, FYCOMPA 24 mg and 36 mg
Aggression 1 1 2 3 produced responses significantly higher than ketamine 100 mg. For Sedation, FYCOMPA 24 and 36 mg produced
responses similar to alprazolam 3 mg and higher than ketamine 100 mg. Additionally, on VAS measures related to
Anger <1 0 1 3 dissociative phenomena such as Floating, Spaced Out and Detached, FYCOMPA at supra-therapeutic doses
Anxiety 1 2 3 4 produced responses similar to ketamine 100 mg and greater than both doses of alprazolam tested. Of note, due to
somnolence a number of subjects had missing data around Tmax of FYCOMPA. The above described data might
Confusional state <1 1 1 2 represent an underestimate of FYCOMPAs effects. The duration of effects of higher doses of FYCOMPA on the
Euphoric mood 0 0 <1 2 majority of measures was much greater than alprazolam 3 mg and ketamine 100 mg. In this study, the incidence
of euphoria following FYCOMPA administration 8 mg, 24 mg and 36 mg was 37%, 46%, 46%, respectively, which
Irritability 3 4 7 12 was higher than alprazolam 3 mg (13%) but lower than ketamine 100 mg (89%). Dependence Physical dependence
Mood altered <1 1 <1 2 is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. The
potential for FYCOMPA to produce withdrawal symptoms has not been adequately evaluated.
Respiratory, Thoracic and Mediastinal Disorders
OVERDOSAGE
Cough 3 1 1 4 Signs, Symptoms, and Laboratory Findings of Acute Overdose in Humans There is limited clinical experience
Oropharyngeal pain 1 2 2 2 with FYCOMPA overdose. The highest reported overdose (approximately 264 mg) was intentional. This patient
experienced serious adverse reactions of altered mental status, agitation, and aggressive behavior and recovered
Weight gain Weight gain has been observed with FYCOMPA use in adults. In the controlled Phase 3 epilepsy clinical without sequelae. In general, the adverse reactions associated with overdoses were similar to the reactions at
trials, FYCOMPA-treated adults gained an average of 1.1 kg (2.5 lbs) compared to an average of 0.3 kg (0.7 lbs) in therapeutic doses with dizziness reported most frequently. There were no reported sequelae. Treatment or
placebo-treated adults with a median exposure of 19 weeks. The percentages of adults who gained at least 7% and Management of Overdose There is no available specific antidote to the overdose reactions of FYCOMPA. In the
15% of their baseline body weight in FYCOMPA-treated patients were 9.1% and 0.9%, respectively, as compared to event of overdose, standard medical practice for the management of any overdose should be used. An adequate
4.5% and 0.2% of placebo-treated patients, respectively. Clinical monitoring of weight is recommended. Comparison airway, oxygenation, and ventilation should be ensured; monitoring of cardiac rhythm and vital sign measurement is
of Sex and Race No significant sex differences were noted in the incidence of adverse reactions. Although there were recommended. A certified poison control center should be contacted for updated information on the management of
few non-Caucasian patients, no differences in the incidences of adverse reactions compared to Caucasian patients overdose with FYCOMPA. Due to its long half-life, the reactions caused by FYCOMPA could be prolonged.
were observed.
PATIENT COUNSELING INFORMATION
DRUG INTERACTIONS See FDA-approved patient labeling (Medication Guide). Inform patients of the availability of a Medication
Contraceptives With concomitant use, FYCOMPA at a dose of 12 mg/day reduced levonorgestrel exposure by Guide, and instruct them to read the Medication Guide prior to taking FYCOMPA. Instruct patients to take FYCOMPA
approximately 40% [see Clinical Pharmacology (12.3)]. Use of FYCOMPA with oral or implant contraceptives containing only as prescribed. Serious Psychiatric and Behavioral Reactions Counsel patients, families and caregivers
levonorgestrel may render them less effective. Additional non-hormonal forms of contraception are recommended. of patients of the need to monitor for the emergence of anger, aggression, hostility, unusual changes in mood,
Cytochrome P450 (CYP) Inducers The concomitant use of known CYP enzyme inducers including carbamazepine, personality, or behavior, and other behavioral symptoms. Advise them to report any such symptoms immediately
phenytoin, or oxcarbazepine with FYCOMPA decreased the plasma levels of perampanel by approximately 50~67% to their health care providers. Suicidal Thinking and Behavior Counsel patients, their caregivers, and families that
[see Clinical Pharmacology (12.3)]. The starting doses for FYCOMPA should be increased in the presence of enzyme- AEDs, including FYCOMPA, may increase the risk of suicidal thinking and behavior and advise them of the need to
inducing AEDs [see Dosage and Administration (2.1)]. When these enzyme-inducing AEDs are introduced or withdrawn be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior,
from a patients treatment regimen, patient should be closely monitored for clinical response and tolerability. Dose or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers and
adjustment of FYCOMPA may be necessary. As noted, however, the decrease in the therapeutic effect seen in patients families to report behaviors of concern immediately to healthcare providers. Neurologic Effects: Dizziness, Gait
on concomitant treatment, was not affected by use of higher doses (8 mg to 12 mg) [see Dosage and Administration Disturbance, Somnolence, and Fatigue Counsel patients that FYCOMPA may cause dizziness, gait disturbance,
(2.1)]. Concomitant use of FYCOMPA with other strong CYP3A inducers (e.g., rifampin, St. Johns wort) should be somnolence, and fatigue. Advise patients taking FYCOMPA not to drive, operate complex machinery, or engage
avoided. Alcohol and Other CNS Depressants The concomitant use of FYCOMPA and CNS depressants including in other hazardous activities until they have become accustomed to any such effects associated with FYCOMPA.
alcohol may increase CNS depression. A pharmacodynamic interaction study in healthy subjects found that the effects Falls Counsel patients that FYCOMPA may cause falls and injuries. Withdrawal of Antiepileptic Drugs Counsel
of FYCOMPA on complex tasks such as driving ability were additive or supra-additive to the impairment effects of patients that abrupt discontinuation of FYCOMPA may increase seizure frequency. Contraceptives Counsel
alcohol [see Clinical Pharmacology (12.3)]. Multiple dosing of FYCOMPA 12 mg/day also enhanced the effects of patients that FYCOMPA may decrease efficacy of contraceptives containing levonorgestrel. Alcohol and Other
alcohol to interfere with vigilance and alertness, and increased levels of anger, confusion, and depression. These CNS Depressants Counsel patients that FYCOMPA may enhance the impairment effects of alcohol. These
effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Care should be effects may also be seen if FYCOMPA is taken with other CNS depressants. Missed Doses Counsel patients that
taken when administering FYCOMPA with these agents. Patients should limit activity until they have experience with if they miss a dose, they should resume dosing the following day at their prescribed daily dose. Instruct patients
concomitant use of CNS depressants (e.g. benzodiazepines, narcotics, barbiturates, sedating antihistamines). Advise to contact their physician if more than one day of dosing is missed. Controlled Substance Counsel patients
patients not to drive or operate machinery until they have gained sufficient experience on FYCOMPA to gauge whether that FYCOMPA is a controlled substance that can be misused and abused. Pregnancy Registry To provide
it adversely affects these activities. information regarding the effects of in utero exposure to FYCOMPA, recommend pregnant patients treated
USE IN SPECIFIC POPULATIONS with FYCOMPA to enroll in the NAAED Pregnancy Registry. This can be done by calling the toll free number
Pregnancy Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. In 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the
animal studies, perampanel induced developmental toxicity in pregnant rat and rabbit at clinically relevant doses. website http://www.aedpregnancyregistry.org.
FYCOMPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. FYCOMPA is a registered trademark owned by Eisai R&D Management Co., Ltd.
Oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in Manufactured and Marketed by Eisai Inc., Woodcliff Lake, NJ 07677
an increase in visceral abnormalities (diverticulum of the intestine) at all doses tested. In a dose-ranging study at 2014 Eisai Inc. FYCOXXXX
higher oral doses (10, 30, or 60 mg/kg/day), embryo lethality and reduced fetal body weight were observed at the
mid and high doses tested. The lowest dose tested (1 mg/kg/day) is similar to a human dose of 8 mg/day based
on body surface area (mg/m2). Upon oral administration of perampanel (1, 3, or 10 mg/kg/day) to pregnant rabbits
throughout organogenesis, embryo lethality was observed at the mid and high doses tested; the no effect dose for
135
 NOTES

136
VISIT SUPERNUS PHARMACEUTICALS AT BOOTH #605

Get your Passport to Prizes For more information visit

stamped at booth #605 each day www.TrokendiXR.com and
of the convention to be eligible www.OxtellarXR.com
for the daily prize drawing

Proudly Supports the American Epilepsy Society (AES) 2014 Annual Meeting
Trokendi XR and Oxtellar XR are registered trademarks of Supernus Pharmaceuticals, Inc.
2014 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2014-0040
 COME VISIT OUR BOOTH!

Learn more
about APTIOM
at Booth 105

Under license from

is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc., is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
2014 Sunovion Pharmaceuticals Inc. All rights reserved. 09/14 APT435-14